CA2551486A1 - Fused bicycloheterocycle substituted quinuclidine derivatives - Google Patents
Fused bicycloheterocycle substituted quinuclidine derivatives Download PDFInfo
- Publication number
- CA2551486A1 CA2551486A1 CA002551486A CA2551486A CA2551486A1 CA 2551486 A1 CA2551486 A1 CA 2551486A1 CA 002551486 A CA002551486 A CA 002551486A CA 2551486 A CA2551486 A CA 2551486A CA 2551486 A1 CA2551486 A1 CA 2551486A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- yloxy
- formula
- mmol
- aza
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000008584 quinuclidines Chemical class 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 322
- 238000000034 method Methods 0.000 claims abstract description 67
- 125000003118 aryl group Chemical group 0.000 claims abstract description 40
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 24
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 21
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 64
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 claims description 31
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 claims description 31
- 229910052739 hydrogen Inorganic materials 0.000 claims description 29
- 239000001257 hydrogen Substances 0.000 claims description 28
- 230000000694 effects Effects 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- 125000004432 carbon atom Chemical group C* 0.000 claims description 16
- 150000002148 esters Chemical class 0.000 claims description 16
- 208000024827 Alzheimer disease Diseases 0.000 claims description 15
- 208000035475 disorder Diseases 0.000 claims description 15
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 15
- 150000001408 amides Chemical class 0.000 claims description 13
- 206010012289 Dementia Diseases 0.000 claims description 12
- 239000000651 prodrug Substances 0.000 claims description 11
- 229940002612 prodrug Drugs 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 208000002193 Pain Diseases 0.000 claims description 10
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 10
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 10
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 9
- 201000000980 schizophrenia Diseases 0.000 claims description 9
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 8
- 208000010877 cognitive disease Diseases 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 7
- 210000003169 central nervous system Anatomy 0.000 claims description 6
- 239000003693 atypical antipsychotic agent Substances 0.000 claims description 5
- 229940127236 atypical antipsychotics Drugs 0.000 claims description 5
- 230000004770 neurodegeneration Effects 0.000 claims description 5
- 208000030507 AIDS Diseases 0.000 claims description 4
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 4
- 201000010374 Down Syndrome Diseases 0.000 claims description 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 4
- 206010039966 Senile dementia Diseases 0.000 claims description 4
- 206010044688 Trisomy 21 Diseases 0.000 claims description 4
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 4
- 210000004204 blood vessel Anatomy 0.000 claims description 4
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 4
- 210000004558 lewy body Anatomy 0.000 claims description 4
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 4
- 208000000094 Chronic Pain Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 206010065390 Inflammatory pain Diseases 0.000 claims description 3
- 208000004550 Postoperative Pain Diseases 0.000 claims description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
- 206010053648 Vascular occlusion Diseases 0.000 claims description 3
- 208000005298 acute pain Diseases 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 230000003292 diminished effect Effects 0.000 claims description 3
- 208000004296 neuralgia Diseases 0.000 claims description 3
- 208000021722 neuropathic pain Diseases 0.000 claims description 3
- 230000009529 traumatic brain injury Effects 0.000 claims description 3
- 208000021331 vascular occlusion disease Diseases 0.000 claims description 3
- 230000029663 wound healing Effects 0.000 claims description 3
- IYQKLJISQKXUEU-NRFANRHFSA-N 1-[5-[6-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]oxy]pyridazin-3-yl]-1h-indol-3-yl]-n,n-dimethylmethanamine Chemical compound C1N(CC2)CCC2[C@H]1OC(N=N1)=CC=C1C1=CC=C2NC=C(CN(C)C)C2=C1 IYQKLJISQKXUEU-NRFANRHFSA-N 0.000 claims description 2
- QGGUZNMEZCYFGG-UHFFFAOYSA-N 2-[4-(1-azabicyclo[2.2.2]octan-3-yloxy)phenyl]-1h-indole Chemical compound C1=CC=C2NC(C3=CC=C(C=C3)OC3C4CCN(C3)CC4)=CC2=C1 QGGUZNMEZCYFGG-UHFFFAOYSA-N 0.000 claims description 2
- ILDQLEZWIYUAFF-UHFFFAOYSA-N 3-[4-(1-azabicyclo[2.2.2]octan-3-yloxy)phenyl]-1h-indole Chemical compound C1=CC=C2C(C3=CC=C(C=C3)OC3C4CCN(C3)CC4)=CNC2=C1 ILDQLEZWIYUAFF-UHFFFAOYSA-N 0.000 claims description 2
- AGQZHWHGJXEHAU-UHFFFAOYSA-N 3-[6-(1-azabicyclo[2.2.2]octan-3-yloxy)pyridazin-3-yl]-1h-indole Chemical compound C1=CC=C2C(C3=CC=C(N=N3)OC3C4CCN(C3)CC4)=CNC2=C1 AGQZHWHGJXEHAU-UHFFFAOYSA-N 0.000 claims description 2
- AGQZHWHGJXEHAU-SFHVURJKSA-N 3-[6-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]oxy]pyridazin-3-yl]-1h-indole Chemical compound C1=CC=C2C(C3=CC=C(N=N3)O[C@@H]3C4CCN(C3)CC4)=CNC2=C1 AGQZHWHGJXEHAU-SFHVURJKSA-N 0.000 claims description 2
- UXEQQXQWJSFLPE-QFIPXVFZSA-N 3-[6-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]oxy]pyridazin-3-yl]-9h-carbazole Chemical compound C1=CC=C2C3=CC(C4=CC=C(N=N4)O[C@@H]4C5CCN(C4)CC5)=CC=C3NC2=C1 UXEQQXQWJSFLPE-QFIPXVFZSA-N 0.000 claims description 2
- AGQZHWHGJXEHAU-GOSISDBHSA-N 3-[6-[[(3s)-1-azabicyclo[2.2.2]octan-3-yl]oxy]pyridazin-3-yl]-1h-indole Chemical compound C1=CC=C2C(C3=CC=C(N=N3)O[C@H]3C4CCN(C3)CC4)=CNC2=C1 AGQZHWHGJXEHAU-GOSISDBHSA-N 0.000 claims description 2
- MXYDEQXRKKUFTL-SFHVURJKSA-N 4-[2-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]oxy]pyrimidin-5-yl]-1h-indole Chemical compound O([C@@H]1C2CCN(C1)CC2)C(N=C1)=NC=C1C1=CC=CC2=C1C=CN2 MXYDEQXRKKUFTL-SFHVURJKSA-N 0.000 claims description 2
- JVFHKRDZWLICSZ-XJCQOYGMSA-N 4-[2-[[(3r)-1-oxido-1-azoniabicyclo[2.2.2]octan-3-yl]oxy]pyrimidin-5-yl]-1h-indole Chemical compound O([C@@H]1C2CC[N+](CC2)(C1)[O-])C(N=C1)=NC=C1C1=CC=CC2=C1C=CN2 JVFHKRDZWLICSZ-XJCQOYGMSA-N 0.000 claims description 2
- NLYRWVYFBQLDNN-UHFFFAOYSA-N 4-[4-(1-azabicyclo[2.2.2]octan-3-yloxy)phenyl]-1h-indole Chemical compound C1CN(C2)CCC1C2OC(C=C1)=CC=C1C1=CC=CC2=C1C=CN2 NLYRWVYFBQLDNN-UHFFFAOYSA-N 0.000 claims description 2
- GHFNBRCTKJMLHZ-UHFFFAOYSA-N 4-[6-(1-azabicyclo[2.2.2]octan-3-yloxy)pyridazin-3-yl]-1h-indole Chemical compound C1CN(C2)CCC1C2OC(N=N1)=CC=C1C1=CC=CC2=C1C=CN2 GHFNBRCTKJMLHZ-UHFFFAOYSA-N 0.000 claims description 2
- UOBMVUNFDOOGIA-KRWDZBQOSA-N 5-[2-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]oxy]pyrimidin-5-yl]-1,3-benzoxazole Chemical compound C1=C2OC=NC2=CC(C2=CN=C(N=C2)O[C@@H]2C3CCN(C2)CC3)=C1 UOBMVUNFDOOGIA-KRWDZBQOSA-N 0.000 claims description 2
- GTSOUQUYFXGNJP-SFHVURJKSA-N 5-[2-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]oxy]pyrimidin-5-yl]-1h-indole Chemical compound C1=C2NC=CC2=CC(C2=CN=C(N=C2)O[C@@H]2C3CCN(C2)CC3)=C1 GTSOUQUYFXGNJP-SFHVURJKSA-N 0.000 claims description 2
- BVZJRDALCRCJQU-QFIPXVFZSA-N 5-[2-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]oxy]pyrimidin-5-yl]-2-phenyl-1,3-benzoxazole Chemical compound O([C@@H]1C2CCN(C1)CC2)C(N=C1)=NC=C1C(C=C1N=2)=CC=C1OC=2C1=CC=CC=C1 BVZJRDALCRCJQU-QFIPXVFZSA-N 0.000 claims description 2
- HFEZNZAPCVCKMP-INIZCTEOSA-N 5-[2-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]oxy]pyrimidin-5-yl]-3h-1,3-benzoxazol-2-one Chemical compound C1N(CC2)CCC2[C@H]1OC(N=C1)=NC=C1C1=CC=C(OC(=O)N2)C2=C1 HFEZNZAPCVCKMP-INIZCTEOSA-N 0.000 claims description 2
- GTSOUQUYFXGNJP-GOSISDBHSA-N 5-[2-[[(3s)-1-azabicyclo[2.2.2]octan-3-yl]oxy]pyrimidin-5-yl]-1h-indole Chemical compound C1=C2NC=CC2=CC(C2=CN=C(N=C2)O[C@H]2C3CCN(C2)CC3)=C1 GTSOUQUYFXGNJP-GOSISDBHSA-N 0.000 claims description 2
- YULBEJGLTXDNOV-UHFFFAOYSA-N 5-[4-(1-azabicyclo[2.2.2]octan-3-yloxy)phenyl]-1h-indole Chemical compound C1=C2NC=CC2=CC(C2=CC=C(C=C2)OC2C3CCN(C2)CC3)=C1 YULBEJGLTXDNOV-UHFFFAOYSA-N 0.000 claims description 2
- FXRKSLCORBVZAL-UHFFFAOYSA-N 5-[4-(1-azabicyclo[2.2.2]octan-3-yloxy)phenyl]-3-methyl-2h-indazole Chemical compound C1N(CC2)CCC2C1OC(C=C1)=CC=C1C1=CC=C2NN=C(C)C2=C1 FXRKSLCORBVZAL-UHFFFAOYSA-N 0.000 claims description 2
- YULBEJGLTXDNOV-NRFANRHFSA-N 5-[4-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]oxy]phenyl]-1h-indole Chemical compound C1=C2NC=CC2=CC(C2=CC=C(C=C2)O[C@@H]2C3CCN(C2)CC3)=C1 YULBEJGLTXDNOV-NRFANRHFSA-N 0.000 claims description 2
- LUKNJAQKVPBDSC-UHFFFAOYSA-N 5-[6-(1-azabicyclo[2.2.2]octan-3-yloxy)pyridazin-3-yl]-1h-indole Chemical compound C1=C2NC=CC2=CC(C2=CC=C(N=N2)OC2C3CCN(C2)CC3)=C1 LUKNJAQKVPBDSC-UHFFFAOYSA-N 0.000 claims description 2
- ACLCJNOKGJPMLH-INIZCTEOSA-N 5-[6-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]oxy]pyridazin-3-yl]-1,3-dihydrobenzimidazol-2-one Chemical compound C1N(CC2)CCC2[C@H]1OC(N=N1)=CC=C1C1=CC=C2NC(=O)NC2=C1 ACLCJNOKGJPMLH-INIZCTEOSA-N 0.000 claims description 2
- UFGNPNHROKRPMA-KRWDZBQOSA-N 5-[6-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]oxy]pyridazin-3-yl]-1,3-dihydroindol-2-one Chemical compound C1N(CC2)CCC2[C@H]1OC(N=N1)=CC=C1C1=CC=C(NC(=O)C2)C2=C1 UFGNPNHROKRPMA-KRWDZBQOSA-N 0.000 claims description 2
- OCUUBBDATKSJCC-IBGZPJMESA-N 5-[6-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]oxy]pyridazin-3-yl]-1-methylindole Chemical compound C1N(CC2)CCC2[C@H]1OC(N=N1)=CC=C1C1=CC=C2N(C)C=CC2=C1 OCUUBBDATKSJCC-IBGZPJMESA-N 0.000 claims description 2
- LUKNJAQKVPBDSC-SFHVURJKSA-N 5-[6-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]oxy]pyridazin-3-yl]-1h-indole Chemical compound C1=C2NC=CC2=CC(C2=CC=C(N=N2)O[C@@H]2C3CCN(C2)CC3)=C1 LUKNJAQKVPBDSC-SFHVURJKSA-N 0.000 claims description 2
- XZVULKFJGAJNOG-IBGZPJMESA-N 5-[6-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]oxy]pyridazin-3-yl]-3-methyl-1h-indole Chemical compound C1N(CC2)CCC2[C@H]1OC(N=N1)=CC=C1C1=CC=C2NC=C(C)C2=C1 XZVULKFJGAJNOG-IBGZPJMESA-N 0.000 claims description 2
- JQQQPXXRUGNREH-SFHVURJKSA-N 5-[6-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]oxy]pyridazin-3-yl]-3-methyl-2h-indazole Chemical compound C1N(CC2)CCC2[C@H]1OC(N=N1)=CC=C1C1=CC=C2NN=C(C)C2=C1 JQQQPXXRUGNREH-SFHVURJKSA-N 0.000 claims description 2
- NSPBIYQIBBJULY-IBGZPJMESA-N 5-[6-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]oxy]pyridin-3-yl]-1h-indole Chemical compound C1=C2NC=CC2=CC(C2=CC=C(N=C2)O[C@@H]2C3CCN(C2)CC3)=C1 NSPBIYQIBBJULY-IBGZPJMESA-N 0.000 claims description 2
- WYRNXLDJVZZQOW-XJCQOYGMSA-N 5-[6-[[(3r)-1-oxido-1-azoniabicyclo[2.2.2]octan-3-yl]oxy]pyridazin-3-yl]-1h-indole Chemical compound C1=C2NC=CC2=CC(C2=CC=C(N=N2)O[C@@H]2C3CC[N+](CC3)(C2)[O-])=C1 WYRNXLDJVZZQOW-XJCQOYGMSA-N 0.000 claims description 2
- LUKNJAQKVPBDSC-GOSISDBHSA-N 5-[6-[[(3s)-1-azabicyclo[2.2.2]octan-3-yl]oxy]pyridazin-3-yl]-1h-indole Chemical compound C1=C2NC=CC2=CC(C2=CC=C(N=N2)O[C@H]2C3CCN(C2)CC3)=C1 LUKNJAQKVPBDSC-GOSISDBHSA-N 0.000 claims description 2
- CQLRRWLSSBLWCT-UHFFFAOYSA-N 6-[4-(1-azabicyclo[2.2.2]octan-3-yloxy)phenyl]-1,3-benzothiazol-2-amine Chemical compound C1N(CC2)CCC2C1OC(C=C1)=CC=C1C1=CC=C2N=C(N)SC2=C1 CQLRRWLSSBLWCT-UHFFFAOYSA-N 0.000 claims description 2
- QOIFHUCHKRDTMO-UHFFFAOYSA-N 6-[4-(1-azabicyclo[2.2.2]octan-3-yloxy)phenyl]-1h-indole Chemical compound C1=C2C=CNC2=CC(C2=CC=C(C=C2)OC2C3CCN(C2)CC3)=C1 QOIFHUCHKRDTMO-UHFFFAOYSA-N 0.000 claims description 2
- CQLRRWLSSBLWCT-SFHVURJKSA-N 6-[4-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]oxy]phenyl]-1,3-benzothiazol-2-amine Chemical compound C1N(CC2)CCC2[C@H]1OC(C=C1)=CC=C1C1=CC=C2N=C(N)SC2=C1 CQLRRWLSSBLWCT-SFHVURJKSA-N 0.000 claims description 2
- BVKMGWVIBHOSIG-KRWDZBQOSA-N 6-[4-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]oxy]phenyl]-4-bromo-1,3-benzothiazol-2-amine Chemical compound C1N(CC2)CCC2[C@H]1OC(C=C1)=CC=C1C1=CC(Br)=C2N=C(N)SC2=C1 BVKMGWVIBHOSIG-KRWDZBQOSA-N 0.000 claims description 2
- VCVSVFQKULDZAO-HNNXBMFYSA-N 6-[6-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]oxy]pyridazin-3-yl]-1,3-benzothiazol-2-amine Chemical compound C1N(CC2)CCC2[C@H]1OC(N=N1)=CC=C1C1=CC=C2N=C(N)SC2=C1 VCVSVFQKULDZAO-HNNXBMFYSA-N 0.000 claims description 2
- MSGNEVBGFWYKGM-KRWDZBQOSA-N 6-[6-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]oxy]pyridazin-3-yl]-1h-benzimidazole Chemical compound C1=C2NC=NC2=CC(C2=CC=C(N=N2)O[C@@H]2C3CCN(C2)CC3)=C1 MSGNEVBGFWYKGM-KRWDZBQOSA-N 0.000 claims description 2
- UCMSCKUCBHWGGD-KRWDZBQOSA-N [2-amino-6-[4-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]oxy]phenyl]-1,3-benzothiazol-4-yl] thiocyanate Chemical compound C1N(CC2)CCC2[C@H]1OC(C=C1)=CC=C1C1=CC(SC#N)=C2N=C(N)SC2=C1 UCMSCKUCBHWGGD-KRWDZBQOSA-N 0.000 claims description 2
- 208000000509 infertility Diseases 0.000 claims description 2
- 230000036512 infertility Effects 0.000 claims description 2
- 231100000535 infertility Toxicity 0.000 claims description 2
- FOCQNTNWTGIHSZ-UHFFFAOYSA-N n-[4-(3-methyl-2h-indazol-5-yl)phenyl]-1-azabicyclo[2.2.2]octan-3-amine Chemical compound C1N(CC2)CCC2C1NC(C=C1)=CC=C1C1=CC=C2NN=C(C)C2=C1 FOCQNTNWTGIHSZ-UHFFFAOYSA-N 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 4
- AISLHDKYJVYDRH-SFHVURJKSA-N 5-[2-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]oxy]pyrimidin-5-yl]-2-ethyl-1,3-benzoxazole Chemical compound C1N(CC2)CCC2[C@H]1OC(N=C1)=NC=C1C1=CC=C(OC(CC)=N2)C2=C1 AISLHDKYJVYDRH-SFHVURJKSA-N 0.000 claims 1
- AFDHPNZUBQZHGV-SFHVURJKSA-N 5-[2-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]oxy]pyrimidin-5-yl]-2-methyl-1,3-benzoxazole Chemical compound C1N(CC2)CCC2[C@H]1OC(N=C1)=NC=C1C1=CC=C(OC(C)=N2)C2=C1 AFDHPNZUBQZHGV-SFHVURJKSA-N 0.000 claims 1
- PQNZDACRFIZDAW-SFHVURJKSA-N 5-[6-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]oxy]pyridazin-3-yl]-3-bromo-1h-indole Chemical compound C1N(CC2)CCC2[C@H]1OC(N=N1)=CC=C1C1=CC=C2NC=C(Br)C2=C1 PQNZDACRFIZDAW-SFHVURJKSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 71
- 239000003446 ligand Substances 0.000 abstract description 22
- 102000015296 acetylcholine-gated cation-selective channel activity proteins Human genes 0.000 abstract description 19
- 108040006409 acetylcholine-gated cation-selective channel activity proteins Proteins 0.000 abstract description 19
- 230000001668 ameliorated effect Effects 0.000 abstract description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 275
- 239000000047 product Substances 0.000 description 138
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 131
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 117
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 108
- 239000007787 solid Substances 0.000 description 106
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 100
- -1 2,2-dimethyl-1-oxopropyl Chemical group 0.000 description 96
- 229910001868 water Inorganic materials 0.000 description 90
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 69
- 235000019439 ethyl acetate Nutrition 0.000 description 53
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 49
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 45
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 40
- 229910052681 coesite Inorganic materials 0.000 description 38
- 229910052906 cristobalite Inorganic materials 0.000 description 38
- 229910052682 stishovite Inorganic materials 0.000 description 38
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 38
- 229910052905 tridymite Inorganic materials 0.000 description 38
- 239000002904 solvent Substances 0.000 description 36
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 35
- 238000004587 chromatography analysis Methods 0.000 description 34
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 33
- 239000000243 solution Substances 0.000 description 33
- 229910052718 tin Inorganic materials 0.000 description 31
- 238000006243 chemical reaction Methods 0.000 description 30
- 238000002953 preparative HPLC Methods 0.000 description 27
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical group [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 25
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 24
- 239000003054 catalyst Substances 0.000 description 23
- 229910052763 palladium Inorganic materials 0.000 description 23
- 239000002253 acid Substances 0.000 description 22
- 235000011087 fumaric acid Nutrition 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 229910052796 boron Inorganic materials 0.000 description 21
- 102000005962 receptors Human genes 0.000 description 21
- 108020003175 receptors Proteins 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 20
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 20
- 230000002829 reductive effect Effects 0.000 description 19
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Substances CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 19
- CCRMAATUKBYMPA-UHFFFAOYSA-N trimethyltin Chemical compound C[Sn](C)C.C[Sn](C)C CCRMAATUKBYMPA-UHFFFAOYSA-N 0.000 description 19
- 125000003545 alkoxy group Chemical group 0.000 description 18
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical group I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
- 230000027455 binding Effects 0.000 description 17
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 17
- 229910004373 HOAc Inorganic materials 0.000 description 16
- 239000000126 substance Substances 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 239000001530 fumaric acid Substances 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 14
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 14
- 239000012267 brine Substances 0.000 description 14
- 150000001649 bromium compounds Chemical group 0.000 description 14
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 14
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 13
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 12
- 150000004820 halides Chemical class 0.000 description 12
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 11
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 11
- ZOCHARZZJNPSEU-UHFFFAOYSA-N diboron Chemical compound B#B ZOCHARZZJNPSEU-UHFFFAOYSA-N 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- WYBQOWXCLDXZNR-UHFFFAOYSA-N 2-(1,3,2-benzodioxaborol-2-yl)-1,3,2-benzodioxaborole Chemical compound O1C2=CC=CC=C2OB1B1OC2=CC=CC=C2O1 WYBQOWXCLDXZNR-UHFFFAOYSA-N 0.000 description 10
- 238000006555 catalytic reaction Methods 0.000 description 10
- 235000019441 ethanol Nutrition 0.000 description 10
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 10
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical class C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 10
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 10
- VHADYSUJZAPXOW-UHFFFAOYSA-N 1h-indol-5-ylboronic acid Chemical compound OB(O)C1=CC=C2NC=CC2=C1 VHADYSUJZAPXOW-UHFFFAOYSA-N 0.000 description 9
- IVLICPVPXWEGCA-UHFFFAOYSA-N 3-quinuclidinol Chemical compound C1C[C@@H]2C(O)C[N@]1CC2 IVLICPVPXWEGCA-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 101001047090 Homo sapiens Potassium voltage-gated channel subfamily H member 2 Proteins 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 9
- 229910052794 bromium Inorganic materials 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 9
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 9
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 8
- 102100022807 Potassium voltage-gated channel subfamily H member 2 Human genes 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- 230000009286 beneficial effect Effects 0.000 description 8
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 239000002502 liposome Substances 0.000 description 8
- CPRRHERYRRXBRZ-SRVKXCTJSA-N methyl n-[(2s)-1-[[(2s)-1-hydroxy-3-[(3s)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate Chemical compound COC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)C[C@@H]1CCNC1=O CPRRHERYRRXBRZ-SRVKXCTJSA-N 0.000 description 8
- 229960002715 nicotine Drugs 0.000 description 8
- 231100000252 nontoxic Toxicity 0.000 description 8
- 230000003000 nontoxic effect Effects 0.000 description 8
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 7
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 125000001072 heteroaryl group Chemical group 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 7
- 238000004809 thin layer chromatography Methods 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 229910000024 caesium carbonate Inorganic materials 0.000 description 6
- 229910052801 chlorine Inorganic materials 0.000 description 6
- 230000002526 effect on cardiovascular system Effects 0.000 description 6
- ANJTVLIZGCUXLD-UHFFFAOYSA-N ent-cytisine Natural products C1NCC2CN3C(=O)C=CC=C3C1C2 ANJTVLIZGCUXLD-UHFFFAOYSA-N 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- REUAXQZIRFXQML-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-amine Chemical compound C1CC2C(N)CN1CC2 REUAXQZIRFXQML-UHFFFAOYSA-N 0.000 description 5
- ZKMZPXWMMSBLNO-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-one Chemical compound C1CC2C(=O)CN1CC2 ZKMZPXWMMSBLNO-UHFFFAOYSA-N 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- 101150041968 CDC13 gene Proteins 0.000 description 5
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- YNHIGQDRGKUECZ-UHFFFAOYSA-L PdCl2(PPh3)2 Substances [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 5
- 125000005083 alkoxyalkoxy group Chemical group 0.000 description 5
- 125000005138 alkoxysulfonyl group Chemical group 0.000 description 5
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 5
- 125000000304 alkynyl group Chemical group 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 125000004438 haloalkoxy group Chemical group 0.000 description 5
- 125000001188 haloalkyl group Chemical group 0.000 description 5
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000001537 neural effect Effects 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 229910052725 zinc Inorganic materials 0.000 description 5
- 239000011701 zinc Substances 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 4
- 125000004414 alkyl thio group Chemical group 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 125000002843 carboxylic acid group Chemical group 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000007278 cognition impairment Effects 0.000 description 4
- 230000003920 cognitive function Effects 0.000 description 4
- 230000006735 deficit Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- 229910052727 yttrium Inorganic materials 0.000 description 4
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
- DIKFUZHWPMJLIM-UHFFFAOYSA-N 1-oxido-1-azoniabicyclo[2.2.2]octane;potassium Chemical compound [K].C1CC2CC[N+]1([O-])CC2 DIKFUZHWPMJLIM-UHFFFAOYSA-N 0.000 description 3
- BZYQYFBFBXSMHK-UHFFFAOYSA-N 2-chloro-1-azabicyclo[2.2.2]octane Chemical compound C1CN2C(Cl)CC1CC2 BZYQYFBFBXSMHK-UHFFFAOYSA-N 0.000 description 3
- CLXGESVVZOJONY-UHFFFAOYSA-N 3-(6-chloropyridazin-3-yl)-1h-indole Chemical compound N1=NC(Cl)=CC=C1C1=CNC2=CC=CC=C12 CLXGESVVZOJONY-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 239000005909 Kieselgur Substances 0.000 description 3
- 229910002666 PdCl2 Inorganic materials 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- 239000012445 acidic reagent Substances 0.000 description 3
- 125000004423 acyloxy group Chemical group 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 125000000676 alkoxyimino group Chemical group 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 235000012216 bentonite Nutrition 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 235000011148 calcium chloride Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000002274 desiccant Substances 0.000 description 3
- LCSNDSFWVKMJCT-UHFFFAOYSA-N dicyclohexyl-(2-phenylphenyl)phosphane Chemical group C1CCCCC1P(C=1C(=CC=CC=1)C=1C=CC=CC=1)C1CCCCC1 LCSNDSFWVKMJCT-UHFFFAOYSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 230000013016 learning Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000015654 memory Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 3
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 3
- 150000003335 secondary amines Chemical class 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000005309 thioalkoxy group Chemical group 0.000 description 3
- 125000003396 thiol group Chemical class [H]S* 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 235000010487 tragacanth Nutrition 0.000 description 3
- 239000000196 tragacanth Substances 0.000 description 3
- 229940116362 tragacanth Drugs 0.000 description 3
- BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- GUSWJGOYDXFJSI-UHFFFAOYSA-N 3,6-dichloropyridazine Chemical compound ClC1=CC=C(Cl)N=N1 GUSWJGOYDXFJSI-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 2
- ZEZKXPQIDURFKA-UHFFFAOYSA-N 5-bromo-2-iodopyrimidine Chemical compound BrC1=CN=C(I)N=C1 ZEZKXPQIDURFKA-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 102000020897 Formins Human genes 0.000 description 2
- 108091022623 Formins Proteins 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 108090000862 Ion Channels Proteins 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- AHKAOMZZTQULDS-ZDUSSCGKSA-N [(3r)-1-azabicyclo[2.2.2]octan-3-yl] benzoate Chemical compound O([C@@H]1C2CCN(CC2)C1)C(=O)C1=CC=CC=C1 AHKAOMZZTQULDS-ZDUSSCGKSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000030120 acrosome reaction Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical compound C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000031709 bromination Effects 0.000 description 2
- 238000005893 bromination reaction Methods 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 229940027564 cytisine Drugs 0.000 description 2
- 125000005265 dialkylamine group Chemical group 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 239000003885 eye ointment Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- QNLOWBMKUIXCOW-UHFFFAOYSA-N indol-2-one Chemical compound C1=CC=CC2=NC(=O)C=C21 QNLOWBMKUIXCOW-UHFFFAOYSA-N 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- IBIKHMZPHNKTHM-RDTXWAMCSA-N merck compound 25 Chemical compound C1C[C@@H](C(O)=O)[C@H](O)CN1C(C1=C(F)C=CC=C11)=NN1C(=O)C1=C(Cl)C=CC=C1C1CC1 IBIKHMZPHNKTHM-RDTXWAMCSA-N 0.000 description 2
- XLTANAWLDBYGFU-VTLKBQQISA-N methyllycaconitine Chemical compound C([C@]12CN([C@@H]3[C@@]4(O)[C@]5(O)[C@H]6[C@@H](OC)[C@@H]([C@H](C5)OC)C[C@H]6[C@@]3([C@@H]1[C@@H]4OC)[C@@H](OC)CC2)CC)OC(=O)C1=CC=CC=C1N1C(=O)C[C@H](C)C1=O XLTANAWLDBYGFU-VTLKBQQISA-N 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- WWECJGLXBSQKRF-UHFFFAOYSA-N n,n-dimethylformamide;methanol Chemical compound OC.CN(C)C=O WWECJGLXBSQKRF-UHFFFAOYSA-N 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- 239000004031 partial agonist Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 2
- UFUASNAHBMBJIX-UHFFFAOYSA-N propan-1-one Chemical group CC[C]=O UFUASNAHBMBJIX-UHFFFAOYSA-N 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 2
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 102220044643 rs587781450 Human genes 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 239000003206 sterilizing agent Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 238000011285 therapeutic regimen Methods 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 238000003828 vacuum filtration Methods 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- TZDSNITXVKXHKC-MGVJIHIJSA-N (2S)-2-amino-3-methylbutanoic acid (E)-but-2-enedioic acid Chemical compound CC(C)[C@H](N)C(O)=O.OC(=O)\C=C\C(O)=O TZDSNITXVKXHKC-MGVJIHIJSA-N 0.000 description 1
- IVLICPVPXWEGCA-ZETCQYMHSA-N (3r)-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C1CC2[C@@H](O)CN1CC2 IVLICPVPXWEGCA-ZETCQYMHSA-N 0.000 description 1
- OYEJRVVBERZWPD-FJXQXJEOSA-N (3r)-1-azabicyclo[2.2.2]octan-3-ol;hydrochloride Chemical compound Cl.C1CC2[C@@H](O)CN1CC2 OYEJRVVBERZWPD-FJXQXJEOSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 229930182840 (S)-nicotine Natural products 0.000 description 1
- SKJFTWMIXZFOBU-WLHGVMLRSA-N (e)-but-2-enedioic acid;1h-indole Chemical compound OC(=O)\C=C\C(O)=O.C1=CC=C2NC=CC2=C1 SKJFTWMIXZFOBU-WLHGVMLRSA-N 0.000 description 1
- NDQXKKFRNOPRDW-UHFFFAOYSA-N 1,1,1-triethoxyethane Chemical compound CCOC(C)(OCC)OCC NDQXKKFRNOPRDW-UHFFFAOYSA-N 0.000 description 1
- FGWYWKIOMUZSQF-UHFFFAOYSA-N 1,1,1-triethoxypropane Chemical compound CCOC(CC)(OCC)OCC FGWYWKIOMUZSQF-UHFFFAOYSA-N 0.000 description 1
- FIARMZDBEGVMLV-UHFFFAOYSA-N 1,1,2,2,2-pentafluoroethanolate Chemical group [O-]C(F)(F)C(F)(F)F FIARMZDBEGVMLV-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- LFMWZTSOMGDDJU-UHFFFAOYSA-N 1,4-diiodobenzene Chemical compound IC1=CC=C(I)C=C1 LFMWZTSOMGDDJU-UHFFFAOYSA-N 0.000 description 1
- YEDVRRNLTGKJSW-UHFFFAOYSA-N 1-(4-iodophenyl)-4-nitrobenzene Chemical group C1=CC([N+](=O)[O-])=CC=C1C1=CC=C(I)C=C1 YEDVRRNLTGKJSW-UHFFFAOYSA-N 0.000 description 1
- RFDPHKHXPMDJJD-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-one;hydron;chloride Chemical compound Cl.C1CC2C(=O)CN1CC2 RFDPHKHXPMDJJD-UHFFFAOYSA-N 0.000 description 1
- AHKAOMZZTQULDS-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl benzoate Chemical compound C1N(CC2)CCC2C1OC(=O)C1=CC=CC=C1 AHKAOMZZTQULDS-UHFFFAOYSA-N 0.000 description 1
- UCCUXODGPMAHRL-UHFFFAOYSA-N 1-bromo-4-iodobenzene Chemical compound BrC1=CC=C(I)C=C1 UCCUXODGPMAHRL-UHFFFAOYSA-N 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- QXQAPNSHUJORMC-UHFFFAOYSA-N 1-chloro-4-propylbenzene Chemical compound CCCC1=CC=C(Cl)C=C1 QXQAPNSHUJORMC-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
- WLXGQMVCYPUOLM-UHFFFAOYSA-N 1-hydroxyethanesulfonic acid Chemical compound CC(O)S(O)(=O)=O WLXGQMVCYPUOLM-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- JDIIGWSSTNUWGK-UHFFFAOYSA-N 1h-imidazol-3-ium;chloride Chemical compound [Cl-].[NH2+]1C=CN=C1 JDIIGWSSTNUWGK-UHFFFAOYSA-N 0.000 description 1
- OMPMADRXWAHDGV-UHFFFAOYSA-N 2,2,2-trifluoro-n-(2-iodophenyl)acetamide Chemical compound FC(F)(F)C(=O)NC1=CC=CC=C1I OMPMADRXWAHDGV-UHFFFAOYSA-N 0.000 description 1
- HVHZEKKZMFRULH-UHFFFAOYSA-N 2,6-ditert-butyl-4-methylpyridine Chemical compound CC1=CC(C(C)(C)C)=NC(C(C)(C)C)=C1 HVHZEKKZMFRULH-UHFFFAOYSA-N 0.000 description 1
- DPZHKLJPVMYFCU-UHFFFAOYSA-N 2-(5-bromopyridin-2-yl)acetonitrile Chemical compound BrC1=CC=C(CC#N)N=C1 DPZHKLJPVMYFCU-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- FNRMMDCDHWCQTH-UHFFFAOYSA-N 2-chloropyridine;3-chloropyridine;4-chloropyridine Chemical compound ClC1=CC=NC=C1.ClC1=CC=CN=C1.ClC1=CC=CC=N1 FNRMMDCDHWCQTH-UHFFFAOYSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- JADVVTZXHQUFLS-UHFFFAOYSA-N 3,4-dichloropyridazine Chemical compound ClC1=CC=NN=C1Cl JADVVTZXHQUFLS-UHFFFAOYSA-N 0.000 description 1
- CDDNLMGOLYMTSF-UHFFFAOYSA-N 3-(4-bromophenyl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound C1=CC(Br)=CC=C1C1=NNC(=O)CC1 CDDNLMGOLYMTSF-UHFFFAOYSA-N 0.000 description 1
- CVKKRHPPVAUDMV-UHFFFAOYSA-N 3-(4-bromophenyl)-4,5-dihydro-1h-pyridazin-6-one;4-(4-bromophenyl)-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)C1=CC=C(Br)C=C1.C1=CC(Br)=CC=C1C1=NNC(=O)CC1 CVKKRHPPVAUDMV-UHFFFAOYSA-N 0.000 description 1
- AIOVQWFBJVWQHC-UHFFFAOYSA-N 3-(4-bromophenyl)-6-chloropyridazine Chemical compound N1=NC(Cl)=CC=C1C1=CC=C(Br)C=C1 AIOVQWFBJVWQHC-UHFFFAOYSA-N 0.000 description 1
- YUMBULSFBAGLKM-UHFFFAOYSA-N 3-(4-ethynylphenoxy)-1-azabicyclo[2.2.2]octane Chemical compound C1=CC(C#C)=CC=C1OC1C(CC2)CCN2C1 YUMBULSFBAGLKM-UHFFFAOYSA-N 0.000 description 1
- LTBWKAYPXIIVPC-UHFFFAOYSA-N 3-bromo-9h-carbazole Chemical compound C1=CC=C2C3=CC(Br)=CC=C3NC2=C1 LTBWKAYPXIIVPC-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- NOLVABYTFMDREN-UHFFFAOYSA-N 3-chloro-1-azabicyclo[2.2.2]octane Chemical compound C1CC2C(Cl)CN1CC2 NOLVABYTFMDREN-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- ZBUVLTNGYVADFR-UHFFFAOYSA-N 3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-indole Chemical compound C1=C2C(C)=CNC2=CC=C1B1OC(C)(C)C(C)(C)O1 ZBUVLTNGYVADFR-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- QDCIXBBEUHMLDN-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-indole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=CC2=C1C=CN2 QDCIXBBEUHMLDN-UHFFFAOYSA-N 0.000 description 1
- GRJZJFUBQYULKL-UHFFFAOYSA-N 4-bromo-1h-indole Chemical compound BrC1=CC=CC2=C1C=CN2 GRJZJFUBQYULKL-UHFFFAOYSA-N 0.000 description 1
- QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 1
- BBZKICVNEYBDPK-UHFFFAOYSA-N 4-bromo-2-nitroaniline;tert-butyl n-(4-bromo-2-nitrophenyl)carbamate Chemical compound NC1=CC=C(Br)C=C1[N+]([O-])=O.CC(C)(C)OC(=O)NC1=CC=C(Br)C=C1[N+]([O-])=O BBZKICVNEYBDPK-UHFFFAOYSA-N 0.000 description 1
- WIKVMGUXAJMVEK-UHFFFAOYSA-N 4-bromo-2-nitrophenol;4-bromo-2-nitro-1-phenylmethoxybenzene Chemical compound OC1=CC=C(Br)C=C1[N+]([O-])=O.[O-][N+](=O)C1=CC(Br)=CC=C1OCC1=CC=CC=C1 WIKVMGUXAJMVEK-UHFFFAOYSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
- VLVCDUSVTXIWGW-UHFFFAOYSA-N 4-iodoaniline Chemical compound NC1=CC=C(I)C=C1 VLVCDUSVTXIWGW-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- VIMNAEVMZXIKFL-UHFFFAOYSA-N 5-bromo-1,3-dihydroindol-2-one Chemical compound BrC1=CC=C2NC(=O)CC2=C1 VIMNAEVMZXIKFL-UHFFFAOYSA-N 0.000 description 1
- GDQXDVJFMLNXHX-UHFFFAOYSA-N 5-bromo-3-methyl-1h-indole Chemical compound C1=C(Br)C=C2C(C)=CNC2=C1 GDQXDVJFMLNXHX-UHFFFAOYSA-N 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- MAWGHOPSCKCTPA-UHFFFAOYSA-N 6-bromo-1h-indole Chemical compound BrC1=CC=C2C=CNC2=C1 MAWGHOPSCKCTPA-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- DIXFDYXDUXOMAT-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1N=C(C2=CC(=CC=C12)Br)C.C(C)(C)(C)OC(=O)N1N=C(C2=CC(=CC=C12)[Sn](C)(C)C)C Chemical compound C(C)(C)(C)OC(=O)N1N=C(C2=CC(=CC=C12)Br)C.C(C)(C)(C)OC(=O)N1N=C(C2=CC(=CC=C12)[Sn](C)(C)C)C DIXFDYXDUXOMAT-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000009660 Cholinergic Receptors Human genes 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 229910017852 NH2NH2 Inorganic materials 0.000 description 1
- 229910017974 NH40H Inorganic materials 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 101100451954 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HXT1 gene Proteins 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- AHKAOMZZTQULDS-CYBMUJFWSA-N [(3s)-1-azabicyclo[2.2.2]octan-3-yl] benzoate Chemical compound O([C@H]1C2CCN(CC2)C1)C(=O)C1=CC=CC=C1 AHKAOMZZTQULDS-CYBMUJFWSA-N 0.000 description 1
- XLTANAWLDBYGFU-LSVDIXQKSA-N [3h]-mla Chemical compound C([C@]12[C@H]3[C@H](OC)[C@]4([C@]5(O)[C@H]6[C@@H](OC)[C@@H]([C@H](C5)OC)C[C@H]6[C@]3([C@@H]4N(CC)C2)[C@@H](OC)CC1)O)OC(=O)C=1C([3H])=CC=CC=1N1C(=O)C[C@H](C)C1=O XLTANAWLDBYGFU-LSVDIXQKSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000001343 alkyl silanes Chemical group 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- NWCHELUCVWSRRS-UHFFFAOYSA-N atrolactic acid Chemical compound OC(=O)C(O)(C)C1=CC=CC=C1 NWCHELUCVWSRRS-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- HSEVGTNHODLPRX-LREBCSMRSA-N benzoic acid (2R,3R)-2,3-dihydroxybutanedioic acid Chemical compound C(=O)(O)[C@H](O)[C@@H](O)C(=O)O.C(C1=CC=CC=C1)(=O)O HSEVGTNHODLPRX-LREBCSMRSA-N 0.000 description 1
- HSEVGTNHODLPRX-WUUYCOTASA-N benzoic acid (2S,3S)-2,3-dihydroxybutanedioic acid Chemical compound C(=O)(O)[C@@H](O)[C@H](O)C(=O)O.C(C1=CC=CC=C1)(=O)O HSEVGTNHODLPRX-WUUYCOTASA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 229940045348 brown mixture Drugs 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- USVZFSNDGFNNJT-UHFFFAOYSA-N cyclopenta-1,4-dien-1-yl(diphenyl)phosphane (2,3-dichlorocyclopenta-1,4-dien-1-yl)-diphenylphosphane iron(2+) Chemical compound [Fe++].c1cc[c-](c1)P(c1ccccc1)c1ccccc1.Clc1c(cc[c-]1Cl)P(c1ccccc1)c1ccccc1 USVZFSNDGFNNJT-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- BSHICDXRSZQYBP-UHFFFAOYSA-N dichloromethane;palladium(2+) Chemical compound [Pd+2].ClCCl BSHICDXRSZQYBP-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- SXZIXHOMFPUIRK-UHFFFAOYSA-N diphenylmethanimine Chemical compound C=1C=CC=CC=1C(=N)C1=CC=CC=C1 SXZIXHOMFPUIRK-UHFFFAOYSA-N 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960002994 dofetilide Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 238000010575 fractional recrystallization Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 125000005059 halophenyl group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 229960003162 iloperidone Drugs 0.000 description 1
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 229910003480 inorganic solid Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940125425 inverse agonist Drugs 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- XJTQJERLRPWUGL-UHFFFAOYSA-N iodomethylbenzene Chemical compound ICC1=CC=CC=C1 XJTQJERLRPWUGL-UHFFFAOYSA-N 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 description 1
- KCMMJPYCTNJPQN-UHFFFAOYSA-N n-(2-ethynylphenyl)-2,2,2-trifluoroacetamide Chemical compound FC(F)(F)C(=O)NC1=CC=CC=C1C#C KCMMJPYCTNJPQN-UHFFFAOYSA-N 0.000 description 1
- ANGKVUVZQVUVJO-UHFFFAOYSA-N n-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1B1OC(C)(C)C(C)(C)O1 ANGKVUVZQVUVJO-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 125000006678 phenoxycarbonyl group Chemical group 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002336 repolarization Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003334 secondary amides Chemical class 0.000 description 1
- 230000009151 sensory gating Effects 0.000 description 1
- 230000031893 sensory processing Effects 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
- FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- BQFPCTXLBRVFJL-UHFFFAOYSA-N triethoxymethylbenzene Chemical compound CCOC(OCC)(OCC)C1=CC=CC=C1 BQFPCTXLBRVFJL-UHFFFAOYSA-N 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
- XWNXEWLCHSLQOI-UHFFFAOYSA-K trisodium;triacetate Chemical compound [Na+].[Na+].[Na+].CC([O-])=O.CC([O-])=O.CC([O-])=O XWNXEWLCHSLQOI-UHFFFAOYSA-K 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- 229960000607 ziprasidone Drugs 0.000 description 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 1
- HDOZVRUNCMBHFH-UHFFFAOYSA-N zotepine Chemical compound CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12 HDOZVRUNCMBHFH-UHFFFAOYSA-N 0.000 description 1
- 229960004496 zotepine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compounds of formula (I) wherein n is 0, 1, or 2; A is N or N+-O-; X is O, S, -NH-, and -N-alkyl-; Ar1 is a 6-membered aromatic ring; and Ar2 is a fused bicycloheterocycle. The compounds are useful in treating conditions or disorders prevented by or ameliorated by a7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.
Description
FUSED BICYCLOHETEROCYCLE SUBSTITUTED
QUINUCLIDINE DERIVATIVES
Technical Field The invention relates to fused bicycloheterocycle substituted quinuclidine s derivatives, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.
Description of Related Technology Nicotinic acetylcholine receptors (nAChRs) are widely distributed throughout the central (CNS) and peripheral (PNS) nervous systems. Such receptors play an important role in regulating CNS function, particularly by modulating release of a wide range of neurotransmitters, including, but not necessarily limited to acetylcholine, norepinephrine, dopamine, serotonin and GABA. Consequently, nicotinic receptors mediate a very wide range of physiological effects, and have been 15 targeted for therapeutic treatment of disorders relating to cognitive function, learning and memory, neurodegeneration, pain and inflammation, psychosis and sensory gating, mood and emotion, among others.
Many subtypes of the nAChR exist in the CNS and periphery. Each subtype has a different effect on regulating the overall physiological function.
2o Typically, nAChRs are ion channels that are constructed from a pentameric assembly of subunit proteins. At least 12 subunit proteins, a2-a10 and ~i2-~4, have been identified in neuronal tissue. These subunits provide for a great variety of homomeric and heteromeric combinations that account for the diverse receptor subtypes. For example, the predominant receptor that is responsible for high affinity 25 binding of nicotine in brain tissue has composition (a4)2(~i2)3 (the a4~2 subtype), while another major population of receptors is comprised of the homomeric (a7)5 (the a7 subtype).
Certain compounds, like the plant alkaloid nicotine, interact with all subtypes of the nAChRs, accounting for the profound physiological effects of this compound.
While nicotine has been demonstrated to have many beneficial properties, not all of the effects mediated by nicotine are desirable. For example, nicotine exerts gastrointestinal and cardiovascular side effects that interfere at therapeutic doses, and its addictive nature and acute toxicity are well-known. Ligands that are selective for interaction with only certain subtypes of the nAChR offer potential for achieving beneficial therapeutic effects with an improved margin for safety.
The a7 nAChRs have been shown to play a significant role in enhancing cognitive function, including aspects of learning, memory and attention (Levin, E.D., J. Neurobiol. 53: 633-640, 2002). For example, a7 nAChRs have been linked to conditions and disorders related to attention deficit disorder, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, dementia associated with Lewy bodies, dementia associated with Down's syndrome, AIDS dementia, Pick's Disease, as well as cognitive deficits associated with schizophrenia, among other systemic activities.
The activity at the a7 nAChRs can be modified or regulated by the administration of a7 nAChR ligands. The ligands can exhibit antagonist, agonist, partial agonist, or inverse agonist properties. Thus, a7 ligands have potential in treatment of various 2o cognitive disorders.
Although various classes of compounds demonstrating a7 nAChR-modulating activity exist, it would be beneficial to provide additional compounds demonstrating activity at the a7 nAChRs that can be incorporated into pharmaceutical compositions useful for therapeutic methods. Specifically, it would be beneficial to provide 2s compounds that interact selectively with a7-containing neuronal nAChRs compared to other subtypes.
SUMMARY OF THE INVENTION
The invention is directed to fused bicycloheterocycle substituted quinuclidine 3o compounds as well as compositions comprising such compounds, and method of using the same. Compounds of the invention have the formula:
QUINUCLIDINE DERIVATIVES
Technical Field The invention relates to fused bicycloheterocycle substituted quinuclidine s derivatives, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.
Description of Related Technology Nicotinic acetylcholine receptors (nAChRs) are widely distributed throughout the central (CNS) and peripheral (PNS) nervous systems. Such receptors play an important role in regulating CNS function, particularly by modulating release of a wide range of neurotransmitters, including, but not necessarily limited to acetylcholine, norepinephrine, dopamine, serotonin and GABA. Consequently, nicotinic receptors mediate a very wide range of physiological effects, and have been 15 targeted for therapeutic treatment of disorders relating to cognitive function, learning and memory, neurodegeneration, pain and inflammation, psychosis and sensory gating, mood and emotion, among others.
Many subtypes of the nAChR exist in the CNS and periphery. Each subtype has a different effect on regulating the overall physiological function.
2o Typically, nAChRs are ion channels that are constructed from a pentameric assembly of subunit proteins. At least 12 subunit proteins, a2-a10 and ~i2-~4, have been identified in neuronal tissue. These subunits provide for a great variety of homomeric and heteromeric combinations that account for the diverse receptor subtypes. For example, the predominant receptor that is responsible for high affinity 25 binding of nicotine in brain tissue has composition (a4)2(~i2)3 (the a4~2 subtype), while another major population of receptors is comprised of the homomeric (a7)5 (the a7 subtype).
Certain compounds, like the plant alkaloid nicotine, interact with all subtypes of the nAChRs, accounting for the profound physiological effects of this compound.
While nicotine has been demonstrated to have many beneficial properties, not all of the effects mediated by nicotine are desirable. For example, nicotine exerts gastrointestinal and cardiovascular side effects that interfere at therapeutic doses, and its addictive nature and acute toxicity are well-known. Ligands that are selective for interaction with only certain subtypes of the nAChR offer potential for achieving beneficial therapeutic effects with an improved margin for safety.
The a7 nAChRs have been shown to play a significant role in enhancing cognitive function, including aspects of learning, memory and attention (Levin, E.D., J. Neurobiol. 53: 633-640, 2002). For example, a7 nAChRs have been linked to conditions and disorders related to attention deficit disorder, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, dementia associated with Lewy bodies, dementia associated with Down's syndrome, AIDS dementia, Pick's Disease, as well as cognitive deficits associated with schizophrenia, among other systemic activities.
The activity at the a7 nAChRs can be modified or regulated by the administration of a7 nAChR ligands. The ligands can exhibit antagonist, agonist, partial agonist, or inverse agonist properties. Thus, a7 ligands have potential in treatment of various 2o cognitive disorders.
Although various classes of compounds demonstrating a7 nAChR-modulating activity exist, it would be beneficial to provide additional compounds demonstrating activity at the a7 nAChRs that can be incorporated into pharmaceutical compositions useful for therapeutic methods. Specifically, it would be beneficial to provide 2s compounds that interact selectively with a7-containing neuronal nAChRs compared to other subtypes.
SUMMARY OF THE INVENTION
The invention is directed to fused bicycloheterocycle substituted quinuclidine 3o compounds as well as compositions comprising such compounds, and method of using the same. Compounds of the invention have the formula:
X Are-Ar2 ~n A
or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, wherein:
n is 0, 1, or 2;
A is N or N+-O-;
s .X is selected from the group consisting of O, S, and -N(R')-;
Ar' is a 6-membered aromatic ring containing 0, 1, 2, 3, or 4 nitrogen atoms, wherein Ar' is substituted with 0, 1, 2, 3, or 4 alkyl groups;
Arz is a group of the formula:
,<
z,3,z ~z,s ZS Y~ \ z9 //
Y\Y ZI / I ~Y2a Z~ ~~ ~ ~ Z
Z ~ ~ Ys 2 Z ~Z8 Y a Z"\Z,z N~ a R
~b~ , Or Z', Zz, Z3, and Z4 are independently selected from the group consisting of C
and -C(R3b); provided that zero or one of Z', Zz, Z3, and Z4 is C;
Z5, Z6, Z', and Z$ are independently selected from the group consisting of C
and -C(R3b); provided that zero or one of Z5, Z6, Z', and Z8 is C;
Zs~ Z~o~ Z11~ Z~z~ Z13~ Z14~ Z15~ and Z'6 are independently selected from the 15 group consisting of C and -C(R3~); provided that one of Z9, Z'°, Z", Z'z, Z'3, Z'4, Z'5, and Z'6 is C and the group of formula (c) is attached to Ar' through the C
atom;
Y' at each occurrence is independently selected from the group consisting of O, S, -N(Rz), -C(R3), and -C(R3)(R3a);
Yz is selected from the group consisting of -N(Rz), C(=O), -C(R3), and 20 -C(R3)(R3a);
Y3 is selected from the group consisting of -N(Rz), -C(R3), and -C(R3)(R3a); provided that zero or one of Y', Y2, and Y3 is -C(R3) in a group of formula (a);
wherein when one of Y', Y2, and Y3 is -C(R3) in a group of formula (a), then Z', Z2, Z3, and Z4 are each -C(R3b) and the group of formula (a) is attached to Ar' s through the C atom of -C(R3) of Y', Y2, or Y3; and also when one of Z', Z2, Z3, and Z4 is C, then Y', Y2 and Y3 are other than -C(R3) and the group of formula (a) is attached to Ar' through the C atom of Z', ZZ, Z3, or Z4;
Y2a and Y3a are independently selected from the group consisting of N, C and -C(R3a); provided that when Y' is -C(R3) in a group of formula (b), Y2a and Y3a are selected from the group consisting of N and -C(R3a), and when one of Y2a and Y3a is C, then Y' in a group of formula (b) is O, S, -N(R2), or-C(R3)(R3a);
wherein when one of Z5, Z6, Z', and Z$ is C, then Y' in a group of formula (b) is selected from the group consisting of O, S, -N(R2), and -C(R3)(R3a); Y2a and Y3a are each independently selected from the group consisting of N and -C(R3a);
and the 15 group of formula (b) is attached to Ar' through the C of Z5, Z6, Z', or Z$
; and also wherein when Y' in a group of formula (b) is -C(R3) or one of Y2a and Y3a is C, then Z5, Z6, Z', and Z$ are each -C(R3b) and the group of formula (b) is attached to Ar' through the C atom of-C(R3) of Y' in the group of formula (b) or through the C
atom of Y2a or Y3a;
2o R' and R2 at each occurrence are each independently selected from the group consisting of hydrogen and alkyl;
R3 and R3a at each occurrence are each independently selected from the group consisting of hydrogen, halogen, alkyl, aryl, -OR4, -NR5R6, -alkyl-OR4, and -alkyl-NR5R6;
25 R3b and R3~ at each occurrence are each independently selected from the group consisting of hydrogen, halogen, alkyl, aryl, -OR4, -NR5R6, -alkyl-OR4, -alkyl-NR5R6, and -SCN;
R4 is selected from the group consisting of hydrogen, alkyl, aryl, alkylcarbonyl, and arylcarbonyl;
3o R5 and R6 at each occurrence are each independently selected from the group consisting of hydrogen, alkyl, aryl, alkylcarbonyl, alkoxycarbonyl, aryloxycarbonyl, and arylcarbonyl, provided that at least one of R5 and R6 is hydrogen or alkyl; and R8 is selected from the group consisting of hydrogen and alkyl.
Another aspect of the invention relates to pharmaceutical compositions comprising compounds of the invention. Such compositions can be administered in accordance with a method of the invention, typically as part of a therapeutic regimen for treatment or prevention of conditions and disorders related to nAChR
activity, and more particularly a7 nAChR activity.
Yet another aspect of the invention relates to a method of selectively modulating to nAChR activity, for example a7 nAChR activity. The method is useful for treating and/or preventing conditions and disorders related to a7 nAChR
activity modulation in mammals. More particularly, the method is useful for conditions and disorders related to attention deficit disorder, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS
15 dementia, Pick's Disease, dementia associated with Lewy bodies, dementia associated with Down's syndrome, amyotrophic lateral sclerosis, Huntington's disease, diminished CNS function associated with traumatic brain injury, acute pain, post-surgical pain, chronic pain, inflammatory pain, neuropathic pain, infertility, need for new blood vessel growth associated with wound healing, need for new blood 2o vessel growth associated with vascularization of skin grafts, and lack of circulation, more particularly circulation around a vascular occlusion, among other systemic activities.
The compounds, compositions comprising the compounds, and methods for treating or preventing conditions and disorders by administering the compounds are 25 further described herein.
DETAILED DESCRIPTION OF THE INVENTION
Definition of Terms 3o Certain terms as used in the specification are intended to refer to the following definitions, as detailed below.
or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, wherein:
n is 0, 1, or 2;
A is N or N+-O-;
s .X is selected from the group consisting of O, S, and -N(R')-;
Ar' is a 6-membered aromatic ring containing 0, 1, 2, 3, or 4 nitrogen atoms, wherein Ar' is substituted with 0, 1, 2, 3, or 4 alkyl groups;
Arz is a group of the formula:
,<
z,3,z ~z,s ZS Y~ \ z9 //
Y\Y ZI / I ~Y2a Z~ ~~ ~ ~ Z
Z ~ ~ Ys 2 Z ~Z8 Y a Z"\Z,z N~ a R
~b~ , Or Z', Zz, Z3, and Z4 are independently selected from the group consisting of C
and -C(R3b); provided that zero or one of Z', Zz, Z3, and Z4 is C;
Z5, Z6, Z', and Z$ are independently selected from the group consisting of C
and -C(R3b); provided that zero or one of Z5, Z6, Z', and Z8 is C;
Zs~ Z~o~ Z11~ Z~z~ Z13~ Z14~ Z15~ and Z'6 are independently selected from the 15 group consisting of C and -C(R3~); provided that one of Z9, Z'°, Z", Z'z, Z'3, Z'4, Z'5, and Z'6 is C and the group of formula (c) is attached to Ar' through the C
atom;
Y' at each occurrence is independently selected from the group consisting of O, S, -N(Rz), -C(R3), and -C(R3)(R3a);
Yz is selected from the group consisting of -N(Rz), C(=O), -C(R3), and 20 -C(R3)(R3a);
Y3 is selected from the group consisting of -N(Rz), -C(R3), and -C(R3)(R3a); provided that zero or one of Y', Y2, and Y3 is -C(R3) in a group of formula (a);
wherein when one of Y', Y2, and Y3 is -C(R3) in a group of formula (a), then Z', Z2, Z3, and Z4 are each -C(R3b) and the group of formula (a) is attached to Ar' s through the C atom of -C(R3) of Y', Y2, or Y3; and also when one of Z', Z2, Z3, and Z4 is C, then Y', Y2 and Y3 are other than -C(R3) and the group of formula (a) is attached to Ar' through the C atom of Z', ZZ, Z3, or Z4;
Y2a and Y3a are independently selected from the group consisting of N, C and -C(R3a); provided that when Y' is -C(R3) in a group of formula (b), Y2a and Y3a are selected from the group consisting of N and -C(R3a), and when one of Y2a and Y3a is C, then Y' in a group of formula (b) is O, S, -N(R2), or-C(R3)(R3a);
wherein when one of Z5, Z6, Z', and Z$ is C, then Y' in a group of formula (b) is selected from the group consisting of O, S, -N(R2), and -C(R3)(R3a); Y2a and Y3a are each independently selected from the group consisting of N and -C(R3a);
and the 15 group of formula (b) is attached to Ar' through the C of Z5, Z6, Z', or Z$
; and also wherein when Y' in a group of formula (b) is -C(R3) or one of Y2a and Y3a is C, then Z5, Z6, Z', and Z$ are each -C(R3b) and the group of formula (b) is attached to Ar' through the C atom of-C(R3) of Y' in the group of formula (b) or through the C
atom of Y2a or Y3a;
2o R' and R2 at each occurrence are each independently selected from the group consisting of hydrogen and alkyl;
R3 and R3a at each occurrence are each independently selected from the group consisting of hydrogen, halogen, alkyl, aryl, -OR4, -NR5R6, -alkyl-OR4, and -alkyl-NR5R6;
25 R3b and R3~ at each occurrence are each independently selected from the group consisting of hydrogen, halogen, alkyl, aryl, -OR4, -NR5R6, -alkyl-OR4, -alkyl-NR5R6, and -SCN;
R4 is selected from the group consisting of hydrogen, alkyl, aryl, alkylcarbonyl, and arylcarbonyl;
3o R5 and R6 at each occurrence are each independently selected from the group consisting of hydrogen, alkyl, aryl, alkylcarbonyl, alkoxycarbonyl, aryloxycarbonyl, and arylcarbonyl, provided that at least one of R5 and R6 is hydrogen or alkyl; and R8 is selected from the group consisting of hydrogen and alkyl.
Another aspect of the invention relates to pharmaceutical compositions comprising compounds of the invention. Such compositions can be administered in accordance with a method of the invention, typically as part of a therapeutic regimen for treatment or prevention of conditions and disorders related to nAChR
activity, and more particularly a7 nAChR activity.
Yet another aspect of the invention relates to a method of selectively modulating to nAChR activity, for example a7 nAChR activity. The method is useful for treating and/or preventing conditions and disorders related to a7 nAChR
activity modulation in mammals. More particularly, the method is useful for conditions and disorders related to attention deficit disorder, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS
15 dementia, Pick's Disease, dementia associated with Lewy bodies, dementia associated with Down's syndrome, amyotrophic lateral sclerosis, Huntington's disease, diminished CNS function associated with traumatic brain injury, acute pain, post-surgical pain, chronic pain, inflammatory pain, neuropathic pain, infertility, need for new blood vessel growth associated with wound healing, need for new blood 2o vessel growth associated with vascularization of skin grafts, and lack of circulation, more particularly circulation around a vascular occlusion, among other systemic activities.
The compounds, compositions comprising the compounds, and methods for treating or preventing conditions and disorders by administering the compounds are 25 further described herein.
DETAILED DESCRIPTION OF THE INVENTION
Definition of Terms 3o Certain terms as used in the specification are intended to refer to the following definitions, as detailed below.
The term "acyl", as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of acyl include, but are not limited to, acetyl, 1-oxopropyl, 2,2-dimethyl-1-oxopropyl, 1-oxobutyl, and 1-oxopentyl.
s The term "acyloxy", as used herein, means an acyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of acyloxy include, but are not limited to, acetyloxy, propionyloxy, and isobutyryloxy.
The term "alkenyl", as used herein, means a straight or branched chain hydrocarbon containing from 2 to 10 carbons and containing at least one carbon-carbon double bond formed by the removal of two hydrogens. Representative examples of alkenyl include, but are not limited to, ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl, 2-heptenyl, 2-methyl-1-heptenyl, and 3-decenyl.
15 The term "alkoxy", as used herein, means an alkyl group as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, propoxy, butoxy, tert-butoxy, pentyloxy, and hexyloxy.
The term "alkoxyalkoxy", as used herein, means an alkoxy group, as defined 2o herein, appended to the parent molecular moiety through another alkoxy group, as defined herein. Representative examples of alkoxyalkoxy include, but are not limited to, tert-butoxymethoxy, 2-ethoxyethoxy, 2-methoxyethoxy, and methoxymethoxy.
The term "alkoxyalkyl", as used herein, means an alkoxy group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined 2s herein. Representative examples of alkoxyalkyl include, but are not limited to, tert-butoxymethyl, 2-ethoxyethyl, 2-methoxyethyl, and methoxymethyl.
The term "alkoxycarbonyl", as used herein, means an alkoxy group, as defined herein, appended to the parent molecular moiety through a carbonyl group, represented by -C(O)-, as defined herein. Representative examples of 3o alkoxycarbonyl include, but are not limited to, methoxycarbonyl, ethoxycarbonyl, and tert-butoxycarbonyl.
s The term "acyloxy", as used herein, means an acyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of acyloxy include, but are not limited to, acetyloxy, propionyloxy, and isobutyryloxy.
The term "alkenyl", as used herein, means a straight or branched chain hydrocarbon containing from 2 to 10 carbons and containing at least one carbon-carbon double bond formed by the removal of two hydrogens. Representative examples of alkenyl include, but are not limited to, ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl, 2-heptenyl, 2-methyl-1-heptenyl, and 3-decenyl.
15 The term "alkoxy", as used herein, means an alkyl group as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, propoxy, butoxy, tert-butoxy, pentyloxy, and hexyloxy.
The term "alkoxyalkoxy", as used herein, means an alkoxy group, as defined 2o herein, appended to the parent molecular moiety through another alkoxy group, as defined herein. Representative examples of alkoxyalkoxy include, but are not limited to, tert-butoxymethoxy, 2-ethoxyethoxy, 2-methoxyethoxy, and methoxymethoxy.
The term "alkoxyalkyl", as used herein, means an alkoxy group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined 2s herein. Representative examples of alkoxyalkyl include, but are not limited to, tert-butoxymethyl, 2-ethoxyethyl, 2-methoxyethyl, and methoxymethyl.
The term "alkoxycarbonyl", as used herein, means an alkoxy group, as defined herein, appended to the parent molecular moiety through a carbonyl group, represented by -C(O)-, as defined herein. Representative examples of 3o alkoxycarbonyl include, but are not limited to, methoxycarbonyl, ethoxycarbonyl, and tert-butoxycarbonyl.
The term "alkoxyimino", as used herein, means an alkoxy group, as defined herein, appended to the parent molecular moiety through an imino group, as defined herein. Representative examples of alkoxyimino include, but are not limited to, ethoxy(imino)methyl and methoxy(imino)methyl.
The term "alkoxysulfonyl", as used herein, means an alkoxy group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein. Representative examples of alkoxysulfonyl include, but are not limited to, methoxysulfonyl, ethoxysulfonyl and propoxysulfonyl.
The term "alkyl", as used herein, means a straight or branched chain hydrocarbon containing from 1 to 6 carbon atoms. Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-p.entyl, isopentyl, neopentyl, and n-hexyl.
The term "alkylcarbonyl", as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as 15 defined herein. Representative examples of alkylcarbonyl include, but are not limited to, acetyl, 1-oxopropyl, 2,2-dimethyl-1-oxopropyl, 1-oxobutyl, and 1-oxopentyl.
The term "alkylcarbonyloxy", as used herein, means an alkylcarbonyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of alkylcarbonyloxy include, but are not limited to, 2o acetyloxy, ethylcarbonyloxy, and tert-butylcarbonyloxy.
The term "alkylsulfonyl", as used. herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein. Representative examples of alkylsulfonyl include, but are not limited to, methylsulfonyl and ethylsulfonyl.
25 The term "alkylthio", as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a sulfur atom. Representative examples of alkylthio include, but are not limited, methylthio, ethylthio, tert-butylthio, and hexylthio.
The term "alkynyl", as used herein, means a straight or branched chain 3o hydrocarbon group containing from 2 to 10 carbon atoms and containing at least one _7_ carbon-carbon triple bond. Representative examples of alkynyl include, but are not limited, to acetylenyl, 1-propynyl, 2-propynyl, 3-butynyl, 2-pentynyl, and 1-butynyl.
The term "amido", as used herein, means an amino, alkylamino, or dialkylamino group appended to the parent molecular moiety through a carbonyl s group, as defined herein. Representative examples of amido include, but are not limited to, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, and ethylmethylaminocarbonyl.
The term "aryl", as used herein, means a monocyclic or bicyclic aromatic ring system. Representative examples of aryl include, but are not limited to, phenyl and naphthyl.
The aryl groups of this invention are substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from acyl, acyloxy, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxyimino, alkoxysulfonyl, alkyl, alkylsulfonyl, alkynyl, amino, carboxy, cyano, formyl, haloalkoxy, haloalkyl, halo, ~5 hydroxy, hydroxyalkyl, mercapto, nitro, thioalkoxy, -NRARB, (NRARB)alkyl, (NRARB)alkoxy, (NRARB)carbonyl, and (NRARB)sulfonyl.
The term "arylcarbonyl", as used herein, means an aryl group, as defined herein, or a benzyl group appended to the parent molecular moiety through a carbonyl group, represented by -C(O)-, as defined herein. Representative examples 20 of arylcarbonyl include, but are not limited to, phenylcarbonyl and benzylcarbonyl.
The term "aryloxycarbonyl", as used herein, means an aryl-O- group, wherein the aryl of aryl-O- is as defined herein, or a benzyoxyl group appended to the parent molecular moiety through a carbonyl group, represented by -C(O)-, as defined herein. Representative examples of aryloxycarbonyl include, but are not limited to, 25 phenoxycarbonyl and benzyloxycarbonyl.
The term "arylsulfonyl", as used herein, means an aryl group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein. Representative examples of arylsulfonyl include, but are not limited to, phenylsulfonyl, (methylaminophenyl)sulfonyl, (dimethylaminophenyl)sulfonyl, and 30 (naphthyl)sulfonyl.
The term "carbonyl", as used herein, means a -C(O)- group.
_g_ The term "carboxy", as used herein, means a -C02H group.
The term "cyano", as used herein, means a -CN.group.
The term "formyl", as used herein, means a -C(O)H group.
The term "halo" or "halogen", as used herein, means -CI, -Br, -I or -F.
The term "haloalkoxy", as used herein, means at least one halogen, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein. Representative examples of haloalkoxy include, but are not limited to, chloromethoxy, 2-fluoroethoxy, trifluoromethoxy, and pentafluoroethoxy.
The term "haloalkyl", as used herein, means at least one halogen, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of haloalkyl include, but are not limited to, chloromethyl, 2-fluoroethyl, trifluoromethyl, pentafluoroethyl, and 2-chloro-3-fluoropentyl.
The term "heteroaryl" means an aromatic five- or six-membered ring ~ s containing 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. The heteroaryl groups are connected to the parent molecular moiety through a carbon or nitrogen atom. Representative examples of heteroaryl include, but are not limited to, furyl, imidazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrazolyl, thiadiazolyl, 2o thiazolyl, thienyl, triazinyl, and triazolyl.
The heteroaryl groups of the invention are substituted with 0, 1, 2, or 3 substituents independently selected from alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfonyl, alkylthio, alkynyl, carboxy, cyano, formyl, haloalkoxy, haloalkyl, halo, hydroxy, 25 hydroxyalkyl, mercapto, nitro, -NRARB, (NRARB)alkyl, (NRARB)alkoxy, (NRARB)carbonyl, and (NRARB)sulfonyl.
The term "bicyclic heteroaryl" refers to fused aromatic nine- and ten-membered bicyclic rings containing 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a tautomer thereof. The bicyclic heteroaryl so groups are connected to the parent molecular moiety through a carbon or nitrogen atom. Representative examples of bicyclic heteroaryl rings include, but are not -g_ limited to, indolyl, benzothiazolyl, benzofuranyl, isoquinolinyl, and quinolinyl. Bicyclic heteroaryl groups of the invention are substituted with 0, 1, 2, or 3 substituents independently selected from alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfonyl, s alkylthio, alkynyl, carboxy, cyano, formyl, haloalkoxy, haloalkyl, halo, hydroxy, hydroxyalkyl, mercapto, nitro, -NRARB, (NRARB)alkyl, (NRARB)alkoxy, (NRARB)carbonyl, and (NRARB)sulfonyl.
The term "hydroxy", as used herein, means an -OH group.
The term "hydroxyalkyl", as used herein, means at least one hydroxy group, as defined herein, is appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of hydroxyalkyl include, but are not limited to, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, 2,3-dihydroxypentyl, and 2-ethyl-4-hydroxyheptyl.
The term "mercapto", as used herein, means a -SH group.
15 The term "nitro", as used herein, means a -N02 group.
The term "-NRARB", as used herein, means two groups, RA and RB, which are appended to the parent molecular moiety through a nitrogen atom. RA and RB are each independently hydrogen, alkyl, alkylcarbonyl, or formyl. Representative examples of -NRARg include, but are not limited to, amino, methylamino, 2o acetylamino, and acetylmethylamino.
The term "(NRARB)alkyl", as used herein, means a -NRARB group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of (NRARB)alkyl include, but are not limited to, (amino)methyl, (dimethylamino)methyl, and (ethylamino)methyl.
2s The term "(NRARB)alkoxy", as used herein, means a -NRARB group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein. Representative examples of (NRARB)alkoxy include, but are not limited to, (amino)methoxy, (dimethylamino)methoxy, and (diethylamino)ethoxy.
The term "(NRARB)carbonyl", as used herein, means a -NRARB group, as so defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of (NRARg)carbonyl include, but are not limited to, aminocarbonyl, (methylamino)carbonyl, (dimethylamino)carbonyl, and (ethylmethylamino)carbonyl.
The term "(NRARB)sulfonyl", as used herein, means a -NRARB group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein. Representative examples of (NRARB)sulfonyl include, but are not limited to, aminosulfonyl, (methylamino)sulfonyl, (dimethylamino)sulfonyl, and (ethylmethylamino)sulfonyl.
The term "sulfonyl", as used herein, means a -S(O)2- group.
The term "thioalkoxy", as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a sulfur atom.
Representative examples of thioalkoxy include, but are no limited to, methylthio, ethylthio, and propylthio.
Although typically it may be recognized that an asterisk is used to indicate that the exact subunit composition of a receptor is uncertain, for example a3b4*
indicates ~ 5 a receptor that contains the a3 and X34 proteins in combination with other subunits, the term a7 as used herein is intended to include receptors wherein the exact subunit composition is both certain and uncertain. For example, as used herein a7 includes homomeric (a7)5 receptors and a7* receptors, which denote a nAChR
containing at least one a7 subunit.
Compounds of the Invention Compounds of the invention can have the formula (I) as described above.
More particularly, compounds of formula (1) can include, but are not limited to, compounds wherein Ar' is a group of the formula:
X' X3 S
Xz Xa (b) , In a group of formula (b), X', X2, X3, and X4 are each independently selected from the group consisting of N and -CR'°, wherein R'° at each occurrence is independently selected from the group consisting of hydrogen and alkyl.
Preferably, at least one of X', X2, X3, and X4 is -CR'°, such that group of formula (b) contains 0, 1, 2, or 3 nitrogen atoms.
Specific examples of groups for Ar' are, for example, Rio Rio Rio Rio Rio N
N , N
Rio Rio Rio . Rio Rio Rio Rio a and N N ' , R "' and the like.
Specific examples of groups for Arz in a compound of formula (I) are, for example, Z5 Zs ~,3a N
Zs~Z~ N Zs/Z\ O~ Zs/ \ S\ ZII
\ ,za ~ ( //N Z ~ ~ / ~/N Zs /
Z~ / ~~ Z \ s~ ~,3a ~ s Y3a ~Z5 N
\Zs Y3a , Z , Z Rz (i) (ii) (iii) (iv) Zs/ \ O s/ \ N Zs/ ~ S
\Y2a Z ~ ~ \Y2a I I \Y2a Z ~ s~ N~ Z ~ s~ N~ Z ~ a~ N/
Z , Z ~ Z
(v) (vi) (vii) \ Zg / \ N
N (~ o Z \ Z$/ N/ ~ ZZ\ ~/ ~ Y1 , Z
(viii) (ix) z Zs / Z\ N\ Zs / Z\ S
N \N
7 ~ 7 Z ~Z8~ N/ and Z \ $
Z
(x) (xi) ~nrherein:
Z', Z2, Z3, and Z4 are independently selected from the group consisting of C
and -C(R3b); provided that one of Z', Z2, Z3, and Z4 is C and formula (ix) is attached to Ar' through the C atom of Z', Z2, Z3, and Z4;
Y' is selected from the group consisting of O, S, and -C(R3)(R3a);
Z5, Z6, Z', and Z$ are independently selected from the group consisting of C
and -C(R3b); provided that zero or one of Z5, Z6, Z', and Z$ is C;
Y2a and Y3a are independently selected from the group consisting of C and -C(R3a); wherein when one of Z5, Zs, Z', and Z8 is C, then Y2a and Y3a in the group of formulae (i)-(vii) are each -C(R3a); and each of the group of formulae (i)-(vii) is attached to Ar' through the C of Z5, Zs, Z', or Z$ ; and also wherein when one of Y2a s and Y3a is C in the group of formulae (i)-(vii), then Z5, Zs, Z', and Z8 are each -C(R3b) and each of the group of formulae (i)-(vii) is attached to Ar' through the C
atom of Y2a or Y3a; and R2, R3, R3a and R3b are as defined for a compound of formula (I).
Also, other specific examples of groups for Arz in a compound of formula (I) are, for example, Z13 ~Z\
\Z15 10~Z9 \ Z~16 Z
~Z12 wherein Z9, Z'°, Z", Z'2, Z'3, Z'4, Z15, Z~s, and R$ are as defined for compounds of formula (I).
Specific embodiments contemplated as part of the invention include, but are not limited to, compounds of formula (I), as defined, wherein:
3-[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl]-1 H-indole;
4-[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl]-1 H-indole;
5-[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl]-1 H-indole;
5-{4-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]phenyl}-1 H-indole;
6-[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl]-1 H-indole;
2o 2-[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl]-1H-indole;
5-[6-( 1-azabicyclo[2.2.2]oct-3-yloxy)pyridazin-3-yl]-1 H-indole;
4-[6-(1-azabicyclo[2.2.2]oct-3-yloxy)pyridazin-3-yl]-1 H-indole;
5-{6-[(3R)-1-azabicyclo(2.2.2]oct-3-yloxy]pyridazin-3-yl}-1 H-indole;
5-{6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl}-3-methyl-1 H-indole;
5-{2-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyrimidin-5-yl}-1 H-indole;
4-{2-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyrimidin-5-yl}-1 H-indole;
5-{2-[(3S)-1-azabicyclo[2.2.2]oct-3-yloxy]pyrimidin-5-yl}-1 H-indole;
5-[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl]-3-methyl-1 H-indazole;
6-[4-( 1-azabicyclo[2.2.2]oct-3-yloxy)phenyl]-1,3-benzothiazol-2-amine;
6-{4-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]phenyl}-1,3-benzothiazol-2-amine;
6-{4-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]phenyl}-4-thiocyanato-1,3-benzothiazol-2-amine;
6-{4-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]phenyl}-4-bromo-1,3-benzothiazol-2-amine;
N-[4-(3-methyl-1 H-indazol-5-yl)phenyl]quinuclidin-3-amine;
(R)-3-[6-(3-methyl-1 H-indazol-5-yl)-pyridazin-3-yloxy]-1-aza bicyclo[2.2.2]octane;
(R)-3-[6-(1-methyl-1 H-indol-5-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane;
(R)-{5-[6-(1-aza-bicyclo[2.2.2]oct-3-yloxy)-pyridazin-3-yl]-1 H-indol-3-ylmethyl}-dimethyl-amine;
(R)-3-[6-(1 H-indol-5-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane 1-oxide;
6-{6-[(3R)-1-aza-bicyclo[2.2.2]oct-3-yloxy]-pyridazin-3-yl}-benzothiazol-2-ylamine;
(3R)-3-[6-(3-bromo-1 H-indol-5-yl)-pyridazin-3-yloxy]-1-aza-2o bicyclo[2.2.2]octane;
5-{6-[(3R)-1-aza-bicyclo[2.2.2]oct-3-yloxy]-pyridazin-3-yl}-1,3-dihydro-indol-one;
5-{6-[(3R)-1-oxy-1-aza-bicyclo[2.2.2]oct-3-yloxy]-pyridazin-3-yl}-1,3-dihydro-indol-2-one;
5-{6-[(3R)-1-aza-bicyclo[2.2.2]oct-3-yloxy]-pyridazin-3-yl}-1,3-dihydro-benzoimidazol-2-one;
(R)-3-[6-(1 H-benzoimidazol-5-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane;
(S)-3-[6-(1 H-indol-5-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane;
so (R)-3-[5-(1 H-indol-5-yl)-pyridin-2-yloxy]-1-aza-bicyclo[2.2.2]octane;
(3R)-3-[5-(1 H-indol-4-yl)-pyrimidin-2-yloxy]-1-aza-bicyclo[2.2.2]octane 1-oxide;
(3R)-3-(5-benzooxazol-5-yl-pyrimidin-2-yloxy)-1-aza-bicyclo[2.2.2]octane;
(3R)-3-[5-(2-methyl-benzooxazol- 5-yl)-pyrimidin-2-yloxy]-1-aza-s bicyclo[2.2.2]octane; ' (3R)-3-[5-(2-ethyl-benzooxazol-5-yl)-pyrimid in-2-yloxy]-1-aza-bicyclo[2.2.2]octane;
(3R)-3-[5-(2-phenyl-benzooxazol-5-yl)-pyrimidin-2-yloxy]-1-aza-bicyclo[2.2.2]octane;
(R)-5-[2-(1-aza-bicyclo[2.2.2]oct-3-yloxy)-pyrimidin-5-yl]-3H-benzooxazol-2-one;
(R)-3-[6-(1-aza-bicyclo[2.2.2]oct-3-yloxy)-pyridazin-3-yl]-9H-carbazole;
3-[6-(1 H-indol-3-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane;
(R)-3-[6-(1 H-indol-3-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane; and 15 (S)-3-[6-(1 H-indol-3-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane;
or pharmaceutically acceptable salts, esters, amides, and prodrugs thereof.
Compound names are assigned by using Au'roNoM naming software, which is provided by MDL Information Systems GmbH (formerly known as Beilstein Informationssysteme) of Frankfurt, Germany, and is part of the CHEMDRAW~
2o ULTRA v. 6Ø2 software suite.
Compounds of the invention may exist as stereoisomers wherein, asymmetric or chiral centers are present. These stereoisomers are "R" or "S" depending on the configuration of substituents around the chiral element. The terms "R" and "S"
used herein are configurations as defined in IUPAC 1974 Recommendations for Section 25 E, Fundamental Stereochemistry, Pure Appl. Chem., 1976, 45: 13-30. The invention contemplates various stereoisomers and mixtures thereof and are specifically included within the scope of this invention. Stereoisomers include enantiomers and diastereomers, and mixtures of enantiomers or diastereomers. Individual stereoisomers of compounds of the invention may be prepared synthetically from 3o commercially available starting materials which contain asymmetric or chiral'centers or by preparation of racemic mixtures followed by resolution well-known to those of ordinary skill in the art. These methods of resolution are exemplified by (1 ) attachment of a mixture of enantiomers to a chiral auxiliary, separation of the resulting mixture of diastereomers by recrystallization or chromatography and optional liberation of the optically pure product from the auxiliary as described in Furniss, Hannaford, Smith, and Tatchell, "Vogel's Textbook of Practical Organic Chemistry", 5th edition (1989), Longman Scientific & Technical, Essex CM20 2JE, England, or (2) direct separation of the mixture of optical enantiomers on chiral chromatographic columns or (3) fractional recrystallization methods.
Compounds of the invention demonstrate beneficial binding at a7 neuronal nicotinic receptors. Moreover, such compounds generally demonstrate more beneficial binding at a7 neuronal nicotinic receptors when compared with a less desireable effect of binding to the human ether-a-go-go related gene (hERG) ion channel. As such, compounds of the invention demonstrate an improved cardiovascular profile, i.e. are less like to to induce cardiovascular complications associated with hERG, than other ampiphilic molecules demonstrating at a7 neuronal nicotinic receptor binding.
Methods for Preparing Compounds of the Invention As used in the descriptions of the schemes and the examples, certain 2o abbreviations are intended to have the following meanings: Ac for acetyl;
Bu for butyl; dba for dibenzylidene acetone; DEAD for diethyl azodicarboxylate; DMSO
for dimethylsulfoxide; EtOAc for ethyl acetate; EtOH for ethanol; Et3N for triethylamine;
Et20 for diethyl ether; HPLC for high pressure liquid chromatography;'Pr for isopropyl; Me for methyl; MeOH for methanol; NBS for N-bromosuccinimide; OAc for 2s acetoxy; o-tol. for o-toluene; Ph for phenyl; t-Bu for tert-butyl; TFA for trifluoroacetic acid; and THF for tetrahydrofuran.
The reactions exemplified in the schemes are performed in a solvent appropriate to the reagents and materials employed and suitable for the transformations being effected. The described transformations may require so modifying the order of the synthetic steps or selecting one particular process scheme over another in order to obtain a desired compound of the invention, depending on the functionality present on the molecule.
Nitrogen protecting groups can be used for protecting amine groups present in the described compounds. Such methods, and some suitable nitrogen protecting s groups, are described in Greene and Wuts (Protective Groups In Organic Synthesis, Wiley and Sons, 1999). For example, suitable nitrogen protecting groups include, but are not limited to, tert-butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz), benzyl (Bn), acetyl, and trifluoracetyl. More particularly, the Boc protecting group may be removed by treatment with an acid such as trifluoroacetic acid or hydrochloric acid.
The Cbz and Bn protecting groups may be removed by catalytic hydrogenation.
The acetyl and trifluoracetyl protecting groups may be removed by a hydroxide ion.
The methods described below can entail use of various enantiomers. Where the stereochemistry is shown in the Schemes, it is intended for illustrative purposes only.
Scheme 1 HO ~ ~~~,,,OH x~-Arz Are-X' ' 7+
N (s) X'=Br,CI, I Ph3P X'=Br,CI, I
(3) ~ DEAD
OH I ~ Cul, CsZC03 O ~ Me3SnSnMe3 or ~OR
+ I A~ X~ 1,10-phenanthroline ~~ I Aj X' Pd(o)/L. ROB-B
N Tol. reflux N RO (9) OR
(1 ) (2) I (4) R= alkyl, aryl X'=Br,CI, I Me3SnSnMe3 or M-Arz ROiB-B OR Pd(0)/L. (7) RO OR M=Sn, B, (9) Pd(o)/L.
R=alkyl, aryl O ~ X'-Arz O
Are-M (s) ~~ I Ar Arz N ~ Pd(o)/L. N
M=Sn, B
X'=Br,CI, I
(5) (8) Quinuclidine ethers of general formula (8), wherein Ar' and Arz are as defined s in formula (I), can be prepared as described in Scheme 1. 3-Quinuclidinol of formula (1 ) is treated with a halophenyl iodide of formula (2), wherein X' is bromide, chloride, or iodide, with Cul and Cs2C03 in 1,10-phenanthroline as described in Org.
Lett., 2002, 4, 973, to obtain a halophenoxy quinuclidine of formula (4).
Alternatively, a compound of formula can be obtained by treating 3-quinuclidinol with a halo phenyl 1o alcohol of formula (3), wherein X' is bromide, chloride, or iodide, and diethyl azodicarboxylate in the presence of a phosphine, such as triphenylphosphine.
Compounds of formula (4) can be treated with hexamethylditin or diboron of formula (9), such as bis(pinacolato)diboron and bis(catecholato)diboron, wherein R
is hydrogen, alkyl, butyloxycarbonyl, or benzyloxycarbonyl, in the presence of a 15 palladium catalyst to provide the corresponding tin or boronic acid of formula (5), which is reacted with a desired halide of a fused bicycloheterocycle represented by Arz of formula (6), wherein X' is bromide, chloride, or iodide, to provide compounds of formula (8). Alternatively, halides of a desired Arz group can be treated with hexamethylditin or diboron of formula (9), such as bis(pinacolato)diboron and bis(catecholato)diboron, in the presence of a palladium catalyst to provide a corresponding tin or boronic acid reagent that is reacted with a compound of formula (4) in the presence of a palladium catalyst to provide a compound of formula (8).
Scheme 2 Me3SnSnMe3 or OR
ROB B~OR R alkyl, aryl O X~
~~OK Yi X? 3 O X' 3 (g) ~~~ ~ ' X
+ ~ X ~ ~ X N N.Xa~M
N N.Xa~Y2 ~~ N. a~ 2 Pd(0)/L.
N X Y
M=Sn, B
~ i_ (12) Y , Y -Br, CI, I
(1p) X~, X3, X4 _N CH (13) (11 ) X'-Arz M-Arz Pd(0)/L. X'=Br,CI, I
) M=Sn, B, ~~~0~ X' Xs NUJ IN~Xa~Ar2 (14) Quinuclidine ethers of formula (14), wherein Ar' is a nitrogen-containing 1o heteroaryl, for example pyridazine, and Are is as defined for formula (I), can be prepared as shown in Scheme 2. Potassium quinuclidinoxide (10) can be reacted with a dihaloaromatic ring, for example, dichloropyridazine, of formula (11 ) to obtain a quinuclidine ether of formula (12). The quinuclidine ether can be reacted with a suitable tin or boron reagent, as described in Scheme 1, to provide a fused bicycloheterocycle substituted quinuclidine ether of formula (14).
Alternatively, the quinuclidine ether of formula (12) can be treated with hexamethylditin or diboron of formula (9), such as bis(pinacolato)diboron and bis(catecholato)diboron, to activate the aromatic group to provide (13), wherein M is tin or boronic acid ester, and further treated with a halide of a desired group Arz in the presence of a palladium catalyst to provide compounds of formula (14).
Scheme 3 IA
i ~ ~L~OH
Pd(0)/L. I Ar Ar2 ~J+
N
Cul, CsZC03 M-At2 RaO
1,10-phenanthroline (7) I A j I Ra0 Tol. reflux M=Sn, B, (~ 9) Ra=gn I A j Arz Pd(0)/L. (20) Pd/C, HZ
,,OH HO Ph3P, DEAD O
+ I Aj A~ THF, rt, 2 days ~~ I Aj Arz N
N
(21 ) (8) Quinuclidine ethers of formula (8), wherein Ar' and Arz are as defined for formula (I) also can be obtained by the methods described in Scheme 3. The activated tin or boronic acid reagent of formula (7) can be coupled with the diiodoaromatic ring of formula (17) in the presence of a palladium catalyst to provide a compound of formula (18). Compounds of formula (18) can be reacted with 3-quinuclidinol and Cul with Cs2C03 in 1,10-phenanthroline as described in Org.
Lett.
2002, 4, 973, to provide a desired compound of formula (8).
Alternatively, the compound of formula (7) is treated with a compound of formula (19), wherein Ra is benzyl, in the presence of a palladium catalyst to provide ~5 a compound of formula (20). Compounds of formula (20), wherein Ra is benzyl, are hydrogenated to provide compounds of formula (21 ) under standard hydrogenation conditions, for example Pd/C, and further treated with 3-quinuclidinol in the presence of a phosphine, for example triphenylphosphine, and diethyl azodicarboxylate to provide compounds of formula (8).
i Scheme 4 NHZY' \
+ I Aj X' N
Y'=Br,' I
(27) (28) X'=Br,Cl,l Pd/Ligand Cs2C03, tol.
Pd(0)/L.
NaBH(OAc)3 H Me3SnSnMe3 H
O H2N \ HOAc,Na2S04 \ or N \
+ ~ A j x' --~ C~ N ~ Are-X' -- ~~ ~Ar j M
N ~ RO, ,OR
N B_B\ N
X'=Br,Cl,l RO (9) OR (30) M'=Sn, B
R=alkyl, aryl ) Pd(0)/L. Pd(0)/L X'-Ar2 M-Ar2 (6) X'=Br,CI, I
M=Sn, B, H
~~ N
A j Arz N
(31 ) Compounds of formula (31 ), wherein X is -NH- and Ar' and Arz are as s described for compounds of formula (I), can be prepared as shown in Scheme 4. 3-Quinuclidinone (25) and a haloarylamine of formula (26), wherein X' is bromide, chloride, or iodide, can be treated with sodium triacetoxy borohydride and acetic acid in Na2S04 to provide a compound of formula (29). Alternatively, a compound of formula (29) can be obtained by treating 3-aminoquinuclidine (27) with haloaromatic group as described in formula (28) with Cs2C03 in the presence of palladium catalyst, preferably in toluene. A compound of formula (29) can be treated with a tin or diboron of formula (9), such as bis(pinacolato)diboron and bis(catecholato)diboron, under conditions previously described to provide the corresponding tin or boronic acid reagent of formula (30), which can be reacted with the halide of a desired group represented by Arz in a compound of formula (I) to provide a compound of formula (31 ). Alternatively, the compound of formula (29) is treated with a tin or boronic acid ester of the desired Arz group in the presence of a palladium catalyst to provide a compound of formula (31 ).
Scheme 5 Me3SnSnMe3 RO, or ,OR
SH ,B B~OR
~L~CI 1 ) NaH, DMF S RO 9 S
X ~~~ I Aj X, ( ) ~~~ I Aj M
N \~~ Pd(o)/L. N
HCI 2) Chiral separation N
(37) (38) X'=Br,CI, I R=alkyl, aryl M=Sn, B
(35) (36) M-Ar2 Pd(o)/L. X'-Ar2 (7) Pd(0)/L. (g) X'=Br,CI, I
M=Sn, B, C~~S
A j Ar2 N
(39) Compounds of formula (39), wherein X is S and Ar' and Arz are as defined in a compound of formula (I), can be prepared as shown in Scheme 5. 3-1o Chloroquinuclidine (35) can be reacted with a haloarylthiol of formula (36), wherein X' is bromide, chloride, or iodide, to provide a compound of formula (37). The compound of formula (37) can be treated with a tin or boron reagent of a desired group for Arz as described for a compound of formula (I) to provide a compound of formula (39). Alternatively, the compound of formula (37) can be reacted with a hexamethylditin or diboron reagent of formula (9), such as bis(pinacolato)diboron and bis(catecholato)diboron, in the presence of a palladium catalyst to provide a compound of formula (38), which is reacted with the halide of a desired Arz group in the presence of a palladium catalyst to provide a compound of formula (39).
Scheme 6 Me3SnSnMe3 or RO iB-B OR
RO OR
O ~ (9) O
j Pd(o)/L. ~~~
N X R=alkyl, aryl N M
(4) X'=Br,CI, I (5) M=Sn, B
Pd(o)/L.
Pd(o)/L. X'-Ar2-NHRb M'-Ar2-N H Rb (41 ) X'=Br, CI, I
M'=Sn, B, Zn, Mg, Rb=H, alkyl, Boc, Cbz Are N ~ Ark (42) NHRb Compounds of formula (42), wherein X is O, R3 is NHRb, and Ar', Are are defined as in compounds of formula (I), can be prepared as shown in Scheme 6.
Compounds of formula (4) obtained as shown in Scheme 1 can be treated with a metal of the desired amino-substituted Arz group, as described for compounds of formula (I) to provide compounds of formula (42), wherein Rb is hydrogen, alkyl, butyloxycarbonyl, or benzyloxycarbonyl. Compounds of formula (4) can be treated 1o with a hexamethylditin or diboron reagent of formula (9), such as bis(pinacolato)diboron and bis(catecholato)diboron, in the presence of a palladium catalyst to provide the corresponding tin or boronic acid of formula (5), which is reacted with a desired halide of an amine-substituted fused bicycloheterocycle represented by Arz of formula (41 ), wherein X' is bromide, chloride, or iodide, to 15 provide compounds of formula (42).
Scheme 7 Me3SnSnMe3 or RO, ,OR
,B_B.
O X~ 3 RO OR ~~~0~ X' X3 X (9) Pd 0 /L. N N'X4~M
N X Y () (12) R=alkyl, aryl M=Sn, B
X~, X2~, X3 =N, CH (13) Y=Br, CI, I ~
Pd(0)/L. Pd(0)/L.
M'-Ar2-N H Rb X'-Ar2-N H Rb (45) (46) M'=Sn, B, Zn, Mg, ~ ~ X'=Br, CI, I
Rb=H, Boc,Cbz, alkyl, aryl O~X~ X3 CC /J N. q~ 2 b N X Ar - NHR
(47) Compounds of formula (47), wherein X is O, Ar' is a nitrogen containing aromatic group, for example pyridazine, R3 is NHRb, as previously defined, and Are is defined as in compounds of formula (I), can be prepared as shown in Scheme 7.
Compounds of formula (12), which can be obtained as shown in Scheme 2, are treated with a metal of the desired amino-substituted Are group, as described for compounds of formula (I), of formula (45) to provide compounds of formula (47).
Compounds of formula (12) also can be treated with a hexamethylditin or diboron 1o reagent of formula (9), such as bis(pinacolato)diboron and bis(catecholato)diboron, in the presence of a palladium catalyst to provide the corresponding tin or boronic acid of formula (13), which is reacted with a desired halide of an amine-substituted fused bicycloheterocycle represented by Arz of formula (46), wherein X' is bromide, chloride, or iodide, to provide compounds of formula (47).
Scheme 8 I ~OH
Arz-X" +
N
X"=Br,CI,I,NO2,NR'R"
(51) Cul, Cs2C03 1,10-phenanthroline Tol. reflux ,,,OH HO ~ Ph3P, DEAD ~ A j A~-X"
+ ~ A j Arz-X" THF, rt, 2 days N
N
(52) (50) X~~=gr,CI,I,N02,NR'R"
X"=N02 X"=CI, Br, I
~ ) Pd/C, H2 2) R'CI or R'Br Pd/Ligand, R'NHR"
(53) (54) O ~C~O
W ~ Ar Ai i N ~ Arz N ~ Ar2 NHR' (57) ~ NR'R"
(56) R', R"=H, alkyl, aryl, RCO, Boc, Cbz Quinuclidine ethers of formula (56) and (57), wherein Are is as defined for formula (I) and Are is substituted with a group NR5R6 can be obtained by the methods described in Scheme 8. Compounds of formula (50) can be treated with 3-quinuclidinol in the presence of a phosphine, for example triphenylphosphine, and diethyl azodicarboxylate to provide compounds of formula (52). Alternatively, compounds of formula (51 ), wherein X" is bromide, chloride, or iodide, can be reacted with Cul, Cs2C03 in 1,10-phenanthroline as described in Org. Lett.
2002, 4, 973, to provide a desired compound of formula (52). Compounds of formula (52), wherein X" is N02, can be reduced with hydrogen in the presence of a palladium s catalyst and reacted with a chloride or bromide of a desired R group of formula (53), wherein R' is hydrogen, alkyl, aryl, alkycarbonyl, alkoxycarbonyl, arylcarbonyl, or aryloxycarbonyl, to provide compounds of formula (56). Compounds of formula (52), wherein X" is bromide, chloride, or iodide, can be treated with a compound R'NHR"
of formula (54), wherein R' and R" are as previously described for R' in compounds of formula (53), to provide a corresponding compound of formula (57).
Scheme 9 ~ )NaBH(OAc)3 H
O H2N ~ HOAc,NaZS04 N
I Ar Ar2-X" ~ I Ar -Arz-X"
N + ~ 2) Chiral separation N
(60) X"=Br,CI,I,NOZ,NHR'R"
X"=Br,Cl,l Pd/Ligand, R'NHR"
(54) X'=NOZ N
~ ) Pd/C, HZ
2) R'CI or R'Br I A j Ar2-NR'R"
N
(53) (64) R', R"=H, alkyl, aryl, RCO, Boc, Cbz H
~~~ N
I A j Arz-NHR' N
(63) Compounds of formulas (63) and (64) can be prepared as shown in Scheme 15 9. 3-Quinuclidinone and a halobiarylamine of formula (60), wherein X' is bromide, chloride, or iodide, can be treated with sodium triacetate borohydride and Na2S04in acetic acid to provide a compound of formula (61 ) as described in Tetrahedron Lett.
1996, 37, 6045. Compounds of formula (61 ), wherein X' is bromide, chloride, or iodide, can be treated with a compound R'NHR" of formula (54), wherein R' and R"
are as previously described for R' in compounds of formula (53), to provide a corresponding compound of formula (64). Compounds of formula (61 ), wherein X
is N02, can be reduced with hydrogen in the presence of a palladium catalyst and reacted with a chloride or bromide of a desired R' group of formula (53), wherein R' is hydrogen, alkyl, aryl, alkycarbonyl, alkoxycarbonyl, arylcarbonyl, or aryloxycarbonyl, to provide compounds of formula (63).
Scheme 10 Me3SnSnMe3 or .
RO%B_B OR
RO OR H
N
N ~ (9) ~~~ ~ A% -M
A j X' Pd(0)/L. N
N R=alkyl, aryl M=Sn, B
(29) (30) X'=Br, CI, I
Pd(0)/L.
Pd(0)/L. X-Ar2-N HRb M'-Ar2-N H Rb (46) (45) \ I X=Br, CI, I
M'=Sn, B, Zn, Mg, Rb=H, Boc,Cbz, alkyl, a H
<<~ N
A j Ar2 -NHRb N
(69) Compounds of formula (69), wherein X is -NH-, R3 is NHRb, and Ar', Arz are defined as in compounds of formula (I), can be prepared as shown in Scheme 10.
Compounds of formula (29) obtained as shown in Scheme 7 can be treated with a metal of the desired amino-substituted Arz group, as described for compounds of formula (I), of formula (45) to provide compounds of formula (69). Compounds of formula (29) also can be treated with a hexamethylditin or diboron reagent of formula (9), such as bis(pinacolato)diboron and bis(catecholato)diboron, in the presence of a s palladium catalyst to provide the corresponding tin or boronic acid of formula (30), which is reacted with a desired halide of an amine-substituted fused bicycloheterocycle represented by Arz of formula (46), wherein X' is bromide, chloride, or iodide, to provide compounds of formula (69).
Scheme 11 Ci SH
1 ) NaH, DMF ~~S
Are-X
+ I Ar1-X /
N / 2) Chiral seraration N
HCI
(70) (71) X"=Br,CI,I,NO2,NHR'R"
X=N 02 X=Br,Cl,l ~ ) Pd/C, H2 2) R'CI or R'Br (53) Pd/Ligand R'NHR"
(54) ~~ S
A%
N Ar2-N H R' (72) ~~~S
N Ar2-NR'R
(73) Quinuclidine biarylsulfides of formulas (72) and (73), wherein Ar' is as defined for formula (I) and Arz is substituted with a group NR'R" can be obtained by the methods described in Scheme 11. 3-Chloroquinuclidine can be reacted with a 15 halobiarylthiol of formula (70), wherein X" is bromide, chloride, iodide, N02, or NHR'R", as described in Tetrahedron Lett. 1996, 37, 6045, to provide a compound of formula (71 ). Compounds of formula (71 ), wherein X" is N02, can be reduced with hydrogen in the presence of a palladium catalyst and reacted with a chloride or bromide of a desired R' group of formula (53), wherein R' is hydrogen, alkyl, aryl, alkycarbonyl, alkoxycarbonyl, arylcarbonyl, or aryloxycarbonyl, to provide compounds of formula (72). Compounds of formula (71 ), wherein X" is bromide, chloride, or iodide, can be treated with a compound R'NHR" of formula (54), wherein R' and R" are as previously described for R' in compounds of formula (53), to provide a corresponding compound of formula (73).
Scheme 12 Me3SnSnMe3 or RO, ,0R
,B B~OR S
S \ RO (9) ~(~ I A~ M
- , X Pd(0)/L. N /
N
(37) R=alkyl, aryl M=Sn, B
X'=Br,Cl,l (38) Pd(0)/L. Pd(0)/L.
M'-Ar2-N H Rb ~ X'-Ar2-N H Rb (75) ~ ~ (76) M'=Sn, B, Zn, Mg, ~ ~ X'=Br, CI, I
Rb=H, Boc,Cbz, alkyl ~L~S
Art N / Ar2-NHRb ~ (77) Compounds of formula (77), wherein X is S, R3 is NHRb, and Ar', Arz are defined as in compounds of formula (I) can be prepared as shown in Scheme 12.
Compounds of formula (37) obtained as shown in Scheme 5 can be treated with a metal of the desired amino-substituted Arz group, as described for compounds of formula (I), of formula (75) to provide compounds of formula (77). Compounds of formula (37) also can be treated with a hexamethylditin or diboron reagent of formula (9), such as bis(pinacolato)diboron and bis(catecholato)diboron, in the presence of a palladium catalyst to provide the corresponding tin or boronic acid of formula (38), which is reacted with a desired halide of an amine-substituted fused bicycloheterocycle represented by Arz of formula (76), wherein X' is bromide, chloride, or iodide, to provide compounds of formula (77).
Scheme 13 Y' Br2, KSCN Y, ~. / I N
HOAc CC~ I Aj \ ~ NH2 N NH l~S
Y'=O, NH, S
(8 ~ ) RX
(8~) X=CI,Br, I
Y' N
A j \ ~ ~~NHR°
~~S
N
(82) R~=alkyl, aryl, RCO, Cbz, Boc bromination Br CC~ Y' N
KSCN I Aj \ I ~~NHR' N S
' (83) Y SCN R3bM HOR4 HNR5R6 87 or (87a) I A j \ I N~-NHR° (85) ( [Pd]
N ~S [Pd]
RXh (g4) M=B, Zn, Sn Y, Y, R3b CC~ ~ Aj \ ~ ~NHR°
N N S
A j \ I ~>-NHR' 88 N S ( ) (86) Aminobenzothiazole-substituted quinuclidines of formula (82) can be obtained as shown in Scheme 13. Amino-substituted quinuclidine ethers, thioethers, and amines of formula (80) are obtained by methods described in Schemes 6-12.
Compounds of formula (80) are reacted with bromine and KSCN in acetic acid to provide aminobenzothiazole-substituted quinuclidines of formula (81 ).
Compounds of formula (81 ) can be further treated with the halide of a desired R°
group, wherein R° as defined for R5 or R6 in compounds of formula (I) to provide the desired aminobenzothiazole-substituted quinuclidine derivative (82).
Compounds of formula (82) can be further treated to obtain compounds of formulas (84), (86), and (88). Bromination of compounds with formula (82) provides compounds of formula (83). Compounds of formula (83) are reacted with a nucleophilic agent, for example KSCN, to give compounds of formula (84).
Compounds of formula (83) can be treated with a metal of a suitable aryl group, as described for compounds of formula (I), of formula (85), in the presence of palladium catalyst to provide the corresponding compounds of formula (86). Compounds of formula (83) also can be treated with an alcohol of formula (87) or an amine of formula (87a), wherein R4, R5, and R6 are as defined for compounds of formula (I), in the presence of palladium catalyst to provide the corresponding compounds of formula (88).
Scheme 14 NO
~(~Y I A~ ~ I HN03 Y1 I Ar / ( 2 P
N N P
Y'=O, NH, S
(89) 1 ) Hz, Pd/C 2) (Et0)3CR3 MeOH DMF
R3 = alkyl, aryl Y' N~R3 Aj N \ RP
(91 ) CC_ Y' N
yR3 ~~ N
N
(92) , H
Benzoimidazole-substituted quinuclidines of formula (92), wherein Y' is O, NH, or S and Ar' is as defined for compounds of formula (I), can be obtained as shown in Scheme 14. Compounds of formula (89), which are obtained by treating compounds of formula (80) in Scheme 13 under standard nitrogen-protection conditions, are reacted with nitric acid in sulfuric acid to provide compounds of formula (90). Compounds of formula (90) are hydrogenated by palladium catalysis and treated with excess triethylorthoformate to obtain compounds of formula (91 ).
1o Compounds of formula (91 ) are deprotected under standard nitrogen-deprotection conditions to obtain compounds of formula (92).
Scheme 15 X1~ N02 ROB B OR RO~ _ NO
(9) B i z OBn Pd 0 /L. RO
( ) OBn X'=Br,Cl,l R=alkyl, aryl gg ( ) (95) Y' A% X, N
(97) X'=Br, CI, I
Pd(0)/L. Y'=O, NH, S
~~~Y~ N02 A
N OBn (98) 1 ) H2, Pd/C 2) (Et0)3CR3 MeOH DMF
~~~Y, N
yRs l~0 N
(99) Benzooxazole-substituted quinuclidines of formula (99), wherein Y' is O, NH, or S and Ar' and R3 are as defined for compounds of formula (I), can be obtained as shown in Scheme 14. Compounds of formula (95) can be treated with a diboron reagent of formula (9), such as bis(pinacolato)diboron and bis(catecholato)diboron, in the presence of a palladium catalyst to provide the corresponding tin or boronic acid of formula (96). Compounds of formula (96) are reacted with a desired halide of a quinuclidine-substituted heteroaromatic group Ar' as represented by compounds of 1o formula (97), wherein X' is bromide, chloride, or iodide, to provide compounds of formula (98). Compounds of formula (98) are hydrogenated by palladium catalysis and treated with excess triethylorthoformate to obtain compounds of formula (99).
Compounds of formula (I) wherein A is N can be converted to compounds of formula (I) wherein A is N+-O- by treatment with an oxidizing agent. Examples of the oxidizing agent include, but not limited to, aqueous hydrogen peroxide and m-chloroperbenzoic acid. The reaction is generally performed in a solvent such as, but not limited to, acetonitrile, water, dichloromethane, acetone or mixture thereof, preferably a mixture of acetonitrile and water, at a temperature from about room temperature to about 80°C, for a period of about 1 hour to about 4 days.
s The compounds and intermediates of the invention may be isolated and purified by methods well-known to those skilled in the art of organic synthesis.
Examples of conventional methods for isolating and purifying compounds can include, but are not limited to, chromatography on solid supports such as silica gel, alumina, or silica derivatized with alkylsilane groups, by recrystallization at high or low temperature with an optional pretreatment with activated carbon, thin-layer chromatography, distillation at various pressures, sublimation under vacuum, and trituration, as described for instance in "Vogel's Textbook of Practical Organic Chemistry", 5th edition (1989), by Furniss, Hannaford, Smith, and Tatchell, pub.
Longman Scientific & Technical, Essex CM20 2JE, England.
15 The compounds of the invention have at least one basic nitrogen whereby the compound can be treated with an acid to form a desired salt. For example, a compound may be reacted with an acid at or above room temperature to provide the desired salt, which is deposited, and collected by filtration after cooling.
Examples of acids suitable for the reaction include, but are not limited to tartaric acid, lactic acid, 2o succinic acid, as well as mandelic, atrolactic, methanesulfonic, ethanesulfonic, toluenesulfonic, naphthalenesulfonic, carbonic, fumaric, gluconic, acetic, propionic, salicylic, hydrochloric, hydrobromic, phosphoric, sulfuric, citric, or hydroxybutyric acid, camphorsulfonic, malic, phenylacetic, aspartic, glutamic, and the like.
25 Compositions of the Invention The invention also provides pharmaceutical compositions comprising a therapeutically effective amount of a compound of formula (I) in combination with a pharmaceutically acceptable carrier. The compositions comprise compounds of the invention formulated together with one or more non-toxic pharmaceutically 3o acceptable carriers. The pharmaceutical compositions can be formulated for oral administration in solid or liquid form, for parenteral injection or for rectal administration.
The term "pharmaceutically acceptable carrier," as used herein, means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. Some examples of materials which can serve as pharmaceutically acceptable carriers are sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate;
powdered tragacanth; malt; gelatin; talc; cocoa butter and suppository waxes;
oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols; such a propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible 15 lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be' present in the composition, according to the judgment of one skilled in the art of formulations.
The pharmaceutical compositions of this invention can be administered to 2o humans and other mammals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments or drops), bucally or as an oral or nasal spray. The term "parenterally," as used herein, refers to modes of administration, including intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous, intraarticular injection and infusion.
25 Pharmaceutical compositions for parenteral injection comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propylene glycol, so polyethylene glycol, glycerol, and the like, and suitable mixtures thereof), vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate, or suitable mixtures thereof. Suitable fluidity of the composition may be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surtactants.
These compositions can also contain adjuvants such as preservative agents, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It also can be desirable to include isotonic agents, for example, sugars, sodium chloride and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.
In some cases, in order to prolong the effect of a drug, it is often desirable to slow the absorption of the drug from subcutaneous or intramuscular injection.
This can be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug can depend upon its rate of dissolution, which, in turn; may depend upon crystal size and crystalline form. Alternatively, a parenterally administered drug form can be administered by dissolving or suspending the drug in an oil vehicle.
Suspensions, in addition to the active compounds, can contain suspending 2o agents, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, tragacanth, and mixtures thereof.
If desired, and for more effective distribution, the compounds of the invention can be incorporated into slow-release or targeted-delivery systems such as polymer 2s matrices, liposomes, and microspheres. They may be sterilized, for example, by filtration through a bacteria-retaining filter or by incorporation of sterilizing agents in the form of sterile solid compositions, which may be dissolved in sterile water or some other sterile injectable medium immediately before use.
Injectable depot forms are made by forming microencapsulated matrices of 3o the drug in biodegradable polymers such as polylactide-polyglycolide.
Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides) Depot injectable formulations also are prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.
s The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.
Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions can be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation also can be a sterile injectable solution, suspension or emulsion in a nontoxic, parenterally acceptable diluent or solvent such as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that can be employed are water, Ringer's solution, 15 U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.
Solid dosage forms for oral administration include capsules, tablets, pills, 2o powders, and granules. In such solid dosage forms, one or more compounds of the invention is mixed with at least one inert pharmaceutically acceptable carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and salicylic acid; b) binders such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and 25 acacia; c) humectants such as glycerol; d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; e) solution retarding agents such as paraffin; f) absorption accelerators such as quaternary ammonium compounds; g) wetting agents such as cetyl alcohol and glycerol monostearate; h) absorbents such as kaolin and bentonite 3o clay; and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.
Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using lactose or milk sugar as well as high molecular weight polyethylene glycols.
The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well-known in the pharmaceutical formulating art. They can optionally contain opacifying agents and can also be of a composition that they release the active ingredients) only, or preferentially, in a certain part of the intestinal tract in a delayed manner. Examples of materials useful for delaying release of the active agent can include polymeric substances and waxes.
Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-15 irritating carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
2o In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, 25 germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
3o Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. A desired compound of the invention is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, eardrops, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.
The ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
Powders and sprays can contain, in addition to the compounds of this , invention, lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons.
Compounds of the invention also can be administered in the form of liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes may be used. The present compositions in liposome form may contain, in 2o addition to the compounds of the invention, stabilizers, preservatives, and the like.
The preferred lipids are the natural and synthetic phospholipids and phosphatidylcholines (lecithins) used separately or together.
Methods to form liposomes are known in the art. See, for example, Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, N. Y., (1976), p 33 et seq.
Dosage forms for topical administration of a compound of this invention include powders, sprays, ointments and inhalants. The active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives, buffers or propellants. Ophthalmic formulations, eye ointments, 3o powders and solutions are also contemplated as being within the scope of this invention. Aqueous liquid compositions of the invention also are particularly useful.
The compounds of the invention can be used in the form of pharmaceutically acceptable salts, esters, or amides derived from inorganic or organic acids.
The term "pharmaceutically acceptable salts, esters and amides," as used herein, include salts, zwitterions, esters and amides of compounds of formula (I) which are, within s the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, are commensurate with a reasonable benefit/risk ratio, and are effective for their intended use.
The term "pharmaceutically acceptable salt" refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, and are commensurate with a reasonable benefit/risk ratio.
Pharmaceutically acceptable salts are well-known in the art. The salts can be prepared in situ during the final isolation and purification of the compounds of the 15 invention or separately by reacting a free base function with a suitable organic acid.
Representative acid addition salts include, but are not limited to acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-2o hydroxyethansulfonate (isethionate), lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate; pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, phosphate, glutamate, bicarbonate, p-toluenesulfonate and undecanoate.
Also, the basic nitrogen-containing groups can be quaternized with such 25 agents as lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates such as dimethyl, diethyl, dibutyl and diamyl sulfates; long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; arylalkyl halides such as benzyl and phenethyl bromides and others. Water or oil-soluble or dispersible products are thereby obtained.
3o Examples of acids which can be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, hydrobromic acid, sulphuric acid and phosphoric acid and such organic acids as oxalic acid, malefic acid, succinic acid, and citric acid.
Basic addition salts can be prepared in situ during the final isolation and purification of compounds of this invention by reacting a carboxylic acid-containing moiety with a suitable base such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation or with ammonia or an organic primary, secondary or tertiary amine. Pharmaceutically acceptable salts include, but are not limited to, cations based on alkali metals or alkaline earth metals such as lithium, sodium, potassium, calcium, magnesium, and aluminum salts, and the like, and nontoxic quaternary ammonia and amine cations including ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine and the such as. Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, and piperazine.
The term "pharmaceutically acceptable ester," as used herein, refers to esters of compounds of the invention which hydrolyze in vivo and include those that break down readily in the human body to leave the parent compound or a salt thereof.
Examples of pharmaceutically acceptable, non-toxic esters of the invention include C~-to-C6 alkyl esters and C5-to-C~ cycloalkyl esters, although C~-to-C4 alkyl esters 2o are preferred. Esters of the compounds of formula (I) can be prepared according to conventional methods. Pharmaceutically acceptable esters can be appended onto hydroxy groups by reaction of the compound that contains the hydroxy group with acid and an alkylcarboxylic acid such as acetic acid, or with acid and an arylcarboxylic acid such as benzoic acid. In the case of compounds containing carboxylic acid groups, the pharmaceutically acceptable esters are prepared from compounds containing the carboxylic acid groups by reaction of the compound with base such as triethylamine and an alkyl halide, alkyl trifilate, for example with methyl iodide, benzyl iodide, cyclopentyl'iodide. They also can be prepared by reaction of the compound with an acid such as hydrochloric acid and an alkylcarboxylic acid 3o such as acetic acid, or with acid and an arylcarboxylic acid such as benzoic acid.
The term "pharmaceutically acceptable amide," as used herein, refers to non-toxic amides of the invention derived from ammonia, primary C~-to-C6 alkyl amines and secondary C~-to-C6 dialkyl amines. In the case of secondary amines, the amine can also be in the form of a 5- or 6-membered heterocycle containing one nitrogen atom. Amides derived from ammonia, C~-to-C3 alkyl primary amides and C~-to-C2 dialkyl secondary amides are preferred. Amides of the compounds of formula (I) can be prepared according to conventional methods. Pharmaceutically acceptable amides can be prepared from compounds containing primary or secondary amine groups by reaction of the compound that contains the amino group with an alkyl anhydride, aryl anhydride, acyl halide, or aroyl halide. In the case of compounds containing carboxylic acid groups, the pharmaceutically acceptable esters are prepared from compounds containing the carboxylic acid groups by reaction of the compound with base such as triethylamine, a dehydrating agent such as dicyclohexyl carbodiimide or carbonyl diimidazole, and an alkyl amine, dialkylamine, 15 for example with methylamine, diethylamine, piperidine. They also can be prepared by reaction of the compound with an acid such as sulfuric acid and an alkylcarboxylic acid such as acetic acid, or with acid and an arylcarboxylic acid such as benzoic acid under dehydrating conditions as with molecular sieves added. The composition can contain a compound of the invention in the form of a pharmaceutically acceptable 2o prodrug.
The term "pharmaceutically acceptable prodrug" or "prodrug," as used herein, represents those prodrugs of the compounds of the invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and 2s the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use. Prodrugs of the invention can be rapidly transformed in vivo to a parent compound of formula (I), for example, by hydrolysis in blood. A
thorough discussion is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, V. 14 of the A.C.S. Symposium Series, and in Edward B. Roche, ed., 3o Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press (1987).
The invention contemplates pharmaceutically active compounds either chemically synthesized or formed by in vivo biotransformation to compounds of formula (I).
Methods of the Invention Compounds and compositions of the invention are useful for modulating the effects of nAChRs, and more particularly a7 nAChRs. In particular, the compounds and compositions of the invention can be used for treating and preventing disorders modulated by a7 nAChRs. Typically, such disorders can be ameliorated by selectively modulating the a7 nAChRs in a mammal, preferably by administering a compound or composition of the invention, either alone or in combination with another active agent, for example, as part of a therapeutic regimen.
The compounds of the invention, including but not limited to those specified in the examples, possess an affinity for nAChRs, and more particularly a7 nAChRs.
As ~ 5 a7 nAChRs ligands, the compounds of the invention can be useful for the treatment and prevention of a number of a7 nAChR-mediated diseases or conditions.
For example, a7 nAChRs have been shown to play a significant role in enhancing cognitive function, including aspects of learning, memory and attention (Levin, E.D., J. Neurobiol. 53: 633-640, 2002). As such, a7 ligands are suitable for 2o the treatment of cognitive disorders including, for example, attention deficit disorder, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, Pick's Disease, dementia associated with Lewy bodies, and dementia associated with Down's syndrome, as well as cognitive deficits associated with schizophrenia.
25 In addition, a7-containing nAChRs have been shown to be involved in the neuroprotective effects of nicotine both in vitro (Jonnala, R. B. and Buccafusco, J. J., J. Neurosci. Res. 66: 565-572, 2001 ) and in vivo (Shimohama, S. et al., Brain Res.
779: 359-363, 1998). More particularly, neurodegeneration underlies several progressive CNS disorders, including, but not limited to, Alzheimer's disease, so Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, dementia with Lewy bodies, as well as diminished CNS function resulting from traumatic brain injury. For example, the impaired function of a7 nAChRs by ~-amyloid peptides linked to Alzheimer's disease has been implicated as a key factor in development of the cognitive deficits associated with the disease (Liu, Q.-S., Kawai, H., Berg, D. K., PNAS 98: 4734-4739, 2001 ). The activation of a7 nAChRs has been shown to block this neurotoxicity (Kihara, T. et al., J. Biol. Chem. 276: 13541-13546, 2001 ). As such, selective ligands that enhance a7 activity can counter the deficits of Alzheimer's and other neurodegenerative diseases.
Schizophrenia is a complex disease that is characterized by abnormalities in perception, cognition, and emotions. Significant evidence implicates the involvement of a7 nAChRs in this disease, including a measured deficit of these receptors in post-mortem patients (Leonard, S. Eur. J. Pharmacol. 393: 237-242, 2000).
Deficits in sensory processing (gating) are one of the hallmarks of schizophrenia.
These deficits can be normalized by nicotinic ligands that operate at the a7 nAChR
(Adler L.
E. et al., Schizophrenia Bull. 24: 189-202, 1998; Stevens, K. E. et al., ~5 Psychopharmacology 136: 320-327, 1998). Thus, a7 ligands demonstrate potential in the treatment schizophrenia.
Angiogenesis, a process involved in the growth of new blood vessels, is important in beneficial systemic functions, such as wound healing, vascularization of skin grafts, and enhancement of circulation, for example, increased circulation 2o around a vascular occlusion. Non-selective nAChR agonists like nicotine have been shown to stimulate angiogenesis (Heeschen, C. et al., Nature Medicine 7: 833-839, 2001 ). Improved angiogenesis has been shown to involve activation of the a7 nAChR (Heeschen, C. et al, J. Clin. Invest. 110: 527-536, 2002). Therefore, nAChR
ligands that are selective for the a7 subtype offer improved potential for stimulating 2s angiogenesis with an improved side effect profile.
A population of a7 nAChRs in the spinal cord modulate serotonergic transmission that have been associated with the pain-relieving effects of nicotinic compounds (Cordero-Erausquin, M. and Changeux, J.-P. PNAS 98:2803-2807, 2001 ). The a7 nAChR ligands demonstrate therapeutic potential for the treatment of so pain states, including acute pain, post-surgical pain, as well as chronic pain states including inflammatory pain and neuropathic pain. Moreover, a7 nAChRs are expressed on the surface of primary macrophages that are involved in the inflammation response, and that activation of the a7 receptor inhibits release of TNF
and other cytokines that trigger the inflammation response (Wang, H. et al Nature 421: 384-388, 2003). Therefore, selective a7 ligands demonstrate potential for treating conditions involving inflammation and pain.
The mammalian sperm acrosome reaction is an exocytosis process important in fertilization of the ovum by sperm. Activation of an a7 nAChR on the sperm cell has been shown to be essential for the acrosome reaction (Son, J.-H. and Meizel, S.
Biol. Reproduct. 68: 1348-1353 2003). Consequently, selective a7 agents demonstrate utility for treating fertility disorders.
Compounds of the invention are particularly useful for treating and preventing a condition or disorder affecting cognition, neurodegeneration, and schizophrenia.
Cognitive impairment associated with schizophrenia often limits the ability of patients to function normally, a symptom not adequately treated by commonly available treatments, for example, treatment with an atypical antipsychotic.
(Rowley, M. et al., J. Med. Chem. 44: 477-501, 2001 ). Such cognitive deficit has been linked to dysfunction of the nicotinic cholinergic system, in particular with decreased activity at a7 receptors. (Friedman, J. I. et al., Biol Psychiatry, 51: 349-357, 2002).
Thus, 2o activators of a7 receptors can provide useful treatment for enhancing cognitive function in schizophrenic patients who are being treated with atypical antipsychotics.
Accordingly, the combination of an a7 nAChR ligand and an atypical antipsychotic would offer improved therapeutic utility. Specific examples of suitable atypical antipsychotics include, but are not limited to, clozapine, risperidone, olanzapine, 2s quietapine, ziprasidone, zotepine, iloperidone, and the like.
Actual dosage levels of active ingredients in the pharmaceutical compositions of this invention can be varied so as to obtain an amount of the active compounds) that is effective to achieve the desired therapeutic response for a particular patient, compositions and mode of administration. The selected dosage level will depend 3o upon the activity of the particular compound, the route of administration, the severity of the condition being treated and the condition and prior medical history of the patient being treated. However, it is within the skill of the art to start doses of the compound at levels lower than required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.
When used in the above or other treatments, a therapeutically effective amount of one of the compounds of the invention can be employed in pure form or, where such forms exist, in pharmaceutically acceptable salt, ester, amide or prodrug form. Alternatively, the compound can be administered as a pharmaceutical composition containing the compound of interest in combination with one or more pharmaceutically acceptable carriers. The phrase "therapeutically effective amount"
of the compound of the invention means a sufficient amount of the compound to treat disorders, at a reasonable benefit/risk ratio applicable to any medical treatment. It will be understood, however, that the total daily usage of the compounds and compositions of the invention will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level 15 for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment;
2o drugs used in combination or coincidental with the specific compound employed; and like factors well-known in the medical arts. For example, it is well within the skill of the art to start doses of the compound at levels lower than required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.
25 The total daily dose of the compounds of this invention administered to a human or lower animal range from about 0.10 mg/kg body weight to about 1 g/kg body weight. More preferable doses can be in the range of from about 0.10 mg/kg body weight to about 100 mg/kg body weight. If desired, the effective daily dose can be divided into multiple doses for purposes of administration. Consequently, single 3o dose compositions may contain such amounts or submultiples thereof to make up the daily dose.
The compounds and processes of the invention will be better understood by reference to the following examples and reference examples, which are intended as an illustration of and not a limitation upon the scope of the invention.
EXAMPLES
Example 1 3-(4-(,1-Azabicyclo(2.2.2]oct-3-yloxy)phenyll-1 H-indole o Example 1 A
3-(4-lodophenoxy)quinuclidine Under N2, the mixture of 3-hydroxy quinuclidine (Aldrich, 2.54 g, 20 mmol), 1,4-diiodobenzene ~Aldrich, 7.9 g, 24 mmol), Cul (Strem Chemicals, 0.38 g, 2 mmol) and 1,10-phenanthroline (Aldrich, 0.72 g, 4 mmol) in toluene (anhydrous, Aldrich, 50 ~5 mL) was stirred at 110 °C for 40 h. After the reaction went to completion, the reaction mixture was diluted with chloroform (100 mL) and washed with water (2 x 10 mL).
The organic solution was concentrated and the title compound was purified by chromatography (Si02, CH2C12: MeOH : NH3~H20, 90:10:1, Rf. 0.20) as oil (3.7 g, yield, 56%).'H NMR (300 MHz, CD30D) 8 1.40-1.56 (m, 1H), 1.64-1.80 (m, 2H), 20 1.90-2.08 (m, 1 H), 2.10-2.21 (m, 1 H), 2.60-3.00 (m, 5H), 3.34-3.40 (m, 1 H), 4.46 (m, 1 H), 6.73 (d, J=8.8 Hz, 2H), 7.56 (d, J=8.8, Hz, 2H), ppm. MS (DCI/NH3) m/z (M+H)+.
Example 1 B
25 3-(4-(1-Azabicyclo(2.2.21oct-3-yloxY)phenyll-1 H-indole The mixture of the product of Example 1A (330 mg, 1 mmol), N-(2-ethynyl-phenyl)-2,2,2-trifluoro-acetamide (ref. Tetrahedron Lett. 1992, 33, 3915.; 280 mg, 1.3 mmol), Pd2(dba)3 (Aldrich, 19 mg, 0.02 mmol) and K2C03 (180 mg, 1.3 mmol) in DMSO (3 mL) was stirred at 40 °C under N2 for 2 hours. The reaction was monitored 3o with TLC. After the reaction was complete, it was cooled down to room temperature and diluted with EtOAc (50 mL). It was then washed with brine (3 x 5 mL). The organic solution was concentrated and the title product was purified by preparative HPLC (Gilson, column, Symmetry~ C-8 7 pm, 40 x 100 mm. Eluting Solvent, MeCN
/ H20 (with 0.2% v. TFA) (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (113 mg, yield, 36%).'H NMR (300 MHz, CD30D) b 1.43-1.57 (m, 1 H), 1.62-1.89 (m, 2H), 2.01-2.15 (m, 1 H), 2.16-2.23 (m, 1 H), 2.73-3.03 (m, 5H), 3.28-3.40 (m, 1 H), 4.51-4.58 (m, 1 H), 6.97 (dt, J=8.8, 2.1 Hz, 2H), 7.03-7.17 (m, 2H), 7.36 (s, 1 H), 7.37-7.42 (m, 1 H), 7.57 (dt, J=8.8, 2.0 Hz, 2H), 7.81 (dt, J=
7.8, 1.2 Hz, 1 H) ppm. MS (DCI/NH3) m/z 319 (M+H)+.
Example 1 C
3-f4-(1-Azabicyclo[2.2.21oct-3-yloxy)phenyll-1 H-indole hemifumarate The product of Example 1 B (113 mg, 0.36 mmol) was treated with fumaric acid (46 mg, 0.4 mmol) in EtOAc/EtOH (v. 1:1, 4 mL) at ambient temperature for h. The title compound was obtained as solid (131 mg, yield, 89%).'H NMR (300 ~5 MHz, CD30D) S 1.73-2.13 (m, 3H), 2.23-2.37 (m, 1 H), 2.43-2.51 (m, 1 H), 3.12-3.43 (m, 5H), 3.64-3.76 (m, 1 H), 4.77-4.88 (m, -1 H), 6.67 (s, 1.4H), 6.99-7.18 (m, 4H), 7.38 (s, 1 H), 7.39-7.43 (m, 1 H), 7.61 (dt, J=8.8, 2.0 Hz, 2H), 7.80 (d, J=
7.8 Hz, 1 H) ppm. MS (DCI/NH3): m/z 319 (M+H)+. Anal. Calculated for C2~H22N20~0.85 C4H404:
C, 70.27; H, 6.14; N, 6.72. Found: C, 70.20; H, 6.35; N, 6.88.
Example 2 4-f4-(1-Azabicyclof2.2.21oct-3-yloxy)phenyll-1 H-indole Example 2A
2s 3-f4-(Trimethylstannyl)phenoxylquinuclidine The mixture of the product from Example 1A (330 mg, 1 mmol), hexamethylditin (Aldrich, 654 mg, 2 mmol) and Pd(PPh3)4 (Aldrich, 116 mg, 0.1 mmol) in toluene (10 mL) was stirred at 110 °C under N2 for 2 hours.
The reaction was monitored with TLC. After the reaction was complete, it was cooled down to 3o room temperature and diluted with EtOAc (50 mL). It was then washed with brine (2 x 5 mL). The organic solution was concentrated under reduced pressure and the title compound was purified by flash chromatography (Si02, CH2C12 : MeOH : NH3~H20, 90:10:1, Rf. 0.35) as solid (300 mg, yield, 82%).'H NMR (300 MHz, CD30D) b 0.25 (s, 9H), 1.79-2.16 (m, 3H), 2.23-2.36 (m, 1 H), 2.45-2.52 (m, 1 H), 3.17-3.43 (m, 5H), 3.73-3.83 (m, 1 H), 4.84-4.92 (m, 1 H), 6.96 (d, J=8.5 Hz, 2H), 7.41 (d, J=8.5 Hz, 2H) s ppm. MS (DCI/NH3): m/z 364 (M+H)+, 366 (M+H)+, 368 (M+H)+.
Example 2B
4-[4-(1-Azabicyclof2.2.21oct-3-yloxy)phenyl~-1 H-indole The product of 2A (300 mg, 0.8 mmol), 4-bromoindole (Aldrich, 196 mg, 1 mmol), Pd2(dba)3 (Aldrich, 27 mg, 0.03 mmol) and (o-tol.)3P (Aldrich, 27 mg, 0.09 mmol) in DMF (Aldrich, anhydrous, 5 mL) were heated to 80 °C under N2 and stirred overnight. It was then cooled down to room temperature and diluted with EtOAc (50 mL). The mixture was washed with brine (2 x 5 mL). The organic solution was concentrated under reduced pressure and the title compound was purified by flash ~5 chromatography~(Si02, CH2C12: MeOH : NH3~H20, 90:10:1, Rf. 0.30) as a solid (48 mg, yield, 19%).'H NMR (300 MHz, CD30D) b 1.46-1.58 (m, 1H), 1.64-1.91 (m, 2H), 2.01-2.17 (m, 1 H), 2.19-2.26, (m, 1 H), 2.75-3.03 (m, 5H), 3.32-3.42 (m, 1 H), 4.55-4.63 (m, 1 H), 6.58 (dd, J=3.4, 1.0 Hz, 1 H), 6.98-7.04 (m, 3H), 7.14 (t, J=7.8 Hz, 1 H), 7.25 (d, J=3.1 Hz, 1 H), 7.33 (dt, J=8.1, 1.0 Hz, 1 H), 7.59 (dt, J=9.2, 2.7 Hz, 2H) 2o ppm. MS (DCI/NH3): m/z 319 (M+H)+.
Example 2C
4-f4-(1-Azabicyclo[2.2.2~oct-3-yloxy)phenyl~-1 H-indole fumarate The product of Example 2B (48 mg, 0.15 mmol) was treated with fumaric acid 25 (23 mg, 0.2 mmol) in EtOAc/EtOH (v. 1:1, 3 mL) at ambient temperature for 15 h.
The title compound was obtained as solid (60.2 mg, yield, 90%).'H NMR (300 MHz, CD30D) b 1.82-2.19 (m, 3H), 2.29-2.42 (m, 1 H), 2.51-2.58 (m, 1 H), 3.16-3.46 (m, 5H), 3.75-3.85 (m, 1 H), 4.89-4.96 (m, 1 H), 6.56 (dd, J=3.4, 1.0 Hz, 1 H), 6.69 (s, 2.2H), 7.02 (dd, J=7.1, 1.0 Hz, 1 H), 7.08 (dt, J=8.8, 2.5 Hz, 2H), 7.15 (t, J=7.5 Hz, 30 1 H), 7.26 (d, J=3.4 Hz, 1 H), 7.35 (dt, J=8.1, 1.0 Hz, 1 H), 7.64 (dt, J=8.8, 2.6 Hz, 2H) ppm. MS (DCI/NH3): m/z 319 (M+H)+. Anal. Calculated for C2~H22N20~1.12 C4H404:
C, 68.25; H, 5.95; N, 6.25. Found: C, 68.43; H, 5.58; N, 6.20.
Example 3 5-f4-(1-Azabicyclof2.2.2~oct-3-yloxy)phenyll-1 H-indole Example 3A
5-f4-(,1-Azabicyclof2.2.21oct-3-yloxy)phenyll-1 H-indole Under N2, the product of Example 1A (329 mg, 1 mmol), 5-indolylboronic acid o (Frontier, 193 mg, 1.2 mmol), Pd2(dba)3 (Aldrich, 24 mg, 0.025 mmol), (~Bu3P)2 Pd (26 mg, 0.05mmol), K2C03 (276 mg, 2 mmol) and KF (80 mg, 1.4 mmol) in THF(8 mL) was stirred at 60 °C overnight. The reaction was monitored with TLC. After the reaction was complete, it was diluted with EtOAc (30 mL) and washed with brine (2 x 5 mL). The organic solution was concentrated under reduced pressure and the title product was purified by preparative HPLC (Gilson, column, Symmetry~ C-8 7 Nm, 40 x 100 mm. Eluting Solvent, MeCN / H20 (with 0.2% v. TFA) (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (80 mg, yield, 25%).'H
NMR (300 MHz, CD30D) b 1.44-1.58 (m, 1 H), 1.62-1.90 (m, 2H), 2.01-2.15 (m, 1 H), 2.16-2.24 (m, 1 H), 2.74-3.04 (m, 5H), 3.27-3.40 (m, 1~H), 4.51-4.59 (m, 1 H), 6.46 (dd, 2o J=3.4, 1.1 Hz, 1 H), 6.95 (dt, J=8.8, 2.6 Hz, 2H), 7.22 (d, J=3.1 Hz, 1 H), 7.31 (dd, J=8.5, 2.0 Hz, 1 H), 7.40 (dt, J=8.5, 1.0 Hz, 1 H), 7.54 (dt, J=9.2, 2.6 Hz, 2H), 7.71 (dd, J=1.7, 0.7 Hz, 1 H) ppm. MS (DCI/NH3): m/z 319 (M+H)+.
Example 3B
5-f4-(1-Azabicyclof2.2.21oct-3-yloxy)phenyl]-1 H-indole fumarate The product of Example 3A (80 mg, 0.25 mmol) was treated with fumaric acid (29 mg, 0.25 mmol) in EtOAc/EtOH (v. 1:1, 4 mL) at ambient temperature for 10 h.
The title compound was obtained as solid (57 mg, yield, 52%).'H NMR (300 MHz, CD30D) b 1.78-2.16 (m, 3H), 2.25-2.39 (m, 1 H), 2.46-2.54 (m, 1 H), 3.14-3.45 (m, 5H), 3.69-3.81 (m, 1 H), 4.80-4.89 (m, 1 H), 6.46 (dd, J=3.0, 1.0, 1 H), 6.68 (s, 2H), 7.02 (dt, J=8.8, 2.5 Hz, 2H), 7.23 (d, J=3.1 Hz, 1 H), 7.31 (dd, J=8.5, 2.0 Hz, 1 H), 7.43 (dt, J=8.4, 0.8 Hz, 1 H), 7.58 (dt, J=9.2, 2.6 Hz; 2H), 7.71 (dd, J=1.7, 1.0 Hz, 1 H) ppm. MS (DCI/NH3): m/z 319 (M+H)+. Anal. Calculated for C2~H22NzO~C4H404: C, 69.11; H, 6.03; N, 6.45. Found: C, 69.23; H, 5.81; N, 6.59.
Example 4 5-~4-f(3R)-1-Azabicyclo~2.2.21oct-3-yloxy~phenyl)-1 H-indole Example 4A
(3R)-3-Quinuclidinol o (3R)-3-Quinuclidinol hydrochloride (Aldrich, 20 g, 12.2 mmol) was treated with NaOH aqueous solution(20%, 50 mL) at ambient temperature for 10 min. It was then extracted with CHC13/'PrOH (v. 10 : 1, 3 x 200 mL). The extracts were combine, washed with brine (50 mL) and dried over MgS04. The drying agents were removed by filtration and the filtrates was concentrated under reduced pressure to give the ~5 title compound as white solid (15. 5 g, yield, 99%).'H NMR (300 MHz, CD30D) b 1.36-1.50 (m, 1 H), 1.52-1.60 (m, 1 H), 1.76-1.85 (m, 2H), 1.90-2.05 (m, 1 H), 2.50-2.95(m, 5H), 3.10 (ddd, J=14.2, 8.4, 2.3 Hz, 1 H), 3.82-3.88 (m, 1 H) ppm. MS
(DCI/NH3): m/z 128 (M+H)+. , 2o Example 4B
-3-(4-Bromophenoxy)quinuclidine The product of Example 4A (1.27 g, 10 mmol) was coupled with 1-iodo-4-bromobenzene (Aldrich, 2.83 g, 10 mol) according to the procedure of Example 1A.
The title product was purified by chromatography (Si02, CH2C12 : MeOH :
NH3~H20, 25 90:10:1, Rf. 0.30) as solid (400 mg, yield, 14%).'H NMR (300 MHz, CD30D) b 1.41-1.54 (m, 1 H), 1.59-1.73 (m, 1 H), 1.73-1.86 (m, 1 H), 1.92-2.06 (m, 1 H), 2.09-2.17 (m, 1 H), 2.71-2.97 (m, 5H), 3.24-3.34 (m, 1 H), 4.45-4.52 (m, 1 H), 6.83 (dt, J=9.2, 2.6 Hz, 2H), 7.37 (dt, J=9.2, 2.7 Hz, 2H) ppm. MS (DCI/NH3): m/z 282 (M+H)+, 284 (M+H)+.
3o Example 4C
5-~4-[(,3R)-1-Azabicyclof2.2.21oct-3-yloxy~phenyl)-1 H-indole The product of 4C (282 mg, 1 mmol) coupled with 5-indolylboronic acid (Frontier, 190 mg, 1.2 mmol) according to the procedure of Example 3A. The title product was purified by chromatography (Si02, CH2C12 : MeOH : NH3~H20, 90:10:1, Rf. 0.35) as solid (50 mg, yield, 16%).'H NMR (300 MHz, CD30D) S 1.44-1.58 (m, 1 H), 1.62-1.90 (m, 2H), 2.01-2.15 (m, 1 H), 2.16-2.24 (m, 1 H), 2.74-3.04 (m, 5H), 3.27-3.40 (m, 1 H), 4.51-4.59 (m, 1 H), 6.46 (dd, J=3.4, 1.1 Hz, 1 H), 6.95 (dt, J=8.8, 2.6 Hz, 2H), 7.22 (d, J=3.1 Hz, 1 H), 7.31 (dd, J=8.5, 2.0 Hz, 1 H), 7.40 (dt, J=8.5, 1.0 Hz, 1 H), 7.54 (dt, J=9.2, 2.6 Hz, 2H), 7.71 (dd, J=1.7, 0.7 Hz, 1 H) ppm. MS
(DCI/NH3): m/z 319 (M+H)+.
Example 4D
5-f4-f(3R)-1-Azabicyclof2.2.2~oct-3-yloxylphenyl~-1 H-indole fumarate The product of Example 4C (50 mg, 0.25 mmol) was treated with fumaric acid (29 mg, 0.25 mmol) in EtOAc/EtOH (v. 1:1, 4 mL) at ambient temperature for 10 h.
The title compound was obtained as solid (56.9 mg, yield, 52%).'H NMR (300 MHz, CD30D) b 1.78-2.16 (m, 3H), 2.25-2.39 (m, 1 H), 2.46-2.54 (m, 1 H), 3.14-3.45 (m, 5H), 3.69-3.81 (m, 1 H), 4.80-4.89 (m, 1 H), 6.46 (dd, J=3.0, 1.0, 1 H), 6.68 (s, 2.2H), 7.02 (dt, J=8.8, 2.5 Hz, 2H), 7.23 (d, J=3.1 Hz, 1 H), 7.31 (dd, J=8.5, 2.0 Hz, 1 H), 7.43 (dt, J=8.4, 0.8 Hz, 1 H), 7.58 (dt, J=9.2, 2.6 Hz, 2H), 7.71 (dd, J=1.7, 1.0 Hz, 1 H) 2o ppm. MS (DCI/NH3): m/z 319 (M+H)+. Anal. Calculated for C2~H22N20~1.14 C4H404:
C, 68.11; H, 5.94; N, 6.21. Found: C, 68.12; H, 6.04; N, 6.18.
Example 5 6-f4-(1-Azabicyclo[2.2.21oct-3-yloxy)phenyll-1 H-indole Example 5A
6-f4-( 1-Azabicyclo f 2.2.2~oct-3-yloxy)phenyll-1 H-indole The product of Example 2A (300 mg, 0.8 mmol) was coupled with 6-bromoindole (Aldrich, 196 mg, 1 mmol) according to the procedure in 2B. The title compound was purified by chromatography (Si02, CH2C12 : MeOH : NH3~H20, 90:10:1, Rf. 0.20) as a solid (30 mg, yield, 12%).'H NMR (300 MHz, CD30D) b 1.45-1.58 (m, 1 H), 1.64-1.90 (m, 2H), 2.01-2.15 (m, 1 H), 2.17-2.24 (m, 1 H), 2.75-3.04 (m, 5H), 3.30-3.42 (m, 1 H), 4.53-4.61 (m, 1 H), 6.43 (dd, J=3.1, 0.7 Hz, 1 H), 6.97 (dt, J=8.8, 2.6 Hz, 2H), 7.21-7.27 (m, 2H), 7.52-7.60 (m, 4H) ppm. MS
(DCI/NH3): m/z 319 (M+H)+.
Example 5B
6-f4-(1-Azabicyclof2.2.21oct-3-yloxy)phenyl~-1 H-indole fumarate The product of Example 5A (30 mg, 0.1 mmol) was treated with fumaric acid (12 mg, 0.1 mmol) in EtOAc/EtOH (v. 1:1, 2 mL) at ambient temperature for 15 h.
The title compound was obtained as solid (38.4 mg, yield, 79%).'H NMR (300 MHz, CD30D) b 1.80-2.19 (m, 3H), 2.27-2.40 (m, 1 H), 2.48-2.56 (m, 1 H), 3.17-3.63 (m, 5H), 3.72-3.83 (m, 1 H), 4.80-4.88 (m, 1 H), 6.43 (dd, J=3.1, 0.7 Hz, 1 H), 6.68 (s, 2H), 7.04 (dt, J=8.8, 2.5 Hz, 2H), 7.21-7.27 (m, 2H), 7.53-7.65 (m, 4H) ppm.
MS(DCI/NH3): m/z 319 (M+H)+. Anal. Calcd. for C~9H2oN40~1.3 C4H4O4: C, 67.05;
H, 5.84; N, 5.97. Found: C, 67.15; H, 5.99; N, 5.95.
Example 6 2-[4-(1-Azabicyclo[2.2.21oct-3-yloxy)phenyll-1 H-indole 2o Example 6A
3-(4-Ethynylphenoxy)quinuclidine Under N2, the mixture of the product from Example 1A (800 mg, 2.4 mmol), trimethylsilylacetylene (Aldrich, 392 mg, 4 mmol), Pd(PPh3)4 ( Aldrich, 29 mg, 0.025 mmol) and Cul (Strem Chemicals, 10 mg, 0.05 mmol) in DMF (10 mL) was stirred at ambient temperature overnight. DMF then was removed under reduced pressure.
The residue was treated with tetrabutyl ammonium fluoride (Aldrich, in THF, 1 M, 5 mL) at room temperature for 3 h. The reaction was monitored with TLC. After the reaction was complete, it was diluted with EtOAc (50 mL) and washed with brine (2 x 10 mL). The organic solution was concentrated and the title compound was purified 3o by chromatography (Si02, CH2C12: MeOH : NH3~H20, 90:10:1, Rf. 0.30) as a solid (560 mg, yield, 99%).'H NMR (300 MHz, CD30D) b 1.42-1.54 (m, 1H), 1.61-1.87 -54- ' (m, 2H), 1.93-2.07 (m, 1 H), 2.10-2.18 (m, 1 H), 2.71-3.00 (m, 5H), 3.19-3.37 (m, 2H), 4.49-4.56 (m, 1 H), 6.86 (d, J=8.8 Hz, 2H), 7.37 (d, J=8.8 Hz, 2H) ppm. MS
(DCI/NH3): m/z 228 (M+H)+.
s Example 6B
2,2,2-Trifluoro-N-(2-iodophenyl)acetamide 2-lodo-phenylamine (Aldrich, 1.09 g, 5 mmol) was treated with trifluoroacetic anhydride (Aldrich, 1.26 g, 6 mmol) and 2,6-di-tert-butyl-4-methyl-pyridine (Aldrich, 1.23 g, 6 mmol) in CH2C12 (10 mL)at room temperature overnight. It was then quenched with with water (5 mL) and extracted with EtOAc (3 x 10 mL). The extracts were combined and washed with brine (5 mL). The organic solution was concentrated and the title compound was purified by flash chromatography (Si02, Hexanes/EtOAc, 80:20, Rf. 0.50) as a solid (1.1 g, yield, 70%).'H NMR (300 MHz, CD30D) S 7.07-7.12 (m, 1 H), 7.39-7.47 (m, 2H), 7.95 (dd, J=7.8, 1.3 Hz, 1 H) ppm.
15 MS (DCI): m/z 316 (M+H)+.
Example 6C
2-f4-(1-Azabicyclof2.2.21oct-3-yloxy)phenyll-1 H-indole Under N2, the mixture of product from Example 6A (114 mg, 0.5 mmol), the 2o product from Example 6B (157 mg, 0.5 mmol), Cul (Strem Chemicals, 14 mg, 0.075 mmol), PPh3 (Aldrich, 39 mg, 0.15 mmol) and K3P04 (212 mg, 1 mmol) in dioxane (5 mL) was stirred at 80 °C for 20 h. After the reaction was complete, it was diluted with EtOAc (30 mL) and washed with brine (2 x 5 mL). The organic solution was concentrated under reduced pressure and the title compound was purified by 25 chromatography (Si02, CH2C12: MeOH : NH3~H20, 90:10:1, Rf. 0.30) as solid (70 mg, yield, 44%).'H NMR (300 MHz, CD30D) S 1.45-1.59 (m, 1H), 1.65-1.91 (m, 2H), 2.00-2.14 (m, 1 H), 2.17-2.24 (m, 1 H), 2.75-3.01 (m, 5H), 3.31-3.42 (m, 1 H), 4.54-4.62 (m, 1 H), 6.66 (d, J=0.7 Hz, 1 H), 6.93-7.00 (m, 3H), 7.01-7.08 (m, 1 H), 7.35 (dq, J=8.2, 1.0 Hz, 1 H), 7.48 (dq, J=7.8, 0.7 Hz, 1 H), 7.71 (dt, J=8.8, 2.6 Hz, 2H) ppm.
3o MS (DCI/NH3): m/z 319 (M+H)+.
Example 6D
2-f4-(1-Azabicyclof2.2.21oct-3-yloxy)phenyl]-1H-indole fumarate The product of Example 6C (70 mg, 0.22 mmol) was treated with fumaric acid (29 mg, 0.25 mmol) in EtOAc/EtOH (v. 1:1, 3 mL) at ambient temperature for 10 h.
The title compound was obtained as solid (87 mg, yield, 89%).'H NMR (300 MHz, CD30D) S 1.81-2.18(m, 3H), 2.25-2.39 (m, 1 H), 2.48-2.56 (m, 1 H), 3.19-3.48 (m, 5H), 3.73-3.85 (m, 1 H), 4.86-4.93 (m, 1 H), 6.65-6.80 (m, 2H), 6.94-7.10 (m, 4H), 7.36 (dd, J=8.1, 0.7 Hz, 1 H), 7.49 (dt, J=7.8, 1.0 Hz, 1 H), 7.75 (dt, J=9.2, 2.4 Hz,, 2H) ppm. MS (DCI/NH3): m/z 319 (M+H)+. Anal. Calculated for C2~H2zN20~1.1 C4H4O4:
C, 68.39; H, 5.96; N, 6.28. Found: C, 68.10; H, 6.22; N, 6.25.
Example 7 5-f6-(1-Azabicyclof2.2.21oct-3-yloxy)pyridazin-3-yl1-1 H-indole ~5 Example 7A
3-f (6-Chloropyridazin-3-yl)ox~~quinuclidine 3-Quinuclidinol (Aldrich, 508 mg, 4 mmol) was treated with tBuOK (Aldrich, 448 mg, 4 mmol) in THF(20 mL) at ambient temperature for 1 hour. 3,6-Dichloropyradazine (Aldrich, 740 mg, 5 mmol) was then added. The mixture was 2o stirred at ambient temperature for additional 1 h. The reaction was monitored with TLC. After the reaction was complete, it was concentrated under reduced pressure.
The residue was dissolved in CHC13/'PrOH (v.10 : 1, 50 mL) and washed with brine (2 x 5 mL). The organic solution was concentrated under reduced pressure and the title compound was purified by chromatography (Si02, CH2C12 : MeOH : NH3~H20, 25 90:10:1, Rf. 0.45) as a solid (780 mg, yield, 82%).'H NMR (300 MHz, CD30D) b 1.48-1.61 (m, 1 H), 1.65-1.90 (m, 2H), 1.94-2.08 (m, 1 H), 2.23-2.31 (m, 1 H), 2.73-3.01 (m, 5H), 3.37-3.48 (m, 1 H), 5.18-5.27 (m, 1 H), 7.23 (d, J=9.2 Hz, 1 H), 7.65 (d, J=9.2 Hz, 1 H) ppm. MS (DCI/NH3): 240 (M+H)+, 242 (M+H)+.
30 Example 7B
5-f6-(1-Azabicyclof2.2.21oct-3-yloxy)pyridazin-3-yll-1 H-indole The product of Example 7A (200 mg, 0.8 mmol) was coupled with 5-indolylboronic acid (161 mg, 1 mmol) according to the procedure of Example 3A.
The title product was purified by preparative HPLC (Gilson, column, Symmetry~ C-8 pm, 40 x 100 mm. Eluting Solvent, MeCN / H20 (with 0.2% v. TFA) (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (35 mg, yield, 14%).
'H NMR (300 MHz, CD30D) b 1.50-1.65 (m, 1H), 1.70-1.93 (m, 2H), 2.00-2.16 (m, 1 H), 2.29-2.37 (m, 1 H), 2.78-3.05 (m, 5H), 3.44-3.55 (m, 1 H), 5.26-5.35 (m, 1 H), 6.56(dd, J=3.3, 1.1 Hz, 1 H)), 7.25 (d, J=9.2 Hz, 1 H), 7.31 (d, J=3.4 Hz, 1 H), 7.51 (d, J=8.8 Hz, 1 H), 7.73 (dd, J=8.5, 1.7 Hz, 1 H), 8.08 (d, J=9.5 Hz, 1 H), 8.14 (d, J=1.7 Hz, 1 H) ppm. MS (DCI/NH3): m/z 321 (M+H)+.
Example 7C
5-f6-(1-Azabicyclof2.2.21oct-3-yloxy)pyridazin-3-yl~-1 H-indole hemifumarate The product of Example 7B (35mg, 0.11 mmol) was treated with fumaric acid (23 mg, 0.2 mmol) in EtOAc/EtOH (v. 1:1, 3 mL) at ambient temperature for 10 h.
The title compound was obtained as solid (42 mg, yield, 99%). ~H NMR (300 MHz, CD30D) b 1.76-1.91 (m, 1 H), 1.92-2.13 (m, 2H), 2.22-2.36 (m, 1 H), 2.51-2.59 (m, 1 H), 3.12-3.40 (m, 5H), 3.77-3.88 (m, 1 H), 5.42-5.51 (m, 1 H); 6.56 (dd, J=2.0, 1.OHz, 1 H), 6.67 (s, 1 H), 7.27-7.33 (m, 2H), 7.52 (dt, J=8.5, 1.0 Hz, 1 H), 7.74 (dd, J=8.8, 1.7 Hz, 1 H), 8.10-8.16 (m, 2H) ppm. MS (DCI/NH3): m/z 321 (M+H)+. Anal.
Calculated for C~9H2oN40~0.55 C4H404: C, 66.27; H, 5.82; N, 14.58. Found: C, 66.12; H, 5.53; N, 14.63.
Example 8 4-f6-(1-Azabicyclof2.2.21oct-3-ylox~~pyridazin-3-yl1-1 H-indole Example 8A
4-f6-(1-Azabicyclof2.2.21oct-3-yloxy)pyridazin-3-yl1-1 H-indole Under N2, the mixture of Example 7A (168 mg, 0.7 mmol), 4-(4,4,5,5-tetramethyl-[1,3,2Jdioxaborolan-2-yl)-1 H-indole (ref. W002055517, 170 mg, 0.7 mmol), Pd2(dba)3 (Aldrich, 19 mg, 0.02 mmol), 1,3-bis(2,6-iso-propylphenyl)imidazolium chloride (Strem Chemicals, 26 mg, 0.06 mmol) and aqueous Na2C03 (2 M, 1 mL) in toluene (10 mL) was stirred at 110 °C
overnight, After the reaction was complete, it was cooled down to room temperature and diluted with EtOAc (30 mL). The mixture was then washed with brine (2 x 5 mL) and the title compound was purified by chromatography (Si02, CH2C12 : MeOH : NH3~H20, 90:10:1, Rf. 0.10) as solid (45 mg, yield, 20%).'H NMR (300 MHz, CD30D) b 1.51-1.65 (m, 1 H), 1.70-1.93 (m, 2H), 2.01-2.16 (m, 1 H), 2.31-2.39 (m, 1 H), 2.78-3.09 (m, 5H), 3.45-3.56 (m, 1 H), 5.30-5.38 (m, 1 H), 6.78 (dd, J=3.4, 1.0 Hz, 1 H), 7.25 (t, J=7.8 Hz, 1 H), 7.30 (d, J=9.5 Hz, 1 H), 7.36 (d, J=3.1 Hz, 1 H), 7.40 (dd, J=7.5, 1.0 Hz, 1 H), 7.52 (dt, J= 8.1, 1.0 Hz, 1 H), 8.07 (d, J=9.2 Hz, 1 H) ppm. MS
(DCI/NH3):
m/z 321 (M+H)+.
Example 8B
4-(6-(1-Azabicyclo(2.2.21oct-3-yloxy~yridazin-3-yl~-1 H-indole fumarate The product of Example 8A (45 mg, 0.14 mmol) was treated with fumaric acid (23 mg, 0.2 mmol) in EtOAc/EtOH (v. 1:1, 3 mL) at ambient temperature for 10 h.
The title compound was obtained as solid (56 mg, yield, 85%).'H NMR (300 MHz, CD30D) b 1.90-2.23 (m, 3H), 2.33-2.48 (m, 1 H), 2.62-2.70 (m, 1 H), 3.21-3.54 (m, 5H), 3.92-4.03 (m, 1 H), 5.54-5.62 (m, 1 H), 6.69 (s, 2.5H), 6.78 (dd, J=3.4, 1.0 Hz, 1 H), 7.26 (t, J=7.5 Hz, 1 H), 7.35-7.44 (m, 3H), 7.55 (dt, J=8.1, 1.1 Hz, 1 H), 8.13 (d, J=9.2 Hz, 1 H) ppm. MS (DCI/NH3): m/z 321 (M+H)+. Anal. Calculated for C~9H2oN40~1.3 C4H4O4: C, 61.67; H, 5.39; N, 11.89. Found: C, 61.49; H, 5.52;
N, 12.17.
Example 9 5-{6-((3R)-1-Azabicyclo(2.2.21oct-3-yloxylpyridazin-3-yl}-1 H-indole Example 9A
(3R)-3-((6-Chloropyridazin-3-yl)oxy~guinuclidine 3o The product of Example 4A (635 mg, 5 mmol) was coupled with 3,6-dichloropyridazine (Aldrich, 925 mg, 6.25 mmol) according to the procedure of Example 7A. The title compound was purified by chromatography (Si02, CH2C12 MeOH : NH3~H20, 90:10:1, Rf. 0.45) as solid (750 mg, yield, 63%).'H NMR (300 MHz, CD30D) S 1.54-1.68 (m, 1 H), 1.71-1.95 (m, 2H), 2.00-2.14 (m, 1 H), 2.28-2.36 (m, 1 H), 2.83-3.08 (m, 5H), 3.44-3.56 (m, 1 H), 5.23-5.30 (m, 1 H), 7.24 (d, J= 9.2 Hz, 1 H), 7.66 (d, J= 9.2 Hz, 1 H) ppm. MS (DCI/NH3): 240 (M+H)+, 242 (M+H)+.
Example 9B
5-~6-[(3R)-1-Azabicyclo[2.2.21oct-3-ylox~~pyridazin-3- rl -1 H-indole The product of Example 9A (480 mg, 2 mmol) was coupled with 5-indolylboronic acid (Frontier, 403 mg, 2.5 mmol) according to the procedure of Example 3A. The title product was purified by preparative HPLC (Gilson, column, Symmetry~ C-8 7 Nm, 40 x 100 mm. Eluting Solvent, MeCN / H20 (with 0.2% v.
TFA) (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (240 mg, yield, 38%).'H NMR (300 MHz, CD30D) b 1.49-1.64 (m, 1H), 1.68-1.93 (m, 2H), 2.00-2.15 (m, 1 H), 2.28-2.36 (m, 1 H), 2.76-3.05 (m, 5H), 3.43-3.55 (m, 1 H), 5.26-5.34 (m, 1 H), 6.56 (dd, J=3.4, 1.0 Hz, 1 H), 7.25 (d, J=9.2 Hz, 1 H),~7.31 (d, J=3.1 Hz, 1 H), 7.50 (d, J= 8.5 Hz, 1 H), 7.74 (dd, J=8.5, 1.7 Hz, 1 H), 8.08 (d, J=9.5 Hz, 1 H), 8.14 (d, J=1.4 Hz, 1 H) ppm. MS (DCI/NH3): m/z 321 (M+H)+.
2o Example 9C
5-~6-[(3R)-1-Azabicyclo[2.2.21oct-3-yloxylpyridazin-3-yl;-1 H-indole fumarate The product of Example 9B (240 mg, 0.75 mmol) was treated with fumaric acid (93 mg, 0.8 mmol) in EtOAc/EtOH (v. 1:1, 10 mL) at ambient temperature for 15 h. The title compound was obtained as solid (247 mg, yield, 72%).'H NMR (300 MHz, CD30D) b 1.88-2.22 (m, 3H), 2.31-2.47 (m, 1 H), 2.59-2.68 (m, 1 H), 3.23-3.50 (m, 5H), 3.89-4.00 (m, 1 H), 5.49-5.57 (m, 1 H), 6.56(dd, J=3.0, 1.0 Hz, 1 H), 6.69 (s, 2H), 7.29-7.35 (m, 2H), 7.52 (dt, J= 8.5, 1.0 Hz, 1 H), 7.74 (dd, J=8.5, 1.7 Hz, 1 H), 8.12-8.17 (m, 2H) ppm. MS (DCI/NH3): m/z 321 (M+H)+. Anal. Calcd. for C~9H2oN40~1.1 C4H404~0.4 H20: C, 61.73; H, 5.58; N, 12.31. Found: C, 61.67; H, 5.52; N, 12.33.
Example 10 5-~6-((3R)-1-Azabicyclo(2.2.21oct-3-yloxylpyridazin-3-y~-3-methyl-1 H-indole Example 10A
3-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1 H-indole Under N2, a mixture of 5-bromo-3-methyl-1 H-indole (Aldrich, 1.05 g, 5 mmol), bis(pinacolato)diboron (Aldrich, 1.40 g, 5.5 mmol), PdCl2(dppf)~CH2C12 (Aldrich, 122 mg, 0.15 mmol) and KOAc (Aldrich, 1.47 g, 15 mmol) in DMSO (20 mL) was stirred at 90 °C for 1 h. The reaction was monitored with TLC. After the reaction was o complete, it was then diluted with EtOAc (100 mL) and washed with brine (3 x mL). The organic solution was then concentrated and the title compound was purified by flash chromatography (Si02, Hexane : EtOAc, 80:20, Rf. 0.70) as solid (510 mg, yield, 40%). ~H NMR (300 MHz, CDCI3) b 1.38 (s, 12H), 2.35 (s, 3H), 6.98 (s, 1 H), 7.34 (dd, J=8.1, 0.7, Hz, 1 H), 7.65 (dd, J=8.1, 1.0 Hz, 1 H), 8.12 (s, 1 H) ppm.
~5 MS (DCI/NH3): m/z 258 (M+H)+.
Example 10B
5-{6-((3R)-1-Azabicyclo(2.2.2]oct-3-yloxy]pyridazin-3-yl~-3-methyl-1 H-indole The product of Example 10A (240 mg, 1 mmol) coupled with the product of 2o Example 9A (250 mg, 1 mmol) according to the procedure in Example 8A, The title product was purified by preparative HPLC (Gilson, column, Symmetry~ C-8 7 pm, 40 x 100 mm. Eluting Solvent, MeCN / H20 (with 0.2% v. TFA) (v. 90/10 to 10/90 over20 min. flow rate, 75 mL/min., uv, 250 nm) as solid (40 mg, yield, 12%).'H
NMR (300 MHz, CD30D) b 1.50-1.64 (m, 1 H), 1.69-1.92 (m, 2H), 2.01-2.14 (m, 1 H), 25 2.29-2.35 (m, 1 H), 2.37 (s, 3H), 2.81-3.04 (m, 5H), 3.43-3.55 (m, 1 H), 5.27-5.34 (m, 1 H), 7.06 (d, J=1.4 Hz, , 1 H), 7.24 (d, J=9.2 Hz, 1 H), 7.44 (dd, J=8.5, 0.7 Hz, 1 H), 7.71 (dd, J=8.8, 2.0, Hz, 1 H), 8.07-8.12 (m, 2H) ppm. MS (DCI/NH3): m/z 335 (M+H)+.
so Example 10C
5 ~6-((3R)-1-Azabicyclo(2.2.21oct-3-yloxylpyridazin-3-yl~-3-methyl-1 H-indole fumarate v The product of Example 10B (40 mg, 0.12 mmol) was treated with fumaric acid (23 mg, 0.2 mmol) in EtOAc/EtOH (v. 1:1, 5 mL) at ambient temperature for h. The title compound was obtained as solid (40 mg, yield, 62%).'H NMR (300 MHz, CD30D) i5 1.90-2.24 (m, 3H), 2.33-2.48 (m, 4H), 2.61-2.68 (m, 1H), 3.22-3.53 (m, 5H), 3.93-4.03 (m, 1 H), 5.51-5.58 (m, 1 H), 6.70 (s, 3.6 H), 7.08 (d, J=1.0 Hz, 1 H), 7.32 (d, J=9.5 Hz, 1 H), 7.45 (d, J=8.5 Hz, 1 H), 7.72 (dd, J=8.8, 1.7 Hz, 1 H), 8.10 (d, J=1.7 Hz, 1 H), 8.17 (d, J=9.5 Hz, 1 H) ppm. MS (DCI/NH3): m/z 335 (M+H)+.
Anal.
Calculated for C2oH2zN40~ 1.8 C4H4O4: C, 60.13; H, 5.42; N, 10.31. Found: C, 60.02; H, 5.53; N, 10.27.
Example 11 5-f2-((3R)-1-Azabicyclo~2.2.21oct-3-yloxylpyrimidin-5, yl}-1 H-indole Example 11A
(3R)-3-f(5-Bromopyrimidin-2-yl)oxylguinuclidine The product of Example 4A (508 mg, 4 mmol) was coupled with 5-bromo-2-iodo-pyrimidine (Aldrich, 1.42 g, 5 mmol) according to the procedure of Example 7A.
The title compound was purified by chromatography (Si02, CH2C12 : MeOH
NH3~H20, 90:10:1, Rf. 0.40) as solid (760 mg, yield, 67%).'H NMR (300 MHz, 2o CD30D) b 1.54-1.68 (m, 1 H), 1.68-1.95 (m, 2H), 2.03-2.16 (m, 1 H), 2.24-2.33 (m, 1 H), 2.82-3.11 (m, 5H), 3.41-3.52 (m, 1 H), 5.09-5.17 (m, 1 H), 8.65 (s, 2H).
MS
(DCI/NH3): 284 (M+H)+ 286 (M+H)+.
Example 11 B
5-~2-((3R)-1-Azabicyclof2.2.21oct-3-yloxylpyrimidin-5-yl)-1 H-indole The product of Example 11A (283 mg, 1 mmol) was coupled with 5-indolylboronic acid (Aldrich, 193 mg, 1.2 mmol) according to the procedure of Example 3A. The title product was purified by preparative HPLC (Gilson, column, Symmetry~ C-8 7 Nm, 40 x 100 mm. Eluting Solvent, MeCN / H20 (with 0.2% v.
i 3o TFA) (v. 90/10 to 10/90 over 20 min. flow rate, 75 mL/min., uv, 250 nm) as solid (40 mg, yield, 12%). 'H NMR (300 MHz, CD30D) b 1.50-1.63 (m, 1 H), 1.67-1.93 (m, 2H), 2.04-2.17 (m, 1 H), 2.24-2.31 (m, 1 H), 2.75-3.05 (m, 5H), 3.38-3.48 (m, 1 H), 5.14-5.21 (m, 1 H), 6.53 (dd, J=3.1, 0.7 Hz, 1 H), 7.30 (d, J= 3.1 Hz, 1 H), 7.35 (dd, J=8.5, 1.7 Hz, 1 H), 7.51 (dt, J=8.5, 0.7 Hz, 1 H), 7.80 (dd, J=1.7, 0.7 Hz, 1 H), 8.82 (s, 2H) ppm. MS (DCI/NH3): m/z 321 (M+H)+.
Example 11 C
5-f2-((3R)-1-Azabicyclo(2.2.21oct-3-yloxy]pyrimidin-5-yl}-1H-indole hemifumarate The product of 11 B (40 mg, 0.12 mmol) was treated with fumaric acid (12 mg, 0.1 mmol) in EtOAc/EtOH (v. 1:1, 3 mL) at ambient temperature for 10 h. The title compound was obtained as solid (42 mg, yield, 88%). 'H NMR (300 MHz, CD30D) b 1.72-2.10 (m, 3H), 2.20-2.34 (m, 1 H), 2.43-2.51 (m, 1 H), 3.04-3.43 (m, 5H), 3.65-3.76 (m, 1 H), 5.28-5.36 (m, 1 H), 6.52 (dd, J=3.1, 1.1 Hz, 1 H), 6.67 (s, 1 H), 7.30 (d, J=3.1 Hz, 1 H), 7.35 (dd, J=8.5, 1.7 hz, 1 H), 7.51 (dt, J=8.5, 0.7 Hz, 1 H), 7.80 (dd, J=1.7, 0.7 Hz, 1 H), 8.84 (s, 2H) ppm. MS (DCI/NH3): m/z 321 (M+H)+. Anal.
Calcd.
~5 for C~gH2pN4O'O.6 C4H4O4: C, 65.90; H, 5.79; N, 14.36. Found: C, 65.65; H, 5.24;
N, 14.41.
Example 12 4-~2-((3R)-1-Azabicyclo(2.2.2~oct-3-yloxylpyrimidin-5-yl}-1 H-indole Example 12A
4-~2-((3R)-1-Azabicyclo(2.2.21oct-3-yloxylpyrimidin-5-yl}-1 H-indole The product of ExampIe11A (170 mg, 0.6 mmol) was coupled with 4-(4,4,5,5-tetra-methyl-[1,3,2]dioxaborolan-2-yl)-1 H-indole ((ref. W002055517, 146 mg, 0.6 mmol) according to the procedure in Example 8A. The title compound was purified by chromatography (Si02, CH2C12 : MeOH : NH3~H20, 90:10:1, Rf. 0.10) as a solid (76 mg, yield, 40%).'H NMR (300 MHz, CD30D) b 1.50-1.64 (m, 1H), 1.67-1.93 (m, 2H), 2.05-2.19 (m, 1 H), 2.25-2.33 (m, 1 H), 2.73-3.12 (m, 5H), 3.39-3.50 (m, 1 H), 5.17-5.25 (m, 1 H), 6,.55 (dd, J= 3.4, 1.0 Hz, 1 H), 7.11 (dd, J=7.1, 1.0, Hz, 1 H), 7.23 (t, J=8.1 Hz, 1 H), 7.35 (d, J=3.1 Hz, 1 H), 7.44-7.49 (m, 1 H), 8.85 (s, 2H) ppm. MS
(DCI/NH3): m/z 321 (M+H)+.
Example 12B
4-~2-((3R)-1-Azabicyclo(2 2 2loct-3-yloxylpyrimidin-5-yl~ 1 H indole fumarate The product of Example 12A (76 mg, 0.24 mmol) was treated with fumaric s acid (29 mg, 0.25 mmol) in EtOAc/EtOH (v. 1:1, 4 mL) at ambient temperature for 10 hours. The title compound was obtained as solid (94.6 mg, yield, 90%). 'H NMR
(300 MHz, CD30D) b 1.88-2.21 (m, 3H), 2.33-2.48 (m, 1 H), 2.59-2.66 (m, 1 H), 3.22-3.50 (m, 5H), 3.84-3.95 (m, 1 H), 5.41-5.49 (m, 1 H), 6.55 (dd, J=3.4, 1.0 Hz, 1 H), 6.68 (s, 2H), 7.11 (dd, J=7.5, 1.0 Hz, 1 H), 7.24 (t, J= 8.1 Hz, 1 H), 7.36 (d, J=3.1 Hz, 1 H), 7.48 (dt, J=8.1, 0.7 Hz, 1 H), 8.89 (s, 2H) ppm. MS (DCI/NH3): m/z 321 (M+H)+.
Anal. Calculated for C~gH2pN4O'C4H4O4: C, 63.29; H, 5.54; N, 12.84. Found: C, 62.95; H, 5.85; N, 12.61.
Example 13 15 5-f2-((3S)-1-Azabicyclo(2.2 2loct-3-yloxy~pyrimidin-5-yl~-1 H indole Example 13A
(3R)-1-Azabicyclo(2.2.21oct-3-yl benzoate (L)-tartrate (+/-)-3-Quinuclidinol benzoate (Sigma, 17.9 g, 77.5 mmol) was treated with L-2o tartaric acid (Aldrich, 99% ee, 11.63 g, 77.5 mmol) in EtOH (80%, 222 mL) at ambient temperature for 1 week. The white solid was filtered off and dried under reduced pressure. 6.5 g of 3-(R)-quinuclidinol benzoate ~ (L)-tartrate was obtained with --80% ee (assayed by HPLC. HPLC conditions: chiralpak AD column 25cmX4mm ID. solvent, EtOH : hexanes = 15 : 85. flow rate, 1 mL/min. uv, 220 nm.
2s Retention time: (S)-3-quinuclidinol benzoate, 7.87 min; (R)-3-quinuclidinol benzoate 13.3 min.) Recrystallization of the above solid in EtOH (80%, 35 mL) gave the title product (4.5 g , yield, 15%, >98% ee). MS (DCI/NH3) m/z 232 (M+H)+.
Example 13B
30 (3R)-Quinuclidin-3-of The product of the Example 13A (4.5 g, 11.8 mmol) was treated with Hydrolysis was NaOH (15%, 40 mL) MeOH (40 mL)at 50°C for 10h. The methanol was removed under reduced pressure and the residue was extracted with chloroform (4 x 80 mL). The extracts were combined and dried over MgS04 (anhydrous). The drying agents were filtered off and the filtrate was concentrated to give the title product as white solid (1.35 g, yield, .90%). MS (DCI/NH3) m/z 128 (M+H)+.
Example 13C
(3S)-1-Azabicyclof2.2.21oct-3-yl benzoate (D)-tartrate The mother liquid of Example 13A was combined and concentrated under reduced pressure. The residue was then treated with NaOH (1 N, 50 mL) at room temperature for 30 min. It was extracted with chloroform (3 x mL) The extracts were combined and dried (MgS04). The drying agents were filtered off. The filtrates was concentrated to give 3-quinuclidinol benzoate (15.25 g, 66 mmol) It was then treated ~5 with (D)-tartaric acid (Aldrich, 97%ee, 9.9 g, 66 mmol,) in EtOH (80%, 190 ml) at room temperature for 3 days according to the procedure of Example 1A. The title product was obtained (7.0 g, yield, 28%, 92.3% ee).
Example 13D
20 (3S)-Quinuclidin-3-of The product of Example 13C (7.0 g, 18.4 mmol) was treated with NaOH
(aqueous) according to the procedure of Example 1 B. The title product was obtained as white solid (2.0 g, yield, 86% ) MS (DCI/NH3) m/z 128 (M+H)+.
25 Example 13E
(3S)-3-f (5-Bromopyrimidin-2-yl)oxy]quinuclidine The product of Example 13D (508 mg, 4 mmol) was coupled with 2-iodo-5-bromo-pyrimidine (1.42 g, 5 mmol) according to the procedure of Example 7A.The title compound was purified by chromatography (Si02, CH2C12 : MeOH : NH3~H20, 30 90:10:1, Rf. 0.20) as solid (780 mg, yields, 69%)as a solid.'H NMR (300 MHz, CD30D) b 1.47-1.61 (m, 1 H), 1.63-1.90 (m, 2H), 1.96-2.12 (m, 1 H), 2.19-2.27 (m, 1 H), 2.73-3.03 (m, 5H), 3.33-3.45 (m, 1 H), 5.05-5.14 (m, 1 H), 8.64 (s, 2H) ppm. MS
(DCI/NH3): 284 (M+H)+ 286 (M+H)+.
Example 13F
5-{2-[(3S)-1-Azabicyclof2.2.21oct-3-yloxylpyrimidin-5-yl}-1 H-indole The product of ExampIe13E (283 mg, 1 mmol) was coupled with 5-indolylboronic acid (193 mg, 1.2 mmol) according to the procedure of Example 3A, The title product was purified by preparative HPLC (Gilson, column, Symmetry~
7 pm, 40 x 100 mm. Eluting Solvent, MeCN / H20 (with 0.2% v. TFA) (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (120 mg, yield, 38%).'H NMR (300 MHz, CD30D) b 1.50-1.63 (m, 1H), 1.66-1.92 (m, 2H), 2.03-2.18 (m, 1 H), 2.24-2.32 (m, 1 H), 2.75-3.07 (m, 5H), 3.38-3.49 (m, 1 H), 5.13-5.21 (m, 1 H), 6.53 (dd, J=3.0, 0.7 Hz, 1 H), 7.30 (d, J=3.4 Hz, 1 H), 7.35 (dd, J=8.5, 1.7 Hz, 1 H), 7.51 (dt, J=9.2, 0.7 Hz, 1 H), 7.80 (dd, J=1.7, 0.7 Hz, 1 H), 8.81 (s, 2H) ppm. MS
~5 (DCI/NH3): m/z 321 (M+H)+.
Example 13G
5-~2-f(3S)-1-Azabicyclo[2.2.21oct-3-yloxylpyrimidin-5-yl)-1H-indole hemifumarate The product of Example 13F (120mg, 0.38 mmol) was treated with fumaric 2o acid (44 mg, 0.38 mmol) in EtOAc/EtOH (v. 1:1, 10 mL). The title compound was obtained as solid (123 mg, yield, 84%).'H NMR (300 MHz, CD30D) b 1.75-2.13 (m, 3H), 2.22-2.37 (m, 1 H), 2.46-2.54 (m, 1 H), 3.03-3.45 (m, 5H), 3.68-3.79 (m, 1 H), 5.30-5.38 (m, 1 H), 6.52 (dd, J=3.1, 1.1 Hz, 1 H), 6.67 (s, 1.2H), 7.30 (d, J=3.1 Hz, 1 H), 7.35 (dd, J=8.5, 1.7 Hz, 1 H), 7.51 (dt, J= 8.5, 0.7 Hz, 1 H), 7.80 (dd, J=1.7, 0.7 25 Hz, 1 H), 8.82 (s, 2H) ppm. MS (DCI/NH3): m/z 321 (M+H)+. Anal. Calculated for C~gH2pN4O'O.6 C4H4O4: C, 65.90; H, 5.79; N, 14.36. Found: C, 65.62; H, 5.76;
N, 14.40.
Example 14 30 5-f4-(1-Azabicyclof2.2.2]oct-3-yloxy)phenyll-3-methyl-1 H-indazole trifluoroacetate The product of Example 1A (200 mg, 0.61 mmol) was coupled with t-butyl-(3-methyl-5-trimethylstannanyl-indazole)-1-carboxylate (ref. US 2003199511, 294 mg, 1 mmol) according to the procedure of Example 2B. The title product was purified by preparative HPLC (Gilson, column, Symmetry~ C-8 7 pm, 40 x 100 mm. Eluting Solvent, MeCN / H20 (with 0.2% v. TFA) (v. 90/10 to 10/90 over 20 min. flow rate, 75 mL/min., uv, 250 nm) as solid (70 mg, yield, 26%).'H NMR (300 MHz, CD30D) b 1.85-2.13 (m, 3H), 2.22-2.37 (m, 1 H), 2.46-2.50 (m, 1 H), 2.58 (s, 3H), 3.23-3.45 (m, 5H), 3.78-3.86 (m, 1 H), 4.90-5.00 (m, 1 H), 7.07 (dt, J=8.8, 2.0 Hz, 2H), 7.50 (d, J=8.8 Hz, 1 H), 7.61-7.68 (m, 3H), 7.85 (s, 1 H) ppm. MS (DCI/NH3): m/z 334 (M+H)+.
Anal. Calculated for Cz~H23N30~1.0 CF3C02H~0.5 H20: C, 60.52; H, 5.52; N, 9.21.
Found: C, 60.79; H, 5.39; N, 9.17.
Example 15 6-f4-(1-Azabicyclof2.2.21oct-3-yloxy)phen rLl1-1,3-benzothiazol-2-amine Example 15A
3-((4'-Nitro-1,1'-biphenyl-4-yl)oxylquinuclidine 3-Quinuclidinol (Aldrich, 0.51 g, 4 mmol) was coupled with 4'-nitro-1,1'-biphenyl-4-.0l (TCI, 0.43 g, 2 mmol) with DIAD (di-isopropyl azadicarboxylate, 2o Aldrich, 0.81 g, 4 mmol) and Ph3P (Aldrich, 1.04 g, 4 mmol) in THF
(anhydrous, Aldrich, 40 mL) at ambient temperature for two days. The reaction mixture was concentrated. The title product was purified by chromatography (Si02, CH2CI2 MeOH : NH3~H20, 90:10:1, Rf. 0.20) as solid (400 mg, yield, 62%).'H NMR ( 300 MHz , CD30D) 8 1.45-1.57 (m, 1 H), 1.63-1.91 (m, 2H), 1.97-2.12 (m, 1 H), 2.17-2.24 (m, 1 H), 2.66-3.00 (m, 5H), 3.30-3.41 (m, 1 H), 4.56-4.64 (m, 1 H), 7.05 (dt, J=8.8, 2.6 Hz, 2H), 7.68 (dt, J=9.2, 2.6 Hz, 2H), 7.82 (dt, J=8.8, 2.7 Hz, 2H), 8.28 (dt, J=8.8, 2.8 Hz, 2H) ppm. MS (DCI/NH3) m/z 325 (M+H)+.
Example 15B
4'-( 1-Azabicyclo(2.2.21oct-3-yloxy)-1,1'-biphenyl-4-amine The product of Example 15A (300 mg, 0.92 mmol) was treated with Pd/C
(Aldrich, wt.10%, 30 mg) in methanol (20 mL) under H2 at ambient temperature for 30 min. After the reaction was complete, the catalyst was removed through a short column of diatomaceous earth. The filtrate was concentrated under reduced pressure to provide the title compound (200 mg, yield, 74%).'H NMR (300 MHz, CD30D) 8 1.44-1.58 (m, 1 H), 1.63-1.89 (m, 2H), 1.99-2.13 (m, 1 H), 2.15-2.23 (m, 1 H), 2.72-3.04 (m, 5H), 3.29-3.39 (m, 1 H), 4.50-4.58 (m, 1 H), 6.77 (dt, J=
8.8, 2.5 Hz, 2H), 6.91 (dt, J=8.8, 2.4 Hz, 2H), 7.32 (dt, J= 8.5, 2.5 Hz, 2H), 7.43 (dt,J= 9.2, 2.8 Hz, 2H) ppm. MS (DCI/NH3) m/z 295 (M+H)+.
Example 15C
6-f4-(1-Azabicyclof2.2.21oct-3-yloxy)phenyll-1,3-benzothiazol-2-amine The product of Example 15B (200 mg, 0.68 mmol) and KSCN (Aldrich, 140 mg, 1.52 mmol) were dissolved in HOAc (5 mL). Bromine (Aldrich, 99%, 40 NL, 0.76 mmol, in HOAc (1 mL) was added slowly to the above solution over 5 min. The mixture was stirred at ambient temperature for additional 1 h. and then quenched with aqueous NaOH (10%, 20 mL) at 5-10 °C. It was then extracted with CHC13/'PrOH (v. 10 : 1, 2 x 50 mL). The extracts were combined and concentrated under reduced pressure. The title compound was purified by chromatography (Si02, 2o CH2C12: MeOH : NH3~H20, 90:10:1, Rf. 0.10) as solid (140 mg, yield, 59%).'H
NMR
(300 MHz, CD30D) s 1.27-1.37 (m, 1 H), 1.51-1.72 (m, 2H), 1.79-1.88 (m, 1 H), 2.02-2.07 (m, 1 H), 2.51-2.84 (m, 5H), 3.21-3.39 (m, 1 H), 4.45-4.52 (m, 1 H), 6.97(d, J=8.8 Hz, 2H), 7.35 (d, J=8.5 Hz, 7.45 (dd, J=8.5, 2.1 Hz, 1 H), 7.55 (d, J=8.5, 2H), 7.90 (d, J=2.0 Hz, 1 H) ppm. MS (DCI/NH3) m/z 352 (M+H)+.
Example 15D
6-f4-( 1-Azabicyclo f 2.2.21oct-3-yloxy)phenyll-1,3-benzothiazol-2-amine bistrifluoroacetate The product of Example 15C (140 mg, 0.4 mmol) was treated with 3o trifluroacetic acid (Aldrich, 99%, 114 mg, 80 NL, 1 mmol) in'PrOH (5 mL) at ambient temperature for 15 h. The title compound was obtained as solid (90 mg, yield, 39%).
'H NMR (300 MHz, DMSO-D6) b 1.75-2.16 (m, 3H), 2.30-2.52 (m, 2H), 3.03-3.45 (m, 5H), 3.75-3.82 (m, 1 H), 4.78-4.85 (m, 1 H), 7.05 (d, J=8.8 Hz, 2H), 7.38 (d, J=8.5 Hz, 1 H), 7.50 (dd, J=8.5, 2.1 Hz, 1 H), 7.62 (d, J=8.8 Hz, 2H), 7.76 [s(broad.), 2H), 7.96 (d, J=1.7 Hz, 1 H) ppm. MS (DCI/NH3): m/z 352 (M+H)+. Anal. Calculated for C2oH2~N30S~2.08 CF3C02H C, 49.30; H, 3.95; N, 7.14. Found: C, 49.70; H, 3.42;
N, 7.03.
Example 16 6-~4-((3R)-1-Azabicyclo(2.2.21oct-3-yloxylphenyl~-1,3-benzothiazol-2-amine Example 16A
(3R)-3-((4'-Nitro-1,1'-biphenyl-4-yl)oxy~quinuclidine The product of Example 4A (1.28 g, 10 mmol) was coupled with 4-iodo-4'-nitro-biphenyl (TCI, 1.62 g, 5 mmol) according to the procedure of Example 1A.
The title product was purified by chromatography (Si02, CH2CI2 : MeOH : NH3~H20, 90:10:1, Rf. 0.20) as solid (930 mg, yield, 57%).'H NMR ( 300 MHz , CD30D) ~
1.45-1.57 (m, 1 H), 1.63-1.91 (m, 2H), 1.97-2.12 (m, 1 H), 2.17-2.24 (m, 1 H), 2.66-3.00 (m, 5H), 3.30-3.41 (m, 1 H), 4.56-4.64 (m, 1 H), 7.05 (dt, J=8.8, 2.6 Hz, 2H), 7.68 (dt, J=9.2, 2.6 Hz, 2H), 7.82 (dt, J=8.8, 2.7 Hz, 2H), 8.28 (dt, J=8.8, 2.8 Hz, 2H) ppm. MS (DCI/NH3) m/z 325 (M+H)+.
Example 16B
4'-((3R)-1-Azabicyclo(2.2.21oct-3-yloxyl-1,1'-biphenyl-4-amine The product of Example 16A (580 mg, 1.79 mmol) was treated with Pd/C
(Aldrich, wt.10%, 100 mg) in ethanol (50 mL) under H2 at ambient temperature for 30 2s min. After the reaction was complete, the catalyst was removed through a short column of diatomaceous earth. The filtrate was concentrated under reduced pressure to provide the title compound (520 mg, yield, 99%).'H NMR (300 MHz, CD30D) 8 1.44-1.58 (m, 1 H), 1.63-1.89 (m, 2H), 1.99-2.13 (m, 1 H), 2.15-2.23 (m, 1 H), 2.72-3.04 (m, 5H), 3.29-3.39 (m, 1 H), 4.50-4.58 (m, 1 H), 6.77 (dt, J=
8.8, 2.5 3o Hz, 2H), 6.91 (dt, J=8.8, 2.4 Hz, 2H), 7.32 (dt, J= 8.5, 2.5 Hz, 2H), 7.43 (dt,J= 9.2, 2.8 Hz, 2H) ppm. MS (DCI/NH3) m/z 295 (M+H)+. -Example 16C
6-{~3R)-1-Azabicyclo(2.2.21oct-3-yloxylphenyl}-1,3-benzothiazol-2-amine tri(trifluoroacetate) The product of Example 16B (250 mg, 0.85 mmol) and KSCN (Aldrich, 165 mg, 1.70 mmol) were dissolved in HOAc (5 mL). Bromine [Aldrich, 99%, 47 NL, 0.90 mmol, in HOAc (1 mL)] was slowly added to the above solution over 5 min. The mixture was stirred at ambient temperature for additional 2 hours, and quenched with aqueous NaOH (10%, 20 mL) at 5-10 °C. It was then extracted with CHCI3fPrOH (v.
: 1, 2 x 50 mL). The extracts were combined and concentrated under reduced pressure. The title product was purified by preparative HPLC (Gilson, column, Symmetry~ C-8 7 pm, 40 x 100 mm. Eluting Solvent, MeCN / H20 (with 0.2% v.
TFA) (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (150 mg, yield, 19%). 'H NMR (300 MHz, DMSO-D6) b 1.84 - 2.20 (m, 3 H), 2.22 -~5 2.44 (m, 1 H), 2.47 - 2.69 (m, 1 H), 3.32 - 3.51 (m, 5 H), 3.74 - 3.93 (m;
1 H), 4.89 -5.02 (m, 1 H), 7.01 - 7.15 (m, 2 H), 7.53 (d, J=8.5 Hz, 1 H), 7.59 - 7.66 (m, 2 H), 7.69 (dd, J=8.5, 1.7 Hz, 1 H), 7.98 (d, J=2.0 Hz, 1 H) ppm. MS (DCIlNH3): m/z 352 (M+H)~. Anal. Calculated for C2oH2~N30S~3.00 CF3C02H C, 45.03; H, 3.49; N, 6.06.
Found: C, 44.70; H, 3.42; N, 6.00.
Example 17 6-~~4-f (3R)-1-Azabicyclo[2.2.21oct-3-yloxylphenyl)-4-thiocyanato-1,3-benzothiazol-2-amine trifluoroacetate The product of Example 16B (250 mg, 0.85 mmol) and KSCN (Aldrich, 165 mg, 1.70 mmol) were dissolved in HOAc (5 mL). Bromine [Aldrich, 99%, 47 pL, 0.90 mmol, in HOAc (1 mL)] was added slowly to the above solution over 5 min.
according to procedure of Example 16C. The title product was purified by preparative HPLC (Gilson, column, Symmetry~ C-8 7 pm, 40 x 100 mm. Eluting Solvent, MeCN / H20 (with 0.2% v. TFA) (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (55 mg, yield, 12%).'H NMR (300 MHz, MeOH-D4) b 1.79 - 2.24 (m, 3 H), 2.22 - 2.44 (m, 1 H), 2.46 - 2.65 (m, , 1 H), 3.30 - 3.52 (m, H), 3.74 - 3.90 (m, 1 H), 4.93 (dd, J=9.2, 5.1 Hz, 1 H), 6.96 - 7.23 (m, 2 H) 7.48 -7.70 (m, 3 H) 7.88 (d, J=1.7 Hz, 1 H) ppm. MS (DCI/NH3): m/z 409 (M+H)+.
Example 18 5 6-f4-((3RD-1-Azabicyclo(2.2.21oct-3-yloxy~phen r~l -4-bromo-1,3-benzothiazol-2-amine bis(trifluoroacetate~
The product of Example 16B (250 mg, 0.85 mmol) and KSCN (Aldrich, 165 mg, 1.70 mmol) were dissolved in HOAc (5 mL). Bromine [Aldrich, 99%, 47 pL, 0.90 mmol, in HOAc (1 mL) was added slowly to the above solution over 5 min.
o according to procedure of Example 16C. The title product was purified by preparative HPLC (Gilson, column, Symmetry~ C-8 7 Nm, 40 x 100 mm. Eluting Solvent, MeCN
/ H20 (with 0.2% v. TFA) (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (50 mg, yield, 9%).'H NMR (300 MHz, MeOH-D4) S 1.78 - 2.21 (m, 3 H), 2.23 - 2.44 (m, 1 H), 2.47 - 2.63 (m, 1 H), 3.23 - 3.53 (m, 5 H), 3.66 -3.97 (m, 1 H), 4.88 - 5.03 (m, 1 H), 6.96 - 7.22 (m, 2 H), 7.52 - 7.65 (m, 2 H), 7.68 (d, J=1.7 Hz, 1 H), 7.82 (d, J=1.7 Hz, 1 H) ppm. MS (DC.I/NH3): m/z 430 (M+H)+, 432 (M+H)+.
Anal. Calculated for C2oH2oBrN30S~2.00 CF3C02H C, 43.78; H, 3.37; N, 6.38.
Found: C, 44.70; H, 3.42; N, 6.32.
2o Example 19 N-(4-(3-Methyl-1 H-indazol-5-yl)phenyllquinuclidin-3-amine Example 19A
N-(,4-lodophenyl)quinuclidin-3-amine 3-Quinuclidinone hydrochloride (Aldrich, 3.22 g, 20 mmol) was treated with 4-iodo-aniline (Aldrich, 2.19 g, 10 mmol), Na2S04 (anhydrous, Aldrich, 7.40 g, mmol) and NaBH(OAc)3 (Aldrich, 3.16 g, 15 mmol) in HOAc (25 mL) at ambient temperature for 15 h. After the reaction was complete, the reaction mixture was slowly poured into a flask containing 75 mL of saturated NaHC03 and stirred for 20 3o min. It was then extracted with EtOAc (3 x 100 mL). The extracts were combined and washed with brine (2 x 20 mL). The organic solution was concentrated under reduced pressure and the title compound was purified by chromatography (Si02, CH2C12 : MeOH : NH3~H20, 90:10:2, Rf. 0.10) as oil (3.24 g, yield, 98%).'H NMR
(300 MHz, CD30D,) 8 1.70-1.81 (m, 1 H), 1.93-2.04 (m, 2H), 2.08-2.24 (m, 2H), 2.89 (ddd, J=12.9, 5.1, 2.7 Hz, 1 H), 3.12-3.28 (m, 4H), 3.64 (ddd, J=12.9, 9.5, 2.4 Hz, 1 H), 3.79-3.85 (m, 1 H), 6.46 (dt, J=9.0, 2.7 Hz, 2H), 7.39 (dt, J=9.1, 2.7 Hz, 2H) ppm. MS (DCI/NH3) m/z 329 (M+H)+.
Example 19B
N-[4~3-Methyl-1H-indazol-5-yl)phenyllguinuclidin-3-amine trifluoroacetate The product of Example 19A (200 mg, 0.61 mmol) was coupled with t-Butyl-(3-Methyl-5-trimethylstannanyl-indazole)-1-carboxylate (ref. US 2003199511, mg, 1 mmol) according to the procedure of Example 2B. The title product Was purified by preparative HPLC (Gilson, column, Symmetry~ C-8 7 pm, 40 x 100 mm.
Eluting Solvent, MeCN / H20 (with 0.2% v. TFA) (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (28 mg, yield, 10%).'H NMR (300 MHz, CD30D) S 1.85-1.96 (m, 1 H), 2.08-2.15 (m, 2H), 2.24-2.40 (m, 2H), 2.59 (s, 3H), 3.02-3.15 (m, 1 H), 3.20-3.45 (m, 4H), 3.78-3.88 (m, 1 H), 3.98-4.06 (m, 1 H), 6.77 (dt, J=8.8, 2.0 Hz, 2H), 7.46-7.52 (m, 3H), 7.59 (dd, J=8.9, 1.6 Hz, 1 H), 7.78 (s, 1 H) ppm. MS (DCI/NH3): m/z 333 (M+H)+. Anal. Calculated for C2~H24N4~1.25 CF3C02H:
2o C, 59.43; H, 5.36; N, 11.80. Found: C, 59.20; H, 4.96; N, 11.62.
Example 20 (R)- 3-[6~3-Methyl-1 H-indazol-5-yl~pyridazin-3-yloxyl-1-aza-bicyclo[2.2.21octane fumarate Example 20A
3-Methyl-5-trimethylstannanyl-indazole-1-carboxylic acid tert-butyl ester 5-Bromo-3-methyl-indazole-1-carboxylic acid tert-butyl ester (3.0 g, 9.6 mmol) was coupled with hexamethylditin (Aldrich, 4.73 g, 14.4 mmol) catalyzed by 3o Pd(PPh3)a (Aldrich, 1.1 g, 0.96 mmol) in anhydrous toluene (Aldrich, 50 mL) at 115 °C (oil bath) under N2 for 2 h. After the reaction went to completion, the black reaction mixture was cooled down to ambient temperature and directly loaded to a flash silica gel column (5-30% EtOAc in hexane) for purification to provide the title compound (3.06 g, 80%). 'H NMR (MeOH-da, 300 MHz) 0.23 - 0.45 (m, 9 H) 1.71 (s, 9 H) 2.59 (s, 3 H) 7.67 (d, J=8.1 Hz, 1 H) 7.87 (s, 1 H) 8.06 (d, J=8.5 Hz, 1 H) ppm.
s MS (DCI/NH3) m/z 397(M+H)+.
Example 20B
(,R)-3-[6-(,3-Methyl-1 H-indazol-5-yl)-pyridazin-3-yloxy~-1-aza-bicyclo[2.2.21octane The product of Example 9A (120 mg, 0.5 mmol) was coupled with the product 0 of Example 20A (278 mg, 0.7 mmol) under the catalysis of by Pd2(dba)3 (Aldrich, 24 mg, 0.025 mmol) and (tBu3P)2 Pd (Strem Chemicals, 26 mg, 0.05 mmol) with CsF
(Strem Chemicals, 152 mg, 1 mmol) in dioxane (10 ml) at 80°C under N2 for 16 hours. After the reaction went to completion, it was diluted with EtOAc (50 mL) and washed v~iith brine (2 x 10 mL). The organic solution was concentrated under 15 vacuum and the residue was treated with TFA (1 mL) in CH2C12 (5 mL) at ambient temperature for 2 hours. It was then concentrated. The title product was purified by preparative HPLC (XterraTM, column, Xterra RP-18 5 pm, 30 x 100 mm. Eluting Solvent, MeCN / H20 (NH4HC03, 0.1 M, pH=10) (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (68 mg, 41 %). 'H NMR (MeOH-D4, 2o MHz) 1.50 - 1.66 (m, 1 H) 1.70 - 1.94 (m, 2 H) 2.01 - 2.15 (m, 1 H) 2.29 -2.37 (m, 1 H) 2.62 (s, 3 H) 2.81 - 3.04 (m, 5 H) 3.44 - 3.56 (m, 1 H) 5.28 - 5.36 (m, 1 H) 7.28 (d, J=9.2 Hz, 1 H) 7.59 (d, J=8.8 Hz, 1 H) 8.05 (dd, J=8.8, 1.4 Hz, 1 H) 8.16 (d, J=9.2 Hz, 1 H) 8.31 (s, 1 H) ppm. MS (DCI/NH3) m/z 336 (M+H)+.
2s Example 20C
(R)-3-[6-(3-Methyl-1 H-indazol-5-yl~pyridazin-3-yloxyl-1-aza-bicyclo[2.2.2]octane fi imarato The product of Example 20B (68 mg, 0.11 mmol) was treated with fumaric acid (Aldrich, 14 mg, 0.12 mmol) in EtOAc/MeOH (v.10:1, 5 mL) to provide the title 3o compound as solid (59.1 mg, 65%). 'H NMR (MeOH-D4, 300 MHz) 1.82 - 2.18 (m, 3 H) 2.27 - 2.42 (m, 1 H) 2.55 - 2.66 (m, 4 H) 3.21 - 3.43 (m, 5 H) 3.82 -3.95 (m, 1 H) 5.47 - 5.57 (m, 1 H) 6.68 (s, 2 H) 7.34 (d, J=9.2 Hz, 1 H) 7.60 (d, J=8.8 Hz, 1 H) 8.06 (dd, J=8.8, 1.7 Hz, 1 H) 8.21 (d, J=9.2 Hz, 1 H) 8.32 (s, 1 H) ppm. MS
(DCI/NH3) m/z 336(M+H)+. Anal. Calculated for C~gH2~N5O'1.0 CaH404~0.35 H20:
C, 60.35; H, 5.66; N, 15.30. Found: C, 60.06; H, 5.40; N, 15.56.
Example 21 (R)-3-(6-(1-Methyl-1 H-indol-5-yl)-pyridazin-3-yloxyl-1-aza-bicyclo(2.2.21octane trifluoroacetate The product of Example 4A (120 mg, 0.5 mmol) was coupled with N-methyl-o indole-5-boronic acid (Aldrich, 250 mg, 1.5 mmol) catalyzed by Pd2(dba)3 (24 mg, 0.025 mmol) and (tBu3P)2Pd (26 mg, 0.05 mmol) with CsF (Strem Chemicals, 228 mg,.1.5 mmol) in dioxane (8 mL) at 80°C under N2 for 16 hours according to the procedure of Example 20B. The title product was purified by preparative HPLC
(XterraTM, column, Xterra RP-18 5 Nm, 30 x 100 mm. Eluting Solvent, MeCN / H20 (with 0.2% v. TFA) (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, nm) as solid (109.9 mg, 49%).'H NMR (MeOH-D4, 300 MHz) 1.91 - 2.25 (m, 3 H), 2.34 - 2.48 (m, 1 H), 2.61 - 2.70 (m, 1 H), 3.33 - 3.56 (m, 5 H), 3.86 (s, 3 H), 3.94 -4.04 (m, 1 H), 5.50 - 5.59 (m, 1 H), 6.56 (d, J=3.1 Hz, 1 H), 7.25 (d, J=3.1 Hz, 1 H), 7.29 - 7.36 (m, 1 H), 7.52 (d, J=8.8 Hz, 1 H), 7.81 (dd, J=8.6, 1.9 Hz, 1 H), 8.10 -8.19 (m, 2 H) ppm. MS (DCI/NH3) m/z 335 (M+H)+. Anal. Calculated for C2oH22N40~1.075 C2F302H: C, 58.22; H, 5.09; N, 12.26. Found: C, 58.21; H, 5.00;
N, 12.30.
Example 22 (R)-{5-(6-(1-Aza-bicyclo(2.2.21oct-3-yloxy)-pyridazin-3-yl~-1 H-indol-3-ylmethyl)-dimethyl-amine bis(fumarate) Example 22A
(R)-{5-(6-(1-Aza-bicyclo(2.2.21oct-3-yloxy)-pyridazin-3-yl~-1 H-indol-3-ylmethyl~
3o dimethyl-amine The product of Example 9B (150 mg, 0.47 mmol) was treated with HCHO
(Aldrich, 37%, 76 mg, 0.94 mmol) and dimethylamine (Aldrich, 42 mg, 0.94 mmol) in dioxane/HOAc (v. 1:1, 5 mL) at ambient temperature for 16 hours. It was then concentrated and the title product was purified by preparative HPLC (XterraTM, column, Xterra RP-18 5 Nm, 30 x 100 mm. Eluting Solvent, MeCN / H20 (NH4HC03, 0.1 M, pH=10) (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (80 mg, 45%). ~H NMR (MeOH-D4, 300 MHz) 1.59 - 1.75 (m, 1 H), 1.77 -1.99 (m, 2 H), 2.07 - 2.23 (m, 1 H), 2.36 - 2.44 (m, 1 H), 2.60 - 2.69 (m, 6 H), 2.91 - 3.13 (m, 5 H), 3.52 - 3.65 (m, 1 H), 4.22 (s, 2 H), 5.32 - 5.40 (m, 1 H), 7.30 (d, J=9.5 Hz, 1 H), 7.49 (s, 1 H), 7.56 (d, J=8.5 Hz, 1 H), 7.81 (dd, J=8.5, 1.7 Hz, 1 H), 8.15 (d, J=9.5 Hz, 1 H), 8.29 (s, 1 H) ppm. MS (DCI/NH3) m/z 378(M+H)+.
Example 22B
(R)-f5-[6-(1-Aza-bicyclo[2.2.2]oct-3-yloxy)-pyridazin-3-yl~-1 H-indol-3-ylmethyl}-dimethyl-amine bis(fumarate) The product of Example 22A (80 mg, 0.21 mmol) was treated with fumaric acid (Aldrich, 49 mg, 0.42 mmol) in EtOAc / MeOH (v. 10:1 ) to give the title compound as white solid (74.8 mg, 53%). 'H NMR (MeOH-D4, 300 MHz) 1.79 - 2.17 (m, 3 H), 2.25 - 2.41 (m, 1 H), 2.54 - 2.61 (m, 1 H), 2.84 (s, 6 H), 3.19 -3.42 (m, 5 2o H), 3.78 - 3.90 (m, 1 H), 4.50 (s, 2 H), 5.45 - 5.54 (m, 1 H), 6.66 (s, 5 H), 7.34 (d, J=9.2 Hz, 1 H), 7.54 - 7.63 (m, 2 H), 7.84 (dd, J=8.5, 1.7 Hz, 1 H), 8.17 (d, J=9.2 Hz, 1 H), 8.35 (s, 1 H) ppm. MS (DCI/NH3) m/z 378(M+H)+. Anal. Calculated for C22HZ~N50~2.5 C4H404~0.5 H20: C, 56.80; H, 5.66; N, 10.35. Found: C, 56.62; H, 5.78; N, 10.09.
Example 23 (R)-3-~6-(1 H-Indol-5-yl)-pyridazin-3-yloxyl-1-aza-bicyclo[2.2.21octane 1-oxide trifluoroacetate The product of Example 9B was treated with H202 (Aldrich, aq. 30% 1 mL, 8.8 mmol) in acetonitrile (3 mL) for 5 h. The mixture was quenched by Na2S03 solution carefully until no more peroxide was noticed, and it was then concentrated under vacuum. The title product was purified by preparative HPLC (XterraTM, column, Xterra RP-18, 5 pm, 30 x 100 mm. Eluting Solvent, MeCN / H20 (with 0.2%
v. TFA), (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (15.6 mg, 13%).'H NMR (MeOH-d4, 300 MHz) 2.14 - 2.38 (m, 3 H) 2.55 - 2.71 (m, s H) 3.68 - 3.92 (m, 5 H) 4.37 - 4.47 (m, J=8.5 Hz, 1 H) 5.62 - 5.70 (m, J=4.4 Hz, 1 H) 6.57 (d, J=2.0 Hz, 1 H) 7.30 - 7.38 (m, 2 H) 7.52 (d, J=8.5 Hz, 1 H) 7.74 (dd, J=8.6, 1.9 Hz, 1 H) 8.13 - 8.20 (m, 2 H) ppm. MS (ESI) m/z 337(M+H)+. Anal.
Calculated for Ci9H2oN402~1.15 CF3C02H: C, 54.72; H, 4.56; N, 11.98. Found: C, 54.72; H, 4.07;
N, 12.08.
Example 24 6-{6-f (3R)-1-Aza-bicyclo f 2.2.21oct-3-yloxyl-pyridazin-3-yl~-benzothiazol-2-ylamine tri(hydroAen chloride) ~5 Example 24A
6-(4-Bromo-phenyl)-4,5-dihydro-2H-pyridazin-3-one 4-(4-Bromo-phenyl)-4-oxo-butyric acid (Aldrich, 25.0 g, 97.3 mmol) was treated with NH2NH2~H20 (Aldrich, 55%, 9.1 mL, 156 mmol) in EtOH (Aldrich, 100 mL) at refluxing for 2h. It was cooled down to ambient temperature and the white 2o solid was filtered off to give the title compound (24.2 g, 98%)'H NMR
(CDC13, 300 MHz) 8 2.50 - 2.76 (m, 2 H), 2.85 - 3.09 (m, 2 H), 7.43 - 7.71 (m, 4 H), 8.55 (s, 1 H) ppm. MS (DCI/NH3) m/z 253 (M+H)+, 255 (M+H)+, 270 (M+NH4)+, 272 (M+NH4)+.
Example 24B
25 6-(4-Bromo-phenyl)-4,5-dihydro-2H-pyridazin-3-one The product of Example 24A (24.0 g, 95 mmol) was oxidized with bromine (Aldrich, 18.81g, 6.1 mL, 104.5 mmol) in HOAc (Aldrich, 200 mL) at 100°C for 1h.
The brown mixture was then cooled down to ambient temperature. The white solid was filtered off and the filtrate was washed with water (2 x 20 mL). The solid was so collected and dried under vacuum to give the title compound (25.0 g, 100%).'H
NMR (CDC13, 300 MHz) 8 7.07 (d, J=10.2 Hz, 1 H), 7.55 - 7.69 (m, 4 H), 7.72 (d, J=9.8 Hz, 1 H) ppm. MS (DCI/NH3) m/z 251 (M+H)+, 253 (M+H)+, 268 (M+NH4)+, 270 (M+NHa)+.
Example 24C
3-(4-Bromo-phenyl)-6-chloro-pyridazine The product of Example 24B (25.Og, 100 mmol) was stirred in POC13 (Aldrich, 200 mL) at 100°C for 18 h. Most of POC13 was then distilled off (around 150 mL was collected). The residue was then poured into 300 mL of ice/water and stirred vigorously for 1 h. The solid was filtered off. The filtrate was washed with water (2 x 0 50 mL) and dried under vacuum to give the title compound (26.2 g, 98%).'H
NMR
(MeOH-D4, 300 MHz) 8 7.72 (d, J=8.8 Hz, 2 H), 7.86 (d, J=8.8 Hz, 1 H), 8.02 (d, J=8.8 Hz, 2 H), 8.19 (d, J=9.2 Hz, 1 H) ppm. MS (DCI/NH3) m/z 269 (M+H)+, 271 (M+H)+, 273 (M+H)+.
Example 24D
(3R)-3-(6-(4-Bromo-phenyl)-pyridazin-3-yloxyl-1-aza-bicycl~2.2.2]'octane The product of Example 24C (2.43 g, 9 mmol) was coupled with the product of Example 4A (1.27g, 10 mmol) using t-BuOK (Aldrich, 1.12g, 10 mmol) as base in THF (anhydrous, Aldrich, 50 mL) according to the procedure of Example 7A. The title 2o compound was purified by chromatography (Si02, CH2C12 : MeOH : NH3~H20, 90:10:2, Rf. 0.30) as slightly yellow solid (3.30g, 100%).'H NMR (MeOH-D4, 300 MHz) 1.47 - 1.66 (m, 1 H), 1.66 - 1.93 (m, 2 H), 1.96 - 2.18 (m, 1 H), 2.23 -2.42 (m, 1 H), 2.71 - 3.06 (m, 5 H), 3.38 - 3.58 (m, 1 H), 5.17 - 5.47 (m, 1 H), 7.28 (d, J=9.2 Hz, 1 H), 7.59 - 7.78 (m, 2 H), 7.82 - 7.99 (m, 2 H), 8.06 (d, J=9.2 Hz, 1 H) ppm. MS
(DCI/NH3) m/z 360 (M+H)+, 362 (M+H)+.
Example 24E
~4-(6-((3R)-1-Aza-bicyclo(2.2.21oct-3-yloxyl-pyridazin-3-yl1-phenyl)-benzhydrylidene-amine 3o The product of Example 24D (360 mg, 1 mmol) was coupled with benzhydrylideneamine (Aldrich, 270 mg, 1.5 mmol) under the catalysis of Pd2(dba)3 (Aldrich, 18.3 mg, 0.02 mmol) and Xantphos (Strem Chemicals, 36 mg, 0.06 mmol) with t-BuONa (Aldrich, 150 mg, 1.5 mmol) in toluene (anhydrous, Aldrich, 10 mL) at 100°C for 2h. The mixture was then cooled down to ambient temperature and diluted with EtOAc (50 mL), washed with water (2 x 5 mL). The organic solution was concentrated and the title compound was purified by chromatography (SiO2, MeOH : NH3~H20, 90:10:1, Rf. 0.4) as a solid (360 mg, yield, 78%).'H NMR (300 MHz, CD30D) b 1.45 - 1.63 (m, 1 H), .1.64 - 1.94 (m, 2 H), 1.94 - 2.13 (m, 1 H), 2.23 - 2.41 (m, 1 H), 2.71 - 3.06 (m, 5 H), 3.39 - 3.55 (m, 1 H), 5.10 - 5.37 (m, 1 H), 6.82 -6.93 (m, 2 H), 7.12 - 7.23 (m, 3 H), 7.25 - 7.35 (m, 3 H), 7.39 - 7.57 (m, 3 H), 7.67 -7.74 (m, 2 H), 7.74 - 7.83 (m, 2 H), 7.96 (d, J=9.2 Hz, 1 H) ppm. MS
(DCI/NH3): 461 (M+H )+.
Example 24F
4-{6-[(3R)-1-Aza-bicyclo[2.2.21oct-3-yloxy]-pyridazin-3-yl}-phenylamine ~5 The product of Example 24E (360 mg, 0.78 mmol) was treated with HCI (aq.
10%, 5 mL) in THF (5 mL) at ambient temperature for 4 h. It was then concentrated and the title compound was purified by chromatography (Si02, CH2C12 : MeOH
NH3~H20, 90:10:1, Rf. 0.1 ) as solid (210 mg, yield, 90%). 'H NMR (300 MHz, CD30D) b 1.44 - 1.66 (m, 1 H), 1.65 - 1.94 (m, 2 H), 1.95 - 2.16 (m, 1 H), 2.20 = 2.40 20 (m, 1 H), 2.68 - 3.06 (m, 5 H), 3.37 - 3.57 (m, 1 H), 5.15 - 5.37 (m, 1 H), 6.65 - 6.89 (m, 2 H), 7.18 (d, J=9.5 Hz, 1 H), 7.55 - 7.81 (m, 2 H), 7.93 (d, J=9.2 Hz, 1 H) ppm.
MS (DCI/NH3): 297 (M+H)+.
Example 24G
25 6-~6-[(3R)-1-Aza-bicyclo[2.2.21oct-3-yloxy]=pyridazin-3-yl)-benzothiazol-2-ylamine The product of Example 24F (150 mg, 0.5 mmol) was treated with KSCN
(Aldrich, 97 mg, 1 mmol) and bromine (Aldrich, 96 mg, 0.6 mmol) in HOAc (5 mL) at ambient temperature for 0.5 h. it was then quenched with Na2S03 (aq. 10%, 1 mL) and concentrated. The title compound was purified by chromatography (Si02, so : MeOH : NH3~H20, 90:10:2, Rf. 0.1) as solid (170 mg, yield, 80%).'H NMR
(300 MHz, CD30D) S 1.60-1.70 (m, 1 H), 1.72 - 1.98 (m, 2 H), 2.02 - 2.19 (m, 1 H), 2.23 -2.42 (m, 1 H), 2.82 - 3.13 (m, 5 H), 3.42 - 3.68 (m, 1 H), 5.15 - 5.54 (m, 1 H), 7.26 (d, J=9.2 Hz, 1 H), 7.49 (d, J=8.5 Hz, 1 H), 7.87 (dd, J=8.6, 1.9 Hz, 1 H), 8.07 (d, J=9.5 Hz, 1 H), 8.23 (d, J=1.4 Hz, 1 H) ppm. MS (DCI/NH3): 354 (M+H)+.
Example 24H
6-~6-[ 3R)-1-Aza-bicyclof2.2.21oct-3-yloxyl-pyridazin-3-yl}-benzothiazol-2-ylamine tri(hydrogen chloride) The product of Example 24G (170 mg, 0.48 mmol) was treated with HCI
(Aldrich, 4 M in dioxane, 0.5 mL, 2 mmol) in EtOAc (anhydrous, Aldrich, 5 mL) at o ambient temperature for 0.5 h to give the title compound as a yellow solid (170 mg, yield, 77%). ~H NMR 8 1.88 - 2.29 (m, 3 H) 2.30-2.42 (m, 1 H) 2.57 - 2.75 (m, 1 H), 3.33 - 3.60 (m, 5 H), 3.99 (dd, J=14.2, 8.1 Hz, 1 H), 5.41 - 5.71 (m, 1 H), 7.50 (d, J=9.2 Hz, 1 H), 7.68 (d, J=8.8 Hz, 1 H), 8.16 (dd, J=8.5, 1.7 Hz, 1 H), 8.26 (d, J=9.2 Hz, 1 H), 8.48 (d, J=1.4 Hz, 1 H) ppm; MS (DCI/NH3): 354 (M+H)+. Anal.
Calculated for C~gH~gN5OS 3.00 HC1~1.00 H20: C, 44.96; H, 5.03; N, 14.56. Found: C, 44.70;
H, 5.17; N, 14.24.
Example 25 (,3R)-3-[6-(3-Bromo-1 H-indol-5-yl)-pyridazin-3-yloxyl-1-aza-bicyclo[2.2.21octane 2o tri(hydrog~en chloride) Example 25A
(3R~1-3-[6-(3-Bromo-1 H-indol-5-yl)-pyridazin-3-yloxy~-1-aza-bicyclo[2.2.21octane The product of Example 9B (160 mg, 0.5 mmol) was dissolved in MeCN (10 2s mL) and treated with HOAc (Sigma, 60 mg, 1 mmol) for 10 min.
N-bromosuccinimide (Aldrich, 110 mg, 0.6 mmol) in MeCN (Aldrich, 5 mL) was slowly added over 5 min. The mixture was stirred for 1 hour at ambient temperature and concentrated under vacuum. The title compound was purified by chromatography (Si02, CH2C12: MeOH : NH3~H20, 90:10:1, Rf. 0.15) as a solid (70 3o mg, yield, 35%). ~H NMR (300 MHz, CD30D) b 1.55-1.62 (m, 1 H), 1.70 - 1.96 (m, 2 H), 2.05-2.20 (m, 1 H), 2.29 - 2.43 (m, 1 H), 2.74 - 3.13 (m, 5 H), 3.42 -3.66 (m, 1 H, _78_ 5.24 - 5.46 (m, 1 H), 7.27 (d, J=9.2 Hz, 1 H), 7.38 (s, 1 H), 7.53 (d, J=8.5 Hz, 1 H), 7.82 (dd, J=8.5, 1.7 Hz, 1 H), 8.05 (s, 1 H), 8.11 (d, J=9.5 Hz, 1 H) ppm. MS
(DCI/NH3): 399 (M+H)+, 401 (M+H)+.
Example 25B
(3R)-3-(6-(3-Bromo-1 H-indol-5-yl)-pyridazin-3-yloxyl-1-aza-bicyclo(2.2.21octane tri(hydrogen chloride) The product of Example 25A (50 mg, 0.125 mmol) was treated with HCI
(Aldrich, 4 M in dioxane, 0.25 mL, 1 mmol) in EtOAc (anhydrous, 5 mL) at ambient temperature for 1 h to provide the title compound as yellow solid (60 mg, yield, 95%).
'H NMR (300 MHz, CD30D) 8 1.89 - 2.28 (m, 3 H), 2.29 - 2.56 (m, 1 H), 2.63 -2.80 (m, 1 H), 3.35 - 3.71 (m, 5 H), 3.81 - 4.10 (m, 1 H), 5.37 - 5.74 (m, 1 H), 7.56 (s, 1 H), 7.72 (d, J=8.5 Hz, 1 H) 7.80 (dd, J=8.5, 1.8 Hz, 1 H), 8.01 (d, J=9.5 Hz, 1 H) 8.21 (d, J=1.4 Hz, 1 H), 8.76 (d, J=9.5 Hz, 1 H) ppm; MS (DCI/NH3): 399 (M+H)+, 401 (M+H)+. Anal. Calculated for C~gHIgBrN4O 3.00 HC1~1.50 H20: C, 42.60; H, 4.70; N, 10.46. Found: C, 42.59; H, 4.79; N, 10.09.
Example 26 5-~6-((,3R)- 1-Aza-bicyclo(2.2.21oct-3-yloxyl-pyridazin-3-yl}-1,3-dihydro-indol-2-one 2o bis(hydrogen chloride) Example 26A
5-(4,4,5,5-Tetramethyl-(1,3,21dioxaborolan-2-yl)-1,3-dihydro-indol-2-one 5-Bromo-1,3-dihydro-indol-2-one (Aldrich, 1.06 g, 5 mmol) was coupled with 2s bis(pinacolato)diboron (Aldrich, 1.52 g, 6 mmol) catalyzed by PdCl2(dppf)2~CH2CI2 (Aldrich, 82 mg, 0.1 mmol) using KOAc (Aldrich, 0.98 g, 10 mmol) as base in dioxane (anhydrous, Aldrich, 50 mL) at 80°C for 10h. After being cooled down to ambient temperature, the mixture was diluted with EtOAc (50 mL) and washed with brine (2 x 10 mL). The organic solution was then concentrated under vacuum.
The 3o title compound was purified by chromatography (Si02, hexane : EtOAc, 70:30, Rf.
0.5) as a solid (0.96 g, yield, 74%).'H NMR (300 MHz, CDC13) S 1.24 (s, 3 H), 1.28 (s, 3 H), 1.34 (s, 6 H), 3.69 (s, 2 H), 6.86 (d, J=7.8 Hz, 1 H), 7.57 - 7.78 (m, 2 H) ppm. MS (DCI/NH3): 260 (M+H)+.
Example 26B
5-(6-[(3R)- 1-Aza-bicyclo[2.2.2~oct-3-yloxyl-pyridazin-3-yl~-1 3-dihydro indol 2 one The product of Example 4A (240 mg, 1 mmol) was coupled with the product of Example 26A (520 mg, 2 mmol) catalyzed by PdCl2(PPh3)2 (Aldrich, 35 mg, 0.05 mmol) and 2-(dicyclohexylphosphino)biphenyl (Strem Chemicals, 52.5 mg, 0.15 mmol) in dioxane/EtOH/Na2C03 (aq, 1 M) (v. 1/1/1, 4.5 mL) at 130°C at 330 watts for min in an EmryT"" Creator microwave. The inorganic solid was filtered off with a syringe filter and the mixture was then directed purified by chromatography (Si02, EtOAc: MeOH (v. 2% NH3.H20), 50:50, Rf. 0.2) to give the title compound (240 mg, 71%).'H NMR (300 MHz, MeOH-D4) b 1.53 - 1.72 (m, 1 H), 1.73 - 1.96 (m, 2 H), 2.05 - 2.22 (m, 1 H), 2.24 - 2.49 (m, 1 H), 2.83 - 3.15 (m, 5 H), 3.34 (S, 2 H), 3.47 -15 3.65 (m, 1 H), 5.16 - 5.49 (m, 1 H), 7.02 (d, J=7.7 Hz, 1 H), 7.25 (d, J=9.2 Hz, 1 H), 7.73 - 7.90 (m, 2 H), 8.01 (d, J=9.2 Hz, 1 H) ppm. MS (DCI/NH3): 337 (M+H)+.
Example 26C
5-f6-[(3R)- 1-Aza-bicyclo[2.2.21oct-3-yloxyl-pyridazin-3-yl~-1 3-dihydro indol 2 one 2o bis(hydrogen chloi-ide~
The product of Example 26B (80 mg, 0.24 mmol) was treated with HCI
(Aldrich, 4 M in dioxane, 0.25 mL, 1 mmol) in EtOAc (anhydrous, 5 mL) at ambient temperature for 1 h to provide the title compound as yellow solid (100 mg, yield, 100%).'H NMR (300 MHz, MeOH-D4) 8 1.89 - 2.28 (m, 3 H), 2.29 - 2.49 (m, 1 H), 2.60-2.72 (m, 1 H), 3.34 - 3.63 (m, 5 H), 3.67 (s, 2 H), 3.81 - 4.10 (m, 1 H), 5.45 -5.71 (m, 1 H), 7.12 (d, J=6.1 Hz , 1 H), 7.77 (d, J=9.2 Hz, 1 H), 7.82 - 7.97 (m, 1 H), 8.46 (d, J=9.5 Hz, 1 H) ppm; MS (DCI/NH3): 337 (M+H)+. Anal. Calculated for C~sH2oNa02 2.00 HC1~2.00 H20: C, 51.24; H, 5.88; N, 12.58. Found: C, 51.34; H, 5.75; N, 12.62.
Example 27 5-{6-[(3R)-1-Oxy-1-Aza-bicyclo[2.2.2~oct-3-yloxyl-pyridazin-3-yl~-1,3-dihydro-indol-2-one bis(hydrogen chloride) Example 27A
5-f6-[ 3R)-1-Oxy-1-Aza-bicyclo[2.2.21oct-3-yloxyl-pyridazin-3-yl}-1,3-dihydro-indol-2-one The product of Example 26B (100 mg, 0.30 mmol) was treated with H202 (Aldrich, 30%, 0.5 mL, 1.3 mmol) in MeCN / H20 (v. 4 / 1, 10 mL) at 60°C for 70 hours according to the procedure of Example 23. The title compound was purified by 1o chromatography (Si02, EtOAc: MeOH (v. 2% NH3.H20), 50:50, Rf. 0.1 ) as solid (80 mg, 76%). 'H NMR (300 MHz, MeOH-D4) b 2.01 - 2.29 (m, 3 H), 2.37 - 2.61 (m, 2 H), 3.33 - 3.54 (m, 5 H), 3.68 (s, 2 H), 3.87 - 4.18 (m, 1 H), 5.46 - 5.77 (m, 1 H), 7.03 (d, J=8.1 Hz, 1 H), 7.31 (d, J=9.5 Hz, 1 H), 7.75 - 7.93 (m, 2 H), 8.06 (d, J=9.5 Hz, 1 H) ppm. MS (DCI/NH3): 353 (M+H)+.
Example 27B
5-f 6-f (3R)-1-Oxy-1-Aza-bicyclo[2.2.21oct-3-ylox~~~yridazin-3-yl}-1,3-d ihyd ro-indol-2-one bis(hydrogen chloride) The product of Example 27A (80 mg, 0.23 mmol) was treated with HCI
(Aldrich, 4M in dioxane, 0.25 mL, 1 mmol) in i-PrOH (5 mL) at ambient temperature for 1h to provide the title compound as yellow solid (90 mg, yield, 93%).'H
2.10 - 2.50 (m, 3 H), 2.54 - 2.81 (m, 2 H), 3.35 (s, 2 H), 3.71 - 3.94 (m, 4 H), 4.02 (d, J=13.2 Hz, 1 H), 4.30 - 4.58 (m, 1 H), 5.51 - 5.86 (m, 1 H), 7.18 (d, J=8.9 Hz, 1 H), 7.84 - 8.00 (m, 2 H), 7.99 (d, J=9.2 Hz, 1 H), 8.63 (d, J=9.2 Hz, 1 H) ppm; MS
(DCI/NH3): 353 (M+H)+. Anal. Calculated for C~gH2pN4O3 2.00 HC1~1.65 H20: C, 50.15; H, 5.60; N, 12.31. Found: C, 49.77; H, 5.29; N, 12.03.
Example 28 ~6-[(3R)-1-Aza-bicyclo[2.2.21oct-3-yloxyl-pyridazin-3-yl)-1,3-dihydro-benzoimidazol-2-one trifluroacetate Example 28A
r (4-Bromo-2-nitro-phenyl)-carbamic acid tert-butyl ester 4-Bromo-2-nitro-phenylamine (Aldrich, 10.8 g, 50 mmol) was treated with di(tert-butyl) dicarbonate (Aldrich, 11.99 g, 55 mmol) in THF (Aldrich, 100 mL) at refluxing for 6 hours. It was then concentrated and the title compound was purified by recrystallization in EtOH as white solid (12.8 g, yield, 81 %). ~H NIVIR
(300 MHz, MeOH-D4) b 1.40 (S, 9 H), 7.21 (d, J=8.5 Hz, 1 H), 7.76 (dd, J=8.4, 2.3 Hz, 1 H), 8.21 (d, J=2.1 Hz, 1 H) ppm. MS (DCI/NH3): 334 (M+H)+, 336 (M+H)+.
Example 28B
[2-Nitro-4-(4,4,5,5-tetramethyl-[1,3,21dioxaborolan-2-yl)-phe~ll-carbamic acid tert-butyl ester The product of Example 28A (10.05 g, 30 mmol) was coupled with with bis(pinacoiato)diboron (Aldrich, 9.14 g, 36 mmol) under the catalysis of PdCl2(dppf)2~CH2CI2 (Aldrich, 490 mg, 0.6 mmol) with KOAc (Aldrich, 6.0 g, 60 mmol) in dioxane (anhydrous, Aldrich, 150 mL) at 80°C for 10 hours according to the procedure of Example 26A. The title compound was purified by chromatography (Si02, hexane : EtOAc, 70:30, Rf. 0.5) as solid (9.0 g, yield, 83%). ~H NMR
(300 MHz, CDCI 3) b 1.37 (s, 9 H), 1.38 (s, 12 H), 7.99 (d, J=1.4 Hz, 1 H), 8.02 (d, J=1.4 2o Hz, 1 H), 8.45 (d, J=1.4 Hz, 1 H) ppm. MS (DCI/NH3): 382 (M+NH4)+.
Example 28C
~4-~(6-[(3R)-1-Aza-bicyclo[2.2.21oct-3-yloxyl-pyridazin-3-y~-2-nitro-phenyl}-carbamic, acid tert-butyl ester The product of Example 9A (240 mg, 1 mmol) was coupled with the product of Example 28B (0.72, 2 mmol) under the catalysis of Pd2(dba)3 (24 mg, 0.025 mmol) and (tBu3P)2Pd (26 mg, 0.05 mmol) with CsF (Strem Chemicals, 228 mg, 1.5 mmol) in dioxane (8 mL) and DMF (Aldrich, 1 mL) at 80°C under N2 for 16 hours according to the procedure of Example 20B. The title compound was purified by so chromatography (Si02, EtOAc: MeOH (v. 2°l° NH3.H20), 50:50, Rf. 0.3) as yellow solid (350 mg, 79%). 'H NMR (300 MHz, MeOH-D4) b 1.40 (s, 9 H), 1.51 - 1.70 (m, 1 H), 1.70 - 1.98 (m, 2 H), 2.00 - 2.23 (m, 1 H), 2.37 - 2.51 (m, 1 H), 2.71 -3.18 (m, 5 H), 3.47 - 3.69 (m, 1 H), 5.33 - 5.49 (m, 1 H), 7.30 (d, J=9.2 Hz, 1 H), 7.54 (d, J=8.5 Hz, 1 H), 7.62 (s, 1 H), 8.14 (d, J=9.5 Hz, 1 H), 8.37 (dd, J=8.1, 2.0 Hz, 1 H), 8.80 (d, J=2.0 Hz, 1 H) ppm. MS (DCI/NH3): 442 (M+H)+.
Example 28D
4-~6-f (3R)-1-Aza-bicyclo f2.2.2)oct-3-yloxy)-pyridazin-3-yl~-2-nitro-phenylamine The product of Example 28C (350 mg, 0.79 mmol) was treated with HCI
(Aldrich, 4 M in dioxane, 2 mL, 8 mmol) in EtOH (5 mL) at ambient temperature for 1 h. The mixture was concentrated and the title compound was purified by chromatography (Si02, EtOAc: MeOH (v. 2% NH3.H20), 50:50, Rf. 0.1 ) as white solid (250 mg, 93%). 'H NMR (300 MHz, MeOH-D4) b 1.54 - 1.66 (m, 1 H), 1.72 -2.02 (m, 2 H), 2.07 - 2.24 (m, 1 H), 2.35 - 2.57 (m, 1 H), 2.79 - 3.18 (m, 5 H), 3.48 -3.69 (m, 1 H), 5.27 - 5.47 (m, 1 H), 7.10 (d, J=8.8 Hz, 1 H), 7.22 (d, J=9.5 Hz, 1 H), 7.66 (s, 1 H), 7.98 (d, J=9.2 Hz, 1 H), 8.08 (dd, J=9.0, 2.2 Hz, 1 H), 8.68 (d, J=2.4 Hz, 1 H) ppm. MS (DCI/NH3): 342 (M+H)+.
Example 28E
4-f 6-f (3R)-1-Aza-bicyclo f 2.2.21oct-3-yloxy~-pyridazin-3-yl}-benzene-1,2-diamine 2o The product of Example 28D (200 mg, 0.59 mmol) was hydrogenated under the catalysis of Pd/C (Aldrich, 10wt.%, 50 mg) in EtOH (10 mL) under hydrogen at ambient temperature for 10 h. After the reaction went to completion, the catalyst was removed through a short column of diatomaceous earth (~ 2 g) and the filtrate was washed with EtOH (2 x 5 mL). The ethanol solution was concentrated to give the title compound (180 mg, yield, 98%).'H NMR (500 MHz, CD3-OD) 8 1.58 - 1.73 (m, 1 H), 1.76 - 2.00 (m, 2 H), 2.06 - 2.27 (m, 1 H), 2.29 - 2.47 (m, 1 H), 2.81 - 3.20 (m, 5 H), 3.52 - 3.68 (m, 1 H), 5.11 - 5.57 (m, 1 H), 6.78 (d, J=8.2 Hz, 1 H), 7.12 -7.26 (m, 2 H), 7.32 (d, J=2.1 Hz, 1 H), 7.92 (d, J=9.2 Hz, 1 H) ppm. MS (DCI/NH3): 312 (M+H)+.
Example 28F
5-{6-[(3R)-1-Aza-bicycloj2.2.21oct-3-yloxy]I-pyridazin-3-yl}-1,3-dihydro-benzoimidazol-2-one trifluroacetate The product of Example 28E (62 mg, 0.2 mmol) was treated with 1,1'-carbonyldiimidazole (Aldrich, 50 mg, 0.31 mmol) in THF/DMF (v. 1:1, 5 mL) at ambient temperature for 10h. It was then concentrated. The title product was purified by preparative HPLC (XterraTM, column, Xterra RP-18, 5 pm, 30 x 100 mm.
Eluting Solvent, MeCN / H20 (with 0.2% v. TFA), (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (20.0 mg, 22%).'H NMR (500 MHz, CD3-OD) 8 1.94 - 2.33 (m, 3 H), 2.30 - 2.48 (m, 1 H), 2.65 - 2.79 (m, 1 H), 3.38 - 3.70 (m, 6 H), 3.94 - 4.06 (m, 1 H), 5.41 - 5.73 (m, 1 H), 7.31 (d, J=7.6 Hz, 1 H), 7.62 -7.78 (m, 2 H), 8.00 (d, J=7.0 Hz, 1 H), 8.65 (d, J=7.3 Hz, 1 H) ppm; MS (DCI/NH3): 338 (M+H)+.
Anal. Calculated for C~gHigN5O2 -1.15 CF3C02H 2.30 H20: C, 47.81; H, 4.89; N, 13.73. Found: C, 47.69; H, 5.27; N, 14.09.
Example 29 (R~-3-[6-(1 H-Benzoimidazol-5-yl)-pyridazin-3-yloxyl-1-aza-bicyclo[2.2.21octane Example 29A
(R)-N-(4-[6-(1-Aza-bicycloJ2.2.21oct-3-ylox~~pyridazin-3-yll-phenyl)-acetamide The product of Example 9A (182 mg, 0.76 mmol), N-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-acetamide (Aldrich, 500 mg, 1.9 mmol), dichlorobis(triphenylphosphine)palladium (II) (Aldrich, 53 mg, 0.076 mmol) and (dicyclohexylphosphino)biphenyl (Strem Chemicals, 6.5 mg, 0.019 mmol) were combined with 1 mL each of ethanol, p-dioxane, and 1 M aq. sodium carbonate.
The mixture was heated in a sealed tube to 150 °C at 330 watts for 10 min in an EmryT""
Creator microwave. The mixture was cooled to room temperature, filtered through Celite°, and concentrated onto silica. The product was purified by column chromatography (Si02, 5% methanol containing 1 % NH40H -CH2CI2) to provide the 3o title compound (203 mg, 79%).'H NMR (300 MHz, CD30D) 8 1.96 (m, 1 H), 2.09 (m, 1 H), 2.16 (m, 1 H), 2.16 (s, 3 H), 2.38 (m, 1 H), 2.64 (td, J=6.5, 3.6 Hz, 1 H), 3.33 -3.53 (m, 6 H), 3.97 (dd, J=13.9, 8.1 Hz, 1 H), 5.54 (m, 1 H), 7.32 (d, J=9.4 Hz, 1 H), 7.69 - 7.78 (m, 2 H), 7.91 - 7.98 (m, 2 H), 8.11 (d, J=9.3 Hz, 1 H) ppm; MS
(DCI/NH3): m/z 339 (M+H)+.
Example 29B
4-(6-[(3R)-1-Aza-bicyclo[2.2.21oct-3-ylo~l-pyridazin-3-yl~-2-nitro-phenylamine trifluoroacetate To an ice-cold solution of Example 29A (160 mg, 0.47 mmol) in conc. sulfuric acid (5 mL) was added 90% nitric acid (0.020 mL, 0.47 mmol). After 2 h at 4°C, the mixture was poured over ice and neutralized with ice-cold NaOH (1 N aq.). The mixture was concentrated and the residue was dissolved in MeOH and filtered to give a crude red solid. The product was purified by preparative RP HPLC
(Symmetry~ C-8, 7 pm, 40 x 100 mm; 10-90% MeCN / H20 with 0.2% v. TFA) to give the title compound (54 mg, 0.11 mmol, 23%).'H NMR (400 MHz, CD30D) 8 ~5 1.97 (m, 1 H), 2.03 - 2.23 (m, 2 H), 2.39 (m, 1 H), 2.65 (td, J=6.5, 3.6 Hz, 1 H), 3.35 -3.47 (m, 4 H), 3.49 (m, 1 H), 3.85 (m, 1 H), 3.97 (dd, J=14.0, 8.4 Hz, 1 H), 5.54 (m, 1 H), 7.12 (d, J=8.9 Hz, 1 H), 7.33 (d, J=9.2 Hz, 1 H), 8.04 (dd, J=8.9, 2.1 Hz, 1 H), 8.11 (d, J=9.2 Hz, 1 H), 8.71 (d, J=2.1 Hz, 1 H) ppm. MS (ESI): m/z 342 (M+H)+.
2o Example 29C
(R)-3-[6-(1 H-Benzoimidazol-5-yl)-pyridazin-3-yloxyl-1-aza-bicyclo[2.2.21octarie The product of Example 29B (29 mg, 0.064 mmol) was dissolved in 2.0 mL of methanol and 6 mg of Pd(OH)2/C (Aldrich, 10 wt%) was added. The mixture was stirred under 50 psi of H2 for 30 min. The solution was filtered through a nylon 25 membrane and concentrated. The residue was dissolved in DMF (0.25 mL) and treated with excess triethylorthoformate (0.1 mL). The solution was heated at 80 °C
for 2 h, then cooled down to ambient temperature and stirred for 4 h. The title product was purified by preparative HPLC (XterraTM, column, Xterra RP-18 5 pm, x 100 mm. Eluting Solvent, MeCN / H20 (NH4HC03, 0.1 M, pH=10) (v. 40/60 to 30 70/30 over 20 min.) Ffow rate, 75 mL/min., uv, 250 nm) as solid (13 mg, 0.04 mmol, 63%).'H NMR (300 MHz, CD30D) 8 1.57 (m, 1 H), 1.73 - 1.94 (m, 2 H), 2.08 (m, 1 H), 2.34 (td, J=6.4, 3.6 Hz, 1 H), 2.80 - 3.03 (m, 6 H), 3.50 (ddd, J=14.5, 8.1, 1.5 Hz, 1 H), 5.32 (m, 1 H), 7.28 (d, J=9.2 Hz, 1 H), 7.74 (d, J=8.5 Hz, 1 H), 7.91 (d, J=8.5 Hz, 1 H), 8.11 (d, J=9.2 Hz, 1 H), 8.22 (s, 1 H), 8.25 (s, 1 H) ppm; MS
(DCI/NH3):
m/z 322 (M+H)+.
Example 30 (S)-3-[6-(1 H-Indol-5-yl)-pyridazin-3-ylox~~-1-aza-bicyclo[2.2.2~octane Fumarate Example 30A
(,S)-3-(6-Chloro-pyridazin-3-yloxy~)-1-aza-bicyclo[2.2.21octane The product of Example 13D (254 mg, 2 mmol) was coupled with 3,6-dichloropyridazine (Aldrich, 596 mg, 4 mmol) according to the procedure of Example 7A. The title compound was purified by flash chromatography (Si02, CH2C12 :
MeOH
NH3~H20, 90:10:2, Rf. 0.30) as solid (346 mg, 72%).'H NMR (300 MHz, MeOH-D4) b 1.47 - 1.63 (m, J=12.9 Hz, 1 H), 1.65 - 1.92 (m, 2 H), 1.94 - 2.10 (m, J=5.9, 3.6 Hz, 1 H), 2.22 - 2.32 (m, J=2.7 Hz, 1 H), 2.72 - 3.02 (m, 5 H), 3.36 - 3.49 (m, 1 H), 5.17 -5.28 (m, 1 H), 7.23 (d, J=9.2 Hz, 1 H), 7.65 (d, J=9.5 Hz, 1 H) ppm. MS
(DCI/NH3) m/z 240 (M+H)+, 242 (M+H)+.
2o Example 30B
(S)-3-[6-(1 H-Indol-5-yl)-pyridazin-3-yloxyl-1-aza-bicyclo[2.2.21octane The product of Example 30A (270 mg, 1.1 mmol) was coupled with 5-indolylboronic acid (215 mg, 1.4 mmol) according to the procedure of Example 20B.
The title compound was purified by preparative HPLC (XterraTM, column, Xterra RP-18 5 Nm, 30 x 100 mm. Eluting Solvent, MeCN / H20 (NH4HC03, 0.1 M, PH=10) (v.
90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (200 mg, 57%). 'H NMR (300 MHz, MeOH-D4) b 1.49 - 1.63 (m, 1 H), 1.67 - 1.92 (m, 2 H), 1.99 - 2.14 (m, 1 H), 2.28 - 2.36 (m, 1 H), 2.76 - 3.04 (m, 5 H), 3.48 (ddd, J=14.7, 8.2, 1.9 Hz, 1 H), 5.24 - 5.34 (m, 1 H), 6.56 (d, J=4.1 Hz, 1 H), 7.24 (d, J=9.5 Hz, 1 3o H), 7.30 (d, J=3.4 Hz, 1 H), 7.50 (d, J=8.5 Hz, 1 H), 7.73 (dd, J=8.6, 1.9 Hz, 1 H) ,8.07 (d, J=9.5 Hz, 1 H), 8.13 (s, 1 H) ppm. MS (DCI/NH3) m/z 321 (M+H)+.
Example 30C
(S)-3-f6- 1 H-Indol-5-yl)-pyridazin-3-yloxyl-1-aza-bicyclof2.2.2~octane fumarate The product of Example 30B (200 mg, 0.625 mmol) was treated with fumaric acid (Aldrich, 73 mg, 0.63 mmol) in EtOAc/MeOH (v.10:1, 10 mL) at ambient temperature for 10 hours to give title compound (240.2 mg, 85%). 'H NMR (300 MHz, MeOH-D4) b 1.87 - 2.22 (m, 3 H), 2.31 - 2.45 (m, 1 H), 2.60 - 2.67 (m, 1 H), 3.30 - 3.50 (m, 5 H), 3.89 - 4.00 (m, 1 H), 5.49 - 5.57 (m, 1 H), 6.57 (d, J=3.1 Hz, 1 H), 6.68 (s, 2 H), 7.28 - 7.35 (m, 2 H), 7.52 (d, J=8.5 Hz, 1 H), 7.74 (dd, J=8.6, 1.9 o Hz, 1 H), 8.11 - 8.19 (m, J=9.5 Hz, 2 H) ppm. MS (DCI/NH3) m/z 321 (M+H)+.
Anal.
Calculated for C~9H2oN40~ 1.O C4O4H4'O.SO H2O: C, 62.01; H, 5.66; N, 12.58.
Found:
C, 61.79; H, 5.46; N, 12.43.
Example 31 (R)-3-f5-(1 H-Indol-5-yl)-pyridin-2-yloxyl-1-aza-bicyclof2.2.2~octane trifluoroacetate Example 31 A
(R)-3-(5-Bromo-pyridin-2-yloxy)-1-aza-bicyclo f2.2.2~octane The product of Example 4A (1.27 g, 10 mmol) was coupled with 5-bromo-2-2o chloro-pyridine (Aldrich, 1.54 g, 8 mmol) according to the procedure of Example 7A.
The title compound was purified by column chromatography (Si02, CH2CI2 : MeOH
NH3~H20, 90:10:1, Rf. 0.2) as a solid (2.0 g, yield, 88%). 'H NMR (MeOH-d4, MHz) 1.49 - 1.64 (m, 1 H), 1.66 - 1.91 (m, 2 H), 1.97 - 2.11 (m, 1 H), 2.17 -2.26 (m, 1 H), 2.77 - 3.05 (m, 5 H), 3.36 - 3.47 (m, 1 H), 5.02 - 5.10 (m, 1 H), 6.77 (d, J=8.8 2s Hz, 1 H), 7.78 (dd, J=8.8, 2.7 Hz, 1 H), 8.16 (t, J=2.5 Hz, 1 H) ppm. MS
(DCI/NH3) m/z 283 (M+H)+, 285(M+H)+.
Example 31 B
(R)-3-(5-(1 H-Indol-5-yl)-pyridin-2-yloxyl-1-aza-bicycl~2.2.21octane trifluoroacetate 3o The product of Example 31A (140 mg, 0.5 mmol) was coupled with 5-indolylboronic acid (Ryscor Science, 161 mg, 1.0 mmol) according to the procedure of Example 29A. The title compound was preparative HPLC (XterraTM, column, Xterra RP-18, 5 pm, 30 x 100 mm. Eluting Solvent, MeCN / H20 (with 0.2% v.
TFA), (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (72.9 mg, 32%).'H NMR (MeOH-d4, 300 MHz) 1.86 - 2.22 (m, 3 H), 2.31 - 2.46 (m, 1 H), 2.52 - 2.63 (m, 1 H), 3.29 - 3.50 (m, 5 H), 3.85 - 3.97 (m, 1 H), 5.34 - 5.42 (m, 1 H), 6.49 (d, J=2.4 Hz, 1 H), 6.93 (d, J=8.5 Hz, 1 H), 7.24 - 7.35 (m, 2 H), 7.46 (d, J=8.5 Hz, 1 H), 7.74 (d, J=1.7 Hz, 1 H), 8.00 (dd, J=8.6, 2.5 Hz, 1 H), 8.38 (d, J=2.7 Hz, 1 H) ppm. MS (DCI/NH3) m/z 320(M+H)+. Anal. Calculated for C2oH2~N30~1.14 CF3C02H: C, 59.55; H, 4.97; N, 9.35. Found: C, 59.59; H, 4.99; N, 9.03.
Example 32 (3R)-3-f5-(1 H-Indol-4-yl)-pyrimidin-2-yloxyl-1-aza-bicyclof2.2.21octane 1-oxide The product of Example 12A (10 mg, 0.03 mol) was oxidized with H202 (Aldrich, aq., 30%) according to the procedure of Example 23. The title compound was purified by chromatography [Si02, CH2C12: MeOH (v. 5% NH3.H20), 90 : 10].
'H NMR (300 MHz, CD30D) b 2.01 - 2.32 (m, 3 H), 2.42 - 2.64 (m, 2 H), 3.41 -3.70 (m, 5H), 3.91 - 4.24 (m, 1 H), 5.39 - 5.59 (m, 1 H), 6.55 (d, J=4.0 Hz, 1 H), 7.12 (d, J=8.0 Hz, 1 H), 7.23 (t, J=8.0 Hz, 1 H), 7.36 (d, J=3.0 Hz, 1 H), 7.47 (d, J=8.0 Hz, 1 H), 8.96 (s, 2 H) ppm.
Example 33 (3R)-3-(5-Benzooxazol-5-yl-pyrimidin-2-ylox r~-1-aza-bicyclof2.2.2~octane bis(hydrogien chloride) Example 33A
1-Benzyloxy-4-bromo-2-nitro-benzene 4-Bromo-2-nitro-phenol (Aldrich, 2.18 g, 10 mmol) was treated with K2C03 (Aldrich, 2.76 g, 20 mmol) in DMF (Aldrich, 100 mL) at ambient temperature for min. Benzyl chloride (Aldrich, 1.52 g, 12 mmol) was added. The mixture was stirred L
so at 100°C for 6 h. It was then poured into ice/water (200 mL) and stirred at ambient temperature for 10 hours. The white solid was filtered and dried to give the title _88_ compound (3.0 g, yield, 100%).'H NMR (300 MHz, CDC13) ~ 5.23 (s, 2 H), 7.01 (d, J=9.2 Hz, 1 H), 7.31 - 7.49 (m, 5 H), 7.58 (dd, J=9.0, 2.5 Hz, 1 H), 7.98 (d, J=2.7 Hz, 1 H) ppm. MS (DCI/NH3): 325 (M+H)+, 327 (M+H)+.
Example 33B
[2-Nitro-4-(4,4,5,5-tetramethyl-(1,3,21dioxaborolan-2-yl)-phenyll-carbamic acid tert-butyl ester The product of Example 33A (3.0 g, 10 mmol) was coupled with bis(pinacolato)diboron (Aldrich, 3.04 g, 12 mmol) according to the procedure of Example 28B. The title compound was purified by chromatography (Si02, hexane EtOAc, 70:30, Rf. 0.5) as a solid (3.05 g, yield, 86%).'H NMR (300 MHz, MEOH-D4) b 1.34 (s, 12 H), 5.30 (s, 2 H), 7.27 - 7.43 (m, 4 H), 7.42 - 7.51 (m, 2 H), 7.89 (dd, J=8.3, 1.5 Hz, 1 H), 8.09 (d, J=1.7 Hz, 1 H) ppm. MS (DCI/NH3): 373 (M+NH4)+.
Example 33C
(3R)-3-(5-(4-Benzyloxy-3-nitro-phenyl)-pyrimidin-2yloxy~-1-aza-bicyclo(2 2 2loctane The product of Example 11A (1.42 g, 5 mmol) was coupled with the product of Example 33B (2.50 g, 7.0 mmol) according to the procedure of Example 20B. The title compound was purified by chromatography (Si02, EtOAc: MeOH (v. 2%
2o NH3.H20), 50:50, Rf. 0.3) as solid (1.75 g, 81%).'H NMR (300 MHz, MeOH-D4) b 1.46 - 1.61 (m, 1 H), 1.63 - 1.92 (m, 2 H), 1.97 - 2.15 (m, 1 H), 2.17 - 2.33 (m, 1 H), 2.69 - 3.04 (m, 5 H), 3.35 - 3.49 (m, 1 H), 5.11 - 5.22 (m, 1 H), 5.34 (s, 2 H), 7.25 -7.55 (m, 5 H), 7.85 (dd, J=8.8, 2.4 Hz, 1 H), 8.13 (d, J=2.0 Hz, 1 H), 8.63 (s, 1 H), 8.82 (s, 2 H) ppm. MS (DCI/NH3): 433 (M+H)+.
Example 33D
2-Amino-4-f 2-((3R)-1-aza-bicyclo(2.2.21oct-3=ylo~1-pyrimid in-5-yl}-phenol The product of Example 33C (380 mg, 0.88) was hydrogenated under the catalysis of Pd/C (Aldrich, 10 wt. %, 100 mg) according to the procedure of Example 28E. The title compound was obtained as yellow solid (220 mg, yield, 92%).'H
NMR
(300 MHz, CD30D) 8 1.47 - 1.93 (m, 3 H), 1.95 - 2.35 (m, 2 H) 2.70 - 3.05 (m, 5 H), _89_ 3.33 - 3.48 (m, 1 H), 5.04 - 5.30 (m, J=8.8 Hz, 1 H), 6.72 - 6.88 (m, 2 H), 6.98 (d, J=1.7 Hz, 1 H), 8.70 (s, 2 H)ppm. MS (DCI/NH3): 313 (M+H)+.
Example 33E
(3R)-3-(5-Benzooxazol-5-yl-pyrimidin-2-yloxy)-1-aza-bicyclof2.2.21octane The product of Example 33D (62 mg, 0.2 mmol) was treated with triethyl orthoformate (Aldrich, 0.5 mL) in DMF (1 mL) at 100°C for 10h. It was then concentrated. The title product was purified by preparative HPLC (XterraTM, column, Xterra RP-18, 5 Nm, 30 x 100 mm. Eluting Solvent, MeCN / H20 (NH4HC03, 0.1 M, 1o pH=10) (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (50.0 mg, 78%). ~H NMR (300 MHz, CD3-OD) 8 1.46 - 1.64 (m, 1 H), 1.64 - 1.93 (m, 2 H), 2.00 - 2.19 (m, 1 H), 2.19 - 2.39 (m, 1 H), 2.67 - 3.13 (m, 5 H), 3.36 -3.51 (m, 1 H), 5.09 - 5.38 (m, 1 H), 7.72 (dd, J=8.5, 2.0 Hz, 1 H), 7.81 (d, J=8.9 Hz, 1 H), 8.03 (d, J=1.7 Hz, 1 H), 8.53 (s, 1 H), 8.87 (s, 2 H) ppm; MS (DCI/NH3): 323 (M+H)+.
Example 33F
(3R)-3-(5-Benzooxazol-5-yl-pyrimidin-2-yloxy)-1-aza-bicyclof2.2.21octane bis(hydrogen chloride) The product of Example 33E (50 mg, 0.15 mmol) was treated with HCI
(Aldrich, 4M in dioxane, 0.50 mL, 2.0 mmol) in EtOAc (5 mL) at ambient temperature for 1 hour to afford the title compound as yellow solid (55.0 mg, 93%).'H NMR
(300 MHz, CD3-OD) 8 1.83 - 2.28 (m, 3 H), 2.30 - 2.50 (m, 1 H), 2.58 - 2.75 (m, 1 H), 3.34 - 3.51 (m, 5 H), 3.84 - 3.97 (m, 1 H), 5.33 - 5.52 (m, 1 H), 7.15 (d, J=8.5 Hz, 1 H), 7.51 - 7.67 (m, 1 H), 7.80 (s, 1 H), 8.09 (s, 1 H), 8.81 (s, 2 H) ppm; MS
(DCI/NH3):
323 (M+H)+. Anal. Calculated for C~gHIgN4O2 2.38 HCI 2.60 H20: C, 47.41; H, 5.65; N, 12.29. Found: C, 47.33; H, 5.25; N, 11.92.
Example 34 (3R)-3-(5-(2-Methyl-benzooxazol-5-yl )-pyrimid in-2-yloxyl-1-aza-bicyclo f 2.2.21octane 3o hydrogen chloride Example 34A
~3R)-3-f 5-(2-Methyl-benzooxazol-5-ail)-pyrimidin-2-yloxyl-1-aza-bicyclo f 2.2.21octane The product of Example 33D (62 mg, 0.2 mmol) was treated with triethyl orthoacetate (Aldrich, 0.5 mL) in DMF (1 mL) at 100°C for 10h. It was then concentrated. The title product was purified by preparative HPLC (XterraTM, column, Xterra RP-18, 5 Nm, 30 x 100 mm. Eluting Solvent, MeCN / H20 (NH4HC03, 0.1 M, pH=10) (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (20.0 mg, 30%).'H NMR (500 MHz, CD30D) 8 1.51 - 1.64 (m, 1 H), 1.66 - 1.77 (m, H), 1.78 - 1.91 (m, 1 H), 2.02 - 2.16 (m, 1 H), 2.19 - 2.36 (m, 1 H), 2.67 (s, 3 H), 2.74 - 3.07 (m, 5 H), 3.37 - 3.48 (m, 1 H), 5.07 - 5.39 (m, 1 H), 7.62 (dd, J=8.5, 1.3 Hz, 1 H), 7.68 (d, J=8.3 Hz, 1 H),7.87 (d, J=1.2 Hz, 1 H), 8.79 - 8.93 (s, 2 H) ppm;
MS
(DCI/NH3): 327 (M+H)+.
Example 34B
(3R)-3-f5-(2-Methyl-benzooxazol-5-yl)-pyrimidin-2-yloxyl-1-aza-bicyclof2.2.2~octane hydrogen chloride The product of Example 34A (20 mg, 0.06 mmol) was treated with HCI
(Aldrich, 4M in dioxane, 0.25 mL, 1.0 mmol) in EtOAc (3 mL) at ambient temperature for 1 hour to afford the title compound as yellow solid (20.0 mg, 92%).'H NMR
(500 2o MHz, CD30D) 8 1.92 - 2.25 (m, 3 H), 2.33 - 2.47 (m, 1 H), 2.59 - 2.65 (m, 1 H), 2.65 - 2.71 (s, 3 H), 3.33 - 3.54 (m, 5 H); 3.87 - 4.00 (m, 1 H), 5.34 - 5.54 (m, 1 H), 7.63 (d, J= 8.5 Hz, 1 H), 7.70 (d, J= 8.5 Hz, 1 H), 7.88 (s, 1 H), 8.90 (s, 2 H) ppm; MS
(DCI/NH3): 327 (M+H)+. Anal. Calculated for C~gH2pN4O2 1.20 HCI 1.50 H20: C, 56.39; H, 5.60; N, 13.45. Found: C, 56.05; H, 5.99; N, 13.76.
Example 35 (3R)-3-f 5-(2-Ethyl-benzooxazol-5-yl)-pyrimid i n-2-yloxyl-1-aza-bicyclo f 2.2.21octane bis(hydroqen chloride) Example 35A
~3R)-3-[5-(2-Ethyl-benzooxazol-5-yl)-p rLrimidin-2-yloxyl-1-aza-bicyclo[2.2.~octane The product of Example 33D (62 mg, 0.2 mmol) was treated with triethyl orthopropionate (Aldrich, 0.5 mL) in DMF (1 mL) at 100°C for 10h. It was then concentrated. The title product was purified by preparative HPLC (XterraTM, column, Xterra RP-18, 5 Nm, 30 x 100 mm. Eluting Solvent, MeCN / H20 (NH4HC03, 0.1 M, pH=10), (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (20.0 mg, 30%).'H NMR (500 MHz, CD30D) 8 1.45 (t, J=7.6 Hz, 3 H), 1.49 - 1.64 (m, 1 H), 1.66 - 1.78 (m, 1 H), 1.79 - 1.94 (m, 1 H), 2.04 - 2.16 (m, 1 H), 2.21 - 2.36 (m, 1 H), 2.72 - 3.11 (m, 7 H), 3.37 - 3.53 (m, 1 H), 5.07 - 5.31 (m, 1 H), 7.62 (dd, J=
8.5, 1.7 Hz, 1 H) 7.69 (d, J= 8.6 Hz, 1 H), 7.89 (d, J=1.2 Hz, 1 H), 8.82 -8.90 (m, 2 H) ppm; MS (DCI/NH3): 351 (M+H)+.
Example 35B
(3R)-3-f5-(2-Methyl-benzooxazol-5-yl)-pyrimidin-2-yloxyl-1-aza-bicyclof2.2.2]octane bis(,hydroqen chloride) -The product of Example 35A (20 mg, 0.06 mmol) was treated with HCI
(Aldrich, 4M in dioxane, 0.25 mL, 1.0 mmol) in EtOAc (3 mL) at ambient temperature for 1 hour to afford the title compound as yellow solid (15.0 mg, 92%).'H NMR
(500 2o MHz, CD3-OD) 8 1.46 (t, J=7.6 Hz, 3 H), 1.89 - 2.25 (m, 3 H), 2.28 - 2.52 (m, 1 H), 2.54 - 2.72 (m, 1 H), 3.02 (q, J=7.6 Hz, 2 H), 3.22 - 3.56 (m, 5 H), 3.92 (dd, J=13.6, 8.7 Hz, 1 H), 4.99 - 5.63 (m, 1 H), 7.63 (d, J=8.5 Hz, 1 H), 7.71 (d, J=8.5 Hz, 1 H), 7.90 (s, 1 H), 8.90 (s, 2 H) ppm; MS (DCI/NH3): 351 (M+H)+. Anal. Calculated for C2oH22N402 2.00 HCI: C, 56.74; H, 5.71; N, 13.23. Found: C, 56.82; H, 5.69; N, 13.13.
Example 36 (3R)-3-f 5-(2-Phenyl-benzooxazol-5y~-pyrimid in-2-yloxyl-1-aza-bicyclo f 2.2.21octane bis~droqen chloride) Example 36A
(3R)-3-(5-(2-Phenyl-benzooxazol-5-yl)-~~rimidin-2-yloxy~-1-aza-bicyclo(2.2.21octane The product of Example 33D (62 mg, 0.2 mmol) was treated with triethyl orthobenzoate (Aldrich, 0.5 mL) in DMF (1 mL) at 100°C for 10h. It was then concentrated. The title product was purified by preparative HPLC (XterraTM, column, Xterra RP-18, 5 pm, 30 x 100 mm. Eluting Solvent, MeCN / H20 (NH4HC03, 0.1 M, pH=10), (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (40.0 mg, 50%).'H NMR (500 MHz, CD30D) 8 1.52 - 1.64 (m, 1 H), 1.68 - 1.80 (m, H), 1.80 - 1.92 (m, 1 H), 2.06 - 2.18 (m, 1 H), 2.25 - 2.31 (m, 1 H), 2.75 -3.10 (m, 5 H), 3.39 - 3.49 (m, 1 H), 5.14 - 5:27 (m, 1 H), 7.55 - 7.66 (m, 3 H), 7.69 (dd, J=8.5, 1.8 Hz, 1 H), 7.81 (d, J=8.2 Hz, 1 H), 8.00 (d, J=1.5 Hz, 1 H), 8.27 (dd, J=8.1, 1.7 Hz, 2 H), 8.89 (s, 2H) ppm; MS (DCI/NH3): 399 (M+H)+.
Example 36B
~5 (3R)-3-(5- 2-Phenyl-benzooxazol-5-yl)-pyrimidin-2-yloxy~-1-aza-bicyclo(2.2.21octane bis(hydrogen chloride) The product of Example 36A (40 mg, 0.10 mmol) was treated with HCI
(Aldrich, 4M in dioxane, 0.25 mL, 1.0 mmol) in EtOAc (3 mL) at ambient temperature for 1 hour to afford the title compound as yellow solid (20.0 mg, 92%).'H NMR
(500 2o MHz, CD30D) 8 1.93 - 2.23 (m, 3 H), 2.33 - 2.48 (m, 1 H), 2.60 - 2.71 (m, 1 H), 3.34 -3.57 (m, 5 H), 3.90 - 3.99 (m, 1 H), 5.35 - 5.61 (m, 1 H), 7.54 - 7.68 (m, 3 H), 7.72 (dd, J=8.4, 1.7 Hz, 1 H), 7.84 (d, J=8.5 Hz, 1 H), 8.03 (d, J=1.2 Hz, 1 H), 8.21 - 8.37 (m, 2 H), 8.98 (s, 2 H) ppm; MS (DCI/NH3): 399 (M+H)+. Anal. Calculated for C2aH22NaO2 1.40 HCI 1.50 H20: C, 60.49; H, 5.58. Found: C, 60.12; H, 5.72.
Example 37 (R)-5-(2- 1-Aza-bicyclo(2.2.21oct-3-ylox~~hyrimidin-5-yl~-3H-benzooxazol-2-one bis(hydrochloride) 3o Example 37A
(R)-5-(2-( 1-Aza-bicyclo(2.2.21oct-3-yloxy)-pyrimidin-5-yll-3H-benzooxazol-2-one The product of Example 33D (62 mg, 0.2 mmol) was treated with 1,1'-carbonyldiimidazole (Aldrich, 50 mg, 0.31 mmol) in THF/DMF (v. 1:1, 5 mL) at ambient temperature for 10h. It was then concentrated. The title product was purified by preparative HPLC (XterraTM, column, Xterra RP-18, 5 pm, 30 x 100 mm.
Eluting Solvent, MeCN / H20 (NH4HC03, 0.1 M, pH=10), (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (60.0 mg, 34%).'H NMR (500 MHz, CD3-OD) 8 1.46 - 1.96 (m, 3 H), 2.02 - 2.18 (m, 1 H), 2.19 - 2.38 (m, 1 H), 2.70 - 3.11 (m, 5 H), 3.37 - 3.51 (m, 1 H), 5.08 - 5.29 (m, 1 H), 7.14 - 7.60 (m, 3 H), 8.79 (s, 2 H) ppm; MS (DCI/NH3): 338 (M+H)+.
Example 37B
(R)-5-[2-(1-Aza-bicyclo[2.2.21oct-3-yloxy)-pyrimidin-5-yl1-3H-benzooxazol-2-one bis(hydrochloride) The product of Example 37A (60 mg, 0.18 mmol) was treated with HCI
(Aldrich, 4M in dioxane, 0.25 mL, 1.0 mmol) in EtOAc (3 mL) at ambient temperature for 1 hour to afford the title compound as yellow solid (60.0 mg, 83%). ~H NMR
(500 F
MHz, CD30D) 8 1.89 - 2.28 (m, 3 H), 2.30 - 2.54 (m, 1 H), 2.61 - 2.76 (m, 1 H), 3.36 -3.52 (m, 5 H), 3.82 - 3.99 (m, 1 H), 5.40-5.52 (m, 1 H) 7.20 - 7.47 (m, 2 H), 7.68 (s, 1.
H), 8.80 (s, 2 H) ppm; MS (DCI/NH3): 338 (M+H)+. Anal. Calculated for CigH~gN4O3 2.00 HCI 1.50 H20: C, 49.33; H, 5.29; N, 12.78. Found: C, 49.40; H, 5.07; N, 12.60.
Example 38 (R)-3-[6-(1-Aza-bicyclo[2.2.21oct-3-yloxy)-pyridazin-3-yl~-9H-carbazole Example 38A
3-(4,4,5,5-Tetramethyl-[1,3,21dioxaborolan-2-yl)-9H-carbazole 3-Bromo-9H-carbazole (Aldrich, 0.97 g, 3.96 mmol) was coupled with bis(pinacolato)diboron (Aldrich, 1.13 g, 4.46 mmol) under the catalysis of dichloro [1,1'-bis(diphenylphosphino)ferrocene]palladium (II) dichloromethane (Aldrich, mg, 0.125 mmol) with KOAc (Aldrich, 1.21 g, 12.3 mmol) in DMF (anhydrous, Aldrich, 25 mL) at 80°C overnight according to the procedure of Example 26A, The title compound was purified by chromatography (Si02, gradient 5 to 50% EtOAc-hexanes) to give 0.80 g (2.73 mmol, 69% yield). ~H NMR (300 MHz, CDC13) 8 1.40 (s, 12 H), 7.26 (s, 1 H), 7.40 - 7.47 (m, 3 H), 7.88 (d, J=7.0 Hz, 1 H), 8.11 (d, J=7.0 Hz, 2 H), 8.58 (s, 1 H) ppm. MS (DCI/NH3) m/z 294 (M+H)+.
Example 38B
(R)-3-f 6-( 1-Aza-bicyclo f 2.2.2]oct-3-yloxy)-pyridazin-3-yll-9H-carbazole The product of Example 9A (0.173g, 0.72 mmol) was coupled with the product of Example 38A (0.267 g, 0.91 mmol) under the catalysis of dichlorobis(triphenyl-phosphine)palladium(II) (Aldrich, 5.3 mg, 0.007 mmol) and 2-(dicyclohexylphosphino)biphenyl (Strem Chemicals, 7.3 mg, 0.021 mmol) at 150 °C
for 10 min. according to the procedure of Example 29A. The title product was purified by preparative HPLC (XterraTM, column, Xterra RP-18 5 pm, 30 x 100 mm.
~5 Eluting Solvent, MeCN / H20 (NH4HC03, 0.1 M, pH=10) (v. 40/60 to 70/30 over min.) Flow rate, 75 mL/min., uv, 250 nm) as solid. 'H NMR (300 MHz, CD30D) 8 1.45 - 1.62 (m, 1 H), 1.68 - 1.92 (m, 2 H), 2.00 - 2.15 (m, 1 H), 2.27 - 2.40 (m, Hz, 1 H), 2.75 - 3.05 (m, 5 H), 3.43 - 3.59 (m, Hz, 1 H), 5.22 - 5.42 (m, Hz, 1 H), 7.16 7.24 (m, 1 H), 7.28 (d, J=9 Hz, 1 H), 7.36 = 7.44 (m, 1 H), 7.45 - 7.52 (m, 1 H), 7.57 20 (d, J=8 Hz, 1 H), 8.02 (dd, J=9, 2 Hz, 1 H), 8.17 (t, J=9 Hz, 2 H), 8.67 (s, 1 H) ppm;
MS (DCI/NH3) m/z 371 (M+H)+.
Example 39 3-f6-(1H-Indol-3-yl)-pyridazin-3-yloxyl-1-aza-bicyclo(2.2.21octane hemifumarate Example 39A
3-f 6-( 9 H-I ndol-3-yl)-pyridazin-3-yloxy]-1-aza-bicyclo f 2.2.21octane 3-Quinuclidinol (Aldrich, 254 mg, 2 mmol) was coupled with 3-(6-chloro-pyridazin-3-yl)-1 H-indole (Bionet, 458 mg, 2 mmol) at 60°C for 16 hours according to 3o the procedure of Example 7A. The title compound was purified by preparative HPLC
(XterraTM, column, Xterra RP-18, 5 pm, 30 x 100 mm. Eluting Solvent, MeCN /
(NH4HC03, 0.1 M, pH=10), (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (400 mg, 63%).'H NMR (MeOH-D4, 300 MHz) 1.50 - 1.64 (m, 1 H), 1.71 - 1.93 (m, 2 H), 2.00 - 2.15 (m, 1 H), 2.29 - 2.36 (m, 1 H), 2.78 -3.04 (m, 5 H), 3.43 - 3.55 (m, 1 H), 5.24 - 5.32 (m, 1 H), 7.12 - 7.25 (m, 3 H), 7.42 -7.48 (m, 1 s H), 7.87 (s, 1 H), 8.01 (d, J=9.2 Hz, 1 H), 8.26 - 8.33 (m, 1 H) ppm. MS
(DCI/NH3) m/z 321 (M+H)+.
Example 39B
3-f6-(1 H-Indol-3-yl)-pyridazin-3-yloxy~-1-aza-bicyclo(2.2.21octane hemifumarate The product of Example 39A (200 mg, 0.63 mmol) was treated with fumaric acid (Aldrich, 73 mg, 0.63 mmol) in EtOAc/MeOH(v.10:1, 10 mL) at ambient temperature overnight to give the title compound (247.3 mg, 100%). 'H NMR
(MeOH-D4, 300 MHz) 1.76 - 1.91 (m, 1 H), 1.92 - 2.14 (m, 2 H), 2.22 - 2.37 (m, 1 H), 2.51 - 2.58 (m, 1 H), 3.16 - 3.39 (m, 5 H), 3.82 (ddd, J=14.0, 8.2, 1.9 Hz, 1 H), 5.40 -15 5.49 (m, 1 H), 6.67 (s, 1 H), 7.12 - 7.26 (m, 3 H), 7.42 - 7.49 (m, 1 H), 7.89 (s, 1 H), 8.05 (d, J=9.5 Hz, 1 H), 8.26 - 8.32 (m, 1 H) ppm. MS (DCI/NH3) m/z 321 (M+H)+.
Anal. Calculated for C~9H2oN40~0.5 C404H4~0.35 H20: C, 65.56; H, 5.95; N, 14.56.
Found: C, 65.49; H, 6.21; N, 14.34.
2o Example 40 (R)-3-f6-(1 H-Indol-3-yl)-pvridazin-3-yloxyl-1-aza-bicyclof2.2.21octane fumarate The product of Example 4A (127 mg, 1 mmol ) was coupled with 3-(6-chloro-pyridazin-3-yl)-1 H-indole (Bionet, 229 mg, 1 mmol) according to the procedure of Example 39. The title compound was obtained as solid (208.3 mg, yield, 35%).
~H
25 NMR (MeOH-d4, 300 MHz) 1.90 - 2.24 (m, 3 H), 2.33 - 2.48 (m, 1 H), 2.61 -2.69 (m, 1 H), 3.32 - 3.55 (m, 5 H), 3.98 (dd, J=13.7, 8.3 Hz, 1 H), 5.49 - 5.57 (m, 1 H), 6.71 (s, 4 H), 7.13 - 7.28 (m, 3 H), 7.46 (d, J=7.1 Hz, 1 H), 7.90 (s, 1 H), 8.07 (d, J=9.2 Hz, 1 H), 8.30 (d, J=7.1 Hz, 1 H) ppm. MS (DCI/NH3) m/z 321 (M+H)+. Anal.
Calculated for C~sH2oN40~2.1 C404H4~0.35 EtOAc: C, 58.14; H, 5.29; N, 9.42.
3o Found: C, 57.91; H, 5.35; N, 9.42.
r Example 41 (S)-3-[6-(1 H-Indol-3-yl)-pyridazin-3-yloxyl-1-aza-bicyclo[2.2.2~octane fumarate The product of Example 13D (127 mg, 1 mmol) was coupled with 3-(6-chloro-pyridazin-3-yl)-1 H-indole (Bionet, 229 mg, 1 mmol) according to the procedure of s Example 39. The title compound was obtained as solid (239 mg, yield, 39%).'H
NMR
(MeOH-d4, 300 MHz) 1.90 - 2.24 (m, 3 H), 2.33 - 2.48 (m, 1 H), 2.61 - 2.69 (m, 1 H), 3.33 - 3.55 (m, 5 H), 3.93 - 4.04 (m, 1 H), 5.49 - 5.57 (m, 1 H), 6.72 (s, 4 H), 7.13 7.28 (m, 3 H), 7.46 (d, J=8.1 Hz, 1 H), 7.90 (s, 1 H), 8.07 (d, J=9.2 Hz, 1 H), 8.30 (d, J=7.1 Hz, 1 H) ppm. MS (DCI/NH3) m/z 321 (M+H)+. Anal. Calculated for C~9HZON40~2.1 C404H4~0.5 EtOAc: C, 58.06; H, 5.37; N, 9.21. Found: C, 57.81;
H, 5.54; N, 9.53.
Example 42 DETERMINATION OF BIOLOGICAL ACTIVITY
To determine the effectiveness of representative compounds of this invention as a7 nAChRs, the compounds of the invention were evaluated according to the [3H]-methyllycaconitine (MLA) binding assay and considering the [3H]-cytisine binding assay, which were performed as described below.
20 [3H1-Cytisine binding Binding conditions were modified from the procedures described in Pabreza LA, Dhawan, S, Kellar KJ, [3H]-Cytisine Binding to Nicotinic Cholinergic Receptors in Brain, Mol. Pharm. 39: 9-12, 1991. Membrane enriched fractions from rat brain minus cerebellum (ABS Inc., Wilmington, DE) were slowly thawed at 4 °C, washed 2s and resuspended in 30 volumes of BSS-Tris buffer (120 mM NaCI/5 mM KCI/2 mM
CaCl2/2 mM MgCl2/50 mM Tris-CI, pH 7.4, 4 °C). Samples containing 100-200 pg of protein and 0.75 nM [3H]-cytisine (30 C;/mmol; Perkin Elmer/NEN Life Science Products, Boston, MA) were incubated in a final volume of 500 pL for 75 minutes at 4 °C. Seven log-dilution concentrations of each compound were tested in duplicate.
so Non-specific binding was determined in the presence of 10 NM (-)-nicotine.
Bound radioactivity was isolated by vacuum filtration onto prewetted glass fiber filter plates (Millipore, Bedford, MA) using a 96-well filtration apparatus (Packard Instruments, Meriden, CT) and were then rapidly rinsed with 2 mL of ice-cold BSS buffer (120 mM
NaCI/5 mM KCI/2 mM CaCl2/2 mM MgCl2). Packard MicroScint-20°
scintillation cocktail (40 NL) was added to each well and radioactivity determined using a s Packard TopCount~ instrument. The IC5o values were determined by nonlinear regression in Microsoft Excel° software. K; values were calculated from the ICSOs using the Cheng-Prusoff equation, where K; = ICSO/1+[Ligand]/Kp].
L3H1-Methyllycaconitine (MLA) binding Binding conditions were similar to those for [3H]-cytisine binding. Membrane enriched fractions from rat brain minus cerebellum (ABS Inc., Wilmington, DE) were slowly thawed at 4 °C, washed and resuspended in 30 volumes of BSS-Tris buffer (120 mM NaCI, 5 mM KCI, 2 mM CaCl2, 2 mM MgCl2, and 50 mM Tris-CI, pH 7.4, 22 °C). Samples containing 100-200 pg of protein, 5 nM [3H]-MLA (25 C;/mmol; Perkin 15 Elmer/NEN Life Science Products, Boston, MA) and 0.1 % bovine serum albumin (BSA, Millipore, Bedford, MA) were incubated in a final volume of 500 pL for minutes at 22 °C. Seven log-dilution concentrations of each compound were tested in duplicate. Non-specific binding was determined in the presence of 10 pM
MLA.
Bound radioactivity was isolated by vacuum filtration onto glass fiber filter plates 2o prewetted with 2% BSA using a 96-well filtration apparatus (Packard Instruments, Meriden, CT) and were then rapidly rinsed with 2 mL of ice-cold BSS. Packard MicroScint-20~ scintillation cocktail (40 pL) was added to each well and radioactivity was determined using a Packard TopCount~ instrument. The ICSO values were determined by nonlinear regression in Microsoft Excel° software. K;
values were 2s calculated from the IC5os using the Cheng-Prusoff equation, where K; _ ICSO/1 +[Ligand]/Kp].
Compounds of the invention had K; values of from about 1 nanomolar to about micromolar when tested by the MLA assay, many having a K; of less than 1 micromolar. [3H]-Cytisine binding values of compounds of the invention ranged from 3o about 50 nanomolar to at least 100 micromolar. The determination of preferred compounds typically considered the K; value as measured by MLA assay in view of _98_ the K; value as measured by [3H]-cytisine binding, such that in the formula D
= K; 3H-cytisine /K. M~a" D is about 50. Preferred compounds typically exhibited greater potency at a7 receptors compared to a4[i2 receptors.
Compounds of the invention are a7 nAChRs ligands that modulate function of a7 nAChRs by altering the activity of the receptor. The compounds can be inverse agonists that inhibit the basal activity of the receptor or antagonists that completely block the action of receptor-activating agonists. The compounds also can be partial agonists that partially block or partially activate the a7 nAChR receptor or agonists that activate the receptor.
Some compounds of the invention also have been evaluated for potential binding to the hERG ion channel. Blockade of the hERG ion channel has been associated with interference of heart muscle repolarization, which presents a cardiovascular risk. Binding affinities to the hERG channel were measured by displacement of the radioligand [3H]-dofetilide and expressed in K; value, i.e. K; hERG~
Compounds of the invention demonstrating a higher ratio of a7 receptor binding to the ratio of hERG binding, i.e. (K; MLA)/(Ki hERG), were considered to demonstrate a better cardiovascular risk profile. Compounds of the invention that were tested all demonstrated a beneficial cardiovascular risk profile for a7 receptor ligands.
It is understood that the foregoing detailed description and accompanying 2o examples are merely illustrative and are not to be taken as limitations upon the scope of the invention, which is defined solely by the appended claims and their equivalents. Various changes and modifications to the disclosed embodiments will be apparent to those skilled in the art. Such changes and modifications, including without limitation those relating to the chemical structures, substituents, derivatives, 2s intermediates, syntheses, formulations and/or methods of use of the invention, may be made without departing from the spirit and scope thereof.
_99_
The term "alkoxysulfonyl", as used herein, means an alkoxy group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein. Representative examples of alkoxysulfonyl include, but are not limited to, methoxysulfonyl, ethoxysulfonyl and propoxysulfonyl.
The term "alkyl", as used herein, means a straight or branched chain hydrocarbon containing from 1 to 6 carbon atoms. Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-p.entyl, isopentyl, neopentyl, and n-hexyl.
The term "alkylcarbonyl", as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as 15 defined herein. Representative examples of alkylcarbonyl include, but are not limited to, acetyl, 1-oxopropyl, 2,2-dimethyl-1-oxopropyl, 1-oxobutyl, and 1-oxopentyl.
The term "alkylcarbonyloxy", as used herein, means an alkylcarbonyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of alkylcarbonyloxy include, but are not limited to, 2o acetyloxy, ethylcarbonyloxy, and tert-butylcarbonyloxy.
The term "alkylsulfonyl", as used. herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein. Representative examples of alkylsulfonyl include, but are not limited to, methylsulfonyl and ethylsulfonyl.
25 The term "alkylthio", as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a sulfur atom. Representative examples of alkylthio include, but are not limited, methylthio, ethylthio, tert-butylthio, and hexylthio.
The term "alkynyl", as used herein, means a straight or branched chain 3o hydrocarbon group containing from 2 to 10 carbon atoms and containing at least one _7_ carbon-carbon triple bond. Representative examples of alkynyl include, but are not limited, to acetylenyl, 1-propynyl, 2-propynyl, 3-butynyl, 2-pentynyl, and 1-butynyl.
The term "amido", as used herein, means an amino, alkylamino, or dialkylamino group appended to the parent molecular moiety through a carbonyl s group, as defined herein. Representative examples of amido include, but are not limited to, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, and ethylmethylaminocarbonyl.
The term "aryl", as used herein, means a monocyclic or bicyclic aromatic ring system. Representative examples of aryl include, but are not limited to, phenyl and naphthyl.
The aryl groups of this invention are substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from acyl, acyloxy, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxyimino, alkoxysulfonyl, alkyl, alkylsulfonyl, alkynyl, amino, carboxy, cyano, formyl, haloalkoxy, haloalkyl, halo, ~5 hydroxy, hydroxyalkyl, mercapto, nitro, thioalkoxy, -NRARB, (NRARB)alkyl, (NRARB)alkoxy, (NRARB)carbonyl, and (NRARB)sulfonyl.
The term "arylcarbonyl", as used herein, means an aryl group, as defined herein, or a benzyl group appended to the parent molecular moiety through a carbonyl group, represented by -C(O)-, as defined herein. Representative examples 20 of arylcarbonyl include, but are not limited to, phenylcarbonyl and benzylcarbonyl.
The term "aryloxycarbonyl", as used herein, means an aryl-O- group, wherein the aryl of aryl-O- is as defined herein, or a benzyoxyl group appended to the parent molecular moiety through a carbonyl group, represented by -C(O)-, as defined herein. Representative examples of aryloxycarbonyl include, but are not limited to, 25 phenoxycarbonyl and benzyloxycarbonyl.
The term "arylsulfonyl", as used herein, means an aryl group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein. Representative examples of arylsulfonyl include, but are not limited to, phenylsulfonyl, (methylaminophenyl)sulfonyl, (dimethylaminophenyl)sulfonyl, and 30 (naphthyl)sulfonyl.
The term "carbonyl", as used herein, means a -C(O)- group.
_g_ The term "carboxy", as used herein, means a -C02H group.
The term "cyano", as used herein, means a -CN.group.
The term "formyl", as used herein, means a -C(O)H group.
The term "halo" or "halogen", as used herein, means -CI, -Br, -I or -F.
The term "haloalkoxy", as used herein, means at least one halogen, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein. Representative examples of haloalkoxy include, but are not limited to, chloromethoxy, 2-fluoroethoxy, trifluoromethoxy, and pentafluoroethoxy.
The term "haloalkyl", as used herein, means at least one halogen, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of haloalkyl include, but are not limited to, chloromethyl, 2-fluoroethyl, trifluoromethyl, pentafluoroethyl, and 2-chloro-3-fluoropentyl.
The term "heteroaryl" means an aromatic five- or six-membered ring ~ s containing 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. The heteroaryl groups are connected to the parent molecular moiety through a carbon or nitrogen atom. Representative examples of heteroaryl include, but are not limited to, furyl, imidazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrazolyl, thiadiazolyl, 2o thiazolyl, thienyl, triazinyl, and triazolyl.
The heteroaryl groups of the invention are substituted with 0, 1, 2, or 3 substituents independently selected from alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfonyl, alkylthio, alkynyl, carboxy, cyano, formyl, haloalkoxy, haloalkyl, halo, hydroxy, 25 hydroxyalkyl, mercapto, nitro, -NRARB, (NRARB)alkyl, (NRARB)alkoxy, (NRARB)carbonyl, and (NRARB)sulfonyl.
The term "bicyclic heteroaryl" refers to fused aromatic nine- and ten-membered bicyclic rings containing 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a tautomer thereof. The bicyclic heteroaryl so groups are connected to the parent molecular moiety through a carbon or nitrogen atom. Representative examples of bicyclic heteroaryl rings include, but are not -g_ limited to, indolyl, benzothiazolyl, benzofuranyl, isoquinolinyl, and quinolinyl. Bicyclic heteroaryl groups of the invention are substituted with 0, 1, 2, or 3 substituents independently selected from alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfonyl, s alkylthio, alkynyl, carboxy, cyano, formyl, haloalkoxy, haloalkyl, halo, hydroxy, hydroxyalkyl, mercapto, nitro, -NRARB, (NRARB)alkyl, (NRARB)alkoxy, (NRARB)carbonyl, and (NRARB)sulfonyl.
The term "hydroxy", as used herein, means an -OH group.
The term "hydroxyalkyl", as used herein, means at least one hydroxy group, as defined herein, is appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of hydroxyalkyl include, but are not limited to, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, 2,3-dihydroxypentyl, and 2-ethyl-4-hydroxyheptyl.
The term "mercapto", as used herein, means a -SH group.
15 The term "nitro", as used herein, means a -N02 group.
The term "-NRARB", as used herein, means two groups, RA and RB, which are appended to the parent molecular moiety through a nitrogen atom. RA and RB are each independently hydrogen, alkyl, alkylcarbonyl, or formyl. Representative examples of -NRARg include, but are not limited to, amino, methylamino, 2o acetylamino, and acetylmethylamino.
The term "(NRARB)alkyl", as used herein, means a -NRARB group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of (NRARB)alkyl include, but are not limited to, (amino)methyl, (dimethylamino)methyl, and (ethylamino)methyl.
2s The term "(NRARB)alkoxy", as used herein, means a -NRARB group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein. Representative examples of (NRARB)alkoxy include, but are not limited to, (amino)methoxy, (dimethylamino)methoxy, and (diethylamino)ethoxy.
The term "(NRARB)carbonyl", as used herein, means a -NRARB group, as so defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of (NRARg)carbonyl include, but are not limited to, aminocarbonyl, (methylamino)carbonyl, (dimethylamino)carbonyl, and (ethylmethylamino)carbonyl.
The term "(NRARB)sulfonyl", as used herein, means a -NRARB group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein. Representative examples of (NRARB)sulfonyl include, but are not limited to, aminosulfonyl, (methylamino)sulfonyl, (dimethylamino)sulfonyl, and (ethylmethylamino)sulfonyl.
The term "sulfonyl", as used herein, means a -S(O)2- group.
The term "thioalkoxy", as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a sulfur atom.
Representative examples of thioalkoxy include, but are no limited to, methylthio, ethylthio, and propylthio.
Although typically it may be recognized that an asterisk is used to indicate that the exact subunit composition of a receptor is uncertain, for example a3b4*
indicates ~ 5 a receptor that contains the a3 and X34 proteins in combination with other subunits, the term a7 as used herein is intended to include receptors wherein the exact subunit composition is both certain and uncertain. For example, as used herein a7 includes homomeric (a7)5 receptors and a7* receptors, which denote a nAChR
containing at least one a7 subunit.
Compounds of the Invention Compounds of the invention can have the formula (I) as described above.
More particularly, compounds of formula (1) can include, but are not limited to, compounds wherein Ar' is a group of the formula:
X' X3 S
Xz Xa (b) , In a group of formula (b), X', X2, X3, and X4 are each independently selected from the group consisting of N and -CR'°, wherein R'° at each occurrence is independently selected from the group consisting of hydrogen and alkyl.
Preferably, at least one of X', X2, X3, and X4 is -CR'°, such that group of formula (b) contains 0, 1, 2, or 3 nitrogen atoms.
Specific examples of groups for Ar' are, for example, Rio Rio Rio Rio Rio N
N , N
Rio Rio Rio . Rio Rio Rio Rio a and N N ' , R "' and the like.
Specific examples of groups for Arz in a compound of formula (I) are, for example, Z5 Zs ~,3a N
Zs~Z~ N Zs/Z\ O~ Zs/ \ S\ ZII
\ ,za ~ ( //N Z ~ ~ / ~/N Zs /
Z~ / ~~ Z \ s~ ~,3a ~ s Y3a ~Z5 N
\Zs Y3a , Z , Z Rz (i) (ii) (iii) (iv) Zs/ \ O s/ \ N Zs/ ~ S
\Y2a Z ~ ~ \Y2a I I \Y2a Z ~ s~ N~ Z ~ s~ N~ Z ~ a~ N/
Z , Z ~ Z
(v) (vi) (vii) \ Zg / \ N
N (~ o Z \ Z$/ N/ ~ ZZ\ ~/ ~ Y1 , Z
(viii) (ix) z Zs / Z\ N\ Zs / Z\ S
N \N
7 ~ 7 Z ~Z8~ N/ and Z \ $
Z
(x) (xi) ~nrherein:
Z', Z2, Z3, and Z4 are independently selected from the group consisting of C
and -C(R3b); provided that one of Z', Z2, Z3, and Z4 is C and formula (ix) is attached to Ar' through the C atom of Z', Z2, Z3, and Z4;
Y' is selected from the group consisting of O, S, and -C(R3)(R3a);
Z5, Z6, Z', and Z$ are independently selected from the group consisting of C
and -C(R3b); provided that zero or one of Z5, Z6, Z', and Z$ is C;
Y2a and Y3a are independently selected from the group consisting of C and -C(R3a); wherein when one of Z5, Zs, Z', and Z8 is C, then Y2a and Y3a in the group of formulae (i)-(vii) are each -C(R3a); and each of the group of formulae (i)-(vii) is attached to Ar' through the C of Z5, Zs, Z', or Z$ ; and also wherein when one of Y2a s and Y3a is C in the group of formulae (i)-(vii), then Z5, Zs, Z', and Z8 are each -C(R3b) and each of the group of formulae (i)-(vii) is attached to Ar' through the C
atom of Y2a or Y3a; and R2, R3, R3a and R3b are as defined for a compound of formula (I).
Also, other specific examples of groups for Arz in a compound of formula (I) are, for example, Z13 ~Z\
\Z15 10~Z9 \ Z~16 Z
~Z12 wherein Z9, Z'°, Z", Z'2, Z'3, Z'4, Z15, Z~s, and R$ are as defined for compounds of formula (I).
Specific embodiments contemplated as part of the invention include, but are not limited to, compounds of formula (I), as defined, wherein:
3-[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl]-1 H-indole;
4-[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl]-1 H-indole;
5-[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl]-1 H-indole;
5-{4-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]phenyl}-1 H-indole;
6-[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl]-1 H-indole;
2o 2-[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl]-1H-indole;
5-[6-( 1-azabicyclo[2.2.2]oct-3-yloxy)pyridazin-3-yl]-1 H-indole;
4-[6-(1-azabicyclo[2.2.2]oct-3-yloxy)pyridazin-3-yl]-1 H-indole;
5-{6-[(3R)-1-azabicyclo(2.2.2]oct-3-yloxy]pyridazin-3-yl}-1 H-indole;
5-{6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl}-3-methyl-1 H-indole;
5-{2-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyrimidin-5-yl}-1 H-indole;
4-{2-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyrimidin-5-yl}-1 H-indole;
5-{2-[(3S)-1-azabicyclo[2.2.2]oct-3-yloxy]pyrimidin-5-yl}-1 H-indole;
5-[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl]-3-methyl-1 H-indazole;
6-[4-( 1-azabicyclo[2.2.2]oct-3-yloxy)phenyl]-1,3-benzothiazol-2-amine;
6-{4-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]phenyl}-1,3-benzothiazol-2-amine;
6-{4-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]phenyl}-4-thiocyanato-1,3-benzothiazol-2-amine;
6-{4-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]phenyl}-4-bromo-1,3-benzothiazol-2-amine;
N-[4-(3-methyl-1 H-indazol-5-yl)phenyl]quinuclidin-3-amine;
(R)-3-[6-(3-methyl-1 H-indazol-5-yl)-pyridazin-3-yloxy]-1-aza bicyclo[2.2.2]octane;
(R)-3-[6-(1-methyl-1 H-indol-5-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane;
(R)-{5-[6-(1-aza-bicyclo[2.2.2]oct-3-yloxy)-pyridazin-3-yl]-1 H-indol-3-ylmethyl}-dimethyl-amine;
(R)-3-[6-(1 H-indol-5-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane 1-oxide;
6-{6-[(3R)-1-aza-bicyclo[2.2.2]oct-3-yloxy]-pyridazin-3-yl}-benzothiazol-2-ylamine;
(3R)-3-[6-(3-bromo-1 H-indol-5-yl)-pyridazin-3-yloxy]-1-aza-2o bicyclo[2.2.2]octane;
5-{6-[(3R)-1-aza-bicyclo[2.2.2]oct-3-yloxy]-pyridazin-3-yl}-1,3-dihydro-indol-one;
5-{6-[(3R)-1-oxy-1-aza-bicyclo[2.2.2]oct-3-yloxy]-pyridazin-3-yl}-1,3-dihydro-indol-2-one;
5-{6-[(3R)-1-aza-bicyclo[2.2.2]oct-3-yloxy]-pyridazin-3-yl}-1,3-dihydro-benzoimidazol-2-one;
(R)-3-[6-(1 H-benzoimidazol-5-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane;
(S)-3-[6-(1 H-indol-5-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane;
so (R)-3-[5-(1 H-indol-5-yl)-pyridin-2-yloxy]-1-aza-bicyclo[2.2.2]octane;
(3R)-3-[5-(1 H-indol-4-yl)-pyrimidin-2-yloxy]-1-aza-bicyclo[2.2.2]octane 1-oxide;
(3R)-3-(5-benzooxazol-5-yl-pyrimidin-2-yloxy)-1-aza-bicyclo[2.2.2]octane;
(3R)-3-[5-(2-methyl-benzooxazol- 5-yl)-pyrimidin-2-yloxy]-1-aza-s bicyclo[2.2.2]octane; ' (3R)-3-[5-(2-ethyl-benzooxazol-5-yl)-pyrimid in-2-yloxy]-1-aza-bicyclo[2.2.2]octane;
(3R)-3-[5-(2-phenyl-benzooxazol-5-yl)-pyrimidin-2-yloxy]-1-aza-bicyclo[2.2.2]octane;
(R)-5-[2-(1-aza-bicyclo[2.2.2]oct-3-yloxy)-pyrimidin-5-yl]-3H-benzooxazol-2-one;
(R)-3-[6-(1-aza-bicyclo[2.2.2]oct-3-yloxy)-pyridazin-3-yl]-9H-carbazole;
3-[6-(1 H-indol-3-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane;
(R)-3-[6-(1 H-indol-3-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane; and 15 (S)-3-[6-(1 H-indol-3-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane;
or pharmaceutically acceptable salts, esters, amides, and prodrugs thereof.
Compound names are assigned by using Au'roNoM naming software, which is provided by MDL Information Systems GmbH (formerly known as Beilstein Informationssysteme) of Frankfurt, Germany, and is part of the CHEMDRAW~
2o ULTRA v. 6Ø2 software suite.
Compounds of the invention may exist as stereoisomers wherein, asymmetric or chiral centers are present. These stereoisomers are "R" or "S" depending on the configuration of substituents around the chiral element. The terms "R" and "S"
used herein are configurations as defined in IUPAC 1974 Recommendations for Section 25 E, Fundamental Stereochemistry, Pure Appl. Chem., 1976, 45: 13-30. The invention contemplates various stereoisomers and mixtures thereof and are specifically included within the scope of this invention. Stereoisomers include enantiomers and diastereomers, and mixtures of enantiomers or diastereomers. Individual stereoisomers of compounds of the invention may be prepared synthetically from 3o commercially available starting materials which contain asymmetric or chiral'centers or by preparation of racemic mixtures followed by resolution well-known to those of ordinary skill in the art. These methods of resolution are exemplified by (1 ) attachment of a mixture of enantiomers to a chiral auxiliary, separation of the resulting mixture of diastereomers by recrystallization or chromatography and optional liberation of the optically pure product from the auxiliary as described in Furniss, Hannaford, Smith, and Tatchell, "Vogel's Textbook of Practical Organic Chemistry", 5th edition (1989), Longman Scientific & Technical, Essex CM20 2JE, England, or (2) direct separation of the mixture of optical enantiomers on chiral chromatographic columns or (3) fractional recrystallization methods.
Compounds of the invention demonstrate beneficial binding at a7 neuronal nicotinic receptors. Moreover, such compounds generally demonstrate more beneficial binding at a7 neuronal nicotinic receptors when compared with a less desireable effect of binding to the human ether-a-go-go related gene (hERG) ion channel. As such, compounds of the invention demonstrate an improved cardiovascular profile, i.e. are less like to to induce cardiovascular complications associated with hERG, than other ampiphilic molecules demonstrating at a7 neuronal nicotinic receptor binding.
Methods for Preparing Compounds of the Invention As used in the descriptions of the schemes and the examples, certain 2o abbreviations are intended to have the following meanings: Ac for acetyl;
Bu for butyl; dba for dibenzylidene acetone; DEAD for diethyl azodicarboxylate; DMSO
for dimethylsulfoxide; EtOAc for ethyl acetate; EtOH for ethanol; Et3N for triethylamine;
Et20 for diethyl ether; HPLC for high pressure liquid chromatography;'Pr for isopropyl; Me for methyl; MeOH for methanol; NBS for N-bromosuccinimide; OAc for 2s acetoxy; o-tol. for o-toluene; Ph for phenyl; t-Bu for tert-butyl; TFA for trifluoroacetic acid; and THF for tetrahydrofuran.
The reactions exemplified in the schemes are performed in a solvent appropriate to the reagents and materials employed and suitable for the transformations being effected. The described transformations may require so modifying the order of the synthetic steps or selecting one particular process scheme over another in order to obtain a desired compound of the invention, depending on the functionality present on the molecule.
Nitrogen protecting groups can be used for protecting amine groups present in the described compounds. Such methods, and some suitable nitrogen protecting s groups, are described in Greene and Wuts (Protective Groups In Organic Synthesis, Wiley and Sons, 1999). For example, suitable nitrogen protecting groups include, but are not limited to, tert-butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz), benzyl (Bn), acetyl, and trifluoracetyl. More particularly, the Boc protecting group may be removed by treatment with an acid such as trifluoroacetic acid or hydrochloric acid.
The Cbz and Bn protecting groups may be removed by catalytic hydrogenation.
The acetyl and trifluoracetyl protecting groups may be removed by a hydroxide ion.
The methods described below can entail use of various enantiomers. Where the stereochemistry is shown in the Schemes, it is intended for illustrative purposes only.
Scheme 1 HO ~ ~~~,,,OH x~-Arz Are-X' ' 7+
N (s) X'=Br,CI, I Ph3P X'=Br,CI, I
(3) ~ DEAD
OH I ~ Cul, CsZC03 O ~ Me3SnSnMe3 or ~OR
+ I A~ X~ 1,10-phenanthroline ~~ I Aj X' Pd(o)/L. ROB-B
N Tol. reflux N RO (9) OR
(1 ) (2) I (4) R= alkyl, aryl X'=Br,CI, I Me3SnSnMe3 or M-Arz ROiB-B OR Pd(0)/L. (7) RO OR M=Sn, B, (9) Pd(o)/L.
R=alkyl, aryl O ~ X'-Arz O
Are-M (s) ~~ I Ar Arz N ~ Pd(o)/L. N
M=Sn, B
X'=Br,CI, I
(5) (8) Quinuclidine ethers of general formula (8), wherein Ar' and Arz are as defined s in formula (I), can be prepared as described in Scheme 1. 3-Quinuclidinol of formula (1 ) is treated with a halophenyl iodide of formula (2), wherein X' is bromide, chloride, or iodide, with Cul and Cs2C03 in 1,10-phenanthroline as described in Org.
Lett., 2002, 4, 973, to obtain a halophenoxy quinuclidine of formula (4).
Alternatively, a compound of formula can be obtained by treating 3-quinuclidinol with a halo phenyl 1o alcohol of formula (3), wherein X' is bromide, chloride, or iodide, and diethyl azodicarboxylate in the presence of a phosphine, such as triphenylphosphine.
Compounds of formula (4) can be treated with hexamethylditin or diboron of formula (9), such as bis(pinacolato)diboron and bis(catecholato)diboron, wherein R
is hydrogen, alkyl, butyloxycarbonyl, or benzyloxycarbonyl, in the presence of a 15 palladium catalyst to provide the corresponding tin or boronic acid of formula (5), which is reacted with a desired halide of a fused bicycloheterocycle represented by Arz of formula (6), wherein X' is bromide, chloride, or iodide, to provide compounds of formula (8). Alternatively, halides of a desired Arz group can be treated with hexamethylditin or diboron of formula (9), such as bis(pinacolato)diboron and bis(catecholato)diboron, in the presence of a palladium catalyst to provide a corresponding tin or boronic acid reagent that is reacted with a compound of formula (4) in the presence of a palladium catalyst to provide a compound of formula (8).
Scheme 2 Me3SnSnMe3 or OR
ROB B~OR R alkyl, aryl O X~
~~OK Yi X? 3 O X' 3 (g) ~~~ ~ ' X
+ ~ X ~ ~ X N N.Xa~M
N N.Xa~Y2 ~~ N. a~ 2 Pd(0)/L.
N X Y
M=Sn, B
~ i_ (12) Y , Y -Br, CI, I
(1p) X~, X3, X4 _N CH (13) (11 ) X'-Arz M-Arz Pd(0)/L. X'=Br,CI, I
) M=Sn, B, ~~~0~ X' Xs NUJ IN~Xa~Ar2 (14) Quinuclidine ethers of formula (14), wherein Ar' is a nitrogen-containing 1o heteroaryl, for example pyridazine, and Are is as defined for formula (I), can be prepared as shown in Scheme 2. Potassium quinuclidinoxide (10) can be reacted with a dihaloaromatic ring, for example, dichloropyridazine, of formula (11 ) to obtain a quinuclidine ether of formula (12). The quinuclidine ether can be reacted with a suitable tin or boron reagent, as described in Scheme 1, to provide a fused bicycloheterocycle substituted quinuclidine ether of formula (14).
Alternatively, the quinuclidine ether of formula (12) can be treated with hexamethylditin or diboron of formula (9), such as bis(pinacolato)diboron and bis(catecholato)diboron, to activate the aromatic group to provide (13), wherein M is tin or boronic acid ester, and further treated with a halide of a desired group Arz in the presence of a palladium catalyst to provide compounds of formula (14).
Scheme 3 IA
i ~ ~L~OH
Pd(0)/L. I Ar Ar2 ~J+
N
Cul, CsZC03 M-At2 RaO
1,10-phenanthroline (7) I A j I Ra0 Tol. reflux M=Sn, B, (~ 9) Ra=gn I A j Arz Pd(0)/L. (20) Pd/C, HZ
,,OH HO Ph3P, DEAD O
+ I Aj A~ THF, rt, 2 days ~~ I Aj Arz N
N
(21 ) (8) Quinuclidine ethers of formula (8), wherein Ar' and Arz are as defined for formula (I) also can be obtained by the methods described in Scheme 3. The activated tin or boronic acid reagent of formula (7) can be coupled with the diiodoaromatic ring of formula (17) in the presence of a palladium catalyst to provide a compound of formula (18). Compounds of formula (18) can be reacted with 3-quinuclidinol and Cul with Cs2C03 in 1,10-phenanthroline as described in Org.
Lett.
2002, 4, 973, to provide a desired compound of formula (8).
Alternatively, the compound of formula (7) is treated with a compound of formula (19), wherein Ra is benzyl, in the presence of a palladium catalyst to provide ~5 a compound of formula (20). Compounds of formula (20), wherein Ra is benzyl, are hydrogenated to provide compounds of formula (21 ) under standard hydrogenation conditions, for example Pd/C, and further treated with 3-quinuclidinol in the presence of a phosphine, for example triphenylphosphine, and diethyl azodicarboxylate to provide compounds of formula (8).
i Scheme 4 NHZY' \
+ I Aj X' N
Y'=Br,' I
(27) (28) X'=Br,Cl,l Pd/Ligand Cs2C03, tol.
Pd(0)/L.
NaBH(OAc)3 H Me3SnSnMe3 H
O H2N \ HOAc,Na2S04 \ or N \
+ ~ A j x' --~ C~ N ~ Are-X' -- ~~ ~Ar j M
N ~ RO, ,OR
N B_B\ N
X'=Br,Cl,l RO (9) OR (30) M'=Sn, B
R=alkyl, aryl ) Pd(0)/L. Pd(0)/L X'-Ar2 M-Ar2 (6) X'=Br,CI, I
M=Sn, B, H
~~ N
A j Arz N
(31 ) Compounds of formula (31 ), wherein X is -NH- and Ar' and Arz are as s described for compounds of formula (I), can be prepared as shown in Scheme 4. 3-Quinuclidinone (25) and a haloarylamine of formula (26), wherein X' is bromide, chloride, or iodide, can be treated with sodium triacetoxy borohydride and acetic acid in Na2S04 to provide a compound of formula (29). Alternatively, a compound of formula (29) can be obtained by treating 3-aminoquinuclidine (27) with haloaromatic group as described in formula (28) with Cs2C03 in the presence of palladium catalyst, preferably in toluene. A compound of formula (29) can be treated with a tin or diboron of formula (9), such as bis(pinacolato)diboron and bis(catecholato)diboron, under conditions previously described to provide the corresponding tin or boronic acid reagent of formula (30), which can be reacted with the halide of a desired group represented by Arz in a compound of formula (I) to provide a compound of formula (31 ). Alternatively, the compound of formula (29) is treated with a tin or boronic acid ester of the desired Arz group in the presence of a palladium catalyst to provide a compound of formula (31 ).
Scheme 5 Me3SnSnMe3 RO, or ,OR
SH ,B B~OR
~L~CI 1 ) NaH, DMF S RO 9 S
X ~~~ I Aj X, ( ) ~~~ I Aj M
N \~~ Pd(o)/L. N
HCI 2) Chiral separation N
(37) (38) X'=Br,CI, I R=alkyl, aryl M=Sn, B
(35) (36) M-Ar2 Pd(o)/L. X'-Ar2 (7) Pd(0)/L. (g) X'=Br,CI, I
M=Sn, B, C~~S
A j Ar2 N
(39) Compounds of formula (39), wherein X is S and Ar' and Arz are as defined in a compound of formula (I), can be prepared as shown in Scheme 5. 3-1o Chloroquinuclidine (35) can be reacted with a haloarylthiol of formula (36), wherein X' is bromide, chloride, or iodide, to provide a compound of formula (37). The compound of formula (37) can be treated with a tin or boron reagent of a desired group for Arz as described for a compound of formula (I) to provide a compound of formula (39). Alternatively, the compound of formula (37) can be reacted with a hexamethylditin or diboron reagent of formula (9), such as bis(pinacolato)diboron and bis(catecholato)diboron, in the presence of a palladium catalyst to provide a compound of formula (38), which is reacted with the halide of a desired Arz group in the presence of a palladium catalyst to provide a compound of formula (39).
Scheme 6 Me3SnSnMe3 or RO iB-B OR
RO OR
O ~ (9) O
j Pd(o)/L. ~~~
N X R=alkyl, aryl N M
(4) X'=Br,CI, I (5) M=Sn, B
Pd(o)/L.
Pd(o)/L. X'-Ar2-NHRb M'-Ar2-N H Rb (41 ) X'=Br, CI, I
M'=Sn, B, Zn, Mg, Rb=H, alkyl, Boc, Cbz Are N ~ Ark (42) NHRb Compounds of formula (42), wherein X is O, R3 is NHRb, and Ar', Are are defined as in compounds of formula (I), can be prepared as shown in Scheme 6.
Compounds of formula (4) obtained as shown in Scheme 1 can be treated with a metal of the desired amino-substituted Arz group, as described for compounds of formula (I) to provide compounds of formula (42), wherein Rb is hydrogen, alkyl, butyloxycarbonyl, or benzyloxycarbonyl. Compounds of formula (4) can be treated 1o with a hexamethylditin or diboron reagent of formula (9), such as bis(pinacolato)diboron and bis(catecholato)diboron, in the presence of a palladium catalyst to provide the corresponding tin or boronic acid of formula (5), which is reacted with a desired halide of an amine-substituted fused bicycloheterocycle represented by Arz of formula (41 ), wherein X' is bromide, chloride, or iodide, to 15 provide compounds of formula (42).
Scheme 7 Me3SnSnMe3 or RO, ,OR
,B_B.
O X~ 3 RO OR ~~~0~ X' X3 X (9) Pd 0 /L. N N'X4~M
N X Y () (12) R=alkyl, aryl M=Sn, B
X~, X2~, X3 =N, CH (13) Y=Br, CI, I ~
Pd(0)/L. Pd(0)/L.
M'-Ar2-N H Rb X'-Ar2-N H Rb (45) (46) M'=Sn, B, Zn, Mg, ~ ~ X'=Br, CI, I
Rb=H, Boc,Cbz, alkyl, aryl O~X~ X3 CC /J N. q~ 2 b N X Ar - NHR
(47) Compounds of formula (47), wherein X is O, Ar' is a nitrogen containing aromatic group, for example pyridazine, R3 is NHRb, as previously defined, and Are is defined as in compounds of formula (I), can be prepared as shown in Scheme 7.
Compounds of formula (12), which can be obtained as shown in Scheme 2, are treated with a metal of the desired amino-substituted Are group, as described for compounds of formula (I), of formula (45) to provide compounds of formula (47).
Compounds of formula (12) also can be treated with a hexamethylditin or diboron 1o reagent of formula (9), such as bis(pinacolato)diboron and bis(catecholato)diboron, in the presence of a palladium catalyst to provide the corresponding tin or boronic acid of formula (13), which is reacted with a desired halide of an amine-substituted fused bicycloheterocycle represented by Arz of formula (46), wherein X' is bromide, chloride, or iodide, to provide compounds of formula (47).
Scheme 8 I ~OH
Arz-X" +
N
X"=Br,CI,I,NO2,NR'R"
(51) Cul, Cs2C03 1,10-phenanthroline Tol. reflux ,,,OH HO ~ Ph3P, DEAD ~ A j A~-X"
+ ~ A j Arz-X" THF, rt, 2 days N
N
(52) (50) X~~=gr,CI,I,N02,NR'R"
X"=N02 X"=CI, Br, I
~ ) Pd/C, H2 2) R'CI or R'Br Pd/Ligand, R'NHR"
(53) (54) O ~C~O
W ~ Ar Ai i N ~ Arz N ~ Ar2 NHR' (57) ~ NR'R"
(56) R', R"=H, alkyl, aryl, RCO, Boc, Cbz Quinuclidine ethers of formula (56) and (57), wherein Are is as defined for formula (I) and Are is substituted with a group NR5R6 can be obtained by the methods described in Scheme 8. Compounds of formula (50) can be treated with 3-quinuclidinol in the presence of a phosphine, for example triphenylphosphine, and diethyl azodicarboxylate to provide compounds of formula (52). Alternatively, compounds of formula (51 ), wherein X" is bromide, chloride, or iodide, can be reacted with Cul, Cs2C03 in 1,10-phenanthroline as described in Org. Lett.
2002, 4, 973, to provide a desired compound of formula (52). Compounds of formula (52), wherein X" is N02, can be reduced with hydrogen in the presence of a palladium s catalyst and reacted with a chloride or bromide of a desired R group of formula (53), wherein R' is hydrogen, alkyl, aryl, alkycarbonyl, alkoxycarbonyl, arylcarbonyl, or aryloxycarbonyl, to provide compounds of formula (56). Compounds of formula (52), wherein X" is bromide, chloride, or iodide, can be treated with a compound R'NHR"
of formula (54), wherein R' and R" are as previously described for R' in compounds of formula (53), to provide a corresponding compound of formula (57).
Scheme 9 ~ )NaBH(OAc)3 H
O H2N ~ HOAc,NaZS04 N
I Ar Ar2-X" ~ I Ar -Arz-X"
N + ~ 2) Chiral separation N
(60) X"=Br,CI,I,NOZ,NHR'R"
X"=Br,Cl,l Pd/Ligand, R'NHR"
(54) X'=NOZ N
~ ) Pd/C, HZ
2) R'CI or R'Br I A j Ar2-NR'R"
N
(53) (64) R', R"=H, alkyl, aryl, RCO, Boc, Cbz H
~~~ N
I A j Arz-NHR' N
(63) Compounds of formulas (63) and (64) can be prepared as shown in Scheme 15 9. 3-Quinuclidinone and a halobiarylamine of formula (60), wherein X' is bromide, chloride, or iodide, can be treated with sodium triacetate borohydride and Na2S04in acetic acid to provide a compound of formula (61 ) as described in Tetrahedron Lett.
1996, 37, 6045. Compounds of formula (61 ), wherein X' is bromide, chloride, or iodide, can be treated with a compound R'NHR" of formula (54), wherein R' and R"
are as previously described for R' in compounds of formula (53), to provide a corresponding compound of formula (64). Compounds of formula (61 ), wherein X
is N02, can be reduced with hydrogen in the presence of a palladium catalyst and reacted with a chloride or bromide of a desired R' group of formula (53), wherein R' is hydrogen, alkyl, aryl, alkycarbonyl, alkoxycarbonyl, arylcarbonyl, or aryloxycarbonyl, to provide compounds of formula (63).
Scheme 10 Me3SnSnMe3 or .
RO%B_B OR
RO OR H
N
N ~ (9) ~~~ ~ A% -M
A j X' Pd(0)/L. N
N R=alkyl, aryl M=Sn, B
(29) (30) X'=Br, CI, I
Pd(0)/L.
Pd(0)/L. X-Ar2-N HRb M'-Ar2-N H Rb (46) (45) \ I X=Br, CI, I
M'=Sn, B, Zn, Mg, Rb=H, Boc,Cbz, alkyl, a H
<<~ N
A j Ar2 -NHRb N
(69) Compounds of formula (69), wherein X is -NH-, R3 is NHRb, and Ar', Arz are defined as in compounds of formula (I), can be prepared as shown in Scheme 10.
Compounds of formula (29) obtained as shown in Scheme 7 can be treated with a metal of the desired amino-substituted Arz group, as described for compounds of formula (I), of formula (45) to provide compounds of formula (69). Compounds of formula (29) also can be treated with a hexamethylditin or diboron reagent of formula (9), such as bis(pinacolato)diboron and bis(catecholato)diboron, in the presence of a s palladium catalyst to provide the corresponding tin or boronic acid of formula (30), which is reacted with a desired halide of an amine-substituted fused bicycloheterocycle represented by Arz of formula (46), wherein X' is bromide, chloride, or iodide, to provide compounds of formula (69).
Scheme 11 Ci SH
1 ) NaH, DMF ~~S
Are-X
+ I Ar1-X /
N / 2) Chiral seraration N
HCI
(70) (71) X"=Br,CI,I,NO2,NHR'R"
X=N 02 X=Br,Cl,l ~ ) Pd/C, H2 2) R'CI or R'Br (53) Pd/Ligand R'NHR"
(54) ~~ S
A%
N Ar2-N H R' (72) ~~~S
N Ar2-NR'R
(73) Quinuclidine biarylsulfides of formulas (72) and (73), wherein Ar' is as defined for formula (I) and Arz is substituted with a group NR'R" can be obtained by the methods described in Scheme 11. 3-Chloroquinuclidine can be reacted with a 15 halobiarylthiol of formula (70), wherein X" is bromide, chloride, iodide, N02, or NHR'R", as described in Tetrahedron Lett. 1996, 37, 6045, to provide a compound of formula (71 ). Compounds of formula (71 ), wherein X" is N02, can be reduced with hydrogen in the presence of a palladium catalyst and reacted with a chloride or bromide of a desired R' group of formula (53), wherein R' is hydrogen, alkyl, aryl, alkycarbonyl, alkoxycarbonyl, arylcarbonyl, or aryloxycarbonyl, to provide compounds of formula (72). Compounds of formula (71 ), wherein X" is bromide, chloride, or iodide, can be treated with a compound R'NHR" of formula (54), wherein R' and R" are as previously described for R' in compounds of formula (53), to provide a corresponding compound of formula (73).
Scheme 12 Me3SnSnMe3 or RO, ,0R
,B B~OR S
S \ RO (9) ~(~ I A~ M
- , X Pd(0)/L. N /
N
(37) R=alkyl, aryl M=Sn, B
X'=Br,Cl,l (38) Pd(0)/L. Pd(0)/L.
M'-Ar2-N H Rb ~ X'-Ar2-N H Rb (75) ~ ~ (76) M'=Sn, B, Zn, Mg, ~ ~ X'=Br, CI, I
Rb=H, Boc,Cbz, alkyl ~L~S
Art N / Ar2-NHRb ~ (77) Compounds of formula (77), wherein X is S, R3 is NHRb, and Ar', Arz are defined as in compounds of formula (I) can be prepared as shown in Scheme 12.
Compounds of formula (37) obtained as shown in Scheme 5 can be treated with a metal of the desired amino-substituted Arz group, as described for compounds of formula (I), of formula (75) to provide compounds of formula (77). Compounds of formula (37) also can be treated with a hexamethylditin or diboron reagent of formula (9), such as bis(pinacolato)diboron and bis(catecholato)diboron, in the presence of a palladium catalyst to provide the corresponding tin or boronic acid of formula (38), which is reacted with a desired halide of an amine-substituted fused bicycloheterocycle represented by Arz of formula (76), wherein X' is bromide, chloride, or iodide, to provide compounds of formula (77).
Scheme 13 Y' Br2, KSCN Y, ~. / I N
HOAc CC~ I Aj \ ~ NH2 N NH l~S
Y'=O, NH, S
(8 ~ ) RX
(8~) X=CI,Br, I
Y' N
A j \ ~ ~~NHR°
~~S
N
(82) R~=alkyl, aryl, RCO, Cbz, Boc bromination Br CC~ Y' N
KSCN I Aj \ I ~~NHR' N S
' (83) Y SCN R3bM HOR4 HNR5R6 87 or (87a) I A j \ I N~-NHR° (85) ( [Pd]
N ~S [Pd]
RXh (g4) M=B, Zn, Sn Y, Y, R3b CC~ ~ Aj \ ~ ~NHR°
N N S
A j \ I ~>-NHR' 88 N S ( ) (86) Aminobenzothiazole-substituted quinuclidines of formula (82) can be obtained as shown in Scheme 13. Amino-substituted quinuclidine ethers, thioethers, and amines of formula (80) are obtained by methods described in Schemes 6-12.
Compounds of formula (80) are reacted with bromine and KSCN in acetic acid to provide aminobenzothiazole-substituted quinuclidines of formula (81 ).
Compounds of formula (81 ) can be further treated with the halide of a desired R°
group, wherein R° as defined for R5 or R6 in compounds of formula (I) to provide the desired aminobenzothiazole-substituted quinuclidine derivative (82).
Compounds of formula (82) can be further treated to obtain compounds of formulas (84), (86), and (88). Bromination of compounds with formula (82) provides compounds of formula (83). Compounds of formula (83) are reacted with a nucleophilic agent, for example KSCN, to give compounds of formula (84).
Compounds of formula (83) can be treated with a metal of a suitable aryl group, as described for compounds of formula (I), of formula (85), in the presence of palladium catalyst to provide the corresponding compounds of formula (86). Compounds of formula (83) also can be treated with an alcohol of formula (87) or an amine of formula (87a), wherein R4, R5, and R6 are as defined for compounds of formula (I), in the presence of palladium catalyst to provide the corresponding compounds of formula (88).
Scheme 14 NO
~(~Y I A~ ~ I HN03 Y1 I Ar / ( 2 P
N N P
Y'=O, NH, S
(89) 1 ) Hz, Pd/C 2) (Et0)3CR3 MeOH DMF
R3 = alkyl, aryl Y' N~R3 Aj N \ RP
(91 ) CC_ Y' N
yR3 ~~ N
N
(92) , H
Benzoimidazole-substituted quinuclidines of formula (92), wherein Y' is O, NH, or S and Ar' is as defined for compounds of formula (I), can be obtained as shown in Scheme 14. Compounds of formula (89), which are obtained by treating compounds of formula (80) in Scheme 13 under standard nitrogen-protection conditions, are reacted with nitric acid in sulfuric acid to provide compounds of formula (90). Compounds of formula (90) are hydrogenated by palladium catalysis and treated with excess triethylorthoformate to obtain compounds of formula (91 ).
1o Compounds of formula (91 ) are deprotected under standard nitrogen-deprotection conditions to obtain compounds of formula (92).
Scheme 15 X1~ N02 ROB B OR RO~ _ NO
(9) B i z OBn Pd 0 /L. RO
( ) OBn X'=Br,Cl,l R=alkyl, aryl gg ( ) (95) Y' A% X, N
(97) X'=Br, CI, I
Pd(0)/L. Y'=O, NH, S
~~~Y~ N02 A
N OBn (98) 1 ) H2, Pd/C 2) (Et0)3CR3 MeOH DMF
~~~Y, N
yRs l~0 N
(99) Benzooxazole-substituted quinuclidines of formula (99), wherein Y' is O, NH, or S and Ar' and R3 are as defined for compounds of formula (I), can be obtained as shown in Scheme 14. Compounds of formula (95) can be treated with a diboron reagent of formula (9), such as bis(pinacolato)diboron and bis(catecholato)diboron, in the presence of a palladium catalyst to provide the corresponding tin or boronic acid of formula (96). Compounds of formula (96) are reacted with a desired halide of a quinuclidine-substituted heteroaromatic group Ar' as represented by compounds of 1o formula (97), wherein X' is bromide, chloride, or iodide, to provide compounds of formula (98). Compounds of formula (98) are hydrogenated by palladium catalysis and treated with excess triethylorthoformate to obtain compounds of formula (99).
Compounds of formula (I) wherein A is N can be converted to compounds of formula (I) wherein A is N+-O- by treatment with an oxidizing agent. Examples of the oxidizing agent include, but not limited to, aqueous hydrogen peroxide and m-chloroperbenzoic acid. The reaction is generally performed in a solvent such as, but not limited to, acetonitrile, water, dichloromethane, acetone or mixture thereof, preferably a mixture of acetonitrile and water, at a temperature from about room temperature to about 80°C, for a period of about 1 hour to about 4 days.
s The compounds and intermediates of the invention may be isolated and purified by methods well-known to those skilled in the art of organic synthesis.
Examples of conventional methods for isolating and purifying compounds can include, but are not limited to, chromatography on solid supports such as silica gel, alumina, or silica derivatized with alkylsilane groups, by recrystallization at high or low temperature with an optional pretreatment with activated carbon, thin-layer chromatography, distillation at various pressures, sublimation under vacuum, and trituration, as described for instance in "Vogel's Textbook of Practical Organic Chemistry", 5th edition (1989), by Furniss, Hannaford, Smith, and Tatchell, pub.
Longman Scientific & Technical, Essex CM20 2JE, England.
15 The compounds of the invention have at least one basic nitrogen whereby the compound can be treated with an acid to form a desired salt. For example, a compound may be reacted with an acid at or above room temperature to provide the desired salt, which is deposited, and collected by filtration after cooling.
Examples of acids suitable for the reaction include, but are not limited to tartaric acid, lactic acid, 2o succinic acid, as well as mandelic, atrolactic, methanesulfonic, ethanesulfonic, toluenesulfonic, naphthalenesulfonic, carbonic, fumaric, gluconic, acetic, propionic, salicylic, hydrochloric, hydrobromic, phosphoric, sulfuric, citric, or hydroxybutyric acid, camphorsulfonic, malic, phenylacetic, aspartic, glutamic, and the like.
25 Compositions of the Invention The invention also provides pharmaceutical compositions comprising a therapeutically effective amount of a compound of formula (I) in combination with a pharmaceutically acceptable carrier. The compositions comprise compounds of the invention formulated together with one or more non-toxic pharmaceutically 3o acceptable carriers. The pharmaceutical compositions can be formulated for oral administration in solid or liquid form, for parenteral injection or for rectal administration.
The term "pharmaceutically acceptable carrier," as used herein, means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. Some examples of materials which can serve as pharmaceutically acceptable carriers are sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate;
powdered tragacanth; malt; gelatin; talc; cocoa butter and suppository waxes;
oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols; such a propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible 15 lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be' present in the composition, according to the judgment of one skilled in the art of formulations.
The pharmaceutical compositions of this invention can be administered to 2o humans and other mammals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments or drops), bucally or as an oral or nasal spray. The term "parenterally," as used herein, refers to modes of administration, including intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous, intraarticular injection and infusion.
25 Pharmaceutical compositions for parenteral injection comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propylene glycol, so polyethylene glycol, glycerol, and the like, and suitable mixtures thereof), vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate, or suitable mixtures thereof. Suitable fluidity of the composition may be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surtactants.
These compositions can also contain adjuvants such as preservative agents, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It also can be desirable to include isotonic agents, for example, sugars, sodium chloride and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.
In some cases, in order to prolong the effect of a drug, it is often desirable to slow the absorption of the drug from subcutaneous or intramuscular injection.
This can be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug can depend upon its rate of dissolution, which, in turn; may depend upon crystal size and crystalline form. Alternatively, a parenterally administered drug form can be administered by dissolving or suspending the drug in an oil vehicle.
Suspensions, in addition to the active compounds, can contain suspending 2o agents, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, tragacanth, and mixtures thereof.
If desired, and for more effective distribution, the compounds of the invention can be incorporated into slow-release or targeted-delivery systems such as polymer 2s matrices, liposomes, and microspheres. They may be sterilized, for example, by filtration through a bacteria-retaining filter or by incorporation of sterilizing agents in the form of sterile solid compositions, which may be dissolved in sterile water or some other sterile injectable medium immediately before use.
Injectable depot forms are made by forming microencapsulated matrices of 3o the drug in biodegradable polymers such as polylactide-polyglycolide.
Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides) Depot injectable formulations also are prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.
s The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.
Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions can be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation also can be a sterile injectable solution, suspension or emulsion in a nontoxic, parenterally acceptable diluent or solvent such as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that can be employed are water, Ringer's solution, 15 U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.
Solid dosage forms for oral administration include capsules, tablets, pills, 2o powders, and granules. In such solid dosage forms, one or more compounds of the invention is mixed with at least one inert pharmaceutically acceptable carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and salicylic acid; b) binders such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and 25 acacia; c) humectants such as glycerol; d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; e) solution retarding agents such as paraffin; f) absorption accelerators such as quaternary ammonium compounds; g) wetting agents such as cetyl alcohol and glycerol monostearate; h) absorbents such as kaolin and bentonite 3o clay; and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.
Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using lactose or milk sugar as well as high molecular weight polyethylene glycols.
The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well-known in the pharmaceutical formulating art. They can optionally contain opacifying agents and can also be of a composition that they release the active ingredients) only, or preferentially, in a certain part of the intestinal tract in a delayed manner. Examples of materials useful for delaying release of the active agent can include polymeric substances and waxes.
Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-15 irritating carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
2o In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, 25 germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
3o Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. A desired compound of the invention is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, eardrops, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.
The ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
Powders and sprays can contain, in addition to the compounds of this , invention, lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons.
Compounds of the invention also can be administered in the form of liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes may be used. The present compositions in liposome form may contain, in 2o addition to the compounds of the invention, stabilizers, preservatives, and the like.
The preferred lipids are the natural and synthetic phospholipids and phosphatidylcholines (lecithins) used separately or together.
Methods to form liposomes are known in the art. See, for example, Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, N. Y., (1976), p 33 et seq.
Dosage forms for topical administration of a compound of this invention include powders, sprays, ointments and inhalants. The active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives, buffers or propellants. Ophthalmic formulations, eye ointments, 3o powders and solutions are also contemplated as being within the scope of this invention. Aqueous liquid compositions of the invention also are particularly useful.
The compounds of the invention can be used in the form of pharmaceutically acceptable salts, esters, or amides derived from inorganic or organic acids.
The term "pharmaceutically acceptable salts, esters and amides," as used herein, include salts, zwitterions, esters and amides of compounds of formula (I) which are, within s the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, are commensurate with a reasonable benefit/risk ratio, and are effective for their intended use.
The term "pharmaceutically acceptable salt" refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, and are commensurate with a reasonable benefit/risk ratio.
Pharmaceutically acceptable salts are well-known in the art. The salts can be prepared in situ during the final isolation and purification of the compounds of the 15 invention or separately by reacting a free base function with a suitable organic acid.
Representative acid addition salts include, but are not limited to acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-2o hydroxyethansulfonate (isethionate), lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate; pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, phosphate, glutamate, bicarbonate, p-toluenesulfonate and undecanoate.
Also, the basic nitrogen-containing groups can be quaternized with such 25 agents as lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates such as dimethyl, diethyl, dibutyl and diamyl sulfates; long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; arylalkyl halides such as benzyl and phenethyl bromides and others. Water or oil-soluble or dispersible products are thereby obtained.
3o Examples of acids which can be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, hydrobromic acid, sulphuric acid and phosphoric acid and such organic acids as oxalic acid, malefic acid, succinic acid, and citric acid.
Basic addition salts can be prepared in situ during the final isolation and purification of compounds of this invention by reacting a carboxylic acid-containing moiety with a suitable base such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation or with ammonia or an organic primary, secondary or tertiary amine. Pharmaceutically acceptable salts include, but are not limited to, cations based on alkali metals or alkaline earth metals such as lithium, sodium, potassium, calcium, magnesium, and aluminum salts, and the like, and nontoxic quaternary ammonia and amine cations including ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine and the such as. Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, and piperazine.
The term "pharmaceutically acceptable ester," as used herein, refers to esters of compounds of the invention which hydrolyze in vivo and include those that break down readily in the human body to leave the parent compound or a salt thereof.
Examples of pharmaceutically acceptable, non-toxic esters of the invention include C~-to-C6 alkyl esters and C5-to-C~ cycloalkyl esters, although C~-to-C4 alkyl esters 2o are preferred. Esters of the compounds of formula (I) can be prepared according to conventional methods. Pharmaceutically acceptable esters can be appended onto hydroxy groups by reaction of the compound that contains the hydroxy group with acid and an alkylcarboxylic acid such as acetic acid, or with acid and an arylcarboxylic acid such as benzoic acid. In the case of compounds containing carboxylic acid groups, the pharmaceutically acceptable esters are prepared from compounds containing the carboxylic acid groups by reaction of the compound with base such as triethylamine and an alkyl halide, alkyl trifilate, for example with methyl iodide, benzyl iodide, cyclopentyl'iodide. They also can be prepared by reaction of the compound with an acid such as hydrochloric acid and an alkylcarboxylic acid 3o such as acetic acid, or with acid and an arylcarboxylic acid such as benzoic acid.
The term "pharmaceutically acceptable amide," as used herein, refers to non-toxic amides of the invention derived from ammonia, primary C~-to-C6 alkyl amines and secondary C~-to-C6 dialkyl amines. In the case of secondary amines, the amine can also be in the form of a 5- or 6-membered heterocycle containing one nitrogen atom. Amides derived from ammonia, C~-to-C3 alkyl primary amides and C~-to-C2 dialkyl secondary amides are preferred. Amides of the compounds of formula (I) can be prepared according to conventional methods. Pharmaceutically acceptable amides can be prepared from compounds containing primary or secondary amine groups by reaction of the compound that contains the amino group with an alkyl anhydride, aryl anhydride, acyl halide, or aroyl halide. In the case of compounds containing carboxylic acid groups, the pharmaceutically acceptable esters are prepared from compounds containing the carboxylic acid groups by reaction of the compound with base such as triethylamine, a dehydrating agent such as dicyclohexyl carbodiimide or carbonyl diimidazole, and an alkyl amine, dialkylamine, 15 for example with methylamine, diethylamine, piperidine. They also can be prepared by reaction of the compound with an acid such as sulfuric acid and an alkylcarboxylic acid such as acetic acid, or with acid and an arylcarboxylic acid such as benzoic acid under dehydrating conditions as with molecular sieves added. The composition can contain a compound of the invention in the form of a pharmaceutically acceptable 2o prodrug.
The term "pharmaceutically acceptable prodrug" or "prodrug," as used herein, represents those prodrugs of the compounds of the invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and 2s the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use. Prodrugs of the invention can be rapidly transformed in vivo to a parent compound of formula (I), for example, by hydrolysis in blood. A
thorough discussion is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, V. 14 of the A.C.S. Symposium Series, and in Edward B. Roche, ed., 3o Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press (1987).
The invention contemplates pharmaceutically active compounds either chemically synthesized or formed by in vivo biotransformation to compounds of formula (I).
Methods of the Invention Compounds and compositions of the invention are useful for modulating the effects of nAChRs, and more particularly a7 nAChRs. In particular, the compounds and compositions of the invention can be used for treating and preventing disorders modulated by a7 nAChRs. Typically, such disorders can be ameliorated by selectively modulating the a7 nAChRs in a mammal, preferably by administering a compound or composition of the invention, either alone or in combination with another active agent, for example, as part of a therapeutic regimen.
The compounds of the invention, including but not limited to those specified in the examples, possess an affinity for nAChRs, and more particularly a7 nAChRs.
As ~ 5 a7 nAChRs ligands, the compounds of the invention can be useful for the treatment and prevention of a number of a7 nAChR-mediated diseases or conditions.
For example, a7 nAChRs have been shown to play a significant role in enhancing cognitive function, including aspects of learning, memory and attention (Levin, E.D., J. Neurobiol. 53: 633-640, 2002). As such, a7 ligands are suitable for 2o the treatment of cognitive disorders including, for example, attention deficit disorder, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, Pick's Disease, dementia associated with Lewy bodies, and dementia associated with Down's syndrome, as well as cognitive deficits associated with schizophrenia.
25 In addition, a7-containing nAChRs have been shown to be involved in the neuroprotective effects of nicotine both in vitro (Jonnala, R. B. and Buccafusco, J. J., J. Neurosci. Res. 66: 565-572, 2001 ) and in vivo (Shimohama, S. et al., Brain Res.
779: 359-363, 1998). More particularly, neurodegeneration underlies several progressive CNS disorders, including, but not limited to, Alzheimer's disease, so Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, dementia with Lewy bodies, as well as diminished CNS function resulting from traumatic brain injury. For example, the impaired function of a7 nAChRs by ~-amyloid peptides linked to Alzheimer's disease has been implicated as a key factor in development of the cognitive deficits associated with the disease (Liu, Q.-S., Kawai, H., Berg, D. K., PNAS 98: 4734-4739, 2001 ). The activation of a7 nAChRs has been shown to block this neurotoxicity (Kihara, T. et al., J. Biol. Chem. 276: 13541-13546, 2001 ). As such, selective ligands that enhance a7 activity can counter the deficits of Alzheimer's and other neurodegenerative diseases.
Schizophrenia is a complex disease that is characterized by abnormalities in perception, cognition, and emotions. Significant evidence implicates the involvement of a7 nAChRs in this disease, including a measured deficit of these receptors in post-mortem patients (Leonard, S. Eur. J. Pharmacol. 393: 237-242, 2000).
Deficits in sensory processing (gating) are one of the hallmarks of schizophrenia.
These deficits can be normalized by nicotinic ligands that operate at the a7 nAChR
(Adler L.
E. et al., Schizophrenia Bull. 24: 189-202, 1998; Stevens, K. E. et al., ~5 Psychopharmacology 136: 320-327, 1998). Thus, a7 ligands demonstrate potential in the treatment schizophrenia.
Angiogenesis, a process involved in the growth of new blood vessels, is important in beneficial systemic functions, such as wound healing, vascularization of skin grafts, and enhancement of circulation, for example, increased circulation 2o around a vascular occlusion. Non-selective nAChR agonists like nicotine have been shown to stimulate angiogenesis (Heeschen, C. et al., Nature Medicine 7: 833-839, 2001 ). Improved angiogenesis has been shown to involve activation of the a7 nAChR (Heeschen, C. et al, J. Clin. Invest. 110: 527-536, 2002). Therefore, nAChR
ligands that are selective for the a7 subtype offer improved potential for stimulating 2s angiogenesis with an improved side effect profile.
A population of a7 nAChRs in the spinal cord modulate serotonergic transmission that have been associated with the pain-relieving effects of nicotinic compounds (Cordero-Erausquin, M. and Changeux, J.-P. PNAS 98:2803-2807, 2001 ). The a7 nAChR ligands demonstrate therapeutic potential for the treatment of so pain states, including acute pain, post-surgical pain, as well as chronic pain states including inflammatory pain and neuropathic pain. Moreover, a7 nAChRs are expressed on the surface of primary macrophages that are involved in the inflammation response, and that activation of the a7 receptor inhibits release of TNF
and other cytokines that trigger the inflammation response (Wang, H. et al Nature 421: 384-388, 2003). Therefore, selective a7 ligands demonstrate potential for treating conditions involving inflammation and pain.
The mammalian sperm acrosome reaction is an exocytosis process important in fertilization of the ovum by sperm. Activation of an a7 nAChR on the sperm cell has been shown to be essential for the acrosome reaction (Son, J.-H. and Meizel, S.
Biol. Reproduct. 68: 1348-1353 2003). Consequently, selective a7 agents demonstrate utility for treating fertility disorders.
Compounds of the invention are particularly useful for treating and preventing a condition or disorder affecting cognition, neurodegeneration, and schizophrenia.
Cognitive impairment associated with schizophrenia often limits the ability of patients to function normally, a symptom not adequately treated by commonly available treatments, for example, treatment with an atypical antipsychotic.
(Rowley, M. et al., J. Med. Chem. 44: 477-501, 2001 ). Such cognitive deficit has been linked to dysfunction of the nicotinic cholinergic system, in particular with decreased activity at a7 receptors. (Friedman, J. I. et al., Biol Psychiatry, 51: 349-357, 2002).
Thus, 2o activators of a7 receptors can provide useful treatment for enhancing cognitive function in schizophrenic patients who are being treated with atypical antipsychotics.
Accordingly, the combination of an a7 nAChR ligand and an atypical antipsychotic would offer improved therapeutic utility. Specific examples of suitable atypical antipsychotics include, but are not limited to, clozapine, risperidone, olanzapine, 2s quietapine, ziprasidone, zotepine, iloperidone, and the like.
Actual dosage levels of active ingredients in the pharmaceutical compositions of this invention can be varied so as to obtain an amount of the active compounds) that is effective to achieve the desired therapeutic response for a particular patient, compositions and mode of administration. The selected dosage level will depend 3o upon the activity of the particular compound, the route of administration, the severity of the condition being treated and the condition and prior medical history of the patient being treated. However, it is within the skill of the art to start doses of the compound at levels lower than required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.
When used in the above or other treatments, a therapeutically effective amount of one of the compounds of the invention can be employed in pure form or, where such forms exist, in pharmaceutically acceptable salt, ester, amide or prodrug form. Alternatively, the compound can be administered as a pharmaceutical composition containing the compound of interest in combination with one or more pharmaceutically acceptable carriers. The phrase "therapeutically effective amount"
of the compound of the invention means a sufficient amount of the compound to treat disorders, at a reasonable benefit/risk ratio applicable to any medical treatment. It will be understood, however, that the total daily usage of the compounds and compositions of the invention will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level 15 for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment;
2o drugs used in combination or coincidental with the specific compound employed; and like factors well-known in the medical arts. For example, it is well within the skill of the art to start doses of the compound at levels lower than required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.
25 The total daily dose of the compounds of this invention administered to a human or lower animal range from about 0.10 mg/kg body weight to about 1 g/kg body weight. More preferable doses can be in the range of from about 0.10 mg/kg body weight to about 100 mg/kg body weight. If desired, the effective daily dose can be divided into multiple doses for purposes of administration. Consequently, single 3o dose compositions may contain such amounts or submultiples thereof to make up the daily dose.
The compounds and processes of the invention will be better understood by reference to the following examples and reference examples, which are intended as an illustration of and not a limitation upon the scope of the invention.
EXAMPLES
Example 1 3-(4-(,1-Azabicyclo(2.2.2]oct-3-yloxy)phenyll-1 H-indole o Example 1 A
3-(4-lodophenoxy)quinuclidine Under N2, the mixture of 3-hydroxy quinuclidine (Aldrich, 2.54 g, 20 mmol), 1,4-diiodobenzene ~Aldrich, 7.9 g, 24 mmol), Cul (Strem Chemicals, 0.38 g, 2 mmol) and 1,10-phenanthroline (Aldrich, 0.72 g, 4 mmol) in toluene (anhydrous, Aldrich, 50 ~5 mL) was stirred at 110 °C for 40 h. After the reaction went to completion, the reaction mixture was diluted with chloroform (100 mL) and washed with water (2 x 10 mL).
The organic solution was concentrated and the title compound was purified by chromatography (Si02, CH2C12: MeOH : NH3~H20, 90:10:1, Rf. 0.20) as oil (3.7 g, yield, 56%).'H NMR (300 MHz, CD30D) 8 1.40-1.56 (m, 1H), 1.64-1.80 (m, 2H), 20 1.90-2.08 (m, 1 H), 2.10-2.21 (m, 1 H), 2.60-3.00 (m, 5H), 3.34-3.40 (m, 1 H), 4.46 (m, 1 H), 6.73 (d, J=8.8 Hz, 2H), 7.56 (d, J=8.8, Hz, 2H), ppm. MS (DCI/NH3) m/z (M+H)+.
Example 1 B
25 3-(4-(1-Azabicyclo(2.2.21oct-3-yloxY)phenyll-1 H-indole The mixture of the product of Example 1A (330 mg, 1 mmol), N-(2-ethynyl-phenyl)-2,2,2-trifluoro-acetamide (ref. Tetrahedron Lett. 1992, 33, 3915.; 280 mg, 1.3 mmol), Pd2(dba)3 (Aldrich, 19 mg, 0.02 mmol) and K2C03 (180 mg, 1.3 mmol) in DMSO (3 mL) was stirred at 40 °C under N2 for 2 hours. The reaction was monitored 3o with TLC. After the reaction was complete, it was cooled down to room temperature and diluted with EtOAc (50 mL). It was then washed with brine (3 x 5 mL). The organic solution was concentrated and the title product was purified by preparative HPLC (Gilson, column, Symmetry~ C-8 7 pm, 40 x 100 mm. Eluting Solvent, MeCN
/ H20 (with 0.2% v. TFA) (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (113 mg, yield, 36%).'H NMR (300 MHz, CD30D) b 1.43-1.57 (m, 1 H), 1.62-1.89 (m, 2H), 2.01-2.15 (m, 1 H), 2.16-2.23 (m, 1 H), 2.73-3.03 (m, 5H), 3.28-3.40 (m, 1 H), 4.51-4.58 (m, 1 H), 6.97 (dt, J=8.8, 2.1 Hz, 2H), 7.03-7.17 (m, 2H), 7.36 (s, 1 H), 7.37-7.42 (m, 1 H), 7.57 (dt, J=8.8, 2.0 Hz, 2H), 7.81 (dt, J=
7.8, 1.2 Hz, 1 H) ppm. MS (DCI/NH3) m/z 319 (M+H)+.
Example 1 C
3-f4-(1-Azabicyclo[2.2.21oct-3-yloxy)phenyll-1 H-indole hemifumarate The product of Example 1 B (113 mg, 0.36 mmol) was treated with fumaric acid (46 mg, 0.4 mmol) in EtOAc/EtOH (v. 1:1, 4 mL) at ambient temperature for h. The title compound was obtained as solid (131 mg, yield, 89%).'H NMR (300 ~5 MHz, CD30D) S 1.73-2.13 (m, 3H), 2.23-2.37 (m, 1 H), 2.43-2.51 (m, 1 H), 3.12-3.43 (m, 5H), 3.64-3.76 (m, 1 H), 4.77-4.88 (m, -1 H), 6.67 (s, 1.4H), 6.99-7.18 (m, 4H), 7.38 (s, 1 H), 7.39-7.43 (m, 1 H), 7.61 (dt, J=8.8, 2.0 Hz, 2H), 7.80 (d, J=
7.8 Hz, 1 H) ppm. MS (DCI/NH3): m/z 319 (M+H)+. Anal. Calculated for C2~H22N20~0.85 C4H404:
C, 70.27; H, 6.14; N, 6.72. Found: C, 70.20; H, 6.35; N, 6.88.
Example 2 4-f4-(1-Azabicyclof2.2.21oct-3-yloxy)phenyll-1 H-indole Example 2A
2s 3-f4-(Trimethylstannyl)phenoxylquinuclidine The mixture of the product from Example 1A (330 mg, 1 mmol), hexamethylditin (Aldrich, 654 mg, 2 mmol) and Pd(PPh3)4 (Aldrich, 116 mg, 0.1 mmol) in toluene (10 mL) was stirred at 110 °C under N2 for 2 hours.
The reaction was monitored with TLC. After the reaction was complete, it was cooled down to 3o room temperature and diluted with EtOAc (50 mL). It was then washed with brine (2 x 5 mL). The organic solution was concentrated under reduced pressure and the title compound was purified by flash chromatography (Si02, CH2C12 : MeOH : NH3~H20, 90:10:1, Rf. 0.35) as solid (300 mg, yield, 82%).'H NMR (300 MHz, CD30D) b 0.25 (s, 9H), 1.79-2.16 (m, 3H), 2.23-2.36 (m, 1 H), 2.45-2.52 (m, 1 H), 3.17-3.43 (m, 5H), 3.73-3.83 (m, 1 H), 4.84-4.92 (m, 1 H), 6.96 (d, J=8.5 Hz, 2H), 7.41 (d, J=8.5 Hz, 2H) s ppm. MS (DCI/NH3): m/z 364 (M+H)+, 366 (M+H)+, 368 (M+H)+.
Example 2B
4-[4-(1-Azabicyclof2.2.21oct-3-yloxy)phenyl~-1 H-indole The product of 2A (300 mg, 0.8 mmol), 4-bromoindole (Aldrich, 196 mg, 1 mmol), Pd2(dba)3 (Aldrich, 27 mg, 0.03 mmol) and (o-tol.)3P (Aldrich, 27 mg, 0.09 mmol) in DMF (Aldrich, anhydrous, 5 mL) were heated to 80 °C under N2 and stirred overnight. It was then cooled down to room temperature and diluted with EtOAc (50 mL). The mixture was washed with brine (2 x 5 mL). The organic solution was concentrated under reduced pressure and the title compound was purified by flash ~5 chromatography~(Si02, CH2C12: MeOH : NH3~H20, 90:10:1, Rf. 0.30) as a solid (48 mg, yield, 19%).'H NMR (300 MHz, CD30D) b 1.46-1.58 (m, 1H), 1.64-1.91 (m, 2H), 2.01-2.17 (m, 1 H), 2.19-2.26, (m, 1 H), 2.75-3.03 (m, 5H), 3.32-3.42 (m, 1 H), 4.55-4.63 (m, 1 H), 6.58 (dd, J=3.4, 1.0 Hz, 1 H), 6.98-7.04 (m, 3H), 7.14 (t, J=7.8 Hz, 1 H), 7.25 (d, J=3.1 Hz, 1 H), 7.33 (dt, J=8.1, 1.0 Hz, 1 H), 7.59 (dt, J=9.2, 2.7 Hz, 2H) 2o ppm. MS (DCI/NH3): m/z 319 (M+H)+.
Example 2C
4-f4-(1-Azabicyclo[2.2.2~oct-3-yloxy)phenyl~-1 H-indole fumarate The product of Example 2B (48 mg, 0.15 mmol) was treated with fumaric acid 25 (23 mg, 0.2 mmol) in EtOAc/EtOH (v. 1:1, 3 mL) at ambient temperature for 15 h.
The title compound was obtained as solid (60.2 mg, yield, 90%).'H NMR (300 MHz, CD30D) b 1.82-2.19 (m, 3H), 2.29-2.42 (m, 1 H), 2.51-2.58 (m, 1 H), 3.16-3.46 (m, 5H), 3.75-3.85 (m, 1 H), 4.89-4.96 (m, 1 H), 6.56 (dd, J=3.4, 1.0 Hz, 1 H), 6.69 (s, 2.2H), 7.02 (dd, J=7.1, 1.0 Hz, 1 H), 7.08 (dt, J=8.8, 2.5 Hz, 2H), 7.15 (t, J=7.5 Hz, 30 1 H), 7.26 (d, J=3.4 Hz, 1 H), 7.35 (dt, J=8.1, 1.0 Hz, 1 H), 7.64 (dt, J=8.8, 2.6 Hz, 2H) ppm. MS (DCI/NH3): m/z 319 (M+H)+. Anal. Calculated for C2~H22N20~1.12 C4H404:
C, 68.25; H, 5.95; N, 6.25. Found: C, 68.43; H, 5.58; N, 6.20.
Example 3 5-f4-(1-Azabicyclof2.2.2~oct-3-yloxy)phenyll-1 H-indole Example 3A
5-f4-(,1-Azabicyclof2.2.21oct-3-yloxy)phenyll-1 H-indole Under N2, the product of Example 1A (329 mg, 1 mmol), 5-indolylboronic acid o (Frontier, 193 mg, 1.2 mmol), Pd2(dba)3 (Aldrich, 24 mg, 0.025 mmol), (~Bu3P)2 Pd (26 mg, 0.05mmol), K2C03 (276 mg, 2 mmol) and KF (80 mg, 1.4 mmol) in THF(8 mL) was stirred at 60 °C overnight. The reaction was monitored with TLC. After the reaction was complete, it was diluted with EtOAc (30 mL) and washed with brine (2 x 5 mL). The organic solution was concentrated under reduced pressure and the title product was purified by preparative HPLC (Gilson, column, Symmetry~ C-8 7 Nm, 40 x 100 mm. Eluting Solvent, MeCN / H20 (with 0.2% v. TFA) (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (80 mg, yield, 25%).'H
NMR (300 MHz, CD30D) b 1.44-1.58 (m, 1 H), 1.62-1.90 (m, 2H), 2.01-2.15 (m, 1 H), 2.16-2.24 (m, 1 H), 2.74-3.04 (m, 5H), 3.27-3.40 (m, 1~H), 4.51-4.59 (m, 1 H), 6.46 (dd, 2o J=3.4, 1.1 Hz, 1 H), 6.95 (dt, J=8.8, 2.6 Hz, 2H), 7.22 (d, J=3.1 Hz, 1 H), 7.31 (dd, J=8.5, 2.0 Hz, 1 H), 7.40 (dt, J=8.5, 1.0 Hz, 1 H), 7.54 (dt, J=9.2, 2.6 Hz, 2H), 7.71 (dd, J=1.7, 0.7 Hz, 1 H) ppm. MS (DCI/NH3): m/z 319 (M+H)+.
Example 3B
5-f4-(1-Azabicyclof2.2.21oct-3-yloxy)phenyl]-1 H-indole fumarate The product of Example 3A (80 mg, 0.25 mmol) was treated with fumaric acid (29 mg, 0.25 mmol) in EtOAc/EtOH (v. 1:1, 4 mL) at ambient temperature for 10 h.
The title compound was obtained as solid (57 mg, yield, 52%).'H NMR (300 MHz, CD30D) b 1.78-2.16 (m, 3H), 2.25-2.39 (m, 1 H), 2.46-2.54 (m, 1 H), 3.14-3.45 (m, 5H), 3.69-3.81 (m, 1 H), 4.80-4.89 (m, 1 H), 6.46 (dd, J=3.0, 1.0, 1 H), 6.68 (s, 2H), 7.02 (dt, J=8.8, 2.5 Hz, 2H), 7.23 (d, J=3.1 Hz, 1 H), 7.31 (dd, J=8.5, 2.0 Hz, 1 H), 7.43 (dt, J=8.4, 0.8 Hz, 1 H), 7.58 (dt, J=9.2, 2.6 Hz; 2H), 7.71 (dd, J=1.7, 1.0 Hz, 1 H) ppm. MS (DCI/NH3): m/z 319 (M+H)+. Anal. Calculated for C2~H22NzO~C4H404: C, 69.11; H, 6.03; N, 6.45. Found: C, 69.23; H, 5.81; N, 6.59.
Example 4 5-~4-f(3R)-1-Azabicyclo~2.2.21oct-3-yloxy~phenyl)-1 H-indole Example 4A
(3R)-3-Quinuclidinol o (3R)-3-Quinuclidinol hydrochloride (Aldrich, 20 g, 12.2 mmol) was treated with NaOH aqueous solution(20%, 50 mL) at ambient temperature for 10 min. It was then extracted with CHC13/'PrOH (v. 10 : 1, 3 x 200 mL). The extracts were combine, washed with brine (50 mL) and dried over MgS04. The drying agents were removed by filtration and the filtrates was concentrated under reduced pressure to give the ~5 title compound as white solid (15. 5 g, yield, 99%).'H NMR (300 MHz, CD30D) b 1.36-1.50 (m, 1 H), 1.52-1.60 (m, 1 H), 1.76-1.85 (m, 2H), 1.90-2.05 (m, 1 H), 2.50-2.95(m, 5H), 3.10 (ddd, J=14.2, 8.4, 2.3 Hz, 1 H), 3.82-3.88 (m, 1 H) ppm. MS
(DCI/NH3): m/z 128 (M+H)+. , 2o Example 4B
-3-(4-Bromophenoxy)quinuclidine The product of Example 4A (1.27 g, 10 mmol) was coupled with 1-iodo-4-bromobenzene (Aldrich, 2.83 g, 10 mol) according to the procedure of Example 1A.
The title product was purified by chromatography (Si02, CH2C12 : MeOH :
NH3~H20, 25 90:10:1, Rf. 0.30) as solid (400 mg, yield, 14%).'H NMR (300 MHz, CD30D) b 1.41-1.54 (m, 1 H), 1.59-1.73 (m, 1 H), 1.73-1.86 (m, 1 H), 1.92-2.06 (m, 1 H), 2.09-2.17 (m, 1 H), 2.71-2.97 (m, 5H), 3.24-3.34 (m, 1 H), 4.45-4.52 (m, 1 H), 6.83 (dt, J=9.2, 2.6 Hz, 2H), 7.37 (dt, J=9.2, 2.7 Hz, 2H) ppm. MS (DCI/NH3): m/z 282 (M+H)+, 284 (M+H)+.
3o Example 4C
5-~4-[(,3R)-1-Azabicyclof2.2.21oct-3-yloxy~phenyl)-1 H-indole The product of 4C (282 mg, 1 mmol) coupled with 5-indolylboronic acid (Frontier, 190 mg, 1.2 mmol) according to the procedure of Example 3A. The title product was purified by chromatography (Si02, CH2C12 : MeOH : NH3~H20, 90:10:1, Rf. 0.35) as solid (50 mg, yield, 16%).'H NMR (300 MHz, CD30D) S 1.44-1.58 (m, 1 H), 1.62-1.90 (m, 2H), 2.01-2.15 (m, 1 H), 2.16-2.24 (m, 1 H), 2.74-3.04 (m, 5H), 3.27-3.40 (m, 1 H), 4.51-4.59 (m, 1 H), 6.46 (dd, J=3.4, 1.1 Hz, 1 H), 6.95 (dt, J=8.8, 2.6 Hz, 2H), 7.22 (d, J=3.1 Hz, 1 H), 7.31 (dd, J=8.5, 2.0 Hz, 1 H), 7.40 (dt, J=8.5, 1.0 Hz, 1 H), 7.54 (dt, J=9.2, 2.6 Hz, 2H), 7.71 (dd, J=1.7, 0.7 Hz, 1 H) ppm. MS
(DCI/NH3): m/z 319 (M+H)+.
Example 4D
5-f4-f(3R)-1-Azabicyclof2.2.2~oct-3-yloxylphenyl~-1 H-indole fumarate The product of Example 4C (50 mg, 0.25 mmol) was treated with fumaric acid (29 mg, 0.25 mmol) in EtOAc/EtOH (v. 1:1, 4 mL) at ambient temperature for 10 h.
The title compound was obtained as solid (56.9 mg, yield, 52%).'H NMR (300 MHz, CD30D) b 1.78-2.16 (m, 3H), 2.25-2.39 (m, 1 H), 2.46-2.54 (m, 1 H), 3.14-3.45 (m, 5H), 3.69-3.81 (m, 1 H), 4.80-4.89 (m, 1 H), 6.46 (dd, J=3.0, 1.0, 1 H), 6.68 (s, 2.2H), 7.02 (dt, J=8.8, 2.5 Hz, 2H), 7.23 (d, J=3.1 Hz, 1 H), 7.31 (dd, J=8.5, 2.0 Hz, 1 H), 7.43 (dt, J=8.4, 0.8 Hz, 1 H), 7.58 (dt, J=9.2, 2.6 Hz, 2H), 7.71 (dd, J=1.7, 1.0 Hz, 1 H) 2o ppm. MS (DCI/NH3): m/z 319 (M+H)+. Anal. Calculated for C2~H22N20~1.14 C4H404:
C, 68.11; H, 5.94; N, 6.21. Found: C, 68.12; H, 6.04; N, 6.18.
Example 5 6-f4-(1-Azabicyclo[2.2.21oct-3-yloxy)phenyll-1 H-indole Example 5A
6-f4-( 1-Azabicyclo f 2.2.2~oct-3-yloxy)phenyll-1 H-indole The product of Example 2A (300 mg, 0.8 mmol) was coupled with 6-bromoindole (Aldrich, 196 mg, 1 mmol) according to the procedure in 2B. The title compound was purified by chromatography (Si02, CH2C12 : MeOH : NH3~H20, 90:10:1, Rf. 0.20) as a solid (30 mg, yield, 12%).'H NMR (300 MHz, CD30D) b 1.45-1.58 (m, 1 H), 1.64-1.90 (m, 2H), 2.01-2.15 (m, 1 H), 2.17-2.24 (m, 1 H), 2.75-3.04 (m, 5H), 3.30-3.42 (m, 1 H), 4.53-4.61 (m, 1 H), 6.43 (dd, J=3.1, 0.7 Hz, 1 H), 6.97 (dt, J=8.8, 2.6 Hz, 2H), 7.21-7.27 (m, 2H), 7.52-7.60 (m, 4H) ppm. MS
(DCI/NH3): m/z 319 (M+H)+.
Example 5B
6-f4-(1-Azabicyclof2.2.21oct-3-yloxy)phenyl~-1 H-indole fumarate The product of Example 5A (30 mg, 0.1 mmol) was treated with fumaric acid (12 mg, 0.1 mmol) in EtOAc/EtOH (v. 1:1, 2 mL) at ambient temperature for 15 h.
The title compound was obtained as solid (38.4 mg, yield, 79%).'H NMR (300 MHz, CD30D) b 1.80-2.19 (m, 3H), 2.27-2.40 (m, 1 H), 2.48-2.56 (m, 1 H), 3.17-3.63 (m, 5H), 3.72-3.83 (m, 1 H), 4.80-4.88 (m, 1 H), 6.43 (dd, J=3.1, 0.7 Hz, 1 H), 6.68 (s, 2H), 7.04 (dt, J=8.8, 2.5 Hz, 2H), 7.21-7.27 (m, 2H), 7.53-7.65 (m, 4H) ppm.
MS(DCI/NH3): m/z 319 (M+H)+. Anal. Calcd. for C~9H2oN40~1.3 C4H4O4: C, 67.05;
H, 5.84; N, 5.97. Found: C, 67.15; H, 5.99; N, 5.95.
Example 6 2-[4-(1-Azabicyclo[2.2.21oct-3-yloxy)phenyll-1 H-indole 2o Example 6A
3-(4-Ethynylphenoxy)quinuclidine Under N2, the mixture of the product from Example 1A (800 mg, 2.4 mmol), trimethylsilylacetylene (Aldrich, 392 mg, 4 mmol), Pd(PPh3)4 ( Aldrich, 29 mg, 0.025 mmol) and Cul (Strem Chemicals, 10 mg, 0.05 mmol) in DMF (10 mL) was stirred at ambient temperature overnight. DMF then was removed under reduced pressure.
The residue was treated with tetrabutyl ammonium fluoride (Aldrich, in THF, 1 M, 5 mL) at room temperature for 3 h. The reaction was monitored with TLC. After the reaction was complete, it was diluted with EtOAc (50 mL) and washed with brine (2 x 10 mL). The organic solution was concentrated and the title compound was purified 3o by chromatography (Si02, CH2C12: MeOH : NH3~H20, 90:10:1, Rf. 0.30) as a solid (560 mg, yield, 99%).'H NMR (300 MHz, CD30D) b 1.42-1.54 (m, 1H), 1.61-1.87 -54- ' (m, 2H), 1.93-2.07 (m, 1 H), 2.10-2.18 (m, 1 H), 2.71-3.00 (m, 5H), 3.19-3.37 (m, 2H), 4.49-4.56 (m, 1 H), 6.86 (d, J=8.8 Hz, 2H), 7.37 (d, J=8.8 Hz, 2H) ppm. MS
(DCI/NH3): m/z 228 (M+H)+.
s Example 6B
2,2,2-Trifluoro-N-(2-iodophenyl)acetamide 2-lodo-phenylamine (Aldrich, 1.09 g, 5 mmol) was treated with trifluoroacetic anhydride (Aldrich, 1.26 g, 6 mmol) and 2,6-di-tert-butyl-4-methyl-pyridine (Aldrich, 1.23 g, 6 mmol) in CH2C12 (10 mL)at room temperature overnight. It was then quenched with with water (5 mL) and extracted with EtOAc (3 x 10 mL). The extracts were combined and washed with brine (5 mL). The organic solution was concentrated and the title compound was purified by flash chromatography (Si02, Hexanes/EtOAc, 80:20, Rf. 0.50) as a solid (1.1 g, yield, 70%).'H NMR (300 MHz, CD30D) S 7.07-7.12 (m, 1 H), 7.39-7.47 (m, 2H), 7.95 (dd, J=7.8, 1.3 Hz, 1 H) ppm.
15 MS (DCI): m/z 316 (M+H)+.
Example 6C
2-f4-(1-Azabicyclof2.2.21oct-3-yloxy)phenyll-1 H-indole Under N2, the mixture of product from Example 6A (114 mg, 0.5 mmol), the 2o product from Example 6B (157 mg, 0.5 mmol), Cul (Strem Chemicals, 14 mg, 0.075 mmol), PPh3 (Aldrich, 39 mg, 0.15 mmol) and K3P04 (212 mg, 1 mmol) in dioxane (5 mL) was stirred at 80 °C for 20 h. After the reaction was complete, it was diluted with EtOAc (30 mL) and washed with brine (2 x 5 mL). The organic solution was concentrated under reduced pressure and the title compound was purified by 25 chromatography (Si02, CH2C12: MeOH : NH3~H20, 90:10:1, Rf. 0.30) as solid (70 mg, yield, 44%).'H NMR (300 MHz, CD30D) S 1.45-1.59 (m, 1H), 1.65-1.91 (m, 2H), 2.00-2.14 (m, 1 H), 2.17-2.24 (m, 1 H), 2.75-3.01 (m, 5H), 3.31-3.42 (m, 1 H), 4.54-4.62 (m, 1 H), 6.66 (d, J=0.7 Hz, 1 H), 6.93-7.00 (m, 3H), 7.01-7.08 (m, 1 H), 7.35 (dq, J=8.2, 1.0 Hz, 1 H), 7.48 (dq, J=7.8, 0.7 Hz, 1 H), 7.71 (dt, J=8.8, 2.6 Hz, 2H) ppm.
3o MS (DCI/NH3): m/z 319 (M+H)+.
Example 6D
2-f4-(1-Azabicyclof2.2.21oct-3-yloxy)phenyl]-1H-indole fumarate The product of Example 6C (70 mg, 0.22 mmol) was treated with fumaric acid (29 mg, 0.25 mmol) in EtOAc/EtOH (v. 1:1, 3 mL) at ambient temperature for 10 h.
The title compound was obtained as solid (87 mg, yield, 89%).'H NMR (300 MHz, CD30D) S 1.81-2.18(m, 3H), 2.25-2.39 (m, 1 H), 2.48-2.56 (m, 1 H), 3.19-3.48 (m, 5H), 3.73-3.85 (m, 1 H), 4.86-4.93 (m, 1 H), 6.65-6.80 (m, 2H), 6.94-7.10 (m, 4H), 7.36 (dd, J=8.1, 0.7 Hz, 1 H), 7.49 (dt, J=7.8, 1.0 Hz, 1 H), 7.75 (dt, J=9.2, 2.4 Hz,, 2H) ppm. MS (DCI/NH3): m/z 319 (M+H)+. Anal. Calculated for C2~H2zN20~1.1 C4H4O4:
C, 68.39; H, 5.96; N, 6.28. Found: C, 68.10; H, 6.22; N, 6.25.
Example 7 5-f6-(1-Azabicyclof2.2.21oct-3-yloxy)pyridazin-3-yl1-1 H-indole ~5 Example 7A
3-f (6-Chloropyridazin-3-yl)ox~~quinuclidine 3-Quinuclidinol (Aldrich, 508 mg, 4 mmol) was treated with tBuOK (Aldrich, 448 mg, 4 mmol) in THF(20 mL) at ambient temperature for 1 hour. 3,6-Dichloropyradazine (Aldrich, 740 mg, 5 mmol) was then added. The mixture was 2o stirred at ambient temperature for additional 1 h. The reaction was monitored with TLC. After the reaction was complete, it was concentrated under reduced pressure.
The residue was dissolved in CHC13/'PrOH (v.10 : 1, 50 mL) and washed with brine (2 x 5 mL). The organic solution was concentrated under reduced pressure and the title compound was purified by chromatography (Si02, CH2C12 : MeOH : NH3~H20, 25 90:10:1, Rf. 0.45) as a solid (780 mg, yield, 82%).'H NMR (300 MHz, CD30D) b 1.48-1.61 (m, 1 H), 1.65-1.90 (m, 2H), 1.94-2.08 (m, 1 H), 2.23-2.31 (m, 1 H), 2.73-3.01 (m, 5H), 3.37-3.48 (m, 1 H), 5.18-5.27 (m, 1 H), 7.23 (d, J=9.2 Hz, 1 H), 7.65 (d, J=9.2 Hz, 1 H) ppm. MS (DCI/NH3): 240 (M+H)+, 242 (M+H)+.
30 Example 7B
5-f6-(1-Azabicyclof2.2.21oct-3-yloxy)pyridazin-3-yll-1 H-indole The product of Example 7A (200 mg, 0.8 mmol) was coupled with 5-indolylboronic acid (161 mg, 1 mmol) according to the procedure of Example 3A.
The title product was purified by preparative HPLC (Gilson, column, Symmetry~ C-8 pm, 40 x 100 mm. Eluting Solvent, MeCN / H20 (with 0.2% v. TFA) (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (35 mg, yield, 14%).
'H NMR (300 MHz, CD30D) b 1.50-1.65 (m, 1H), 1.70-1.93 (m, 2H), 2.00-2.16 (m, 1 H), 2.29-2.37 (m, 1 H), 2.78-3.05 (m, 5H), 3.44-3.55 (m, 1 H), 5.26-5.35 (m, 1 H), 6.56(dd, J=3.3, 1.1 Hz, 1 H)), 7.25 (d, J=9.2 Hz, 1 H), 7.31 (d, J=3.4 Hz, 1 H), 7.51 (d, J=8.8 Hz, 1 H), 7.73 (dd, J=8.5, 1.7 Hz, 1 H), 8.08 (d, J=9.5 Hz, 1 H), 8.14 (d, J=1.7 Hz, 1 H) ppm. MS (DCI/NH3): m/z 321 (M+H)+.
Example 7C
5-f6-(1-Azabicyclof2.2.21oct-3-yloxy)pyridazin-3-yl~-1 H-indole hemifumarate The product of Example 7B (35mg, 0.11 mmol) was treated with fumaric acid (23 mg, 0.2 mmol) in EtOAc/EtOH (v. 1:1, 3 mL) at ambient temperature for 10 h.
The title compound was obtained as solid (42 mg, yield, 99%). ~H NMR (300 MHz, CD30D) b 1.76-1.91 (m, 1 H), 1.92-2.13 (m, 2H), 2.22-2.36 (m, 1 H), 2.51-2.59 (m, 1 H), 3.12-3.40 (m, 5H), 3.77-3.88 (m, 1 H), 5.42-5.51 (m, 1 H); 6.56 (dd, J=2.0, 1.OHz, 1 H), 6.67 (s, 1 H), 7.27-7.33 (m, 2H), 7.52 (dt, J=8.5, 1.0 Hz, 1 H), 7.74 (dd, J=8.8, 1.7 Hz, 1 H), 8.10-8.16 (m, 2H) ppm. MS (DCI/NH3): m/z 321 (M+H)+. Anal.
Calculated for C~9H2oN40~0.55 C4H404: C, 66.27; H, 5.82; N, 14.58. Found: C, 66.12; H, 5.53; N, 14.63.
Example 8 4-f6-(1-Azabicyclof2.2.21oct-3-ylox~~pyridazin-3-yl1-1 H-indole Example 8A
4-f6-(1-Azabicyclof2.2.21oct-3-yloxy)pyridazin-3-yl1-1 H-indole Under N2, the mixture of Example 7A (168 mg, 0.7 mmol), 4-(4,4,5,5-tetramethyl-[1,3,2Jdioxaborolan-2-yl)-1 H-indole (ref. W002055517, 170 mg, 0.7 mmol), Pd2(dba)3 (Aldrich, 19 mg, 0.02 mmol), 1,3-bis(2,6-iso-propylphenyl)imidazolium chloride (Strem Chemicals, 26 mg, 0.06 mmol) and aqueous Na2C03 (2 M, 1 mL) in toluene (10 mL) was stirred at 110 °C
overnight, After the reaction was complete, it was cooled down to room temperature and diluted with EtOAc (30 mL). The mixture was then washed with brine (2 x 5 mL) and the title compound was purified by chromatography (Si02, CH2C12 : MeOH : NH3~H20, 90:10:1, Rf. 0.10) as solid (45 mg, yield, 20%).'H NMR (300 MHz, CD30D) b 1.51-1.65 (m, 1 H), 1.70-1.93 (m, 2H), 2.01-2.16 (m, 1 H), 2.31-2.39 (m, 1 H), 2.78-3.09 (m, 5H), 3.45-3.56 (m, 1 H), 5.30-5.38 (m, 1 H), 6.78 (dd, J=3.4, 1.0 Hz, 1 H), 7.25 (t, J=7.8 Hz, 1 H), 7.30 (d, J=9.5 Hz, 1 H), 7.36 (d, J=3.1 Hz, 1 H), 7.40 (dd, J=7.5, 1.0 Hz, 1 H), 7.52 (dt, J= 8.1, 1.0 Hz, 1 H), 8.07 (d, J=9.2 Hz, 1 H) ppm. MS
(DCI/NH3):
m/z 321 (M+H)+.
Example 8B
4-(6-(1-Azabicyclo(2.2.21oct-3-yloxy~yridazin-3-yl~-1 H-indole fumarate The product of Example 8A (45 mg, 0.14 mmol) was treated with fumaric acid (23 mg, 0.2 mmol) in EtOAc/EtOH (v. 1:1, 3 mL) at ambient temperature for 10 h.
The title compound was obtained as solid (56 mg, yield, 85%).'H NMR (300 MHz, CD30D) b 1.90-2.23 (m, 3H), 2.33-2.48 (m, 1 H), 2.62-2.70 (m, 1 H), 3.21-3.54 (m, 5H), 3.92-4.03 (m, 1 H), 5.54-5.62 (m, 1 H), 6.69 (s, 2.5H), 6.78 (dd, J=3.4, 1.0 Hz, 1 H), 7.26 (t, J=7.5 Hz, 1 H), 7.35-7.44 (m, 3H), 7.55 (dt, J=8.1, 1.1 Hz, 1 H), 8.13 (d, J=9.2 Hz, 1 H) ppm. MS (DCI/NH3): m/z 321 (M+H)+. Anal. Calculated for C~9H2oN40~1.3 C4H4O4: C, 61.67; H, 5.39; N, 11.89. Found: C, 61.49; H, 5.52;
N, 12.17.
Example 9 5-{6-((3R)-1-Azabicyclo(2.2.21oct-3-yloxylpyridazin-3-yl}-1 H-indole Example 9A
(3R)-3-((6-Chloropyridazin-3-yl)oxy~guinuclidine 3o The product of Example 4A (635 mg, 5 mmol) was coupled with 3,6-dichloropyridazine (Aldrich, 925 mg, 6.25 mmol) according to the procedure of Example 7A. The title compound was purified by chromatography (Si02, CH2C12 MeOH : NH3~H20, 90:10:1, Rf. 0.45) as solid (750 mg, yield, 63%).'H NMR (300 MHz, CD30D) S 1.54-1.68 (m, 1 H), 1.71-1.95 (m, 2H), 2.00-2.14 (m, 1 H), 2.28-2.36 (m, 1 H), 2.83-3.08 (m, 5H), 3.44-3.56 (m, 1 H), 5.23-5.30 (m, 1 H), 7.24 (d, J= 9.2 Hz, 1 H), 7.66 (d, J= 9.2 Hz, 1 H) ppm. MS (DCI/NH3): 240 (M+H)+, 242 (M+H)+.
Example 9B
5-~6-[(3R)-1-Azabicyclo[2.2.21oct-3-ylox~~pyridazin-3- rl -1 H-indole The product of Example 9A (480 mg, 2 mmol) was coupled with 5-indolylboronic acid (Frontier, 403 mg, 2.5 mmol) according to the procedure of Example 3A. The title product was purified by preparative HPLC (Gilson, column, Symmetry~ C-8 7 Nm, 40 x 100 mm. Eluting Solvent, MeCN / H20 (with 0.2% v.
TFA) (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (240 mg, yield, 38%).'H NMR (300 MHz, CD30D) b 1.49-1.64 (m, 1H), 1.68-1.93 (m, 2H), 2.00-2.15 (m, 1 H), 2.28-2.36 (m, 1 H), 2.76-3.05 (m, 5H), 3.43-3.55 (m, 1 H), 5.26-5.34 (m, 1 H), 6.56 (dd, J=3.4, 1.0 Hz, 1 H), 7.25 (d, J=9.2 Hz, 1 H),~7.31 (d, J=3.1 Hz, 1 H), 7.50 (d, J= 8.5 Hz, 1 H), 7.74 (dd, J=8.5, 1.7 Hz, 1 H), 8.08 (d, J=9.5 Hz, 1 H), 8.14 (d, J=1.4 Hz, 1 H) ppm. MS (DCI/NH3): m/z 321 (M+H)+.
2o Example 9C
5-~6-[(3R)-1-Azabicyclo[2.2.21oct-3-yloxylpyridazin-3-yl;-1 H-indole fumarate The product of Example 9B (240 mg, 0.75 mmol) was treated with fumaric acid (93 mg, 0.8 mmol) in EtOAc/EtOH (v. 1:1, 10 mL) at ambient temperature for 15 h. The title compound was obtained as solid (247 mg, yield, 72%).'H NMR (300 MHz, CD30D) b 1.88-2.22 (m, 3H), 2.31-2.47 (m, 1 H), 2.59-2.68 (m, 1 H), 3.23-3.50 (m, 5H), 3.89-4.00 (m, 1 H), 5.49-5.57 (m, 1 H), 6.56(dd, J=3.0, 1.0 Hz, 1 H), 6.69 (s, 2H), 7.29-7.35 (m, 2H), 7.52 (dt, J= 8.5, 1.0 Hz, 1 H), 7.74 (dd, J=8.5, 1.7 Hz, 1 H), 8.12-8.17 (m, 2H) ppm. MS (DCI/NH3): m/z 321 (M+H)+. Anal. Calcd. for C~9H2oN40~1.1 C4H404~0.4 H20: C, 61.73; H, 5.58; N, 12.31. Found: C, 61.67; H, 5.52; N, 12.33.
Example 10 5-~6-((3R)-1-Azabicyclo(2.2.21oct-3-yloxylpyridazin-3-y~-3-methyl-1 H-indole Example 10A
3-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1 H-indole Under N2, a mixture of 5-bromo-3-methyl-1 H-indole (Aldrich, 1.05 g, 5 mmol), bis(pinacolato)diboron (Aldrich, 1.40 g, 5.5 mmol), PdCl2(dppf)~CH2C12 (Aldrich, 122 mg, 0.15 mmol) and KOAc (Aldrich, 1.47 g, 15 mmol) in DMSO (20 mL) was stirred at 90 °C for 1 h. The reaction was monitored with TLC. After the reaction was o complete, it was then diluted with EtOAc (100 mL) and washed with brine (3 x mL). The organic solution was then concentrated and the title compound was purified by flash chromatography (Si02, Hexane : EtOAc, 80:20, Rf. 0.70) as solid (510 mg, yield, 40%). ~H NMR (300 MHz, CDCI3) b 1.38 (s, 12H), 2.35 (s, 3H), 6.98 (s, 1 H), 7.34 (dd, J=8.1, 0.7, Hz, 1 H), 7.65 (dd, J=8.1, 1.0 Hz, 1 H), 8.12 (s, 1 H) ppm.
~5 MS (DCI/NH3): m/z 258 (M+H)+.
Example 10B
5-{6-((3R)-1-Azabicyclo(2.2.2]oct-3-yloxy]pyridazin-3-yl~-3-methyl-1 H-indole The product of Example 10A (240 mg, 1 mmol) coupled with the product of 2o Example 9A (250 mg, 1 mmol) according to the procedure in Example 8A, The title product was purified by preparative HPLC (Gilson, column, Symmetry~ C-8 7 pm, 40 x 100 mm. Eluting Solvent, MeCN / H20 (with 0.2% v. TFA) (v. 90/10 to 10/90 over20 min. flow rate, 75 mL/min., uv, 250 nm) as solid (40 mg, yield, 12%).'H
NMR (300 MHz, CD30D) b 1.50-1.64 (m, 1 H), 1.69-1.92 (m, 2H), 2.01-2.14 (m, 1 H), 25 2.29-2.35 (m, 1 H), 2.37 (s, 3H), 2.81-3.04 (m, 5H), 3.43-3.55 (m, 1 H), 5.27-5.34 (m, 1 H), 7.06 (d, J=1.4 Hz, , 1 H), 7.24 (d, J=9.2 Hz, 1 H), 7.44 (dd, J=8.5, 0.7 Hz, 1 H), 7.71 (dd, J=8.8, 2.0, Hz, 1 H), 8.07-8.12 (m, 2H) ppm. MS (DCI/NH3): m/z 335 (M+H)+.
so Example 10C
5 ~6-((3R)-1-Azabicyclo(2.2.21oct-3-yloxylpyridazin-3-yl~-3-methyl-1 H-indole fumarate v The product of Example 10B (40 mg, 0.12 mmol) was treated with fumaric acid (23 mg, 0.2 mmol) in EtOAc/EtOH (v. 1:1, 5 mL) at ambient temperature for h. The title compound was obtained as solid (40 mg, yield, 62%).'H NMR (300 MHz, CD30D) i5 1.90-2.24 (m, 3H), 2.33-2.48 (m, 4H), 2.61-2.68 (m, 1H), 3.22-3.53 (m, 5H), 3.93-4.03 (m, 1 H), 5.51-5.58 (m, 1 H), 6.70 (s, 3.6 H), 7.08 (d, J=1.0 Hz, 1 H), 7.32 (d, J=9.5 Hz, 1 H), 7.45 (d, J=8.5 Hz, 1 H), 7.72 (dd, J=8.8, 1.7 Hz, 1 H), 8.10 (d, J=1.7 Hz, 1 H), 8.17 (d, J=9.5 Hz, 1 H) ppm. MS (DCI/NH3): m/z 335 (M+H)+.
Anal.
Calculated for C2oH2zN40~ 1.8 C4H4O4: C, 60.13; H, 5.42; N, 10.31. Found: C, 60.02; H, 5.53; N, 10.27.
Example 11 5-f2-((3R)-1-Azabicyclo~2.2.21oct-3-yloxylpyrimidin-5, yl}-1 H-indole Example 11A
(3R)-3-f(5-Bromopyrimidin-2-yl)oxylguinuclidine The product of Example 4A (508 mg, 4 mmol) was coupled with 5-bromo-2-iodo-pyrimidine (Aldrich, 1.42 g, 5 mmol) according to the procedure of Example 7A.
The title compound was purified by chromatography (Si02, CH2C12 : MeOH
NH3~H20, 90:10:1, Rf. 0.40) as solid (760 mg, yield, 67%).'H NMR (300 MHz, 2o CD30D) b 1.54-1.68 (m, 1 H), 1.68-1.95 (m, 2H), 2.03-2.16 (m, 1 H), 2.24-2.33 (m, 1 H), 2.82-3.11 (m, 5H), 3.41-3.52 (m, 1 H), 5.09-5.17 (m, 1 H), 8.65 (s, 2H).
MS
(DCI/NH3): 284 (M+H)+ 286 (M+H)+.
Example 11 B
5-~2-((3R)-1-Azabicyclof2.2.21oct-3-yloxylpyrimidin-5-yl)-1 H-indole The product of Example 11A (283 mg, 1 mmol) was coupled with 5-indolylboronic acid (Aldrich, 193 mg, 1.2 mmol) according to the procedure of Example 3A. The title product was purified by preparative HPLC (Gilson, column, Symmetry~ C-8 7 Nm, 40 x 100 mm. Eluting Solvent, MeCN / H20 (with 0.2% v.
i 3o TFA) (v. 90/10 to 10/90 over 20 min. flow rate, 75 mL/min., uv, 250 nm) as solid (40 mg, yield, 12%). 'H NMR (300 MHz, CD30D) b 1.50-1.63 (m, 1 H), 1.67-1.93 (m, 2H), 2.04-2.17 (m, 1 H), 2.24-2.31 (m, 1 H), 2.75-3.05 (m, 5H), 3.38-3.48 (m, 1 H), 5.14-5.21 (m, 1 H), 6.53 (dd, J=3.1, 0.7 Hz, 1 H), 7.30 (d, J= 3.1 Hz, 1 H), 7.35 (dd, J=8.5, 1.7 Hz, 1 H), 7.51 (dt, J=8.5, 0.7 Hz, 1 H), 7.80 (dd, J=1.7, 0.7 Hz, 1 H), 8.82 (s, 2H) ppm. MS (DCI/NH3): m/z 321 (M+H)+.
Example 11 C
5-f2-((3R)-1-Azabicyclo(2.2.21oct-3-yloxy]pyrimidin-5-yl}-1H-indole hemifumarate The product of 11 B (40 mg, 0.12 mmol) was treated with fumaric acid (12 mg, 0.1 mmol) in EtOAc/EtOH (v. 1:1, 3 mL) at ambient temperature for 10 h. The title compound was obtained as solid (42 mg, yield, 88%). 'H NMR (300 MHz, CD30D) b 1.72-2.10 (m, 3H), 2.20-2.34 (m, 1 H), 2.43-2.51 (m, 1 H), 3.04-3.43 (m, 5H), 3.65-3.76 (m, 1 H), 5.28-5.36 (m, 1 H), 6.52 (dd, J=3.1, 1.1 Hz, 1 H), 6.67 (s, 1 H), 7.30 (d, J=3.1 Hz, 1 H), 7.35 (dd, J=8.5, 1.7 hz, 1 H), 7.51 (dt, J=8.5, 0.7 Hz, 1 H), 7.80 (dd, J=1.7, 0.7 Hz, 1 H), 8.84 (s, 2H) ppm. MS (DCI/NH3): m/z 321 (M+H)+. Anal.
Calcd.
~5 for C~gH2pN4O'O.6 C4H4O4: C, 65.90; H, 5.79; N, 14.36. Found: C, 65.65; H, 5.24;
N, 14.41.
Example 12 4-~2-((3R)-1-Azabicyclo(2.2.2~oct-3-yloxylpyrimidin-5-yl}-1 H-indole Example 12A
4-~2-((3R)-1-Azabicyclo(2.2.21oct-3-yloxylpyrimidin-5-yl}-1 H-indole The product of ExampIe11A (170 mg, 0.6 mmol) was coupled with 4-(4,4,5,5-tetra-methyl-[1,3,2]dioxaborolan-2-yl)-1 H-indole ((ref. W002055517, 146 mg, 0.6 mmol) according to the procedure in Example 8A. The title compound was purified by chromatography (Si02, CH2C12 : MeOH : NH3~H20, 90:10:1, Rf. 0.10) as a solid (76 mg, yield, 40%).'H NMR (300 MHz, CD30D) b 1.50-1.64 (m, 1H), 1.67-1.93 (m, 2H), 2.05-2.19 (m, 1 H), 2.25-2.33 (m, 1 H), 2.73-3.12 (m, 5H), 3.39-3.50 (m, 1 H), 5.17-5.25 (m, 1 H), 6,.55 (dd, J= 3.4, 1.0 Hz, 1 H), 7.11 (dd, J=7.1, 1.0, Hz, 1 H), 7.23 (t, J=8.1 Hz, 1 H), 7.35 (d, J=3.1 Hz, 1 H), 7.44-7.49 (m, 1 H), 8.85 (s, 2H) ppm. MS
(DCI/NH3): m/z 321 (M+H)+.
Example 12B
4-~2-((3R)-1-Azabicyclo(2 2 2loct-3-yloxylpyrimidin-5-yl~ 1 H indole fumarate The product of Example 12A (76 mg, 0.24 mmol) was treated with fumaric s acid (29 mg, 0.25 mmol) in EtOAc/EtOH (v. 1:1, 4 mL) at ambient temperature for 10 hours. The title compound was obtained as solid (94.6 mg, yield, 90%). 'H NMR
(300 MHz, CD30D) b 1.88-2.21 (m, 3H), 2.33-2.48 (m, 1 H), 2.59-2.66 (m, 1 H), 3.22-3.50 (m, 5H), 3.84-3.95 (m, 1 H), 5.41-5.49 (m, 1 H), 6.55 (dd, J=3.4, 1.0 Hz, 1 H), 6.68 (s, 2H), 7.11 (dd, J=7.5, 1.0 Hz, 1 H), 7.24 (t, J= 8.1 Hz, 1 H), 7.36 (d, J=3.1 Hz, 1 H), 7.48 (dt, J=8.1, 0.7 Hz, 1 H), 8.89 (s, 2H) ppm. MS (DCI/NH3): m/z 321 (M+H)+.
Anal. Calculated for C~gH2pN4O'C4H4O4: C, 63.29; H, 5.54; N, 12.84. Found: C, 62.95; H, 5.85; N, 12.61.
Example 13 15 5-f2-((3S)-1-Azabicyclo(2.2 2loct-3-yloxy~pyrimidin-5-yl~-1 H indole Example 13A
(3R)-1-Azabicyclo(2.2.21oct-3-yl benzoate (L)-tartrate (+/-)-3-Quinuclidinol benzoate (Sigma, 17.9 g, 77.5 mmol) was treated with L-2o tartaric acid (Aldrich, 99% ee, 11.63 g, 77.5 mmol) in EtOH (80%, 222 mL) at ambient temperature for 1 week. The white solid was filtered off and dried under reduced pressure. 6.5 g of 3-(R)-quinuclidinol benzoate ~ (L)-tartrate was obtained with --80% ee (assayed by HPLC. HPLC conditions: chiralpak AD column 25cmX4mm ID. solvent, EtOH : hexanes = 15 : 85. flow rate, 1 mL/min. uv, 220 nm.
2s Retention time: (S)-3-quinuclidinol benzoate, 7.87 min; (R)-3-quinuclidinol benzoate 13.3 min.) Recrystallization of the above solid in EtOH (80%, 35 mL) gave the title product (4.5 g , yield, 15%, >98% ee). MS (DCI/NH3) m/z 232 (M+H)+.
Example 13B
30 (3R)-Quinuclidin-3-of The product of the Example 13A (4.5 g, 11.8 mmol) was treated with Hydrolysis was NaOH (15%, 40 mL) MeOH (40 mL)at 50°C for 10h. The methanol was removed under reduced pressure and the residue was extracted with chloroform (4 x 80 mL). The extracts were combined and dried over MgS04 (anhydrous). The drying agents were filtered off and the filtrate was concentrated to give the title product as white solid (1.35 g, yield, .90%). MS (DCI/NH3) m/z 128 (M+H)+.
Example 13C
(3S)-1-Azabicyclof2.2.21oct-3-yl benzoate (D)-tartrate The mother liquid of Example 13A was combined and concentrated under reduced pressure. The residue was then treated with NaOH (1 N, 50 mL) at room temperature for 30 min. It was extracted with chloroform (3 x mL) The extracts were combined and dried (MgS04). The drying agents were filtered off. The filtrates was concentrated to give 3-quinuclidinol benzoate (15.25 g, 66 mmol) It was then treated ~5 with (D)-tartaric acid (Aldrich, 97%ee, 9.9 g, 66 mmol,) in EtOH (80%, 190 ml) at room temperature for 3 days according to the procedure of Example 1A. The title product was obtained (7.0 g, yield, 28%, 92.3% ee).
Example 13D
20 (3S)-Quinuclidin-3-of The product of Example 13C (7.0 g, 18.4 mmol) was treated with NaOH
(aqueous) according to the procedure of Example 1 B. The title product was obtained as white solid (2.0 g, yield, 86% ) MS (DCI/NH3) m/z 128 (M+H)+.
25 Example 13E
(3S)-3-f (5-Bromopyrimidin-2-yl)oxy]quinuclidine The product of Example 13D (508 mg, 4 mmol) was coupled with 2-iodo-5-bromo-pyrimidine (1.42 g, 5 mmol) according to the procedure of Example 7A.The title compound was purified by chromatography (Si02, CH2C12 : MeOH : NH3~H20, 30 90:10:1, Rf. 0.20) as solid (780 mg, yields, 69%)as a solid.'H NMR (300 MHz, CD30D) b 1.47-1.61 (m, 1 H), 1.63-1.90 (m, 2H), 1.96-2.12 (m, 1 H), 2.19-2.27 (m, 1 H), 2.73-3.03 (m, 5H), 3.33-3.45 (m, 1 H), 5.05-5.14 (m, 1 H), 8.64 (s, 2H) ppm. MS
(DCI/NH3): 284 (M+H)+ 286 (M+H)+.
Example 13F
5-{2-[(3S)-1-Azabicyclof2.2.21oct-3-yloxylpyrimidin-5-yl}-1 H-indole The product of ExampIe13E (283 mg, 1 mmol) was coupled with 5-indolylboronic acid (193 mg, 1.2 mmol) according to the procedure of Example 3A, The title product was purified by preparative HPLC (Gilson, column, Symmetry~
7 pm, 40 x 100 mm. Eluting Solvent, MeCN / H20 (with 0.2% v. TFA) (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (120 mg, yield, 38%).'H NMR (300 MHz, CD30D) b 1.50-1.63 (m, 1H), 1.66-1.92 (m, 2H), 2.03-2.18 (m, 1 H), 2.24-2.32 (m, 1 H), 2.75-3.07 (m, 5H), 3.38-3.49 (m, 1 H), 5.13-5.21 (m, 1 H), 6.53 (dd, J=3.0, 0.7 Hz, 1 H), 7.30 (d, J=3.4 Hz, 1 H), 7.35 (dd, J=8.5, 1.7 Hz, 1 H), 7.51 (dt, J=9.2, 0.7 Hz, 1 H), 7.80 (dd, J=1.7, 0.7 Hz, 1 H), 8.81 (s, 2H) ppm. MS
~5 (DCI/NH3): m/z 321 (M+H)+.
Example 13G
5-~2-f(3S)-1-Azabicyclo[2.2.21oct-3-yloxylpyrimidin-5-yl)-1H-indole hemifumarate The product of Example 13F (120mg, 0.38 mmol) was treated with fumaric 2o acid (44 mg, 0.38 mmol) in EtOAc/EtOH (v. 1:1, 10 mL). The title compound was obtained as solid (123 mg, yield, 84%).'H NMR (300 MHz, CD30D) b 1.75-2.13 (m, 3H), 2.22-2.37 (m, 1 H), 2.46-2.54 (m, 1 H), 3.03-3.45 (m, 5H), 3.68-3.79 (m, 1 H), 5.30-5.38 (m, 1 H), 6.52 (dd, J=3.1, 1.1 Hz, 1 H), 6.67 (s, 1.2H), 7.30 (d, J=3.1 Hz, 1 H), 7.35 (dd, J=8.5, 1.7 Hz, 1 H), 7.51 (dt, J= 8.5, 0.7 Hz, 1 H), 7.80 (dd, J=1.7, 0.7 25 Hz, 1 H), 8.82 (s, 2H) ppm. MS (DCI/NH3): m/z 321 (M+H)+. Anal. Calculated for C~gH2pN4O'O.6 C4H4O4: C, 65.90; H, 5.79; N, 14.36. Found: C, 65.62; H, 5.76;
N, 14.40.
Example 14 30 5-f4-(1-Azabicyclof2.2.2]oct-3-yloxy)phenyll-3-methyl-1 H-indazole trifluoroacetate The product of Example 1A (200 mg, 0.61 mmol) was coupled with t-butyl-(3-methyl-5-trimethylstannanyl-indazole)-1-carboxylate (ref. US 2003199511, 294 mg, 1 mmol) according to the procedure of Example 2B. The title product was purified by preparative HPLC (Gilson, column, Symmetry~ C-8 7 pm, 40 x 100 mm. Eluting Solvent, MeCN / H20 (with 0.2% v. TFA) (v. 90/10 to 10/90 over 20 min. flow rate, 75 mL/min., uv, 250 nm) as solid (70 mg, yield, 26%).'H NMR (300 MHz, CD30D) b 1.85-2.13 (m, 3H), 2.22-2.37 (m, 1 H), 2.46-2.50 (m, 1 H), 2.58 (s, 3H), 3.23-3.45 (m, 5H), 3.78-3.86 (m, 1 H), 4.90-5.00 (m, 1 H), 7.07 (dt, J=8.8, 2.0 Hz, 2H), 7.50 (d, J=8.8 Hz, 1 H), 7.61-7.68 (m, 3H), 7.85 (s, 1 H) ppm. MS (DCI/NH3): m/z 334 (M+H)+.
Anal. Calculated for Cz~H23N30~1.0 CF3C02H~0.5 H20: C, 60.52; H, 5.52; N, 9.21.
Found: C, 60.79; H, 5.39; N, 9.17.
Example 15 6-f4-(1-Azabicyclof2.2.21oct-3-yloxy)phen rLl1-1,3-benzothiazol-2-amine Example 15A
3-((4'-Nitro-1,1'-biphenyl-4-yl)oxylquinuclidine 3-Quinuclidinol (Aldrich, 0.51 g, 4 mmol) was coupled with 4'-nitro-1,1'-biphenyl-4-.0l (TCI, 0.43 g, 2 mmol) with DIAD (di-isopropyl azadicarboxylate, 2o Aldrich, 0.81 g, 4 mmol) and Ph3P (Aldrich, 1.04 g, 4 mmol) in THF
(anhydrous, Aldrich, 40 mL) at ambient temperature for two days. The reaction mixture was concentrated. The title product was purified by chromatography (Si02, CH2CI2 MeOH : NH3~H20, 90:10:1, Rf. 0.20) as solid (400 mg, yield, 62%).'H NMR ( 300 MHz , CD30D) 8 1.45-1.57 (m, 1 H), 1.63-1.91 (m, 2H), 1.97-2.12 (m, 1 H), 2.17-2.24 (m, 1 H), 2.66-3.00 (m, 5H), 3.30-3.41 (m, 1 H), 4.56-4.64 (m, 1 H), 7.05 (dt, J=8.8, 2.6 Hz, 2H), 7.68 (dt, J=9.2, 2.6 Hz, 2H), 7.82 (dt, J=8.8, 2.7 Hz, 2H), 8.28 (dt, J=8.8, 2.8 Hz, 2H) ppm. MS (DCI/NH3) m/z 325 (M+H)+.
Example 15B
4'-( 1-Azabicyclo(2.2.21oct-3-yloxy)-1,1'-biphenyl-4-amine The product of Example 15A (300 mg, 0.92 mmol) was treated with Pd/C
(Aldrich, wt.10%, 30 mg) in methanol (20 mL) under H2 at ambient temperature for 30 min. After the reaction was complete, the catalyst was removed through a short column of diatomaceous earth. The filtrate was concentrated under reduced pressure to provide the title compound (200 mg, yield, 74%).'H NMR (300 MHz, CD30D) 8 1.44-1.58 (m, 1 H), 1.63-1.89 (m, 2H), 1.99-2.13 (m, 1 H), 2.15-2.23 (m, 1 H), 2.72-3.04 (m, 5H), 3.29-3.39 (m, 1 H), 4.50-4.58 (m, 1 H), 6.77 (dt, J=
8.8, 2.5 Hz, 2H), 6.91 (dt, J=8.8, 2.4 Hz, 2H), 7.32 (dt, J= 8.5, 2.5 Hz, 2H), 7.43 (dt,J= 9.2, 2.8 Hz, 2H) ppm. MS (DCI/NH3) m/z 295 (M+H)+.
Example 15C
6-f4-(1-Azabicyclof2.2.21oct-3-yloxy)phenyll-1,3-benzothiazol-2-amine The product of Example 15B (200 mg, 0.68 mmol) and KSCN (Aldrich, 140 mg, 1.52 mmol) were dissolved in HOAc (5 mL). Bromine (Aldrich, 99%, 40 NL, 0.76 mmol, in HOAc (1 mL) was added slowly to the above solution over 5 min. The mixture was stirred at ambient temperature for additional 1 h. and then quenched with aqueous NaOH (10%, 20 mL) at 5-10 °C. It was then extracted with CHC13/'PrOH (v. 10 : 1, 2 x 50 mL). The extracts were combined and concentrated under reduced pressure. The title compound was purified by chromatography (Si02, 2o CH2C12: MeOH : NH3~H20, 90:10:1, Rf. 0.10) as solid (140 mg, yield, 59%).'H
NMR
(300 MHz, CD30D) s 1.27-1.37 (m, 1 H), 1.51-1.72 (m, 2H), 1.79-1.88 (m, 1 H), 2.02-2.07 (m, 1 H), 2.51-2.84 (m, 5H), 3.21-3.39 (m, 1 H), 4.45-4.52 (m, 1 H), 6.97(d, J=8.8 Hz, 2H), 7.35 (d, J=8.5 Hz, 7.45 (dd, J=8.5, 2.1 Hz, 1 H), 7.55 (d, J=8.5, 2H), 7.90 (d, J=2.0 Hz, 1 H) ppm. MS (DCI/NH3) m/z 352 (M+H)+.
Example 15D
6-f4-( 1-Azabicyclo f 2.2.21oct-3-yloxy)phenyll-1,3-benzothiazol-2-amine bistrifluoroacetate The product of Example 15C (140 mg, 0.4 mmol) was treated with 3o trifluroacetic acid (Aldrich, 99%, 114 mg, 80 NL, 1 mmol) in'PrOH (5 mL) at ambient temperature for 15 h. The title compound was obtained as solid (90 mg, yield, 39%).
'H NMR (300 MHz, DMSO-D6) b 1.75-2.16 (m, 3H), 2.30-2.52 (m, 2H), 3.03-3.45 (m, 5H), 3.75-3.82 (m, 1 H), 4.78-4.85 (m, 1 H), 7.05 (d, J=8.8 Hz, 2H), 7.38 (d, J=8.5 Hz, 1 H), 7.50 (dd, J=8.5, 2.1 Hz, 1 H), 7.62 (d, J=8.8 Hz, 2H), 7.76 [s(broad.), 2H), 7.96 (d, J=1.7 Hz, 1 H) ppm. MS (DCI/NH3): m/z 352 (M+H)+. Anal. Calculated for C2oH2~N30S~2.08 CF3C02H C, 49.30; H, 3.95; N, 7.14. Found: C, 49.70; H, 3.42;
N, 7.03.
Example 16 6-~4-((3R)-1-Azabicyclo(2.2.21oct-3-yloxylphenyl~-1,3-benzothiazol-2-amine Example 16A
(3R)-3-((4'-Nitro-1,1'-biphenyl-4-yl)oxy~quinuclidine The product of Example 4A (1.28 g, 10 mmol) was coupled with 4-iodo-4'-nitro-biphenyl (TCI, 1.62 g, 5 mmol) according to the procedure of Example 1A.
The title product was purified by chromatography (Si02, CH2CI2 : MeOH : NH3~H20, 90:10:1, Rf. 0.20) as solid (930 mg, yield, 57%).'H NMR ( 300 MHz , CD30D) ~
1.45-1.57 (m, 1 H), 1.63-1.91 (m, 2H), 1.97-2.12 (m, 1 H), 2.17-2.24 (m, 1 H), 2.66-3.00 (m, 5H), 3.30-3.41 (m, 1 H), 4.56-4.64 (m, 1 H), 7.05 (dt, J=8.8, 2.6 Hz, 2H), 7.68 (dt, J=9.2, 2.6 Hz, 2H), 7.82 (dt, J=8.8, 2.7 Hz, 2H), 8.28 (dt, J=8.8, 2.8 Hz, 2H) ppm. MS (DCI/NH3) m/z 325 (M+H)+.
Example 16B
4'-((3R)-1-Azabicyclo(2.2.21oct-3-yloxyl-1,1'-biphenyl-4-amine The product of Example 16A (580 mg, 1.79 mmol) was treated with Pd/C
(Aldrich, wt.10%, 100 mg) in ethanol (50 mL) under H2 at ambient temperature for 30 2s min. After the reaction was complete, the catalyst was removed through a short column of diatomaceous earth. The filtrate was concentrated under reduced pressure to provide the title compound (520 mg, yield, 99%).'H NMR (300 MHz, CD30D) 8 1.44-1.58 (m, 1 H), 1.63-1.89 (m, 2H), 1.99-2.13 (m, 1 H), 2.15-2.23 (m, 1 H), 2.72-3.04 (m, 5H), 3.29-3.39 (m, 1 H), 4.50-4.58 (m, 1 H), 6.77 (dt, J=
8.8, 2.5 3o Hz, 2H), 6.91 (dt, J=8.8, 2.4 Hz, 2H), 7.32 (dt, J= 8.5, 2.5 Hz, 2H), 7.43 (dt,J= 9.2, 2.8 Hz, 2H) ppm. MS (DCI/NH3) m/z 295 (M+H)+. -Example 16C
6-{~3R)-1-Azabicyclo(2.2.21oct-3-yloxylphenyl}-1,3-benzothiazol-2-amine tri(trifluoroacetate) The product of Example 16B (250 mg, 0.85 mmol) and KSCN (Aldrich, 165 mg, 1.70 mmol) were dissolved in HOAc (5 mL). Bromine [Aldrich, 99%, 47 NL, 0.90 mmol, in HOAc (1 mL)] was slowly added to the above solution over 5 min. The mixture was stirred at ambient temperature for additional 2 hours, and quenched with aqueous NaOH (10%, 20 mL) at 5-10 °C. It was then extracted with CHCI3fPrOH (v.
: 1, 2 x 50 mL). The extracts were combined and concentrated under reduced pressure. The title product was purified by preparative HPLC (Gilson, column, Symmetry~ C-8 7 pm, 40 x 100 mm. Eluting Solvent, MeCN / H20 (with 0.2% v.
TFA) (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (150 mg, yield, 19%). 'H NMR (300 MHz, DMSO-D6) b 1.84 - 2.20 (m, 3 H), 2.22 -~5 2.44 (m, 1 H), 2.47 - 2.69 (m, 1 H), 3.32 - 3.51 (m, 5 H), 3.74 - 3.93 (m;
1 H), 4.89 -5.02 (m, 1 H), 7.01 - 7.15 (m, 2 H), 7.53 (d, J=8.5 Hz, 1 H), 7.59 - 7.66 (m, 2 H), 7.69 (dd, J=8.5, 1.7 Hz, 1 H), 7.98 (d, J=2.0 Hz, 1 H) ppm. MS (DCIlNH3): m/z 352 (M+H)~. Anal. Calculated for C2oH2~N30S~3.00 CF3C02H C, 45.03; H, 3.49; N, 6.06.
Found: C, 44.70; H, 3.42; N, 6.00.
Example 17 6-~~4-f (3R)-1-Azabicyclo[2.2.21oct-3-yloxylphenyl)-4-thiocyanato-1,3-benzothiazol-2-amine trifluoroacetate The product of Example 16B (250 mg, 0.85 mmol) and KSCN (Aldrich, 165 mg, 1.70 mmol) were dissolved in HOAc (5 mL). Bromine [Aldrich, 99%, 47 pL, 0.90 mmol, in HOAc (1 mL)] was added slowly to the above solution over 5 min.
according to procedure of Example 16C. The title product was purified by preparative HPLC (Gilson, column, Symmetry~ C-8 7 pm, 40 x 100 mm. Eluting Solvent, MeCN / H20 (with 0.2% v. TFA) (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (55 mg, yield, 12%).'H NMR (300 MHz, MeOH-D4) b 1.79 - 2.24 (m, 3 H), 2.22 - 2.44 (m, 1 H), 2.46 - 2.65 (m, , 1 H), 3.30 - 3.52 (m, H), 3.74 - 3.90 (m, 1 H), 4.93 (dd, J=9.2, 5.1 Hz, 1 H), 6.96 - 7.23 (m, 2 H) 7.48 -7.70 (m, 3 H) 7.88 (d, J=1.7 Hz, 1 H) ppm. MS (DCI/NH3): m/z 409 (M+H)+.
Example 18 5 6-f4-((3RD-1-Azabicyclo(2.2.21oct-3-yloxy~phen r~l -4-bromo-1,3-benzothiazol-2-amine bis(trifluoroacetate~
The product of Example 16B (250 mg, 0.85 mmol) and KSCN (Aldrich, 165 mg, 1.70 mmol) were dissolved in HOAc (5 mL). Bromine [Aldrich, 99%, 47 pL, 0.90 mmol, in HOAc (1 mL) was added slowly to the above solution over 5 min.
o according to procedure of Example 16C. The title product was purified by preparative HPLC (Gilson, column, Symmetry~ C-8 7 Nm, 40 x 100 mm. Eluting Solvent, MeCN
/ H20 (with 0.2% v. TFA) (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (50 mg, yield, 9%).'H NMR (300 MHz, MeOH-D4) S 1.78 - 2.21 (m, 3 H), 2.23 - 2.44 (m, 1 H), 2.47 - 2.63 (m, 1 H), 3.23 - 3.53 (m, 5 H), 3.66 -3.97 (m, 1 H), 4.88 - 5.03 (m, 1 H), 6.96 - 7.22 (m, 2 H), 7.52 - 7.65 (m, 2 H), 7.68 (d, J=1.7 Hz, 1 H), 7.82 (d, J=1.7 Hz, 1 H) ppm. MS (DC.I/NH3): m/z 430 (M+H)+, 432 (M+H)+.
Anal. Calculated for C2oH2oBrN30S~2.00 CF3C02H C, 43.78; H, 3.37; N, 6.38.
Found: C, 44.70; H, 3.42; N, 6.32.
2o Example 19 N-(4-(3-Methyl-1 H-indazol-5-yl)phenyllquinuclidin-3-amine Example 19A
N-(,4-lodophenyl)quinuclidin-3-amine 3-Quinuclidinone hydrochloride (Aldrich, 3.22 g, 20 mmol) was treated with 4-iodo-aniline (Aldrich, 2.19 g, 10 mmol), Na2S04 (anhydrous, Aldrich, 7.40 g, mmol) and NaBH(OAc)3 (Aldrich, 3.16 g, 15 mmol) in HOAc (25 mL) at ambient temperature for 15 h. After the reaction was complete, the reaction mixture was slowly poured into a flask containing 75 mL of saturated NaHC03 and stirred for 20 3o min. It was then extracted with EtOAc (3 x 100 mL). The extracts were combined and washed with brine (2 x 20 mL). The organic solution was concentrated under reduced pressure and the title compound was purified by chromatography (Si02, CH2C12 : MeOH : NH3~H20, 90:10:2, Rf. 0.10) as oil (3.24 g, yield, 98%).'H NMR
(300 MHz, CD30D,) 8 1.70-1.81 (m, 1 H), 1.93-2.04 (m, 2H), 2.08-2.24 (m, 2H), 2.89 (ddd, J=12.9, 5.1, 2.7 Hz, 1 H), 3.12-3.28 (m, 4H), 3.64 (ddd, J=12.9, 9.5, 2.4 Hz, 1 H), 3.79-3.85 (m, 1 H), 6.46 (dt, J=9.0, 2.7 Hz, 2H), 7.39 (dt, J=9.1, 2.7 Hz, 2H) ppm. MS (DCI/NH3) m/z 329 (M+H)+.
Example 19B
N-[4~3-Methyl-1H-indazol-5-yl)phenyllguinuclidin-3-amine trifluoroacetate The product of Example 19A (200 mg, 0.61 mmol) was coupled with t-Butyl-(3-Methyl-5-trimethylstannanyl-indazole)-1-carboxylate (ref. US 2003199511, mg, 1 mmol) according to the procedure of Example 2B. The title product Was purified by preparative HPLC (Gilson, column, Symmetry~ C-8 7 pm, 40 x 100 mm.
Eluting Solvent, MeCN / H20 (with 0.2% v. TFA) (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (28 mg, yield, 10%).'H NMR (300 MHz, CD30D) S 1.85-1.96 (m, 1 H), 2.08-2.15 (m, 2H), 2.24-2.40 (m, 2H), 2.59 (s, 3H), 3.02-3.15 (m, 1 H), 3.20-3.45 (m, 4H), 3.78-3.88 (m, 1 H), 3.98-4.06 (m, 1 H), 6.77 (dt, J=8.8, 2.0 Hz, 2H), 7.46-7.52 (m, 3H), 7.59 (dd, J=8.9, 1.6 Hz, 1 H), 7.78 (s, 1 H) ppm. MS (DCI/NH3): m/z 333 (M+H)+. Anal. Calculated for C2~H24N4~1.25 CF3C02H:
2o C, 59.43; H, 5.36; N, 11.80. Found: C, 59.20; H, 4.96; N, 11.62.
Example 20 (R)- 3-[6~3-Methyl-1 H-indazol-5-yl~pyridazin-3-yloxyl-1-aza-bicyclo[2.2.21octane fumarate Example 20A
3-Methyl-5-trimethylstannanyl-indazole-1-carboxylic acid tert-butyl ester 5-Bromo-3-methyl-indazole-1-carboxylic acid tert-butyl ester (3.0 g, 9.6 mmol) was coupled with hexamethylditin (Aldrich, 4.73 g, 14.4 mmol) catalyzed by 3o Pd(PPh3)a (Aldrich, 1.1 g, 0.96 mmol) in anhydrous toluene (Aldrich, 50 mL) at 115 °C (oil bath) under N2 for 2 h. After the reaction went to completion, the black reaction mixture was cooled down to ambient temperature and directly loaded to a flash silica gel column (5-30% EtOAc in hexane) for purification to provide the title compound (3.06 g, 80%). 'H NMR (MeOH-da, 300 MHz) 0.23 - 0.45 (m, 9 H) 1.71 (s, 9 H) 2.59 (s, 3 H) 7.67 (d, J=8.1 Hz, 1 H) 7.87 (s, 1 H) 8.06 (d, J=8.5 Hz, 1 H) ppm.
s MS (DCI/NH3) m/z 397(M+H)+.
Example 20B
(,R)-3-[6-(,3-Methyl-1 H-indazol-5-yl)-pyridazin-3-yloxy~-1-aza-bicyclo[2.2.21octane The product of Example 9A (120 mg, 0.5 mmol) was coupled with the product 0 of Example 20A (278 mg, 0.7 mmol) under the catalysis of by Pd2(dba)3 (Aldrich, 24 mg, 0.025 mmol) and (tBu3P)2 Pd (Strem Chemicals, 26 mg, 0.05 mmol) with CsF
(Strem Chemicals, 152 mg, 1 mmol) in dioxane (10 ml) at 80°C under N2 for 16 hours. After the reaction went to completion, it was diluted with EtOAc (50 mL) and washed v~iith brine (2 x 10 mL). The organic solution was concentrated under 15 vacuum and the residue was treated with TFA (1 mL) in CH2C12 (5 mL) at ambient temperature for 2 hours. It was then concentrated. The title product was purified by preparative HPLC (XterraTM, column, Xterra RP-18 5 pm, 30 x 100 mm. Eluting Solvent, MeCN / H20 (NH4HC03, 0.1 M, pH=10) (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (68 mg, 41 %). 'H NMR (MeOH-D4, 2o MHz) 1.50 - 1.66 (m, 1 H) 1.70 - 1.94 (m, 2 H) 2.01 - 2.15 (m, 1 H) 2.29 -2.37 (m, 1 H) 2.62 (s, 3 H) 2.81 - 3.04 (m, 5 H) 3.44 - 3.56 (m, 1 H) 5.28 - 5.36 (m, 1 H) 7.28 (d, J=9.2 Hz, 1 H) 7.59 (d, J=8.8 Hz, 1 H) 8.05 (dd, J=8.8, 1.4 Hz, 1 H) 8.16 (d, J=9.2 Hz, 1 H) 8.31 (s, 1 H) ppm. MS (DCI/NH3) m/z 336 (M+H)+.
2s Example 20C
(R)-3-[6-(3-Methyl-1 H-indazol-5-yl~pyridazin-3-yloxyl-1-aza-bicyclo[2.2.2]octane fi imarato The product of Example 20B (68 mg, 0.11 mmol) was treated with fumaric acid (Aldrich, 14 mg, 0.12 mmol) in EtOAc/MeOH (v.10:1, 5 mL) to provide the title 3o compound as solid (59.1 mg, 65%). 'H NMR (MeOH-D4, 300 MHz) 1.82 - 2.18 (m, 3 H) 2.27 - 2.42 (m, 1 H) 2.55 - 2.66 (m, 4 H) 3.21 - 3.43 (m, 5 H) 3.82 -3.95 (m, 1 H) 5.47 - 5.57 (m, 1 H) 6.68 (s, 2 H) 7.34 (d, J=9.2 Hz, 1 H) 7.60 (d, J=8.8 Hz, 1 H) 8.06 (dd, J=8.8, 1.7 Hz, 1 H) 8.21 (d, J=9.2 Hz, 1 H) 8.32 (s, 1 H) ppm. MS
(DCI/NH3) m/z 336(M+H)+. Anal. Calculated for C~gH2~N5O'1.0 CaH404~0.35 H20:
C, 60.35; H, 5.66; N, 15.30. Found: C, 60.06; H, 5.40; N, 15.56.
Example 21 (R)-3-(6-(1-Methyl-1 H-indol-5-yl)-pyridazin-3-yloxyl-1-aza-bicyclo(2.2.21octane trifluoroacetate The product of Example 4A (120 mg, 0.5 mmol) was coupled with N-methyl-o indole-5-boronic acid (Aldrich, 250 mg, 1.5 mmol) catalyzed by Pd2(dba)3 (24 mg, 0.025 mmol) and (tBu3P)2Pd (26 mg, 0.05 mmol) with CsF (Strem Chemicals, 228 mg,.1.5 mmol) in dioxane (8 mL) at 80°C under N2 for 16 hours according to the procedure of Example 20B. The title product was purified by preparative HPLC
(XterraTM, column, Xterra RP-18 5 Nm, 30 x 100 mm. Eluting Solvent, MeCN / H20 (with 0.2% v. TFA) (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, nm) as solid (109.9 mg, 49%).'H NMR (MeOH-D4, 300 MHz) 1.91 - 2.25 (m, 3 H), 2.34 - 2.48 (m, 1 H), 2.61 - 2.70 (m, 1 H), 3.33 - 3.56 (m, 5 H), 3.86 (s, 3 H), 3.94 -4.04 (m, 1 H), 5.50 - 5.59 (m, 1 H), 6.56 (d, J=3.1 Hz, 1 H), 7.25 (d, J=3.1 Hz, 1 H), 7.29 - 7.36 (m, 1 H), 7.52 (d, J=8.8 Hz, 1 H), 7.81 (dd, J=8.6, 1.9 Hz, 1 H), 8.10 -8.19 (m, 2 H) ppm. MS (DCI/NH3) m/z 335 (M+H)+. Anal. Calculated for C2oH22N40~1.075 C2F302H: C, 58.22; H, 5.09; N, 12.26. Found: C, 58.21; H, 5.00;
N, 12.30.
Example 22 (R)-{5-(6-(1-Aza-bicyclo(2.2.21oct-3-yloxy)-pyridazin-3-yl~-1 H-indol-3-ylmethyl)-dimethyl-amine bis(fumarate) Example 22A
(R)-{5-(6-(1-Aza-bicyclo(2.2.21oct-3-yloxy)-pyridazin-3-yl~-1 H-indol-3-ylmethyl~
3o dimethyl-amine The product of Example 9B (150 mg, 0.47 mmol) was treated with HCHO
(Aldrich, 37%, 76 mg, 0.94 mmol) and dimethylamine (Aldrich, 42 mg, 0.94 mmol) in dioxane/HOAc (v. 1:1, 5 mL) at ambient temperature for 16 hours. It was then concentrated and the title product was purified by preparative HPLC (XterraTM, column, Xterra RP-18 5 Nm, 30 x 100 mm. Eluting Solvent, MeCN / H20 (NH4HC03, 0.1 M, pH=10) (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (80 mg, 45%). ~H NMR (MeOH-D4, 300 MHz) 1.59 - 1.75 (m, 1 H), 1.77 -1.99 (m, 2 H), 2.07 - 2.23 (m, 1 H), 2.36 - 2.44 (m, 1 H), 2.60 - 2.69 (m, 6 H), 2.91 - 3.13 (m, 5 H), 3.52 - 3.65 (m, 1 H), 4.22 (s, 2 H), 5.32 - 5.40 (m, 1 H), 7.30 (d, J=9.5 Hz, 1 H), 7.49 (s, 1 H), 7.56 (d, J=8.5 Hz, 1 H), 7.81 (dd, J=8.5, 1.7 Hz, 1 H), 8.15 (d, J=9.5 Hz, 1 H), 8.29 (s, 1 H) ppm. MS (DCI/NH3) m/z 378(M+H)+.
Example 22B
(R)-f5-[6-(1-Aza-bicyclo[2.2.2]oct-3-yloxy)-pyridazin-3-yl~-1 H-indol-3-ylmethyl}-dimethyl-amine bis(fumarate) The product of Example 22A (80 mg, 0.21 mmol) was treated with fumaric acid (Aldrich, 49 mg, 0.42 mmol) in EtOAc / MeOH (v. 10:1 ) to give the title compound as white solid (74.8 mg, 53%). 'H NMR (MeOH-D4, 300 MHz) 1.79 - 2.17 (m, 3 H), 2.25 - 2.41 (m, 1 H), 2.54 - 2.61 (m, 1 H), 2.84 (s, 6 H), 3.19 -3.42 (m, 5 2o H), 3.78 - 3.90 (m, 1 H), 4.50 (s, 2 H), 5.45 - 5.54 (m, 1 H), 6.66 (s, 5 H), 7.34 (d, J=9.2 Hz, 1 H), 7.54 - 7.63 (m, 2 H), 7.84 (dd, J=8.5, 1.7 Hz, 1 H), 8.17 (d, J=9.2 Hz, 1 H), 8.35 (s, 1 H) ppm. MS (DCI/NH3) m/z 378(M+H)+. Anal. Calculated for C22HZ~N50~2.5 C4H404~0.5 H20: C, 56.80; H, 5.66; N, 10.35. Found: C, 56.62; H, 5.78; N, 10.09.
Example 23 (R)-3-~6-(1 H-Indol-5-yl)-pyridazin-3-yloxyl-1-aza-bicyclo[2.2.21octane 1-oxide trifluoroacetate The product of Example 9B was treated with H202 (Aldrich, aq. 30% 1 mL, 8.8 mmol) in acetonitrile (3 mL) for 5 h. The mixture was quenched by Na2S03 solution carefully until no more peroxide was noticed, and it was then concentrated under vacuum. The title product was purified by preparative HPLC (XterraTM, column, Xterra RP-18, 5 pm, 30 x 100 mm. Eluting Solvent, MeCN / H20 (with 0.2%
v. TFA), (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (15.6 mg, 13%).'H NMR (MeOH-d4, 300 MHz) 2.14 - 2.38 (m, 3 H) 2.55 - 2.71 (m, s H) 3.68 - 3.92 (m, 5 H) 4.37 - 4.47 (m, J=8.5 Hz, 1 H) 5.62 - 5.70 (m, J=4.4 Hz, 1 H) 6.57 (d, J=2.0 Hz, 1 H) 7.30 - 7.38 (m, 2 H) 7.52 (d, J=8.5 Hz, 1 H) 7.74 (dd, J=8.6, 1.9 Hz, 1 H) 8.13 - 8.20 (m, 2 H) ppm. MS (ESI) m/z 337(M+H)+. Anal.
Calculated for Ci9H2oN402~1.15 CF3C02H: C, 54.72; H, 4.56; N, 11.98. Found: C, 54.72; H, 4.07;
N, 12.08.
Example 24 6-{6-f (3R)-1-Aza-bicyclo f 2.2.21oct-3-yloxyl-pyridazin-3-yl~-benzothiazol-2-ylamine tri(hydroAen chloride) ~5 Example 24A
6-(4-Bromo-phenyl)-4,5-dihydro-2H-pyridazin-3-one 4-(4-Bromo-phenyl)-4-oxo-butyric acid (Aldrich, 25.0 g, 97.3 mmol) was treated with NH2NH2~H20 (Aldrich, 55%, 9.1 mL, 156 mmol) in EtOH (Aldrich, 100 mL) at refluxing for 2h. It was cooled down to ambient temperature and the white 2o solid was filtered off to give the title compound (24.2 g, 98%)'H NMR
(CDC13, 300 MHz) 8 2.50 - 2.76 (m, 2 H), 2.85 - 3.09 (m, 2 H), 7.43 - 7.71 (m, 4 H), 8.55 (s, 1 H) ppm. MS (DCI/NH3) m/z 253 (M+H)+, 255 (M+H)+, 270 (M+NH4)+, 272 (M+NH4)+.
Example 24B
25 6-(4-Bromo-phenyl)-4,5-dihydro-2H-pyridazin-3-one The product of Example 24A (24.0 g, 95 mmol) was oxidized with bromine (Aldrich, 18.81g, 6.1 mL, 104.5 mmol) in HOAc (Aldrich, 200 mL) at 100°C for 1h.
The brown mixture was then cooled down to ambient temperature. The white solid was filtered off and the filtrate was washed with water (2 x 20 mL). The solid was so collected and dried under vacuum to give the title compound (25.0 g, 100%).'H
NMR (CDC13, 300 MHz) 8 7.07 (d, J=10.2 Hz, 1 H), 7.55 - 7.69 (m, 4 H), 7.72 (d, J=9.8 Hz, 1 H) ppm. MS (DCI/NH3) m/z 251 (M+H)+, 253 (M+H)+, 268 (M+NH4)+, 270 (M+NHa)+.
Example 24C
3-(4-Bromo-phenyl)-6-chloro-pyridazine The product of Example 24B (25.Og, 100 mmol) was stirred in POC13 (Aldrich, 200 mL) at 100°C for 18 h. Most of POC13 was then distilled off (around 150 mL was collected). The residue was then poured into 300 mL of ice/water and stirred vigorously for 1 h. The solid was filtered off. The filtrate was washed with water (2 x 0 50 mL) and dried under vacuum to give the title compound (26.2 g, 98%).'H
NMR
(MeOH-D4, 300 MHz) 8 7.72 (d, J=8.8 Hz, 2 H), 7.86 (d, J=8.8 Hz, 1 H), 8.02 (d, J=8.8 Hz, 2 H), 8.19 (d, J=9.2 Hz, 1 H) ppm. MS (DCI/NH3) m/z 269 (M+H)+, 271 (M+H)+, 273 (M+H)+.
Example 24D
(3R)-3-(6-(4-Bromo-phenyl)-pyridazin-3-yloxyl-1-aza-bicycl~2.2.2]'octane The product of Example 24C (2.43 g, 9 mmol) was coupled with the product of Example 4A (1.27g, 10 mmol) using t-BuOK (Aldrich, 1.12g, 10 mmol) as base in THF (anhydrous, Aldrich, 50 mL) according to the procedure of Example 7A. The title 2o compound was purified by chromatography (Si02, CH2C12 : MeOH : NH3~H20, 90:10:2, Rf. 0.30) as slightly yellow solid (3.30g, 100%).'H NMR (MeOH-D4, 300 MHz) 1.47 - 1.66 (m, 1 H), 1.66 - 1.93 (m, 2 H), 1.96 - 2.18 (m, 1 H), 2.23 -2.42 (m, 1 H), 2.71 - 3.06 (m, 5 H), 3.38 - 3.58 (m, 1 H), 5.17 - 5.47 (m, 1 H), 7.28 (d, J=9.2 Hz, 1 H), 7.59 - 7.78 (m, 2 H), 7.82 - 7.99 (m, 2 H), 8.06 (d, J=9.2 Hz, 1 H) ppm. MS
(DCI/NH3) m/z 360 (M+H)+, 362 (M+H)+.
Example 24E
~4-(6-((3R)-1-Aza-bicyclo(2.2.21oct-3-yloxyl-pyridazin-3-yl1-phenyl)-benzhydrylidene-amine 3o The product of Example 24D (360 mg, 1 mmol) was coupled with benzhydrylideneamine (Aldrich, 270 mg, 1.5 mmol) under the catalysis of Pd2(dba)3 (Aldrich, 18.3 mg, 0.02 mmol) and Xantphos (Strem Chemicals, 36 mg, 0.06 mmol) with t-BuONa (Aldrich, 150 mg, 1.5 mmol) in toluene (anhydrous, Aldrich, 10 mL) at 100°C for 2h. The mixture was then cooled down to ambient temperature and diluted with EtOAc (50 mL), washed with water (2 x 5 mL). The organic solution was concentrated and the title compound was purified by chromatography (SiO2, MeOH : NH3~H20, 90:10:1, Rf. 0.4) as a solid (360 mg, yield, 78%).'H NMR (300 MHz, CD30D) b 1.45 - 1.63 (m, 1 H), .1.64 - 1.94 (m, 2 H), 1.94 - 2.13 (m, 1 H), 2.23 - 2.41 (m, 1 H), 2.71 - 3.06 (m, 5 H), 3.39 - 3.55 (m, 1 H), 5.10 - 5.37 (m, 1 H), 6.82 -6.93 (m, 2 H), 7.12 - 7.23 (m, 3 H), 7.25 - 7.35 (m, 3 H), 7.39 - 7.57 (m, 3 H), 7.67 -7.74 (m, 2 H), 7.74 - 7.83 (m, 2 H), 7.96 (d, J=9.2 Hz, 1 H) ppm. MS
(DCI/NH3): 461 (M+H )+.
Example 24F
4-{6-[(3R)-1-Aza-bicyclo[2.2.21oct-3-yloxy]-pyridazin-3-yl}-phenylamine ~5 The product of Example 24E (360 mg, 0.78 mmol) was treated with HCI (aq.
10%, 5 mL) in THF (5 mL) at ambient temperature for 4 h. It was then concentrated and the title compound was purified by chromatography (Si02, CH2C12 : MeOH
NH3~H20, 90:10:1, Rf. 0.1 ) as solid (210 mg, yield, 90%). 'H NMR (300 MHz, CD30D) b 1.44 - 1.66 (m, 1 H), 1.65 - 1.94 (m, 2 H), 1.95 - 2.16 (m, 1 H), 2.20 = 2.40 20 (m, 1 H), 2.68 - 3.06 (m, 5 H), 3.37 - 3.57 (m, 1 H), 5.15 - 5.37 (m, 1 H), 6.65 - 6.89 (m, 2 H), 7.18 (d, J=9.5 Hz, 1 H), 7.55 - 7.81 (m, 2 H), 7.93 (d, J=9.2 Hz, 1 H) ppm.
MS (DCI/NH3): 297 (M+H)+.
Example 24G
25 6-~6-[(3R)-1-Aza-bicyclo[2.2.21oct-3-yloxy]=pyridazin-3-yl)-benzothiazol-2-ylamine The product of Example 24F (150 mg, 0.5 mmol) was treated with KSCN
(Aldrich, 97 mg, 1 mmol) and bromine (Aldrich, 96 mg, 0.6 mmol) in HOAc (5 mL) at ambient temperature for 0.5 h. it was then quenched with Na2S03 (aq. 10%, 1 mL) and concentrated. The title compound was purified by chromatography (Si02, so : MeOH : NH3~H20, 90:10:2, Rf. 0.1) as solid (170 mg, yield, 80%).'H NMR
(300 MHz, CD30D) S 1.60-1.70 (m, 1 H), 1.72 - 1.98 (m, 2 H), 2.02 - 2.19 (m, 1 H), 2.23 -2.42 (m, 1 H), 2.82 - 3.13 (m, 5 H), 3.42 - 3.68 (m, 1 H), 5.15 - 5.54 (m, 1 H), 7.26 (d, J=9.2 Hz, 1 H), 7.49 (d, J=8.5 Hz, 1 H), 7.87 (dd, J=8.6, 1.9 Hz, 1 H), 8.07 (d, J=9.5 Hz, 1 H), 8.23 (d, J=1.4 Hz, 1 H) ppm. MS (DCI/NH3): 354 (M+H)+.
Example 24H
6-~6-[ 3R)-1-Aza-bicyclof2.2.21oct-3-yloxyl-pyridazin-3-yl}-benzothiazol-2-ylamine tri(hydrogen chloride) The product of Example 24G (170 mg, 0.48 mmol) was treated with HCI
(Aldrich, 4 M in dioxane, 0.5 mL, 2 mmol) in EtOAc (anhydrous, Aldrich, 5 mL) at o ambient temperature for 0.5 h to give the title compound as a yellow solid (170 mg, yield, 77%). ~H NMR 8 1.88 - 2.29 (m, 3 H) 2.30-2.42 (m, 1 H) 2.57 - 2.75 (m, 1 H), 3.33 - 3.60 (m, 5 H), 3.99 (dd, J=14.2, 8.1 Hz, 1 H), 5.41 - 5.71 (m, 1 H), 7.50 (d, J=9.2 Hz, 1 H), 7.68 (d, J=8.8 Hz, 1 H), 8.16 (dd, J=8.5, 1.7 Hz, 1 H), 8.26 (d, J=9.2 Hz, 1 H), 8.48 (d, J=1.4 Hz, 1 H) ppm; MS (DCI/NH3): 354 (M+H)+. Anal.
Calculated for C~gH~gN5OS 3.00 HC1~1.00 H20: C, 44.96; H, 5.03; N, 14.56. Found: C, 44.70;
H, 5.17; N, 14.24.
Example 25 (,3R)-3-[6-(3-Bromo-1 H-indol-5-yl)-pyridazin-3-yloxyl-1-aza-bicyclo[2.2.21octane 2o tri(hydrog~en chloride) Example 25A
(3R~1-3-[6-(3-Bromo-1 H-indol-5-yl)-pyridazin-3-yloxy~-1-aza-bicyclo[2.2.21octane The product of Example 9B (160 mg, 0.5 mmol) was dissolved in MeCN (10 2s mL) and treated with HOAc (Sigma, 60 mg, 1 mmol) for 10 min.
N-bromosuccinimide (Aldrich, 110 mg, 0.6 mmol) in MeCN (Aldrich, 5 mL) was slowly added over 5 min. The mixture was stirred for 1 hour at ambient temperature and concentrated under vacuum. The title compound was purified by chromatography (Si02, CH2C12: MeOH : NH3~H20, 90:10:1, Rf. 0.15) as a solid (70 3o mg, yield, 35%). ~H NMR (300 MHz, CD30D) b 1.55-1.62 (m, 1 H), 1.70 - 1.96 (m, 2 H), 2.05-2.20 (m, 1 H), 2.29 - 2.43 (m, 1 H), 2.74 - 3.13 (m, 5 H), 3.42 -3.66 (m, 1 H, _78_ 5.24 - 5.46 (m, 1 H), 7.27 (d, J=9.2 Hz, 1 H), 7.38 (s, 1 H), 7.53 (d, J=8.5 Hz, 1 H), 7.82 (dd, J=8.5, 1.7 Hz, 1 H), 8.05 (s, 1 H), 8.11 (d, J=9.5 Hz, 1 H) ppm. MS
(DCI/NH3): 399 (M+H)+, 401 (M+H)+.
Example 25B
(3R)-3-(6-(3-Bromo-1 H-indol-5-yl)-pyridazin-3-yloxyl-1-aza-bicyclo(2.2.21octane tri(hydrogen chloride) The product of Example 25A (50 mg, 0.125 mmol) was treated with HCI
(Aldrich, 4 M in dioxane, 0.25 mL, 1 mmol) in EtOAc (anhydrous, 5 mL) at ambient temperature for 1 h to provide the title compound as yellow solid (60 mg, yield, 95%).
'H NMR (300 MHz, CD30D) 8 1.89 - 2.28 (m, 3 H), 2.29 - 2.56 (m, 1 H), 2.63 -2.80 (m, 1 H), 3.35 - 3.71 (m, 5 H), 3.81 - 4.10 (m, 1 H), 5.37 - 5.74 (m, 1 H), 7.56 (s, 1 H), 7.72 (d, J=8.5 Hz, 1 H) 7.80 (dd, J=8.5, 1.8 Hz, 1 H), 8.01 (d, J=9.5 Hz, 1 H) 8.21 (d, J=1.4 Hz, 1 H), 8.76 (d, J=9.5 Hz, 1 H) ppm; MS (DCI/NH3): 399 (M+H)+, 401 (M+H)+. Anal. Calculated for C~gHIgBrN4O 3.00 HC1~1.50 H20: C, 42.60; H, 4.70; N, 10.46. Found: C, 42.59; H, 4.79; N, 10.09.
Example 26 5-~6-((,3R)- 1-Aza-bicyclo(2.2.21oct-3-yloxyl-pyridazin-3-yl}-1,3-dihydro-indol-2-one 2o bis(hydrogen chloride) Example 26A
5-(4,4,5,5-Tetramethyl-(1,3,21dioxaborolan-2-yl)-1,3-dihydro-indol-2-one 5-Bromo-1,3-dihydro-indol-2-one (Aldrich, 1.06 g, 5 mmol) was coupled with 2s bis(pinacolato)diboron (Aldrich, 1.52 g, 6 mmol) catalyzed by PdCl2(dppf)2~CH2CI2 (Aldrich, 82 mg, 0.1 mmol) using KOAc (Aldrich, 0.98 g, 10 mmol) as base in dioxane (anhydrous, Aldrich, 50 mL) at 80°C for 10h. After being cooled down to ambient temperature, the mixture was diluted with EtOAc (50 mL) and washed with brine (2 x 10 mL). The organic solution was then concentrated under vacuum.
The 3o title compound was purified by chromatography (Si02, hexane : EtOAc, 70:30, Rf.
0.5) as a solid (0.96 g, yield, 74%).'H NMR (300 MHz, CDC13) S 1.24 (s, 3 H), 1.28 (s, 3 H), 1.34 (s, 6 H), 3.69 (s, 2 H), 6.86 (d, J=7.8 Hz, 1 H), 7.57 - 7.78 (m, 2 H) ppm. MS (DCI/NH3): 260 (M+H)+.
Example 26B
5-(6-[(3R)- 1-Aza-bicyclo[2.2.2~oct-3-yloxyl-pyridazin-3-yl~-1 3-dihydro indol 2 one The product of Example 4A (240 mg, 1 mmol) was coupled with the product of Example 26A (520 mg, 2 mmol) catalyzed by PdCl2(PPh3)2 (Aldrich, 35 mg, 0.05 mmol) and 2-(dicyclohexylphosphino)biphenyl (Strem Chemicals, 52.5 mg, 0.15 mmol) in dioxane/EtOH/Na2C03 (aq, 1 M) (v. 1/1/1, 4.5 mL) at 130°C at 330 watts for min in an EmryT"" Creator microwave. The inorganic solid was filtered off with a syringe filter and the mixture was then directed purified by chromatography (Si02, EtOAc: MeOH (v. 2% NH3.H20), 50:50, Rf. 0.2) to give the title compound (240 mg, 71%).'H NMR (300 MHz, MeOH-D4) b 1.53 - 1.72 (m, 1 H), 1.73 - 1.96 (m, 2 H), 2.05 - 2.22 (m, 1 H), 2.24 - 2.49 (m, 1 H), 2.83 - 3.15 (m, 5 H), 3.34 (S, 2 H), 3.47 -15 3.65 (m, 1 H), 5.16 - 5.49 (m, 1 H), 7.02 (d, J=7.7 Hz, 1 H), 7.25 (d, J=9.2 Hz, 1 H), 7.73 - 7.90 (m, 2 H), 8.01 (d, J=9.2 Hz, 1 H) ppm. MS (DCI/NH3): 337 (M+H)+.
Example 26C
5-f6-[(3R)- 1-Aza-bicyclo[2.2.21oct-3-yloxyl-pyridazin-3-yl~-1 3-dihydro indol 2 one 2o bis(hydrogen chloi-ide~
The product of Example 26B (80 mg, 0.24 mmol) was treated with HCI
(Aldrich, 4 M in dioxane, 0.25 mL, 1 mmol) in EtOAc (anhydrous, 5 mL) at ambient temperature for 1 h to provide the title compound as yellow solid (100 mg, yield, 100%).'H NMR (300 MHz, MeOH-D4) 8 1.89 - 2.28 (m, 3 H), 2.29 - 2.49 (m, 1 H), 2.60-2.72 (m, 1 H), 3.34 - 3.63 (m, 5 H), 3.67 (s, 2 H), 3.81 - 4.10 (m, 1 H), 5.45 -5.71 (m, 1 H), 7.12 (d, J=6.1 Hz , 1 H), 7.77 (d, J=9.2 Hz, 1 H), 7.82 - 7.97 (m, 1 H), 8.46 (d, J=9.5 Hz, 1 H) ppm; MS (DCI/NH3): 337 (M+H)+. Anal. Calculated for C~sH2oNa02 2.00 HC1~2.00 H20: C, 51.24; H, 5.88; N, 12.58. Found: C, 51.34; H, 5.75; N, 12.62.
Example 27 5-{6-[(3R)-1-Oxy-1-Aza-bicyclo[2.2.2~oct-3-yloxyl-pyridazin-3-yl~-1,3-dihydro-indol-2-one bis(hydrogen chloride) Example 27A
5-f6-[ 3R)-1-Oxy-1-Aza-bicyclo[2.2.21oct-3-yloxyl-pyridazin-3-yl}-1,3-dihydro-indol-2-one The product of Example 26B (100 mg, 0.30 mmol) was treated with H202 (Aldrich, 30%, 0.5 mL, 1.3 mmol) in MeCN / H20 (v. 4 / 1, 10 mL) at 60°C for 70 hours according to the procedure of Example 23. The title compound was purified by 1o chromatography (Si02, EtOAc: MeOH (v. 2% NH3.H20), 50:50, Rf. 0.1 ) as solid (80 mg, 76%). 'H NMR (300 MHz, MeOH-D4) b 2.01 - 2.29 (m, 3 H), 2.37 - 2.61 (m, 2 H), 3.33 - 3.54 (m, 5 H), 3.68 (s, 2 H), 3.87 - 4.18 (m, 1 H), 5.46 - 5.77 (m, 1 H), 7.03 (d, J=8.1 Hz, 1 H), 7.31 (d, J=9.5 Hz, 1 H), 7.75 - 7.93 (m, 2 H), 8.06 (d, J=9.5 Hz, 1 H) ppm. MS (DCI/NH3): 353 (M+H)+.
Example 27B
5-f 6-f (3R)-1-Oxy-1-Aza-bicyclo[2.2.21oct-3-ylox~~~yridazin-3-yl}-1,3-d ihyd ro-indol-2-one bis(hydrogen chloride) The product of Example 27A (80 mg, 0.23 mmol) was treated with HCI
(Aldrich, 4M in dioxane, 0.25 mL, 1 mmol) in i-PrOH (5 mL) at ambient temperature for 1h to provide the title compound as yellow solid (90 mg, yield, 93%).'H
2.10 - 2.50 (m, 3 H), 2.54 - 2.81 (m, 2 H), 3.35 (s, 2 H), 3.71 - 3.94 (m, 4 H), 4.02 (d, J=13.2 Hz, 1 H), 4.30 - 4.58 (m, 1 H), 5.51 - 5.86 (m, 1 H), 7.18 (d, J=8.9 Hz, 1 H), 7.84 - 8.00 (m, 2 H), 7.99 (d, J=9.2 Hz, 1 H), 8.63 (d, J=9.2 Hz, 1 H) ppm; MS
(DCI/NH3): 353 (M+H)+. Anal. Calculated for C~gH2pN4O3 2.00 HC1~1.65 H20: C, 50.15; H, 5.60; N, 12.31. Found: C, 49.77; H, 5.29; N, 12.03.
Example 28 ~6-[(3R)-1-Aza-bicyclo[2.2.21oct-3-yloxyl-pyridazin-3-yl)-1,3-dihydro-benzoimidazol-2-one trifluroacetate Example 28A
r (4-Bromo-2-nitro-phenyl)-carbamic acid tert-butyl ester 4-Bromo-2-nitro-phenylamine (Aldrich, 10.8 g, 50 mmol) was treated with di(tert-butyl) dicarbonate (Aldrich, 11.99 g, 55 mmol) in THF (Aldrich, 100 mL) at refluxing for 6 hours. It was then concentrated and the title compound was purified by recrystallization in EtOH as white solid (12.8 g, yield, 81 %). ~H NIVIR
(300 MHz, MeOH-D4) b 1.40 (S, 9 H), 7.21 (d, J=8.5 Hz, 1 H), 7.76 (dd, J=8.4, 2.3 Hz, 1 H), 8.21 (d, J=2.1 Hz, 1 H) ppm. MS (DCI/NH3): 334 (M+H)+, 336 (M+H)+.
Example 28B
[2-Nitro-4-(4,4,5,5-tetramethyl-[1,3,21dioxaborolan-2-yl)-phe~ll-carbamic acid tert-butyl ester The product of Example 28A (10.05 g, 30 mmol) was coupled with with bis(pinacoiato)diboron (Aldrich, 9.14 g, 36 mmol) under the catalysis of PdCl2(dppf)2~CH2CI2 (Aldrich, 490 mg, 0.6 mmol) with KOAc (Aldrich, 6.0 g, 60 mmol) in dioxane (anhydrous, Aldrich, 150 mL) at 80°C for 10 hours according to the procedure of Example 26A. The title compound was purified by chromatography (Si02, hexane : EtOAc, 70:30, Rf. 0.5) as solid (9.0 g, yield, 83%). ~H NMR
(300 MHz, CDCI 3) b 1.37 (s, 9 H), 1.38 (s, 12 H), 7.99 (d, J=1.4 Hz, 1 H), 8.02 (d, J=1.4 2o Hz, 1 H), 8.45 (d, J=1.4 Hz, 1 H) ppm. MS (DCI/NH3): 382 (M+NH4)+.
Example 28C
~4-~(6-[(3R)-1-Aza-bicyclo[2.2.21oct-3-yloxyl-pyridazin-3-y~-2-nitro-phenyl}-carbamic, acid tert-butyl ester The product of Example 9A (240 mg, 1 mmol) was coupled with the product of Example 28B (0.72, 2 mmol) under the catalysis of Pd2(dba)3 (24 mg, 0.025 mmol) and (tBu3P)2Pd (26 mg, 0.05 mmol) with CsF (Strem Chemicals, 228 mg, 1.5 mmol) in dioxane (8 mL) and DMF (Aldrich, 1 mL) at 80°C under N2 for 16 hours according to the procedure of Example 20B. The title compound was purified by so chromatography (Si02, EtOAc: MeOH (v. 2°l° NH3.H20), 50:50, Rf. 0.3) as yellow solid (350 mg, 79%). 'H NMR (300 MHz, MeOH-D4) b 1.40 (s, 9 H), 1.51 - 1.70 (m, 1 H), 1.70 - 1.98 (m, 2 H), 2.00 - 2.23 (m, 1 H), 2.37 - 2.51 (m, 1 H), 2.71 -3.18 (m, 5 H), 3.47 - 3.69 (m, 1 H), 5.33 - 5.49 (m, 1 H), 7.30 (d, J=9.2 Hz, 1 H), 7.54 (d, J=8.5 Hz, 1 H), 7.62 (s, 1 H), 8.14 (d, J=9.5 Hz, 1 H), 8.37 (dd, J=8.1, 2.0 Hz, 1 H), 8.80 (d, J=2.0 Hz, 1 H) ppm. MS (DCI/NH3): 442 (M+H)+.
Example 28D
4-~6-f (3R)-1-Aza-bicyclo f2.2.2)oct-3-yloxy)-pyridazin-3-yl~-2-nitro-phenylamine The product of Example 28C (350 mg, 0.79 mmol) was treated with HCI
(Aldrich, 4 M in dioxane, 2 mL, 8 mmol) in EtOH (5 mL) at ambient temperature for 1 h. The mixture was concentrated and the title compound was purified by chromatography (Si02, EtOAc: MeOH (v. 2% NH3.H20), 50:50, Rf. 0.1 ) as white solid (250 mg, 93%). 'H NMR (300 MHz, MeOH-D4) b 1.54 - 1.66 (m, 1 H), 1.72 -2.02 (m, 2 H), 2.07 - 2.24 (m, 1 H), 2.35 - 2.57 (m, 1 H), 2.79 - 3.18 (m, 5 H), 3.48 -3.69 (m, 1 H), 5.27 - 5.47 (m, 1 H), 7.10 (d, J=8.8 Hz, 1 H), 7.22 (d, J=9.5 Hz, 1 H), 7.66 (s, 1 H), 7.98 (d, J=9.2 Hz, 1 H), 8.08 (dd, J=9.0, 2.2 Hz, 1 H), 8.68 (d, J=2.4 Hz, 1 H) ppm. MS (DCI/NH3): 342 (M+H)+.
Example 28E
4-f 6-f (3R)-1-Aza-bicyclo f 2.2.21oct-3-yloxy~-pyridazin-3-yl}-benzene-1,2-diamine 2o The product of Example 28D (200 mg, 0.59 mmol) was hydrogenated under the catalysis of Pd/C (Aldrich, 10wt.%, 50 mg) in EtOH (10 mL) under hydrogen at ambient temperature for 10 h. After the reaction went to completion, the catalyst was removed through a short column of diatomaceous earth (~ 2 g) and the filtrate was washed with EtOH (2 x 5 mL). The ethanol solution was concentrated to give the title compound (180 mg, yield, 98%).'H NMR (500 MHz, CD3-OD) 8 1.58 - 1.73 (m, 1 H), 1.76 - 2.00 (m, 2 H), 2.06 - 2.27 (m, 1 H), 2.29 - 2.47 (m, 1 H), 2.81 - 3.20 (m, 5 H), 3.52 - 3.68 (m, 1 H), 5.11 - 5.57 (m, 1 H), 6.78 (d, J=8.2 Hz, 1 H), 7.12 -7.26 (m, 2 H), 7.32 (d, J=2.1 Hz, 1 H), 7.92 (d, J=9.2 Hz, 1 H) ppm. MS (DCI/NH3): 312 (M+H)+.
Example 28F
5-{6-[(3R)-1-Aza-bicycloj2.2.21oct-3-yloxy]I-pyridazin-3-yl}-1,3-dihydro-benzoimidazol-2-one trifluroacetate The product of Example 28E (62 mg, 0.2 mmol) was treated with 1,1'-carbonyldiimidazole (Aldrich, 50 mg, 0.31 mmol) in THF/DMF (v. 1:1, 5 mL) at ambient temperature for 10h. It was then concentrated. The title product was purified by preparative HPLC (XterraTM, column, Xterra RP-18, 5 pm, 30 x 100 mm.
Eluting Solvent, MeCN / H20 (with 0.2% v. TFA), (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (20.0 mg, 22%).'H NMR (500 MHz, CD3-OD) 8 1.94 - 2.33 (m, 3 H), 2.30 - 2.48 (m, 1 H), 2.65 - 2.79 (m, 1 H), 3.38 - 3.70 (m, 6 H), 3.94 - 4.06 (m, 1 H), 5.41 - 5.73 (m, 1 H), 7.31 (d, J=7.6 Hz, 1 H), 7.62 -7.78 (m, 2 H), 8.00 (d, J=7.0 Hz, 1 H), 8.65 (d, J=7.3 Hz, 1 H) ppm; MS (DCI/NH3): 338 (M+H)+.
Anal. Calculated for C~gHigN5O2 -1.15 CF3C02H 2.30 H20: C, 47.81; H, 4.89; N, 13.73. Found: C, 47.69; H, 5.27; N, 14.09.
Example 29 (R~-3-[6-(1 H-Benzoimidazol-5-yl)-pyridazin-3-yloxyl-1-aza-bicyclo[2.2.21octane Example 29A
(R)-N-(4-[6-(1-Aza-bicycloJ2.2.21oct-3-ylox~~pyridazin-3-yll-phenyl)-acetamide The product of Example 9A (182 mg, 0.76 mmol), N-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-acetamide (Aldrich, 500 mg, 1.9 mmol), dichlorobis(triphenylphosphine)palladium (II) (Aldrich, 53 mg, 0.076 mmol) and (dicyclohexylphosphino)biphenyl (Strem Chemicals, 6.5 mg, 0.019 mmol) were combined with 1 mL each of ethanol, p-dioxane, and 1 M aq. sodium carbonate.
The mixture was heated in a sealed tube to 150 °C at 330 watts for 10 min in an EmryT""
Creator microwave. The mixture was cooled to room temperature, filtered through Celite°, and concentrated onto silica. The product was purified by column chromatography (Si02, 5% methanol containing 1 % NH40H -CH2CI2) to provide the 3o title compound (203 mg, 79%).'H NMR (300 MHz, CD30D) 8 1.96 (m, 1 H), 2.09 (m, 1 H), 2.16 (m, 1 H), 2.16 (s, 3 H), 2.38 (m, 1 H), 2.64 (td, J=6.5, 3.6 Hz, 1 H), 3.33 -3.53 (m, 6 H), 3.97 (dd, J=13.9, 8.1 Hz, 1 H), 5.54 (m, 1 H), 7.32 (d, J=9.4 Hz, 1 H), 7.69 - 7.78 (m, 2 H), 7.91 - 7.98 (m, 2 H), 8.11 (d, J=9.3 Hz, 1 H) ppm; MS
(DCI/NH3): m/z 339 (M+H)+.
Example 29B
4-(6-[(3R)-1-Aza-bicyclo[2.2.21oct-3-ylo~l-pyridazin-3-yl~-2-nitro-phenylamine trifluoroacetate To an ice-cold solution of Example 29A (160 mg, 0.47 mmol) in conc. sulfuric acid (5 mL) was added 90% nitric acid (0.020 mL, 0.47 mmol). After 2 h at 4°C, the mixture was poured over ice and neutralized with ice-cold NaOH (1 N aq.). The mixture was concentrated and the residue was dissolved in MeOH and filtered to give a crude red solid. The product was purified by preparative RP HPLC
(Symmetry~ C-8, 7 pm, 40 x 100 mm; 10-90% MeCN / H20 with 0.2% v. TFA) to give the title compound (54 mg, 0.11 mmol, 23%).'H NMR (400 MHz, CD30D) 8 ~5 1.97 (m, 1 H), 2.03 - 2.23 (m, 2 H), 2.39 (m, 1 H), 2.65 (td, J=6.5, 3.6 Hz, 1 H), 3.35 -3.47 (m, 4 H), 3.49 (m, 1 H), 3.85 (m, 1 H), 3.97 (dd, J=14.0, 8.4 Hz, 1 H), 5.54 (m, 1 H), 7.12 (d, J=8.9 Hz, 1 H), 7.33 (d, J=9.2 Hz, 1 H), 8.04 (dd, J=8.9, 2.1 Hz, 1 H), 8.11 (d, J=9.2 Hz, 1 H), 8.71 (d, J=2.1 Hz, 1 H) ppm. MS (ESI): m/z 342 (M+H)+.
2o Example 29C
(R)-3-[6-(1 H-Benzoimidazol-5-yl)-pyridazin-3-yloxyl-1-aza-bicyclo[2.2.21octarie The product of Example 29B (29 mg, 0.064 mmol) was dissolved in 2.0 mL of methanol and 6 mg of Pd(OH)2/C (Aldrich, 10 wt%) was added. The mixture was stirred under 50 psi of H2 for 30 min. The solution was filtered through a nylon 25 membrane and concentrated. The residue was dissolved in DMF (0.25 mL) and treated with excess triethylorthoformate (0.1 mL). The solution was heated at 80 °C
for 2 h, then cooled down to ambient temperature and stirred for 4 h. The title product was purified by preparative HPLC (XterraTM, column, Xterra RP-18 5 pm, x 100 mm. Eluting Solvent, MeCN / H20 (NH4HC03, 0.1 M, pH=10) (v. 40/60 to 30 70/30 over 20 min.) Ffow rate, 75 mL/min., uv, 250 nm) as solid (13 mg, 0.04 mmol, 63%).'H NMR (300 MHz, CD30D) 8 1.57 (m, 1 H), 1.73 - 1.94 (m, 2 H), 2.08 (m, 1 H), 2.34 (td, J=6.4, 3.6 Hz, 1 H), 2.80 - 3.03 (m, 6 H), 3.50 (ddd, J=14.5, 8.1, 1.5 Hz, 1 H), 5.32 (m, 1 H), 7.28 (d, J=9.2 Hz, 1 H), 7.74 (d, J=8.5 Hz, 1 H), 7.91 (d, J=8.5 Hz, 1 H), 8.11 (d, J=9.2 Hz, 1 H), 8.22 (s, 1 H), 8.25 (s, 1 H) ppm; MS
(DCI/NH3):
m/z 322 (M+H)+.
Example 30 (S)-3-[6-(1 H-Indol-5-yl)-pyridazin-3-ylox~~-1-aza-bicyclo[2.2.2~octane Fumarate Example 30A
(,S)-3-(6-Chloro-pyridazin-3-yloxy~)-1-aza-bicyclo[2.2.21octane The product of Example 13D (254 mg, 2 mmol) was coupled with 3,6-dichloropyridazine (Aldrich, 596 mg, 4 mmol) according to the procedure of Example 7A. The title compound was purified by flash chromatography (Si02, CH2C12 :
MeOH
NH3~H20, 90:10:2, Rf. 0.30) as solid (346 mg, 72%).'H NMR (300 MHz, MeOH-D4) b 1.47 - 1.63 (m, J=12.9 Hz, 1 H), 1.65 - 1.92 (m, 2 H), 1.94 - 2.10 (m, J=5.9, 3.6 Hz, 1 H), 2.22 - 2.32 (m, J=2.7 Hz, 1 H), 2.72 - 3.02 (m, 5 H), 3.36 - 3.49 (m, 1 H), 5.17 -5.28 (m, 1 H), 7.23 (d, J=9.2 Hz, 1 H), 7.65 (d, J=9.5 Hz, 1 H) ppm. MS
(DCI/NH3) m/z 240 (M+H)+, 242 (M+H)+.
2o Example 30B
(S)-3-[6-(1 H-Indol-5-yl)-pyridazin-3-yloxyl-1-aza-bicyclo[2.2.21octane The product of Example 30A (270 mg, 1.1 mmol) was coupled with 5-indolylboronic acid (215 mg, 1.4 mmol) according to the procedure of Example 20B.
The title compound was purified by preparative HPLC (XterraTM, column, Xterra RP-18 5 Nm, 30 x 100 mm. Eluting Solvent, MeCN / H20 (NH4HC03, 0.1 M, PH=10) (v.
90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (200 mg, 57%). 'H NMR (300 MHz, MeOH-D4) b 1.49 - 1.63 (m, 1 H), 1.67 - 1.92 (m, 2 H), 1.99 - 2.14 (m, 1 H), 2.28 - 2.36 (m, 1 H), 2.76 - 3.04 (m, 5 H), 3.48 (ddd, J=14.7, 8.2, 1.9 Hz, 1 H), 5.24 - 5.34 (m, 1 H), 6.56 (d, J=4.1 Hz, 1 H), 7.24 (d, J=9.5 Hz, 1 3o H), 7.30 (d, J=3.4 Hz, 1 H), 7.50 (d, J=8.5 Hz, 1 H), 7.73 (dd, J=8.6, 1.9 Hz, 1 H) ,8.07 (d, J=9.5 Hz, 1 H), 8.13 (s, 1 H) ppm. MS (DCI/NH3) m/z 321 (M+H)+.
Example 30C
(S)-3-f6- 1 H-Indol-5-yl)-pyridazin-3-yloxyl-1-aza-bicyclof2.2.2~octane fumarate The product of Example 30B (200 mg, 0.625 mmol) was treated with fumaric acid (Aldrich, 73 mg, 0.63 mmol) in EtOAc/MeOH (v.10:1, 10 mL) at ambient temperature for 10 hours to give title compound (240.2 mg, 85%). 'H NMR (300 MHz, MeOH-D4) b 1.87 - 2.22 (m, 3 H), 2.31 - 2.45 (m, 1 H), 2.60 - 2.67 (m, 1 H), 3.30 - 3.50 (m, 5 H), 3.89 - 4.00 (m, 1 H), 5.49 - 5.57 (m, 1 H), 6.57 (d, J=3.1 Hz, 1 H), 6.68 (s, 2 H), 7.28 - 7.35 (m, 2 H), 7.52 (d, J=8.5 Hz, 1 H), 7.74 (dd, J=8.6, 1.9 o Hz, 1 H), 8.11 - 8.19 (m, J=9.5 Hz, 2 H) ppm. MS (DCI/NH3) m/z 321 (M+H)+.
Anal.
Calculated for C~9H2oN40~ 1.O C4O4H4'O.SO H2O: C, 62.01; H, 5.66; N, 12.58.
Found:
C, 61.79; H, 5.46; N, 12.43.
Example 31 (R)-3-f5-(1 H-Indol-5-yl)-pyridin-2-yloxyl-1-aza-bicyclof2.2.2~octane trifluoroacetate Example 31 A
(R)-3-(5-Bromo-pyridin-2-yloxy)-1-aza-bicyclo f2.2.2~octane The product of Example 4A (1.27 g, 10 mmol) was coupled with 5-bromo-2-2o chloro-pyridine (Aldrich, 1.54 g, 8 mmol) according to the procedure of Example 7A.
The title compound was purified by column chromatography (Si02, CH2CI2 : MeOH
NH3~H20, 90:10:1, Rf. 0.2) as a solid (2.0 g, yield, 88%). 'H NMR (MeOH-d4, MHz) 1.49 - 1.64 (m, 1 H), 1.66 - 1.91 (m, 2 H), 1.97 - 2.11 (m, 1 H), 2.17 -2.26 (m, 1 H), 2.77 - 3.05 (m, 5 H), 3.36 - 3.47 (m, 1 H), 5.02 - 5.10 (m, 1 H), 6.77 (d, J=8.8 2s Hz, 1 H), 7.78 (dd, J=8.8, 2.7 Hz, 1 H), 8.16 (t, J=2.5 Hz, 1 H) ppm. MS
(DCI/NH3) m/z 283 (M+H)+, 285(M+H)+.
Example 31 B
(R)-3-(5-(1 H-Indol-5-yl)-pyridin-2-yloxyl-1-aza-bicycl~2.2.21octane trifluoroacetate 3o The product of Example 31A (140 mg, 0.5 mmol) was coupled with 5-indolylboronic acid (Ryscor Science, 161 mg, 1.0 mmol) according to the procedure of Example 29A. The title compound was preparative HPLC (XterraTM, column, Xterra RP-18, 5 pm, 30 x 100 mm. Eluting Solvent, MeCN / H20 (with 0.2% v.
TFA), (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (72.9 mg, 32%).'H NMR (MeOH-d4, 300 MHz) 1.86 - 2.22 (m, 3 H), 2.31 - 2.46 (m, 1 H), 2.52 - 2.63 (m, 1 H), 3.29 - 3.50 (m, 5 H), 3.85 - 3.97 (m, 1 H), 5.34 - 5.42 (m, 1 H), 6.49 (d, J=2.4 Hz, 1 H), 6.93 (d, J=8.5 Hz, 1 H), 7.24 - 7.35 (m, 2 H), 7.46 (d, J=8.5 Hz, 1 H), 7.74 (d, J=1.7 Hz, 1 H), 8.00 (dd, J=8.6, 2.5 Hz, 1 H), 8.38 (d, J=2.7 Hz, 1 H) ppm. MS (DCI/NH3) m/z 320(M+H)+. Anal. Calculated for C2oH2~N30~1.14 CF3C02H: C, 59.55; H, 4.97; N, 9.35. Found: C, 59.59; H, 4.99; N, 9.03.
Example 32 (3R)-3-f5-(1 H-Indol-4-yl)-pyrimidin-2-yloxyl-1-aza-bicyclof2.2.21octane 1-oxide The product of Example 12A (10 mg, 0.03 mol) was oxidized with H202 (Aldrich, aq., 30%) according to the procedure of Example 23. The title compound was purified by chromatography [Si02, CH2C12: MeOH (v. 5% NH3.H20), 90 : 10].
'H NMR (300 MHz, CD30D) b 2.01 - 2.32 (m, 3 H), 2.42 - 2.64 (m, 2 H), 3.41 -3.70 (m, 5H), 3.91 - 4.24 (m, 1 H), 5.39 - 5.59 (m, 1 H), 6.55 (d, J=4.0 Hz, 1 H), 7.12 (d, J=8.0 Hz, 1 H), 7.23 (t, J=8.0 Hz, 1 H), 7.36 (d, J=3.0 Hz, 1 H), 7.47 (d, J=8.0 Hz, 1 H), 8.96 (s, 2 H) ppm.
Example 33 (3R)-3-(5-Benzooxazol-5-yl-pyrimidin-2-ylox r~-1-aza-bicyclof2.2.2~octane bis(hydrogien chloride) Example 33A
1-Benzyloxy-4-bromo-2-nitro-benzene 4-Bromo-2-nitro-phenol (Aldrich, 2.18 g, 10 mmol) was treated with K2C03 (Aldrich, 2.76 g, 20 mmol) in DMF (Aldrich, 100 mL) at ambient temperature for min. Benzyl chloride (Aldrich, 1.52 g, 12 mmol) was added. The mixture was stirred L
so at 100°C for 6 h. It was then poured into ice/water (200 mL) and stirred at ambient temperature for 10 hours. The white solid was filtered and dried to give the title _88_ compound (3.0 g, yield, 100%).'H NMR (300 MHz, CDC13) ~ 5.23 (s, 2 H), 7.01 (d, J=9.2 Hz, 1 H), 7.31 - 7.49 (m, 5 H), 7.58 (dd, J=9.0, 2.5 Hz, 1 H), 7.98 (d, J=2.7 Hz, 1 H) ppm. MS (DCI/NH3): 325 (M+H)+, 327 (M+H)+.
Example 33B
[2-Nitro-4-(4,4,5,5-tetramethyl-(1,3,21dioxaborolan-2-yl)-phenyll-carbamic acid tert-butyl ester The product of Example 33A (3.0 g, 10 mmol) was coupled with bis(pinacolato)diboron (Aldrich, 3.04 g, 12 mmol) according to the procedure of Example 28B. The title compound was purified by chromatography (Si02, hexane EtOAc, 70:30, Rf. 0.5) as a solid (3.05 g, yield, 86%).'H NMR (300 MHz, MEOH-D4) b 1.34 (s, 12 H), 5.30 (s, 2 H), 7.27 - 7.43 (m, 4 H), 7.42 - 7.51 (m, 2 H), 7.89 (dd, J=8.3, 1.5 Hz, 1 H), 8.09 (d, J=1.7 Hz, 1 H) ppm. MS (DCI/NH3): 373 (M+NH4)+.
Example 33C
(3R)-3-(5-(4-Benzyloxy-3-nitro-phenyl)-pyrimidin-2yloxy~-1-aza-bicyclo(2 2 2loctane The product of Example 11A (1.42 g, 5 mmol) was coupled with the product of Example 33B (2.50 g, 7.0 mmol) according to the procedure of Example 20B. The title compound was purified by chromatography (Si02, EtOAc: MeOH (v. 2%
2o NH3.H20), 50:50, Rf. 0.3) as solid (1.75 g, 81%).'H NMR (300 MHz, MeOH-D4) b 1.46 - 1.61 (m, 1 H), 1.63 - 1.92 (m, 2 H), 1.97 - 2.15 (m, 1 H), 2.17 - 2.33 (m, 1 H), 2.69 - 3.04 (m, 5 H), 3.35 - 3.49 (m, 1 H), 5.11 - 5.22 (m, 1 H), 5.34 (s, 2 H), 7.25 -7.55 (m, 5 H), 7.85 (dd, J=8.8, 2.4 Hz, 1 H), 8.13 (d, J=2.0 Hz, 1 H), 8.63 (s, 1 H), 8.82 (s, 2 H) ppm. MS (DCI/NH3): 433 (M+H)+.
Example 33D
2-Amino-4-f 2-((3R)-1-aza-bicyclo(2.2.21oct-3=ylo~1-pyrimid in-5-yl}-phenol The product of Example 33C (380 mg, 0.88) was hydrogenated under the catalysis of Pd/C (Aldrich, 10 wt. %, 100 mg) according to the procedure of Example 28E. The title compound was obtained as yellow solid (220 mg, yield, 92%).'H
NMR
(300 MHz, CD30D) 8 1.47 - 1.93 (m, 3 H), 1.95 - 2.35 (m, 2 H) 2.70 - 3.05 (m, 5 H), _89_ 3.33 - 3.48 (m, 1 H), 5.04 - 5.30 (m, J=8.8 Hz, 1 H), 6.72 - 6.88 (m, 2 H), 6.98 (d, J=1.7 Hz, 1 H), 8.70 (s, 2 H)ppm. MS (DCI/NH3): 313 (M+H)+.
Example 33E
(3R)-3-(5-Benzooxazol-5-yl-pyrimidin-2-yloxy)-1-aza-bicyclof2.2.21octane The product of Example 33D (62 mg, 0.2 mmol) was treated with triethyl orthoformate (Aldrich, 0.5 mL) in DMF (1 mL) at 100°C for 10h. It was then concentrated. The title product was purified by preparative HPLC (XterraTM, column, Xterra RP-18, 5 Nm, 30 x 100 mm. Eluting Solvent, MeCN / H20 (NH4HC03, 0.1 M, 1o pH=10) (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (50.0 mg, 78%). ~H NMR (300 MHz, CD3-OD) 8 1.46 - 1.64 (m, 1 H), 1.64 - 1.93 (m, 2 H), 2.00 - 2.19 (m, 1 H), 2.19 - 2.39 (m, 1 H), 2.67 - 3.13 (m, 5 H), 3.36 -3.51 (m, 1 H), 5.09 - 5.38 (m, 1 H), 7.72 (dd, J=8.5, 2.0 Hz, 1 H), 7.81 (d, J=8.9 Hz, 1 H), 8.03 (d, J=1.7 Hz, 1 H), 8.53 (s, 1 H), 8.87 (s, 2 H) ppm; MS (DCI/NH3): 323 (M+H)+.
Example 33F
(3R)-3-(5-Benzooxazol-5-yl-pyrimidin-2-yloxy)-1-aza-bicyclof2.2.21octane bis(hydrogen chloride) The product of Example 33E (50 mg, 0.15 mmol) was treated with HCI
(Aldrich, 4M in dioxane, 0.50 mL, 2.0 mmol) in EtOAc (5 mL) at ambient temperature for 1 hour to afford the title compound as yellow solid (55.0 mg, 93%).'H NMR
(300 MHz, CD3-OD) 8 1.83 - 2.28 (m, 3 H), 2.30 - 2.50 (m, 1 H), 2.58 - 2.75 (m, 1 H), 3.34 - 3.51 (m, 5 H), 3.84 - 3.97 (m, 1 H), 5.33 - 5.52 (m, 1 H), 7.15 (d, J=8.5 Hz, 1 H), 7.51 - 7.67 (m, 1 H), 7.80 (s, 1 H), 8.09 (s, 1 H), 8.81 (s, 2 H) ppm; MS
(DCI/NH3):
323 (M+H)+. Anal. Calculated for C~gHIgN4O2 2.38 HCI 2.60 H20: C, 47.41; H, 5.65; N, 12.29. Found: C, 47.33; H, 5.25; N, 11.92.
Example 34 (3R)-3-(5-(2-Methyl-benzooxazol-5-yl )-pyrimid in-2-yloxyl-1-aza-bicyclo f 2.2.21octane 3o hydrogen chloride Example 34A
~3R)-3-f 5-(2-Methyl-benzooxazol-5-ail)-pyrimidin-2-yloxyl-1-aza-bicyclo f 2.2.21octane The product of Example 33D (62 mg, 0.2 mmol) was treated with triethyl orthoacetate (Aldrich, 0.5 mL) in DMF (1 mL) at 100°C for 10h. It was then concentrated. The title product was purified by preparative HPLC (XterraTM, column, Xterra RP-18, 5 Nm, 30 x 100 mm. Eluting Solvent, MeCN / H20 (NH4HC03, 0.1 M, pH=10) (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (20.0 mg, 30%).'H NMR (500 MHz, CD30D) 8 1.51 - 1.64 (m, 1 H), 1.66 - 1.77 (m, H), 1.78 - 1.91 (m, 1 H), 2.02 - 2.16 (m, 1 H), 2.19 - 2.36 (m, 1 H), 2.67 (s, 3 H), 2.74 - 3.07 (m, 5 H), 3.37 - 3.48 (m, 1 H), 5.07 - 5.39 (m, 1 H), 7.62 (dd, J=8.5, 1.3 Hz, 1 H), 7.68 (d, J=8.3 Hz, 1 H),7.87 (d, J=1.2 Hz, 1 H), 8.79 - 8.93 (s, 2 H) ppm;
MS
(DCI/NH3): 327 (M+H)+.
Example 34B
(3R)-3-f5-(2-Methyl-benzooxazol-5-yl)-pyrimidin-2-yloxyl-1-aza-bicyclof2.2.2~octane hydrogen chloride The product of Example 34A (20 mg, 0.06 mmol) was treated with HCI
(Aldrich, 4M in dioxane, 0.25 mL, 1.0 mmol) in EtOAc (3 mL) at ambient temperature for 1 hour to afford the title compound as yellow solid (20.0 mg, 92%).'H NMR
(500 2o MHz, CD30D) 8 1.92 - 2.25 (m, 3 H), 2.33 - 2.47 (m, 1 H), 2.59 - 2.65 (m, 1 H), 2.65 - 2.71 (s, 3 H), 3.33 - 3.54 (m, 5 H); 3.87 - 4.00 (m, 1 H), 5.34 - 5.54 (m, 1 H), 7.63 (d, J= 8.5 Hz, 1 H), 7.70 (d, J= 8.5 Hz, 1 H), 7.88 (s, 1 H), 8.90 (s, 2 H) ppm; MS
(DCI/NH3): 327 (M+H)+. Anal. Calculated for C~gH2pN4O2 1.20 HCI 1.50 H20: C, 56.39; H, 5.60; N, 13.45. Found: C, 56.05; H, 5.99; N, 13.76.
Example 35 (3R)-3-f 5-(2-Ethyl-benzooxazol-5-yl)-pyrimid i n-2-yloxyl-1-aza-bicyclo f 2.2.21octane bis(hydroqen chloride) Example 35A
~3R)-3-[5-(2-Ethyl-benzooxazol-5-yl)-p rLrimidin-2-yloxyl-1-aza-bicyclo[2.2.~octane The product of Example 33D (62 mg, 0.2 mmol) was treated with triethyl orthopropionate (Aldrich, 0.5 mL) in DMF (1 mL) at 100°C for 10h. It was then concentrated. The title product was purified by preparative HPLC (XterraTM, column, Xterra RP-18, 5 Nm, 30 x 100 mm. Eluting Solvent, MeCN / H20 (NH4HC03, 0.1 M, pH=10), (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (20.0 mg, 30%).'H NMR (500 MHz, CD30D) 8 1.45 (t, J=7.6 Hz, 3 H), 1.49 - 1.64 (m, 1 H), 1.66 - 1.78 (m, 1 H), 1.79 - 1.94 (m, 1 H), 2.04 - 2.16 (m, 1 H), 2.21 - 2.36 (m, 1 H), 2.72 - 3.11 (m, 7 H), 3.37 - 3.53 (m, 1 H), 5.07 - 5.31 (m, 1 H), 7.62 (dd, J=
8.5, 1.7 Hz, 1 H) 7.69 (d, J= 8.6 Hz, 1 H), 7.89 (d, J=1.2 Hz, 1 H), 8.82 -8.90 (m, 2 H) ppm; MS (DCI/NH3): 351 (M+H)+.
Example 35B
(3R)-3-f5-(2-Methyl-benzooxazol-5-yl)-pyrimidin-2-yloxyl-1-aza-bicyclof2.2.2]octane bis(,hydroqen chloride) -The product of Example 35A (20 mg, 0.06 mmol) was treated with HCI
(Aldrich, 4M in dioxane, 0.25 mL, 1.0 mmol) in EtOAc (3 mL) at ambient temperature for 1 hour to afford the title compound as yellow solid (15.0 mg, 92%).'H NMR
(500 2o MHz, CD3-OD) 8 1.46 (t, J=7.6 Hz, 3 H), 1.89 - 2.25 (m, 3 H), 2.28 - 2.52 (m, 1 H), 2.54 - 2.72 (m, 1 H), 3.02 (q, J=7.6 Hz, 2 H), 3.22 - 3.56 (m, 5 H), 3.92 (dd, J=13.6, 8.7 Hz, 1 H), 4.99 - 5.63 (m, 1 H), 7.63 (d, J=8.5 Hz, 1 H), 7.71 (d, J=8.5 Hz, 1 H), 7.90 (s, 1 H), 8.90 (s, 2 H) ppm; MS (DCI/NH3): 351 (M+H)+. Anal. Calculated for C2oH22N402 2.00 HCI: C, 56.74; H, 5.71; N, 13.23. Found: C, 56.82; H, 5.69; N, 13.13.
Example 36 (3R)-3-f 5-(2-Phenyl-benzooxazol-5y~-pyrimid in-2-yloxyl-1-aza-bicyclo f 2.2.21octane bis~droqen chloride) Example 36A
(3R)-3-(5-(2-Phenyl-benzooxazol-5-yl)-~~rimidin-2-yloxy~-1-aza-bicyclo(2.2.21octane The product of Example 33D (62 mg, 0.2 mmol) was treated with triethyl orthobenzoate (Aldrich, 0.5 mL) in DMF (1 mL) at 100°C for 10h. It was then concentrated. The title product was purified by preparative HPLC (XterraTM, column, Xterra RP-18, 5 pm, 30 x 100 mm. Eluting Solvent, MeCN / H20 (NH4HC03, 0.1 M, pH=10), (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (40.0 mg, 50%).'H NMR (500 MHz, CD30D) 8 1.52 - 1.64 (m, 1 H), 1.68 - 1.80 (m, H), 1.80 - 1.92 (m, 1 H), 2.06 - 2.18 (m, 1 H), 2.25 - 2.31 (m, 1 H), 2.75 -3.10 (m, 5 H), 3.39 - 3.49 (m, 1 H), 5.14 - 5:27 (m, 1 H), 7.55 - 7.66 (m, 3 H), 7.69 (dd, J=8.5, 1.8 Hz, 1 H), 7.81 (d, J=8.2 Hz, 1 H), 8.00 (d, J=1.5 Hz, 1 H), 8.27 (dd, J=8.1, 1.7 Hz, 2 H), 8.89 (s, 2H) ppm; MS (DCI/NH3): 399 (M+H)+.
Example 36B
~5 (3R)-3-(5- 2-Phenyl-benzooxazol-5-yl)-pyrimidin-2-yloxy~-1-aza-bicyclo(2.2.21octane bis(hydrogen chloride) The product of Example 36A (40 mg, 0.10 mmol) was treated with HCI
(Aldrich, 4M in dioxane, 0.25 mL, 1.0 mmol) in EtOAc (3 mL) at ambient temperature for 1 hour to afford the title compound as yellow solid (20.0 mg, 92%).'H NMR
(500 2o MHz, CD30D) 8 1.93 - 2.23 (m, 3 H), 2.33 - 2.48 (m, 1 H), 2.60 - 2.71 (m, 1 H), 3.34 -3.57 (m, 5 H), 3.90 - 3.99 (m, 1 H), 5.35 - 5.61 (m, 1 H), 7.54 - 7.68 (m, 3 H), 7.72 (dd, J=8.4, 1.7 Hz, 1 H), 7.84 (d, J=8.5 Hz, 1 H), 8.03 (d, J=1.2 Hz, 1 H), 8.21 - 8.37 (m, 2 H), 8.98 (s, 2 H) ppm; MS (DCI/NH3): 399 (M+H)+. Anal. Calculated for C2aH22NaO2 1.40 HCI 1.50 H20: C, 60.49; H, 5.58. Found: C, 60.12; H, 5.72.
Example 37 (R)-5-(2- 1-Aza-bicyclo(2.2.21oct-3-ylox~~hyrimidin-5-yl~-3H-benzooxazol-2-one bis(hydrochloride) 3o Example 37A
(R)-5-(2-( 1-Aza-bicyclo(2.2.21oct-3-yloxy)-pyrimidin-5-yll-3H-benzooxazol-2-one The product of Example 33D (62 mg, 0.2 mmol) was treated with 1,1'-carbonyldiimidazole (Aldrich, 50 mg, 0.31 mmol) in THF/DMF (v. 1:1, 5 mL) at ambient temperature for 10h. It was then concentrated. The title product was purified by preparative HPLC (XterraTM, column, Xterra RP-18, 5 pm, 30 x 100 mm.
Eluting Solvent, MeCN / H20 (NH4HC03, 0.1 M, pH=10), (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (60.0 mg, 34%).'H NMR (500 MHz, CD3-OD) 8 1.46 - 1.96 (m, 3 H), 2.02 - 2.18 (m, 1 H), 2.19 - 2.38 (m, 1 H), 2.70 - 3.11 (m, 5 H), 3.37 - 3.51 (m, 1 H), 5.08 - 5.29 (m, 1 H), 7.14 - 7.60 (m, 3 H), 8.79 (s, 2 H) ppm; MS (DCI/NH3): 338 (M+H)+.
Example 37B
(R)-5-[2-(1-Aza-bicyclo[2.2.21oct-3-yloxy)-pyrimidin-5-yl1-3H-benzooxazol-2-one bis(hydrochloride) The product of Example 37A (60 mg, 0.18 mmol) was treated with HCI
(Aldrich, 4M in dioxane, 0.25 mL, 1.0 mmol) in EtOAc (3 mL) at ambient temperature for 1 hour to afford the title compound as yellow solid (60.0 mg, 83%). ~H NMR
(500 F
MHz, CD30D) 8 1.89 - 2.28 (m, 3 H), 2.30 - 2.54 (m, 1 H), 2.61 - 2.76 (m, 1 H), 3.36 -3.52 (m, 5 H), 3.82 - 3.99 (m, 1 H), 5.40-5.52 (m, 1 H) 7.20 - 7.47 (m, 2 H), 7.68 (s, 1.
H), 8.80 (s, 2 H) ppm; MS (DCI/NH3): 338 (M+H)+. Anal. Calculated for CigH~gN4O3 2.00 HCI 1.50 H20: C, 49.33; H, 5.29; N, 12.78. Found: C, 49.40; H, 5.07; N, 12.60.
Example 38 (R)-3-[6-(1-Aza-bicyclo[2.2.21oct-3-yloxy)-pyridazin-3-yl~-9H-carbazole Example 38A
3-(4,4,5,5-Tetramethyl-[1,3,21dioxaborolan-2-yl)-9H-carbazole 3-Bromo-9H-carbazole (Aldrich, 0.97 g, 3.96 mmol) was coupled with bis(pinacolato)diboron (Aldrich, 1.13 g, 4.46 mmol) under the catalysis of dichloro [1,1'-bis(diphenylphosphino)ferrocene]palladium (II) dichloromethane (Aldrich, mg, 0.125 mmol) with KOAc (Aldrich, 1.21 g, 12.3 mmol) in DMF (anhydrous, Aldrich, 25 mL) at 80°C overnight according to the procedure of Example 26A, The title compound was purified by chromatography (Si02, gradient 5 to 50% EtOAc-hexanes) to give 0.80 g (2.73 mmol, 69% yield). ~H NMR (300 MHz, CDC13) 8 1.40 (s, 12 H), 7.26 (s, 1 H), 7.40 - 7.47 (m, 3 H), 7.88 (d, J=7.0 Hz, 1 H), 8.11 (d, J=7.0 Hz, 2 H), 8.58 (s, 1 H) ppm. MS (DCI/NH3) m/z 294 (M+H)+.
Example 38B
(R)-3-f 6-( 1-Aza-bicyclo f 2.2.2]oct-3-yloxy)-pyridazin-3-yll-9H-carbazole The product of Example 9A (0.173g, 0.72 mmol) was coupled with the product of Example 38A (0.267 g, 0.91 mmol) under the catalysis of dichlorobis(triphenyl-phosphine)palladium(II) (Aldrich, 5.3 mg, 0.007 mmol) and 2-(dicyclohexylphosphino)biphenyl (Strem Chemicals, 7.3 mg, 0.021 mmol) at 150 °C
for 10 min. according to the procedure of Example 29A. The title product was purified by preparative HPLC (XterraTM, column, Xterra RP-18 5 pm, 30 x 100 mm.
~5 Eluting Solvent, MeCN / H20 (NH4HC03, 0.1 M, pH=10) (v. 40/60 to 70/30 over min.) Flow rate, 75 mL/min., uv, 250 nm) as solid. 'H NMR (300 MHz, CD30D) 8 1.45 - 1.62 (m, 1 H), 1.68 - 1.92 (m, 2 H), 2.00 - 2.15 (m, 1 H), 2.27 - 2.40 (m, Hz, 1 H), 2.75 - 3.05 (m, 5 H), 3.43 - 3.59 (m, Hz, 1 H), 5.22 - 5.42 (m, Hz, 1 H), 7.16 7.24 (m, 1 H), 7.28 (d, J=9 Hz, 1 H), 7.36 = 7.44 (m, 1 H), 7.45 - 7.52 (m, 1 H), 7.57 20 (d, J=8 Hz, 1 H), 8.02 (dd, J=9, 2 Hz, 1 H), 8.17 (t, J=9 Hz, 2 H), 8.67 (s, 1 H) ppm;
MS (DCI/NH3) m/z 371 (M+H)+.
Example 39 3-f6-(1H-Indol-3-yl)-pyridazin-3-yloxyl-1-aza-bicyclo(2.2.21octane hemifumarate Example 39A
3-f 6-( 9 H-I ndol-3-yl)-pyridazin-3-yloxy]-1-aza-bicyclo f 2.2.21octane 3-Quinuclidinol (Aldrich, 254 mg, 2 mmol) was coupled with 3-(6-chloro-pyridazin-3-yl)-1 H-indole (Bionet, 458 mg, 2 mmol) at 60°C for 16 hours according to 3o the procedure of Example 7A. The title compound was purified by preparative HPLC
(XterraTM, column, Xterra RP-18, 5 pm, 30 x 100 mm. Eluting Solvent, MeCN /
(NH4HC03, 0.1 M, pH=10), (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (400 mg, 63%).'H NMR (MeOH-D4, 300 MHz) 1.50 - 1.64 (m, 1 H), 1.71 - 1.93 (m, 2 H), 2.00 - 2.15 (m, 1 H), 2.29 - 2.36 (m, 1 H), 2.78 -3.04 (m, 5 H), 3.43 - 3.55 (m, 1 H), 5.24 - 5.32 (m, 1 H), 7.12 - 7.25 (m, 3 H), 7.42 -7.48 (m, 1 s H), 7.87 (s, 1 H), 8.01 (d, J=9.2 Hz, 1 H), 8.26 - 8.33 (m, 1 H) ppm. MS
(DCI/NH3) m/z 321 (M+H)+.
Example 39B
3-f6-(1 H-Indol-3-yl)-pyridazin-3-yloxy~-1-aza-bicyclo(2.2.21octane hemifumarate The product of Example 39A (200 mg, 0.63 mmol) was treated with fumaric acid (Aldrich, 73 mg, 0.63 mmol) in EtOAc/MeOH(v.10:1, 10 mL) at ambient temperature overnight to give the title compound (247.3 mg, 100%). 'H NMR
(MeOH-D4, 300 MHz) 1.76 - 1.91 (m, 1 H), 1.92 - 2.14 (m, 2 H), 2.22 - 2.37 (m, 1 H), 2.51 - 2.58 (m, 1 H), 3.16 - 3.39 (m, 5 H), 3.82 (ddd, J=14.0, 8.2, 1.9 Hz, 1 H), 5.40 -15 5.49 (m, 1 H), 6.67 (s, 1 H), 7.12 - 7.26 (m, 3 H), 7.42 - 7.49 (m, 1 H), 7.89 (s, 1 H), 8.05 (d, J=9.5 Hz, 1 H), 8.26 - 8.32 (m, 1 H) ppm. MS (DCI/NH3) m/z 321 (M+H)+.
Anal. Calculated for C~9H2oN40~0.5 C404H4~0.35 H20: C, 65.56; H, 5.95; N, 14.56.
Found: C, 65.49; H, 6.21; N, 14.34.
2o Example 40 (R)-3-f6-(1 H-Indol-3-yl)-pvridazin-3-yloxyl-1-aza-bicyclof2.2.21octane fumarate The product of Example 4A (127 mg, 1 mmol ) was coupled with 3-(6-chloro-pyridazin-3-yl)-1 H-indole (Bionet, 229 mg, 1 mmol) according to the procedure of Example 39. The title compound was obtained as solid (208.3 mg, yield, 35%).
~H
25 NMR (MeOH-d4, 300 MHz) 1.90 - 2.24 (m, 3 H), 2.33 - 2.48 (m, 1 H), 2.61 -2.69 (m, 1 H), 3.32 - 3.55 (m, 5 H), 3.98 (dd, J=13.7, 8.3 Hz, 1 H), 5.49 - 5.57 (m, 1 H), 6.71 (s, 4 H), 7.13 - 7.28 (m, 3 H), 7.46 (d, J=7.1 Hz, 1 H), 7.90 (s, 1 H), 8.07 (d, J=9.2 Hz, 1 H), 8.30 (d, J=7.1 Hz, 1 H) ppm. MS (DCI/NH3) m/z 321 (M+H)+. Anal.
Calculated for C~sH2oN40~2.1 C404H4~0.35 EtOAc: C, 58.14; H, 5.29; N, 9.42.
3o Found: C, 57.91; H, 5.35; N, 9.42.
r Example 41 (S)-3-[6-(1 H-Indol-3-yl)-pyridazin-3-yloxyl-1-aza-bicyclo[2.2.2~octane fumarate The product of Example 13D (127 mg, 1 mmol) was coupled with 3-(6-chloro-pyridazin-3-yl)-1 H-indole (Bionet, 229 mg, 1 mmol) according to the procedure of s Example 39. The title compound was obtained as solid (239 mg, yield, 39%).'H
NMR
(MeOH-d4, 300 MHz) 1.90 - 2.24 (m, 3 H), 2.33 - 2.48 (m, 1 H), 2.61 - 2.69 (m, 1 H), 3.33 - 3.55 (m, 5 H), 3.93 - 4.04 (m, 1 H), 5.49 - 5.57 (m, 1 H), 6.72 (s, 4 H), 7.13 7.28 (m, 3 H), 7.46 (d, J=8.1 Hz, 1 H), 7.90 (s, 1 H), 8.07 (d, J=9.2 Hz, 1 H), 8.30 (d, J=7.1 Hz, 1 H) ppm. MS (DCI/NH3) m/z 321 (M+H)+. Anal. Calculated for C~9HZON40~2.1 C404H4~0.5 EtOAc: C, 58.06; H, 5.37; N, 9.21. Found: C, 57.81;
H, 5.54; N, 9.53.
Example 42 DETERMINATION OF BIOLOGICAL ACTIVITY
To determine the effectiveness of representative compounds of this invention as a7 nAChRs, the compounds of the invention were evaluated according to the [3H]-methyllycaconitine (MLA) binding assay and considering the [3H]-cytisine binding assay, which were performed as described below.
20 [3H1-Cytisine binding Binding conditions were modified from the procedures described in Pabreza LA, Dhawan, S, Kellar KJ, [3H]-Cytisine Binding to Nicotinic Cholinergic Receptors in Brain, Mol. Pharm. 39: 9-12, 1991. Membrane enriched fractions from rat brain minus cerebellum (ABS Inc., Wilmington, DE) were slowly thawed at 4 °C, washed 2s and resuspended in 30 volumes of BSS-Tris buffer (120 mM NaCI/5 mM KCI/2 mM
CaCl2/2 mM MgCl2/50 mM Tris-CI, pH 7.4, 4 °C). Samples containing 100-200 pg of protein and 0.75 nM [3H]-cytisine (30 C;/mmol; Perkin Elmer/NEN Life Science Products, Boston, MA) were incubated in a final volume of 500 pL for 75 minutes at 4 °C. Seven log-dilution concentrations of each compound were tested in duplicate.
so Non-specific binding was determined in the presence of 10 NM (-)-nicotine.
Bound radioactivity was isolated by vacuum filtration onto prewetted glass fiber filter plates (Millipore, Bedford, MA) using a 96-well filtration apparatus (Packard Instruments, Meriden, CT) and were then rapidly rinsed with 2 mL of ice-cold BSS buffer (120 mM
NaCI/5 mM KCI/2 mM CaCl2/2 mM MgCl2). Packard MicroScint-20°
scintillation cocktail (40 NL) was added to each well and radioactivity determined using a s Packard TopCount~ instrument. The IC5o values were determined by nonlinear regression in Microsoft Excel° software. K; values were calculated from the ICSOs using the Cheng-Prusoff equation, where K; = ICSO/1+[Ligand]/Kp].
L3H1-Methyllycaconitine (MLA) binding Binding conditions were similar to those for [3H]-cytisine binding. Membrane enriched fractions from rat brain minus cerebellum (ABS Inc., Wilmington, DE) were slowly thawed at 4 °C, washed and resuspended in 30 volumes of BSS-Tris buffer (120 mM NaCI, 5 mM KCI, 2 mM CaCl2, 2 mM MgCl2, and 50 mM Tris-CI, pH 7.4, 22 °C). Samples containing 100-200 pg of protein, 5 nM [3H]-MLA (25 C;/mmol; Perkin 15 Elmer/NEN Life Science Products, Boston, MA) and 0.1 % bovine serum albumin (BSA, Millipore, Bedford, MA) were incubated in a final volume of 500 pL for minutes at 22 °C. Seven log-dilution concentrations of each compound were tested in duplicate. Non-specific binding was determined in the presence of 10 pM
MLA.
Bound radioactivity was isolated by vacuum filtration onto glass fiber filter plates 2o prewetted with 2% BSA using a 96-well filtration apparatus (Packard Instruments, Meriden, CT) and were then rapidly rinsed with 2 mL of ice-cold BSS. Packard MicroScint-20~ scintillation cocktail (40 pL) was added to each well and radioactivity was determined using a Packard TopCount~ instrument. The ICSO values were determined by nonlinear regression in Microsoft Excel° software. K;
values were 2s calculated from the IC5os using the Cheng-Prusoff equation, where K; _ ICSO/1 +[Ligand]/Kp].
Compounds of the invention had K; values of from about 1 nanomolar to about micromolar when tested by the MLA assay, many having a K; of less than 1 micromolar. [3H]-Cytisine binding values of compounds of the invention ranged from 3o about 50 nanomolar to at least 100 micromolar. The determination of preferred compounds typically considered the K; value as measured by MLA assay in view of _98_ the K; value as measured by [3H]-cytisine binding, such that in the formula D
= K; 3H-cytisine /K. M~a" D is about 50. Preferred compounds typically exhibited greater potency at a7 receptors compared to a4[i2 receptors.
Compounds of the invention are a7 nAChRs ligands that modulate function of a7 nAChRs by altering the activity of the receptor. The compounds can be inverse agonists that inhibit the basal activity of the receptor or antagonists that completely block the action of receptor-activating agonists. The compounds also can be partial agonists that partially block or partially activate the a7 nAChR receptor or agonists that activate the receptor.
Some compounds of the invention also have been evaluated for potential binding to the hERG ion channel. Blockade of the hERG ion channel has been associated with interference of heart muscle repolarization, which presents a cardiovascular risk. Binding affinities to the hERG channel were measured by displacement of the radioligand [3H]-dofetilide and expressed in K; value, i.e. K; hERG~
Compounds of the invention demonstrating a higher ratio of a7 receptor binding to the ratio of hERG binding, i.e. (K; MLA)/(Ki hERG), were considered to demonstrate a better cardiovascular risk profile. Compounds of the invention that were tested all demonstrated a beneficial cardiovascular risk profile for a7 receptor ligands.
It is understood that the foregoing detailed description and accompanying 2o examples are merely illustrative and are not to be taken as limitations upon the scope of the invention, which is defined solely by the appended claims and their equivalents. Various changes and modifications to the disclosed embodiments will be apparent to those skilled in the art. Such changes and modifications, including without limitation those relating to the chemical structures, substituents, derivatives, 2s intermediates, syntheses, formulations and/or methods of use of the invention, may be made without departing from the spirit and scope thereof.
_99_
Claims (10)
1. A compound of the formula (I):
or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, wherein:
n is 0, 1, or 2;
A is N or N+-O-;
X is selected from the group consisting of O, S, and -N(R1)-;
Ar1 is a 6-membered aromatic ring containing 0, 1, 2, 3, or 4 nitrogen atoms, wherein Ar1 is substituted with 0, 1, 2, 3, or 4 alkyl groups;
Ar2 is a group of the formula:
Z1, Z2, Z3, and Z4 are independently selected from the group consisting of C
and -C(R3b); provided that zero or one of Z1, Z2, Z3, and Z4 is C;
Z5, Z6, Z7, and Z8 are independently selected from the group consisting of C
and -C(R3b); provided that zero or one of Z5, Z6, Z7, and Z8 is C;
Z9, Z10, Z11, Z12, Z13, Z14, Z15, and Z16 are independently selected from the group consisting of C and -C(R3c); provided that one of Z9, Z10, Z11, Z12, Z13, Z14, Z15, and Z16 is C and the group of formula (c) is attached to Ar1 through the C
atom;
Y1 at each occurrence is independently selected from the group consisting of O, S, -N(R2), -C(R3), and -C(R3)(R3a);
Y2 is selected from the group consisting of -N(R2), C(=O), -C(R3), and -C(R3)(R3a);
Y3 is selected from the group consisting of -N(R2), -C(R3), and -C(R3)(R3a); provided that zero or one of Y1, Y2, and Y3 is -C(R3) in a group of formula (a);
wherein when one of Y1, Y2, and Y3 is -C(R3) in a group of formula (a), then Z1, Z2, Z3, and Z4 are each -C(R3b) and the group of formula (a) is attached to Ar1 through the C atom of -C(R3) of Y1, Y2, or Y3; and also when one of Z1, Z2, Z3, and Z4 is C, then Y1, Y2 and Y3 are other than -C(R3) and the group of formula (a) is attached to Ar1 through the C atom of Z1, Z2, Z3, or Z4;
Y2a and Y3a are independently selected from the group consisting of N, C and -C(R3a); provided that when Y1 is -C(R3) in a group of formula (b), Y2a and Y3a are selected from the group consisting of N and -C(R3a), and when one of Y2a and Y3a is C, then Y1 in a group of formula (b) is O, S, -N(R2), or-C(R3)(R3a);
wherein when one of Z5, Z6, Z7, and Z8 is C, then Y1 in a group of formula (b) is selected from the group consisting of O, S, -N(R2), and -C(R3)(R3a); Y2a and Y3a are each independently selected from the group consisting of N and -C(R3a);
and the group of formula (b) is attached to Ar1 through the C of Z5, Z6, Z7, or Z8;
and also wherein when Y1 in a group of formula (b) is -C(R3) or one of Y2a and Y3a is C, then Z5, Z6, Z7, and Z8 are each -C(R3b) and the group of formula (b) is attached to Ar1 through the C atom of -C(R3) of Y1 in the group of formula (b) or through the C atom of Y2a Or Y3a;
R1 and R2 at each occurrence are each independently selected from the group consisting of hydrogen and alkyl;
R3 and R3a at each occurrence are each independently selected from the group consisting of hydrogen, halogen, alkyl, aryl, -OR4, -NR5R6, -alkyl-OR4, and -alkyl-NR5R6;
R3b and R3c at each occurrence are each independently selected from the group consisting of hydrogen, halogen, alkyl, aryl, -OR4, -NR5R6, -alkyl-OR4, -alkyl-NR5R6, and -SCN;
R4 is selected from the group consisting of hydrogen, alkyl, aryl, alkylcarbonyl, and arylcarbonyl;
R5 and R6 at each occurrence are each independently selected from the group consisting of hydrogen, alkyl, aryl, alkylcarbonyl, alkoxycarbonyl, aryloxycarbonyl, and arylcarbonyl, provided that at least one of R5 and R6 is hydrogen or alkyl; and R8 is selected from the group consisting of hydrogen and alkyl.
or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, wherein:
n is 0, 1, or 2;
A is N or N+-O-;
X is selected from the group consisting of O, S, and -N(R1)-;
Ar1 is a 6-membered aromatic ring containing 0, 1, 2, 3, or 4 nitrogen atoms, wherein Ar1 is substituted with 0, 1, 2, 3, or 4 alkyl groups;
Ar2 is a group of the formula:
Z1, Z2, Z3, and Z4 are independently selected from the group consisting of C
and -C(R3b); provided that zero or one of Z1, Z2, Z3, and Z4 is C;
Z5, Z6, Z7, and Z8 are independently selected from the group consisting of C
and -C(R3b); provided that zero or one of Z5, Z6, Z7, and Z8 is C;
Z9, Z10, Z11, Z12, Z13, Z14, Z15, and Z16 are independently selected from the group consisting of C and -C(R3c); provided that one of Z9, Z10, Z11, Z12, Z13, Z14, Z15, and Z16 is C and the group of formula (c) is attached to Ar1 through the C
atom;
Y1 at each occurrence is independently selected from the group consisting of O, S, -N(R2), -C(R3), and -C(R3)(R3a);
Y2 is selected from the group consisting of -N(R2), C(=O), -C(R3), and -C(R3)(R3a);
Y3 is selected from the group consisting of -N(R2), -C(R3), and -C(R3)(R3a); provided that zero or one of Y1, Y2, and Y3 is -C(R3) in a group of formula (a);
wherein when one of Y1, Y2, and Y3 is -C(R3) in a group of formula (a), then Z1, Z2, Z3, and Z4 are each -C(R3b) and the group of formula (a) is attached to Ar1 through the C atom of -C(R3) of Y1, Y2, or Y3; and also when one of Z1, Z2, Z3, and Z4 is C, then Y1, Y2 and Y3 are other than -C(R3) and the group of formula (a) is attached to Ar1 through the C atom of Z1, Z2, Z3, or Z4;
Y2a and Y3a are independently selected from the group consisting of N, C and -C(R3a); provided that when Y1 is -C(R3) in a group of formula (b), Y2a and Y3a are selected from the group consisting of N and -C(R3a), and when one of Y2a and Y3a is C, then Y1 in a group of formula (b) is O, S, -N(R2), or-C(R3)(R3a);
wherein when one of Z5, Z6, Z7, and Z8 is C, then Y1 in a group of formula (b) is selected from the group consisting of O, S, -N(R2), and -C(R3)(R3a); Y2a and Y3a are each independently selected from the group consisting of N and -C(R3a);
and the group of formula (b) is attached to Ar1 through the C of Z5, Z6, Z7, or Z8;
and also wherein when Y1 in a group of formula (b) is -C(R3) or one of Y2a and Y3a is C, then Z5, Z6, Z7, and Z8 are each -C(R3b) and the group of formula (b) is attached to Ar1 through the C atom of -C(R3) of Y1 in the group of formula (b) or through the C atom of Y2a Or Y3a;
R1 and R2 at each occurrence are each independently selected from the group consisting of hydrogen and alkyl;
R3 and R3a at each occurrence are each independently selected from the group consisting of hydrogen, halogen, alkyl, aryl, -OR4, -NR5R6, -alkyl-OR4, and -alkyl-NR5R6;
R3b and R3c at each occurrence are each independently selected from the group consisting of hydrogen, halogen, alkyl, aryl, -OR4, -NR5R6, -alkyl-OR4, -alkyl-NR5R6, and -SCN;
R4 is selected from the group consisting of hydrogen, alkyl, aryl, alkylcarbonyl, and arylcarbonyl;
R5 and R6 at each occurrence are each independently selected from the group consisting of hydrogen, alkyl, aryl, alkylcarbonyl, alkoxycarbonyl, aryloxycarbonyl, and arylcarbonyl, provided that at least one of R5 and R6 is hydrogen or alkyl; and R8 is selected from the group consisting of hydrogen and alkyl.
2. The compound of claim 1, wherein Ar1 is a group of the formula:
wherein:
X1, X2, X3, and X4 are each independently selected from the group consisting of N
and -CR10; and R10 at each occurrence is independently selected from the group consisting of hydrogen and alkyl.
wherein:
X1, X2, X3, and X4 are each independently selected from the group consisting of N
and -CR10; and R10 at each occurrence is independently selected from the group consisting of hydrogen and alkyl.
3. The compound of claim 1, wherein Ar1 is selected from the group consisting of:
wherein R10 at each occurrence is independently selected from the group consisting of hydrogen and alkyl.
wherein R10 at each occurrence is independently selected from the group consisting of hydrogen and alkyl.
4. The compound of claim 1, wherein Ar2 is selected from the group consisting of:
wherein:
Z1, Z2, Z3, and Z4 are independently selected from the group consisting of C
and -C(R3b); provided that one of Z1, Z2, Z3, and Z4 is C and formula (ix) is attached to Ar1 through the C atom of Z1, Z2, Z3, and Z4;
Y1 is selected from the group consisting of O, S, and -C(R3)(R3a);
Z5, Z6, Z7, and Z8 are independently selected from the group consisting of C
and -C(R3b); provided that zero or one of Z5, Z6, Z7, and Z8 is C;
Y2a and Y3a are independently selected from the group consisting of C and -C(R3a); wherein when one of Z5, Z6, Z7, and Z8 is C, then Y2a and Y3a in the group of formulae (i)-(vii) are each -C(R3a); and each of the group of formulae (i)-(vii) is attached to Ar1 through the C of Z5, Z6, Z7, or Z8; and also wherein when one of Y2a and Y3a is C in the group of formulae (i)-(vii), then Z5, Z6, Z7, and Z8 are each -C(R3b) and each of the group of formulae (i)-(vii) is attached to Ar1 through the C
atom of Y2a or Y3a; and R2, R3, R3a, R3b, R8, Z9, Z10, Z11, Z12, Z13, Z14, Z15, and Z16 are as defined in claim 1.
wherein:
Z1, Z2, Z3, and Z4 are independently selected from the group consisting of C
and -C(R3b); provided that one of Z1, Z2, Z3, and Z4 is C and formula (ix) is attached to Ar1 through the C atom of Z1, Z2, Z3, and Z4;
Y1 is selected from the group consisting of O, S, and -C(R3)(R3a);
Z5, Z6, Z7, and Z8 are independently selected from the group consisting of C
and -C(R3b); provided that zero or one of Z5, Z6, Z7, and Z8 is C;
Y2a and Y3a are independently selected from the group consisting of C and -C(R3a); wherein when one of Z5, Z6, Z7, and Z8 is C, then Y2a and Y3a in the group of formulae (i)-(vii) are each -C(R3a); and each of the group of formulae (i)-(vii) is attached to Ar1 through the C of Z5, Z6, Z7, or Z8; and also wherein when one of Y2a and Y3a is C in the group of formulae (i)-(vii), then Z5, Z6, Z7, and Z8 are each -C(R3b) and each of the group of formulae (i)-(vii) is attached to Ar1 through the C
atom of Y2a or Y3a; and R2, R3, R3a, R3b, R8, Z9, Z10, Z11, Z12, Z13, Z14, Z15, and Z16 are as defined in claim 1.
5. The compound of claim 1, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, selected from the group consisting of:
3-[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl]-1H-indole;
4-[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl]-1H-indole;
5-[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl]-1H-indole;
5-{4-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy)phenyl}-1H-indole;
3-[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl]-1H-indole;
4-[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl]-1H-indole;
5-[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl]-1H-indole;
5-{4-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy)phenyl}-1H-indole;
6-[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl]-1H-indole;
2-[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl]-1H-indole;
5-[6-(1-azabicyclo[2.2.2]oct-3-yloxy)pyridazin-3-yl]-1H-indole;
4-[6-(1-azabicyclo[2.2.2]oct-3-yloxy)pyridazin-3-yl]-1H-indole;
5-{6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl}-1H-indole;
5-{6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl}-3-methyl-1H-indole;
5-{2-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyrimidin-5-yl}-1H-indole;
4-{2-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyrimidin-5-yl}-1H-indole;
5-{2-[(3S)-1-azabicyclo[2.2.2]oct-3-yloxy]pyrimidin-5-yl}-1H-indole;
5-[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl]-3-methyl-1H-indazole;
6-[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl]-1,3-benzothiazol-2-amine;
6-{4-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]phenyl}-1,3-benzothiazol-2-amine;
6-{4-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]phenyl}-4-thiocyanato-1,3-benzothiazol-2-amine;
6-{4-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]phenyl}-4-bromo-1,3-benzothiazol-2-amine;
N-[4-(3-methyl-1H-indazol-5-yl)phenyl]quinuclidin-3-amine;
(R)-3-[6-(3-methyl-1H-indazol-5-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane;
(R)-3-[6-(1-methyl-1H-indol-5-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane;
(R)-{5-[6-(1-aza-bicyclo[2.2.2]oct-3-yloxy)-pyridazin-3-yl]-1H-indol-3-ylmethyl}-dimethyl-amine;
(R)-3-[6-(1H-indol-5-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane 1-oxide;
6-{6-[(3R)-1-aza-bicyclo[2.2.2]oct-3-yloxy]-pyridazin-3-yl}-benzothiazol-2-ylamine;
(3R)-3-[6-(3-bromo-1H-indol-5-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane;
5-{6-[(3R)-1-aza-bicyclo[2.2.2]oct-3-yloxy]-pyridazin-3-yl}-1,3-dihydro-indol-one;
5-{6-[(3R)-1-oxy-1-Aza-bicyclo[2.2.2]oct-3-yloxy]-pyridazin-3-yl}-1,3-dihydro-indol-2-one;
5-{6-[(3R)-1-aza-bicyclo[2.2.2]oct-3-yloxy]-pyridazin-3-yl}-1,3-dihydro-benzoimidazol-2-one;
(R)-3-[6-(1H-benzoimidazol-5-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane;
(S)-3-[6-(1H-indol-5-yl)-pyridazin-3-yloxy]-1-aza-bicyclo(2.2.2]octane;
(R)-3-[5-(1H-indol-5-yl)-pyridin-2-yloxy]-1-aza-bicyclo[2.2.2]octane;
(3R)-3-[5-(1H-indol-4-yl)-pyrimidin-2-yloxy]-1-aza-bicyclo[2.2.2]octane 1-oxide;
(3R)-3-(5-benzooxazol-5-yl-pyrimidin-2-yloxy)-1-aza-bicyclo[2.2.2]octane;
(3R)-3-[5-(2-methyl-benzooxazol-5-yl)-pyrimidin-2-yloxy]-1-aza-bicyclo[2.2.2]octane;
(3R)-3-[5-(2-ethyl-benzooxazol-5-yl)-pyrimidin-2-yloxy]-1-aza-bicyclo[2.2.2]octane;
(3R)-3-[5-(2-phenyl-benzooxazol-5-yl)-pyrimidin-2-yloxy]-1-aza-bicyclo[2.2.2]octane;
(R)-5-[2-(1-aza-bicyclo[2.2.2]oct-3-yloxy)-pyrimidin-5-yl]-3H-benzooxazol-2-one;
(R)-3-[6-(1-aza-bicyclo[2.2.2]oct-3-yloxy)-pyridazin-3-yl]-9H-carbazole;
3-[6-(1H-indol-3-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane;
(R)-3-[6-(1H-indol-3-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane; and (S)-3-[6-(1H-indol-3-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane.
6. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 in combination with a pharmaceutically acceptable carrier.
2-[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl]-1H-indole;
5-[6-(1-azabicyclo[2.2.2]oct-3-yloxy)pyridazin-3-yl]-1H-indole;
4-[6-(1-azabicyclo[2.2.2]oct-3-yloxy)pyridazin-3-yl]-1H-indole;
5-{6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl}-1H-indole;
5-{6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl}-3-methyl-1H-indole;
5-{2-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyrimidin-5-yl}-1H-indole;
4-{2-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyrimidin-5-yl}-1H-indole;
5-{2-[(3S)-1-azabicyclo[2.2.2]oct-3-yloxy]pyrimidin-5-yl}-1H-indole;
5-[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl]-3-methyl-1H-indazole;
6-[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl]-1,3-benzothiazol-2-amine;
6-{4-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]phenyl}-1,3-benzothiazol-2-amine;
6-{4-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]phenyl}-4-thiocyanato-1,3-benzothiazol-2-amine;
6-{4-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]phenyl}-4-bromo-1,3-benzothiazol-2-amine;
N-[4-(3-methyl-1H-indazol-5-yl)phenyl]quinuclidin-3-amine;
(R)-3-[6-(3-methyl-1H-indazol-5-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane;
(R)-3-[6-(1-methyl-1H-indol-5-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane;
(R)-{5-[6-(1-aza-bicyclo[2.2.2]oct-3-yloxy)-pyridazin-3-yl]-1H-indol-3-ylmethyl}-dimethyl-amine;
(R)-3-[6-(1H-indol-5-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane 1-oxide;
6-{6-[(3R)-1-aza-bicyclo[2.2.2]oct-3-yloxy]-pyridazin-3-yl}-benzothiazol-2-ylamine;
(3R)-3-[6-(3-bromo-1H-indol-5-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane;
5-{6-[(3R)-1-aza-bicyclo[2.2.2]oct-3-yloxy]-pyridazin-3-yl}-1,3-dihydro-indol-one;
5-{6-[(3R)-1-oxy-1-Aza-bicyclo[2.2.2]oct-3-yloxy]-pyridazin-3-yl}-1,3-dihydro-indol-2-one;
5-{6-[(3R)-1-aza-bicyclo[2.2.2]oct-3-yloxy]-pyridazin-3-yl}-1,3-dihydro-benzoimidazol-2-one;
(R)-3-[6-(1H-benzoimidazol-5-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane;
(S)-3-[6-(1H-indol-5-yl)-pyridazin-3-yloxy]-1-aza-bicyclo(2.2.2]octane;
(R)-3-[5-(1H-indol-5-yl)-pyridin-2-yloxy]-1-aza-bicyclo[2.2.2]octane;
(3R)-3-[5-(1H-indol-4-yl)-pyrimidin-2-yloxy]-1-aza-bicyclo[2.2.2]octane 1-oxide;
(3R)-3-(5-benzooxazol-5-yl-pyrimidin-2-yloxy)-1-aza-bicyclo[2.2.2]octane;
(3R)-3-[5-(2-methyl-benzooxazol-5-yl)-pyrimidin-2-yloxy]-1-aza-bicyclo[2.2.2]octane;
(3R)-3-[5-(2-ethyl-benzooxazol-5-yl)-pyrimidin-2-yloxy]-1-aza-bicyclo[2.2.2]octane;
(3R)-3-[5-(2-phenyl-benzooxazol-5-yl)-pyrimidin-2-yloxy]-1-aza-bicyclo[2.2.2]octane;
(R)-5-[2-(1-aza-bicyclo[2.2.2]oct-3-yloxy)-pyrimidin-5-yl]-3H-benzooxazol-2-one;
(R)-3-[6-(1-aza-bicyclo[2.2.2]oct-3-yloxy)-pyridazin-3-yl]-9H-carbazole;
3-[6-(1H-indol-3-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane;
(R)-3-[6-(1H-indol-3-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane; and (S)-3-[6-(1H-indol-3-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane.
6. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 in combination with a pharmaceutically acceptable carrier.
7. A method of selectively modulating the effects of .alpha.7 nicotinic acetylcholine receptors in a mammal comprising administering an effective amount of a compound of claim 1.
8. A method of treating or preventing a condition or disorder selected from the group consisting of attention deficit disorder, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS
dementia, Pick's Disease, dementia associated with Lewy bodies, dementia associated with Down's syndrome, amyotrophic lateral sclerosis, Huntington's disease, diminished CNS function associated with traumatic brain injury, acute pain, post-surgical pain, chronic pain, inflammatory pain, neuropathic pain, infertility, need for new blood vessel growth associated with wound healing, need for new blood vessel growth associated with vascularization of skin grafts, and lack of circulation, more particularly circulation around a vascular occlusion, comprising the step of administering a compound of claim 1.
dementia, Pick's Disease, dementia associated with Lewy bodies, dementia associated with Down's syndrome, amyotrophic lateral sclerosis, Huntington's disease, diminished CNS function associated with traumatic brain injury, acute pain, post-surgical pain, chronic pain, inflammatory pain, neuropathic pain, infertility, need for new blood vessel growth associated with wound healing, need for new blood vessel growth associated with vascularization of skin grafts, and lack of circulation, more particularly circulation around a vascular occlusion, comprising the step of administering a compound of claim 1.
9. The method according to claim 1, wherein the condition or disorder is selected from the group consisting of a cognitive disorder, neurodegeneration, and schizophrenia.
10. The method according to claim 1, further comprising administering a compound of claim 1 in combination with an atypical antipsychotic.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/744,208 | 2003-12-22 | ||
PCT/US2004/041471 WO2006065233A1 (en) | 2004-12-10 | 2004-12-10 | Fused bicycloheterocycle substituted quinuclidine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2551486A1 true CA2551486A1 (en) | 2006-06-22 |
Family
ID=34960429
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002551486A Abandoned CA2551486A1 (en) | 2003-12-22 | 2004-12-10 | Fused bicycloheterocycle substituted quinuclidine derivatives |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1824848A1 (en) |
JP (1) | JP2008523058A (en) |
CN (1) | CN1922176A (en) |
AU (1) | AU2004325725A1 (en) |
CA (1) | CA2551486A1 (en) |
WO (1) | WO2006065233A1 (en) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10164139A1 (en) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-heteroaryl carboxamides |
GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
US7655657B2 (en) | 2003-12-22 | 2010-02-02 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
US20050245531A1 (en) * | 2003-12-22 | 2005-11-03 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
US7160876B2 (en) | 2003-12-22 | 2007-01-09 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
AR049401A1 (en) | 2004-06-18 | 2006-07-26 | Novartis Ag | AZA-BICICLONONANS |
GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
GB0521508D0 (en) | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
GB0525672D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
GB0525673D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
US8314119B2 (en) * | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
DE102007058504A1 (en) | 2007-12-05 | 2009-07-09 | Acino Ag | Transdermal therapeutic system containing a modulator of nicotinic acetylcholine receptors (nAChR) |
EP2540297B1 (en) | 2008-11-19 | 2015-04-08 | Forum Pharmaceuticals Inc. | Treatment of Cognitive Disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof |
TWI558398B (en) | 2009-09-22 | 2016-11-21 | 諾華公司 | Use of nicotinic acetylcholine receptor alpha 7 activators |
CN105837566B (en) | 2010-05-17 | 2018-02-06 | 富瑞姆制药公司 | (R) crystal formation of the carboxamide hydrochloride monohydrate of 7 chlorine N (base of quinuclidine 3) benzo [b] thiophene 2 |
CA2808797A1 (en) | 2010-07-26 | 2012-02-02 | Envivo Pharmaceuticals, Inc. | Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptor agonists in combination with acetylcholinesterase inhibitors |
KR20130108586A (en) | 2010-09-23 | 2013-10-04 | 애브비 인코포레이티드 | Monohydrate of an azaadamantane derivative |
EA201391091A1 (en) | 2011-01-27 | 2013-12-30 | Новартис Аг | APPLICATION OF Nicotinic acetylchloroline receptor activators ALPHA-7 |
WO2012127393A1 (en) | 2011-03-18 | 2012-09-27 | Novartis Ag | COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE |
JPWO2013002365A1 (en) | 2011-06-30 | 2015-02-23 | 東レ株式会社 | Antidiarrheal |
TWI589576B (en) | 2011-07-15 | 2017-07-01 | 諾華公司 | Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursors |
CN103930112B (en) | 2011-10-20 | 2018-11-09 | 诺华股份有限公司 | Predict the biomarker of the response to alpha 7 nicotinic acetylcholine receptors activation agent therapy |
EP2846796A4 (en) | 2012-05-08 | 2015-10-21 | Forum Pharmaceuticals Inc | Methods of maintaining, treating or improving cognitive function |
WO2014091388A2 (en) | 2012-12-11 | 2014-06-19 | Novartis Ag | Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment |
ES2865736T3 (en) | 2013-01-15 | 2021-10-15 | Novartis Ag | Use of alpha 7 nicotinic acetylcholine receptor agonists |
KR101879920B1 (en) | 2013-01-15 | 2018-07-18 | 노파르티스 아게 | Use of alpha 7 nicotinic acetylcholine receptor agonists |
JP2018523707A (en) | 2015-08-12 | 2018-08-23 | アクソバント サイエンシズ ゲーエムベーハー | Geminal-substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
YU84791A (en) * | 1990-05-19 | 1994-06-10 | Boehringer Ingelheim Kg. | BICYCLIC 1-AZA-CYCLOALKAL |
AU1752792A (en) * | 1991-03-08 | 1992-10-06 | Rhone-Poulenc Rorer International (Holdings) Inc. | Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors |
WO1995031458A1 (en) * | 1992-10-13 | 1995-11-23 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | 3-hydroxyquinuclidin-3-ylphenylquinolines as squalene synthase inhibitors |
HN1998000118A (en) * | 1997-08-27 | 1999-02-09 | Pfizer Prod Inc | 2 - AMINOPYRIDINES CONTAINING SUBSTITUTES FOR CONDENSED RINGS. |
CA2345767A1 (en) * | 1998-10-16 | 2000-04-27 | Paul Leonce Irma De Nijs | Therapy for improving cognition |
MXPA05001702A (en) * | 2002-08-14 | 2005-04-19 | Neurosearch As | Novel quinuclidine derivatives and their use. |
GB0220581D0 (en) * | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
-
2004
- 2004-12-10 WO PCT/US2004/041471 patent/WO2006065233A1/en active Application Filing
- 2004-12-10 JP JP2007545431A patent/JP2008523058A/en not_active Ceased
- 2004-12-10 EP EP04813737A patent/EP1824848A1/en not_active Withdrawn
- 2004-12-10 CN CNA2004800419490A patent/CN1922176A/en active Pending
- 2004-12-10 AU AU2004325725A patent/AU2004325725A1/en not_active Abandoned
- 2004-12-10 CA CA002551486A patent/CA2551486A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2004325725A1 (en) | 2006-06-22 |
EP1824848A1 (en) | 2007-08-29 |
JP2008523058A (en) | 2008-07-03 |
WO2006065233A1 (en) | 2006-06-22 |
CN1922176A (en) | 2007-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7655657B2 (en) | Fused bicycloheterocycle substituted quinuclidine derivatives | |
US20050245531A1 (en) | Fused bicycloheterocycle substituted quinuclidine derivatives | |
US7674794B2 (en) | Fused bicycloheterocycle substituted quinuclidine derivatives | |
CA2551486A1 (en) | Fused bicycloheterocycle substituted quinuclidine derivatives | |
US7309699B2 (en) | 3-Quinuclidinyl amino-substituted biaryl derivatives | |
RU2437884C2 (en) | Azabicyclic alkane derivatives substituted with condensed bicycloheterocycle | |
US20070060588A1 (en) | Fused bicycloheterocycle substituted quinuclidine derivatives | |
JP5693229B2 (en) | Biaryl-substituted azabicyclic alkane derivatives as modulators of nicotine acetylcholine receptor activity | |
US20050137204A1 (en) | Fused bicycloheterocycle substituted quinuclidine derivatives | |
US20110118301A1 (en) | Amino-Aza-Adamantane Derivatives and Methods of Use | |
US20050137203A1 (en) | 3-quinuclidinyl amino-substituted biaryl derivatives | |
US7045530B2 (en) | Spirocyclic quinuclidinic ether derivatives | |
NZ548231A (en) | Fused bicycloheterocycle substituted quinuclidine derivatives | |
US20050137217A1 (en) | Spirocyclic quinuclidinic ether derivatives | |
MXPA06007189A (en) | Fused bicycloheterocycle substituted quinuclidine derivatives | |
KR20070085053A (en) | Fused bicycloheterocycle substituted quinuclidine derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead | ||
FZDE | Dead |
Effective date: 20120924 |